Details of Disease

General Information of Disease (ID: DISF190Y)

• Disease Name: Prostate cancer
• Synonyms: hereditary prostate cancer; prostate cancer, familial; prostate neoplasm; prostatic neoplasm; tumor of the prostate; tumour of the prostate; malignant tumor of prostate; malignant prostate neoplasm; malignant tumor of the prostate; malignant tumour of the prostate; malignant prostate tumor; malignant tumour of prostate; NGP - new growth of prostate; malignant neoplasm of prostate gland; cancer of prostate gland; malignant neoplasm of prostate; malignant neoplasm of the prostate; malignant prostate tumour; prostate gland cancer; prostatic cancer; malignant prostate gland neoplasm
• Disease Class: 2C82: Prostate cancer
• Definition: A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
• Disease Hierarchy:
  DISHDKGQ: Prostate neoplasm
  DIS0RQDP: Male reproductive organ cancer
  DISAT1Z9: Advanced cancer
  DISF190Y: Prostate cancer
• ICD Code:
  ICD-11: ICD-11: 2C82.0
  ICD-9: ICD-9: 185
  Expand ICD-9: 185
• Disease Identifiers:
  MONDO ID: MONDO_0008315
  MESH ID: D011471
  UMLS CUI: C0376358
  OMIM ID: 176807
  MedGen ID: 138169
  HPO ID: HP:0012125
  SNOMED CT ID: 399068003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 40 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abarelix	DM5WFNP	Approved	Small molecular drug	[1]
ABIRATERONE	DM8V75C	Approved	Small molecular drug	[2]
Abiraterone acetate	DMANBZI	Approved	Small molecular drug	[3]
ARN-509	DMT81LZ	Approved	Small molecular drug	[4]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[5]
Bicalutamide	DMZMSPF	Approved	Small molecular drug	[6]
Capromab	DMHERIJ	Approved	Antibody	[7]
Choline C-11	DMSVRD2	Approved	Small molecular drug	[8]
Cyproterone	DMQXLD2	Approved	Small molecular drug	[9]
Darolutamide	DMV7YFT	Approved	NA	[10]
Degarelix	DM3O8QY	Approved	Small molecular drug	[11]
Denosumab	DMNI0KO	Approved	Antibody	[12]
Docetaxel	DMDI269	Approved	Small molecular drug	[13]
Dutasteride	DMQ4TJK	Approved	Small molecular drug	[14]
Enzalutamide	DMGL19D	Approved	Small molecular drug	[8]
Estramustine	DMWTAOI	Approved	Small molecular drug	[15]
Everolimus	DM8X2EH	Approved	Small molecular drug	[16]
fluciclovine F-18	DMXCQ5T	Approved	Small molecular drug	[17]
Flutamide	DMK0O7U	Approved	Small molecular drug	[18]
Hydroxyflutamide	DMGIZF5	Approved	Small molecular drug	[19]
Leuprolide	DM5XPIJ	Approved	Small molecular drug	[20]
Leuprorelin acetate	DM15HAT	Approved	Small molecular drug	[21]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Approved	Radiopharmaceutical therapy agent	[22]
Masoprocol	DMMVNZ0	Approved	Small molecular drug	[23]
Menadione	DMSJDTY	Approved	Small molecular drug	[24]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[25]
Nilutamide	DMFN07X	Approved	Small molecular drug	[26]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[5]
Olaparib	DM8QB1D	Approved	Small molecular drug	[5]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[5]
Polyestradiol Phosphate	DM0PMGJ	Approved	Small molecular drug	[3]
Radium-223 chloride	DMG21CZ	Approved	NA	[3]
Radium-223-Dichloride	DMXTCVF	Approved	NA	[27]
Relugolix	DMK7IWL	Approved	Small molecular drug	[28]
Sipuleucel-T	DMSEXNP	Approved	NA	[29]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[30]
Tirbanibulin	DMJNV4O	Approved	Small molecular drug	[31]
Tranylcypromine	DMGB5RE	Approved	Small molecular drug	[32]
Triptorelin	DMTK4LS	Approved	Small molecular drug	[33]
Dicycloplatin	DMRCOU5	Registered	NA	[34]

This Disease is Treated as An Indication in 216 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
177-Lu-PSMA-617	DMX178V	Phase 3	Small molecular drug	[35]
Aglatimagene besadenovec	DMACVU8	Phase 3	Gene therapy	[5]
Amonafide	DMAH59S	Phase 3	Small molecular drug	[36]
ASP3550	DMT7RX4	Phase 3	Small molecular drug	[37]
Atrasentan	DMM74PK	Phase 3	Small molecular drug	[38]
BAY 2315497	DMUHH2G	Phase 3	Antibody drug conjugate	[39]
Cadi-05	DMPTCYB	Phase 3	Vaccine	[40]
Custirsen	DMIQ31Y	Phase 3	Small molecular drug	[41]
DCVax	DMC5VJY	Phase 3	NA	[42]
Dutasteride + tamsulosin	DM6P8HU	Phase 3	Combination drug (small molecular drug)	[43]
FP-001	DMICLA1	Phase 3	NA	[5]
GDC-0068	DMWBZJD	Phase 3	Small molecular drug	[44]
GliAtak	DMUEDFT	Phase 3	NA	[45]
GT0918	DMKW0U6	Phase 3	NA	[5]
HC-1119	DMB06MU	Phase 3	Small molecular drug	[46]
HumaSPECT	DM507PU	Phase 3	NA	[47]
Lu-177-PSMA-I&T	DMRWA3M	Phase 3	Radioligand therapy	[39]
NX-1207	DMERJ19	Phase 3	Small molecular drug	[5]
PI-88	DMGZPX6	Phase 3	Small molecular drug	[48]
Picoplatin	DM0PIY6	Phase 3	Small molecular drug	[49]
PNT-2002	DMBN3YQ	Phase 3	Radiopharmaceutical	[50]
PRo antigen cancer vaccine	DMTG6N1	Phase 3	NA	[51]
Prostate dendritic cell-based vaccine	DML0H2M	Phase 3	NA	[52]
Prostvac	DM51OZ5	Phase 3	NA	[53]
PRX-302	DMEH641	Phase 3	NA	[54]
Rilimogene galvacirepvec	DMGTCI0	Phase 3	NA	[55]
Rubraca rucaparib	DM25TMP	Phase 3	NA	[5]
Stapuldencel-T	DMPYDO1	Phase 3	NA	[5]
TAK-700	DM2H8FZ	Phase 3	Small molecular drug	[56]
Tasquinimod	DM9GSVQ	Phase 3	Small molecular drug	[57]
TAVT-45	DMHBRGT	Phase 3	NA	[58]
Tesetaxel	DM9LFYN	Phase 3	Small molecular drug	[59]
TroVax	DMHDNK0	Phase 3	Vaccine	[60]
Genistein	DM0JETC	Phase 2/3	Small molecular drug	[61]
NAL-GLU	DMD5AEB	Phase 2/3	NA	[62]
NLG8189	DM0798Z	Phase 2/3	Small molecular drug	[5]
SM-88	DMD9ISG	Phase 2/3	NA	[5]
177 Lu PSMA-617 targeted radioligand therapy	DMVNM9G	Phase 2	NA	[63]
99mTc-MIP-1404	DML4GU1	Phase 2	?	[64]
ACYLINE	DM9GRTK	Phase 2	NA	[65]
Ad/PSA	DMQJH3U	Phase 2	NA	[66]
AE-37	DMMRSK1	Phase 2	Small molecular drug	[5]
APC-8015F	DM3VP19	Phase 2	NA	[67]
ARC-100	DMF6GK1	Phase 2	Small molecular drug	[68]
AZD4635	DM8SVIY	Phase 2	NA	[69]
AZD5305	DMW9R1C	Phase 2	Small molecule	[70]
AZD5312	DMJ8V3K	Phase 2	NA	[5]
BNT112	DMBLTPN	Phase 2	Vaccine	[71]
CGC-11047	DM17JSI	Phase 2	Small molecular drug	[72]
CORT125281	DMHBOUX	Phase 2	NA	[73]
Coxsackievirus A21	DM2K5VP	Phase 2	NA	[63]
DCVax-Prostate cancer vaccine	DM72V2C	Phase 2	NA	[74]
DKN-01	DMOHT5V	Phase 2	Antibody	[75]
DPV-001	DMMC3XR	Phase 2	NA	[74]
Enoblituzumab	DMDS20X	Phase 2	NA	[76]
Gossypol	DMJWE3I	Phase 2	Small molecular drug	[77]
GTx-758	DMDWYZS	Phase 2	NA	[78]
Inecalcitol oral	DMU5SZP	Phase 2	Small molecular drug	[79]
INO-5151	DMKSVHR	Phase 2	Vaccine	[80]
Intetumumab	DMBXEG9	Phase 2	Monoclonal antibody	[81]
ISIS-EIF4E	DMRN543	Phase 2	Antisense drug	[82]
J 591 Lu-177	DM9XKJU	Phase 2	NA	[83]
JNJ 63723283	DMBXWJ5	Phase 2	Monoclonal antibody	[5]
LOR-2040	DMX2TEM	Phase 2	NA	[84]
Lorigerlimab	DM2E8Z5	Phase 2	Bispecific antibody	[85]
LY3023414	DMD9KYF	Phase 2	NA	[5]
MLN-591RL	DMJHVZC	Phase 2	Antibody	[86]
MT201	DMN2809	Phase 2	NA	[87]
MVI-816	DMDN6FO	Phase 2	NA	[88]
NanoPac	DM0TD4G	Phase 2	NA	[5]
OBI-3424	DM5D6Y7	Phase 2	Small molecular drug	[89]
OGX-427	DMJTU8D	Phase 2	Antisense drug	[90]
Onyvax-P	DMJU9Y8	Phase 2	NA	[91]
Padeliporfin di-potassium	DMLN942	Phase 2	NA	[5]
PCM-075	DMYFRTB	Phase 2	NA	[92]
PEITC	DMOMN31	Phase 2	Small molecular drug	[93]
PHA-739358	DMGYBZI	Phase 2	Small molecular drug	[94]
Prostvac-VF	DMGQB4R	Phase 2	NA	[95]
PSMA ADC	DM1WQVE	Phase 2	NA	[96]
PSMA ADC therapeutic	DMXMJL8	Phase 2	NA	[97]
PSMA-617	DMK4VHP	Phase 2	NA	[5]
RV001V	DMW8UQX	Phase 2	Vaccine	[98]
Sagopilone	DM6JXWL	Phase 2	Small molecular drug	[99]
Samarium SM-153 lexidronam	DMK558N	Phase 2	NA	[100]
Seviteronel	DM9IMEZ	Phase 2	NA	[5]
TAK-448	DMD51RN	Phase 2	NA	[101]
TH-302	DMFU0JY	Phase 2	Small molecular drug	[5]
TOK-001	DMVJWPR	Phase 2	Small molecular drug	[102]
Vudalimab	DMSEEI0	Phase 2	Bispecific antibody	[103]
Xentuzumab	DM4ZIDH	Phase 2	NA	[63]
YM-598	DMUPJWH	Phase 2	NA	[104]
ZEN-3694	DM6VQTF	Phase 2	Small molecular drug	[105]
Zilovertamab	DMMEJ6K	Phase 2	Monoclonal antibody	[106]
177-Lu-PSMA-R2	DMF4AOE	Phase 1/2	Small molecular drug	[107]
177Lu-labelled PSMA-R2	DMWPD7N	Phase 1/2	Radiopharmaceutical therapy agent	[107]
64Cu-SAR-bisPSMA	DMGUHFN	Phase 1/2	NA	[108]
67Cu-SAR-bisPSMA	DMMYR39	Phase 1/2	NA	[109]
Acapatamab	DMTAI2F	Phase 1/2	Antibody	[110]
ADXS-PSA	DMOPVET	Phase 1/2	Antibody	[74]
Anti-OX40 monoclonal antibody	DMK2WK5	Phase 1/2	NA	[111]
APC-100	DM71I53	Phase 1/2	NA	[112]
ARV-110	DMYCID5	Phase 1/2	Small molecular drug	[113]
ARV-766	DM8IUV1	Phase 1/2	Small molecule	[114]
ASP-9521	DM8V0UL	Phase 1/2	NA	[115]
BPX-601	DMV9QGW	Phase 1/2	CAR T Cell Therapy	[116]
BXCL701	DMBPUIK	Phase 1/2	NA	[117]
CAR-T Cells targeting EpCAM	DMREQCF	Phase 1/2	CAR T Cell Therapy	[118]
CDCA1-derived epitope peptide vaccine	DMQZOA9	Phase 1/2	NA	[119]
CFG920	DM2BXDU	Phase 1/2	NA	[120]
CPI-1205	DM3XWJ8	Phase 1/2	NA	[5]
CreaVax-PC	DMNRL9I	Phase 1/2	NA	[121]
Eltanexor oral	DM7CLEZ	Phase 1/2	NA	[5]
Encapsulated cell therapy	DMC0A4W	Phase 1/2	NA	[122]
GX-301	DMVZ5BO	Phase 1/2	NA	[123]
IONIS-AR-2.5Rx	DMF2DMS	Phase 1/2	RNA interference	[124]
LAVA-1207	DMQIZ8V	Phase 1/2	NA	[125]
MK-5684	DMU93NS	Phase 1/2	Small molecule	[126]
MLN-2704	DMGC96P	Phase 1/2	Antibody	[127]
NBTXR3	DMME0MV	Phase 1/2	NA	[5]
ONC1-13B	DM2DHJS	Phase 1/2	NA	[128]
Onyvax-105	DMGIN7J	Phase 1/2	Vaccine	[129]
Padoporfin photodynamic therapy	DM9TC7H	Phase 1/2	NA	[130]
PEP-223/CoVaccine HT	DMM9L1R	Phase 1/2	Vaccine	[131]
Prostate cancer vaccine	DMRSRBL	Phase 1/2	NA	[132]
PVAXrcPSAv53l	DM88K5Q	Phase 1/2	NA	[133]
REGN4336	DMAKSZW	Phase 1/2	Bispecific antibody	[134]
REGN5678	DM0Y6WU	Phase 1/2	Antibody	[135]
REIC gene therapy	DM5MFHO	Phase 1/2	NA	[136]
REIC gene therapy vaccine	DM4DYD9	Phase 1/2	NA	[74]
SHR2554	DMMUCH0	Phase 1/2	Small molecular drug	[137]
TmPSMA	DMRSJOJ	Phase 1/2	Cell therapy	[138]
TRC-253	DMXI8CD	Phase 1/2	NA	[139]
VERU-100	DMYXE9C	Phase 1/2	NA	[140]
131-I-MIP-1095	DMAF638	Phase 1	NA	[5]
177Lu-labelled CTT-1403	DMM2V74	Phase 1	Radiopharmaceutical therapy agent	[141]
225Ac-J591	DMVHFE1	Phase 1	Antibody	[142]
227Th-labelled PSMA-TTC	DM7L45S	Phase 1	Radiopharmaceutical therapy agent	[143]
99mTc-MIP-1405	DMJB6E2	Phase 1	NA	[144]
ABBV-744	DMTEA9C	Phase 1	NA	[5]
AC0176	DM9WJFX	Phase 1	PROTAC	[145]
Ad-OC-hsvTK/valacyclovir	DM9GLHO	Phase 1	NA	[146]
Ad5-TRAIL	DM2UMGE	Phase 1	NA	[147]
Ad5CMV-NIS	DMFTGHX	Phase 1	NA	[148]
AdRTVP-1	DMYHIAR	Phase 1	NA	[149]
ADXS-504	DM6YPWS	Phase 1	Vaccine	[150]
AMG 340	DM3VRX6	Phase 1	Bispecific T-cell engager	[151]
AMG 509	DM2POGY	Phase 1	Antibody	[152]
Anti-OX40 mab	DMFZ52G	Phase 1	Monoclonal antibody	[153]
APVO414	DMXDMH5	Phase 1	NA	[5]
ASG-5ME	DMD0BMN	Phase 1	Antibody	[154]
Autologous T-cell therapy	DMOAET3	Phase 1	Antibody	[155]
AZD-3514	DMC1BXV	Phase 1	NA	[156]
BAY-1075553	DM8U3Q2	Phase 1	NA	[157]
BMTP-11	DMB6FMH	Phase 1	NA	[158]
BPX-101	DM51MSD	Phase 1	Vaccine	[159]
BPX-201	DMPLVZO	Phase 1	NA	[160]
CC-94676	DM4581B	Phase 1	NA	[161]
CCW702	DMPTYE6	Phase 1	Antibody	[162]
CDNA vaccine	DM8DWOL	Phase 1	NA	[163]
CTT1403	DMAV86R	Phase 1	Small molecular drug	[141]
CYT-500	DMAO7WM	Phase 1	NA	[164]
DST-2970	DM69ZBU	Phase 1	Small molecular drug	[165]
EPI-7386	DMUFN29	Phase 1	Small molecular drug	[166]
EZN-4176	DMNPS59	Phase 1	Antisense drug	[167]
FP-253-GDEPT	DM8BG0M	Phase 1	NA	[168]
FT-7051	DMCK3OI	Phase 1	NA	[169]
GSK2636771	DMCBGLW	Phase 1	Small molecular drug	[5]
HPN424	DMLZDVR	Phase 1	NA	[170]
Human and mouse PSMA DNA vaccines	DM3HNV1	Phase 1	NA	[171]
IL-12 gene therapy	DMCCMU5	Phase 1	NA	[172]
INO-5150	DM3U6OD	Phase 1	NA	[74]
Iofolastat I-124	DMNBPKS	Phase 1	Small molecular drug	[173]
IRX4204	DM9SCME	Phase 1	Small molecular drug	[174]
ISIS-AR	DM8P3N5	Phase 1	Antisense drug	[175]
JNJ-26854165	DMNSJ3C	Phase 1	Small molecular drug	[176]
JNJ-64041809	DM34KVS	Phase 1	NA	[5]
JNJ-69086420	DM6VR13	Phase 1	Antibody	[177]
JNJ-75229414	DMV6XBC	Phase 1	CAR-T cell therapy	[178]
JNJ-78278343	DM27FAN	Phase 1	Bispecific antibody	[179]
JNJ-80038114	DMOF322	Phase 1	NA	[180]
KPG-121	DMSKI8W	Phase 1	Small molecular drug	[181]
LY01005	DMT92P5	Phase 1	NA	[5]
MB-105	DMVGTP6	Phase 1	CAR T Cell Therapy	[182]
MEDI3726	DMGRS0L	Phase 1	NA	[5]
MIP-1095	DMELSIU	Phase 1	Small molecule	[183]
MVA-BN Breast	DMFMW5C	Phase 1	NA	[184]
MVI-118	DM25935	Phase 1	NA	[5]
MVT-5873	DMEJ4C1	Phase 1	NA	[5]
ORIC-944	DM0L8R9	Phase 1	Small molecule	[185]
P-PSMA-101	DMY2GDQ	Phase 1	CAR T Cell Therapy	[186]
PAN-301-1	DMZCDF3	Phase 1	NA	[74]
PCUR-101	DMV4LAV	Phase 1	NA	[5]
PF-06753512	DMXO1T5	Phase 1	NA	[74]
PF-06821497	DML3WT6	Phase 1	Small molecular drug	[187]
PF-07220060	DMPKO84	Phase 1	NA	[188]
Prohibitin-TP-01	DMT2RZ6	Phase 1	NA	[189]
ProscaVax	DMGUVNV	Phase 1	NA	[74]
PSA/IL-2/GM-CSF vaccine	DMF2IBC	Phase 1	NA	[5]
PSMA CAR-T cell therapy	DM8Y1M9	Phase 1	CAR T Cell Therapy	[190]
PSMA protein vaccine	DMLA57S	Phase 1	NA	[191]
PSMA subunit vaccine	DMRHQTU	Phase 1	Vaccine	[192]
PSMA VRP	DMZ82K8	Phase 1	Vaccine	[193]
PSMA VRP therapeutic vaccine	DMCOI0G	Phase 1	NA	[194]
PSMA-targeted tubulysin B conjugates	DMOYX6W	Phase 1	NA	[195]
PSMA-VRP	DM03O8T	Phase 1	Vaccine	[196]
Recombinant soluble PSMA protein vaccine	DMVSDCX	Phase 1	NA	[197]
RG7450	DM1NHEA	Phase 1	NA	[198]
STX 64	DMJAPRK	Phase 1	Small molecular drug	[199]
TARP peptide vaccines	DM2HOCS	Phase 1	NA	[200]
TARP peptide-pulsed autologous dendritic cell vaccine	DMWWPZS	Phase 1	NA	[201]
TAS3681	DMFG6ML	Phase 1	NA	[5]
TeloB-Vax	DMZG9U0	Phase 1	NA	[202]
Tigapotide	DMSVO92	Phase 1	NA	[203]
TSD-0014	DMD0KPL	Phase 1	NA	[204]
ZEN003694	DM72GZV	Phase 1	Small molecular drug	[205]
Methylselenocysteine	DMAAB9A	Clinical Trial	Small molecular drug	[206]

This Disease is Treated as An Indication in 2 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27215781-Compound-37	DM0L68P	Patented	Small molecular drug	[207]
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[208]

This Disease is Treated as An Indication in 21 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS 275291	DMKSFPE	Discontinued in Phase 3	Small molecular drug	[209]
Miboplatin	DM1EB5D	Discontinued in Phase 3	NA	[210]
Zibotentan	DMIK6C9	Discontinued in Phase 3	Small molecular drug	[211]
CG7060	DMPSX4Q	Discontinued in Phase 2	NA	[212]
CV-787	DM5CWSX	Discontinued in Phase 2	NA	[213]
Eladem	DM8HOVS	Discontinued in Phase 2	NA	[214]
Gonadimmune	DM9MEAY	Discontinued in Phase 2	NA	[215]
MDX-070	DM9ZEGT	Discontinued in Phase 2	Antibody	[216]
Norelin	DMYCLZR	Discontinued in Phase 2	NA	[217]
HMN-214	DMH4ANG	Discontinued in Phase 1	Small molecular drug	[218]
NBI-42902	DM4MTPU	Discontinued in Phase 1	Small molecular drug	[219]
Rhodamine-123	DMQAK6T	Discontinued in Phase 1	Small molecular drug	[220]
TAK-683	DMRD8HK	Discontinued in Phase 1	Small molecular drug	[221]
TAK-810	DMCFOSG	Discontinued in Phase 1	NA	[222]
ARGENT	DM9FG4E	Terminated	NA	[227]
BBR 3576	DM86OHM	Terminated	Small molecular drug	[228]
CB-1267	DM75KBM	Terminated	NA	[229]
EC-708	DMUESI1	Terminated	NA	[230]
Hormone-dependent vaccine	DMO2B6T	Terminated	NA	[231]
LG-2293	DMNXKR2	Terminated	NA	[232]
LN-030	DM4LWB4	Terminated	NA	[233]

This Disease is Treated as An Indication in 4 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ANAVEX 1007	DM2U16Z	Preclinical	NA	[223]
Dendritic cell vaccine	DMTK2FG	Preclinical	NA	[224]
IRX-4	DMMUVAF	Preclinical	NA	[225]
VPM-4-001	DMZHAVG	Preclinical	Vaccine	[226]

This Disease is Treated as An Indication in 46 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-EC-0652	DMAGTL1	Investigative	NA	[234]
99mTc-MIP-1340	DMQOFX2	Investigative	NA	[234]
AA-123	DMW73A8	Investigative	NA	[235]
Androgen	DM19A89	Investigative	Small molecular drug	[25]
Andromustine	DMHL0ID	Investigative	NA	[25]
ANG-3407	DMVI93X	Investigative	NA	[236]
ANT-G12	DMDB7ID	Investigative	NA	[25]
Anti-PSA mabs	DMO21T7	Investigative	Antibody	[237]
APC-200	DMJSTI4	Investigative	NA	[25]
APC-300	DMNIEHV	Investigative	NA	[238]
APH-0701	DMBT1WS	Investigative	NA	[25]
ATGC-OP0359	DMT5LHJ	Investigative	NA	[25]
Atu-111	DM60C6V	Investigative	NA	[25]
AVP-6	DMGOSPW	Investigative	NA	[25]
CH-4933468	DM1ZF3Y	Investigative	Small molecular drug	[25]
DL-3	DME9ODX	Investigative	NA	[25]
DOX-PSASP-BBN-RGD prodrugs	DMR22EI	Investigative	NA	[25]
EPI-001	DMYWV81	Investigative	Small molecular drug	[239]
G-115	DMC0UAO	Investigative	NA	[25]
Gamma-tocotrienol	DMOQKJ0	Investigative	Small molecular drug	[25]
GSK-650394	DMNRP2L	Investigative	Small molecular drug	[240]
Her2- and PSA-targeted TGX-D1	DM0VC84	Investigative	NA	[241]
J591-Ac-225	DMXC319	Investigative	Antibody	[234]
JX-2011	DMR3KP5	Investigative	NA	[25]
Lm Prostate	DM5BDLP	Investigative	NA	[25]
LXT-101	DM0LKPE	Investigative	NA	[242]
MCTP-39	DMXHAVK	Investigative	Small molecular drug	[243]
MDX-1147	DM9ZTX4	Investigative	NA	[234]
MIP-1375	DM0J38I	Investigative	NA	[234]
NBI-29	DM55W1J	Investigative	NA	[25]
OGX-225	DMIEH7F	Investigative	NA	[25]
Prostaganin	DMIDG94	Investigative	NA	[25]
ProstaRex	DM9GFOM	Investigative	NA	[237]
Prostatix	DMBL16B	Investigative	NA	[25]
Prostaview	DM9XEYP	Investigative	NA	[25]
ProTarg	DM3TX4R	Investigative	NA	[25]
Radiolabeled anti-PSMA huJ591 minibodies	DMNOTO6	Investigative	NA	[25]
ShRNA molecule silencing DNAPK radiosensitizer	DMTKHR3	Investigative	Aptamer	[244]
SPIO-Stasix nanoparticles	DMWUT8D	Investigative	NA	[25]
SX-ARPC	DMEA36L	Investigative	NA	[245]
VN/107-1	DMJRI6A	Investigative	NA	[236]
VTT-201	DMT967L	Investigative	NA	[237]
WJ-9708011	DM3M807	Investigative	NA	[25]
Zn-DPA-P	DM2OPQS	Investigative	NA	[25]
[111In]SRVII23	DMMCD93	Investigative	NA	[25]
[18F]DCFPyL	DMIH2BS	Investigative	Small molecular drug	[25]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1985 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ULK4	OTQCJNRJ	Limited	Autosomal dominant	[247]
XPO7	OTCQF61N	Limited	Autosomal dominant	[247]
ABHD5	OTY829Z3	Limited	Biomarker	[1355]
ABR	OTZQK8JF	Limited	Biomarker	[1356]
ACOXL	OTW680HT	Limited	Biomarker	[1357]
ACTR2	OT3C8U5T	Limited	Altered Expression	[1358]
ADI1	OT8IOD03	Limited	Biomarker	[1359]
AGAP2	OTEYO9TM	Limited	Altered Expression	[1360]
AIP	OTDJ3OSV	Limited	Biomarker	[1361]
AKAP13	OTOZAR14	Limited	Biomarker	[1362]
ALDH3A1	OTAYZZE6	Limited	Biomarker	[1363]
ALOXE3	OT76J52A	Limited	Biomarker	[1364]
AMH	OT5FH4BD	Limited	Biomarker	[256]
APAF1	OTJWIVY0	Limited	Biomarker	[1365]
APOA5	OTEVKLVA	Limited	Biomarker	[1366]
APOBEC3B	OTHLNI51	Limited	Altered Expression	[1367]
ARHGAP1	OT0H2ZBZ	Limited	Biomarker	[1368]
ARHGDIA	OTEXWJDO	Limited	Biomarker	[1369]
ARID4A	OT1XKBZ0	Limited	Biomarker	[344]
ARNT	OTMSIEZY	Limited	Biomarker	[1370]
ARSL	OTF1VTCR	Limited	Biomarker	[1371]
ASAH1	OT1DNGXL	Limited	Biomarker	[1372]
ATAD3A	OTWF6HBP	Limited	Biomarker	[1373]
ATG5	OT4T5SMS	Limited	Biomarker	[1009]
ATM	OTQVOHLT	Limited	Autosomal dominant	[247]
ATP6	OTPHOGLX	Limited	Biomarker	[1374]
ATP6V0C	OTKPL09B	Limited	Biomarker	[1375]
ATPAF1	OTG1V44F	Limited	Genetic Variation	[1376]
ATXN1	OTQF0HNR	Limited	Biomarker	[1377]
AZIN2	OT8OB7CG	Limited	Biomarker	[1378]
BAD	OT63ERYM	Limited	Posttranslational Modification	[1379]
BAG1	OTRQNIA4	Limited	Biomarker	[1380]
BAG5	OT0J97C6	Limited	Altered Expression	[1381]
BBS2	OTPF9JIB	Limited	Altered Expression	[1382]
BCAR1	OTKT2C2N	Limited	Biomarker	[1383]
BCAS2	OTRMF2WY	Limited	Altered Expression	[1384]
BCL10	OT47MCLI	Limited	Altered Expression	[1385]
BCL3	OT1M5B95	Limited	Altered Expression	[1386]
BCR	OTCN76C1	Limited	Biomarker	[1387]
BGLAP	OTK1YLWQ	Limited	Biomarker	[1388]
BNIP2	OTVZD4H6	Limited	Biomarker	[1368]
BNIP3	OT4SO7J4	Limited	Posttranslational Modification	[1389]
BNIP3L	OTJKOMXE	Limited	Biomarker	[1390]
BPIFA2	OTLFSDZD	Limited	Biomarker	[1391]
BPY2	OT2WQPNQ	Limited	Altered Expression	[1392]
BTG3	OT9ANHVT	Limited	Altered Expression	[1393]
BUB1B	OT8KME51	Limited	Biomarker	[1394]
BUD13	OTXG6MX5	Limited	Genetic Variation	[1366]
CADM1	OTRWG9QS	Limited	Altered Expression	[1395]
CALD1	OTNJKJ6Q	Limited	Posttranslational Modification	[1396]
CAND1	OTGB6NU0	Limited	Biomarker	[424]
CAND2	OTOMOG3R	Limited	Biomarker	[287]
CANX	OTYP1F6J	Limited	Biomarker	[1397]
CAPNS1	OT95EBBD	Limited	Altered Expression	[1398]
CARMIL3	OT4ZN0K3	Limited	Altered Expression	[1399]
CBFA2T2	OTNOIB23	Limited	Altered Expression	[1400]
CBX1	OT2L4XZX	Limited	Biomarker	[1401]
CCDC8	OTO295IH	Limited	Biomarker	[1402]
CCHCR1	OT22C116	Limited	Genetic Variation	[1403]
CD109	OTDADBM4	Limited	Biomarker	[425]
CD200R1	OT65Q9M6	Limited	Biomarker	[338]
CD63	OT2UGZA9	Limited	Biomarker	[1404]
CDC42	OT5QBC5M	Limited	Biomarker	[1405]
CDC6	OTX93FE7	Limited	Altered Expression	[1406]
CDH13	OTD2CYM5	Limited	Posttranslational Modification	[1407]
CDK16	OTUBXIIT	Limited	Biomarker	[1408]
CENPF	OT7AG0SW	Limited	Biomarker	[1409]
CEP57	OTPOHLIX	Limited	Altered Expression	[1410]
CHD1	OT9R9G0H	Limited	Genetic Variation	[1411]
CLDN11	OTNN6UTL	Limited	Biomarker	[1412]
CLPTM1L	OTDJWQXI	Limited	Biomarker	[1413]
CMIP	OTZN8Z4A	Limited	Biomarker	[1414]
CMTM3	OTS75IGC	Limited	Biomarker	[1415]
CNN2	OTH3CSXA	Limited	Biomarker	[1416]
COL6A1	OTYKSCOB	Limited	Altered Expression	[1417]
CPD	OT2CS64Y	Limited	Altered Expression	[1418]
CPNE3	OTCR3WG2	Limited	Biomarker	[1419]
CREB3	OT9617UO	Limited	Biomarker	[1420]
CREB3L4	OTSGQGT2	Limited	Biomarker	[1421]
CRIM1	OTTZNV6Y	Limited	Altered Expression	[462]
CRYBB2	OTL0Z8E6	Limited	Genetic Variation	[1422]
CSRP1	OTUS7RM2	Limited	Biomarker	[1423]
CTBP2	OTGZGT87	Limited	Biomarker	[1424]
CUL4B	OT2QX4DO	Limited	Altered Expression	[1425]
CUX1	OTU1LCNJ	Limited	Altered Expression	[896]
CUZD1	OTDQJVZ8	Limited	Altered Expression	[1426]
CXCL14	OTM189TA	Limited	Altered Expression	[1427]
CXCL16	OTD49T9R	Limited	Biomarker	[1428]
CYB5R2	OTTLM7XN	Limited	Posttranslational Modification	[1429]
DAB2IP	OTF456VC	Limited	Genetic Variation	[1430]
DAXX	OTX6O7PL	Limited	Biomarker	[1431]
DCC	OT2C1SHW	Limited	Altered Expression	[1432]
DCTN4	OTM7C943	Limited	Biomarker	[465]
DDX19B	OT2084EJ	Limited	Biomarker	[1433]
DESI1	OTFNIW98	Limited	Genetic Variation	[1434]
DIAPH3	OTPOT23F	Limited	Biomarker	[1435]
DLG5	OTU9Z17K	Limited	Biomarker	[1436]
DMBT1	OTVNU9D9	Limited	Altered Expression	[1437]
DNASE1L1	OT9ZOFN9	Limited	Biomarker	[1438]
DPYSL3	OTINJV20	Limited	Posttranslational Modification	[1439]
DST	OTHZBM4X	Limited	Genetic Variation	[1440]
DUSP2	OTH54FMR	Limited	Altered Expression	[248]
DUSP6	OT4H6RKW	Limited	Biomarker	[1441]
EFCAB13	OTYZ859V	Limited	Genetic Variation	[864]
EFEMP2	OT0I2B4J	Limited	Biomarker	[1442]
EFS	OT06O7XL	Limited	Biomarker	[1443]
EHF	OTY6TPWD	Limited	Altered Expression	[1444]
EIF2S1	OTM0GDTP	Limited	Altered Expression	[1445]
EIF3D	OTDOMP80	Limited	Biomarker	[1446]
ELK1	OTH9MXD6	Limited	Biomarker	[871]
ELOC	OT0XHHWP	Limited	Biomarker	[1447]
EMSY	OTBQ3KQE	Limited	Genetic Variation	[495]
ENO1	OTB1KWJS	Limited	Biomarker	[1448]
ERCC5	OTQAKFJM	Limited	Genetic Variation	[995]
ETV3	OTEN03BM	Limited	Biomarker	[344]
EWSR1	OT7SRHV3	Limited	Biomarker	[1449]
EXO1	OTI87RS5	Limited	Biomarker	[1450]
EXOC4	OT5EWXAN	Limited	Genetic Variation	[1451]
FADD	OTV7GFHH	Limited	Posttranslational Modification	[1452]
FASTK	OTTHFZMP	Limited	Biomarker	[1453]
FASTKD2	OTD635WX	Limited	Biomarker	[1453]
FBLN1	OT5MHHOP	Limited	Biomarker	[1454]
FBRS	OTUVH446	Limited	Biomarker	[1455]
FBXL4	OTZECCIQ	Limited	Biomarker	[1456]
FBXO8	OTZNGJGW	Limited	Biomarker	[1455]
FGF11	OT6513W2	Limited	Biomarker	[1457]
FGF12	OTBM9QIO	Limited	Biomarker	[287]
FGF9	OT2SKDGM	Limited	Biomarker	[1458]
FILIP1L	OTPY8IMS	Limited	Altered Expression	[1459]
FOXA1	OTEBY0TD	Limited	Genetic Variation	[1460]
FOXP2	OTVX6A59	Limited	Altered Expression	[1461]
FOXP4	OTHCGIEZ	Limited	Altered Expression	[1462]
FUT6	OTBZUQ7F	Limited	Biomarker	[1463]
GADD45G	OT8V1J4M	Limited	Biomarker	[1464]
GADD45GIP1	OT4IZ4TP	Limited	Biomarker	[1465]
GADL1	OTJM4A0R	Limited	Biomarker	[1378]
GALNT3	OT7M67WT	Limited	Biomarker	[858]
GCNT1	OTF6OC66	Limited	Altered Expression	[1466]
GDE1	OTU6FSBF	Limited	Altered Expression	[1467]
GDF9	OTNTVKVU	Limited	Biomarker	[1468]
GFRA1	OT3WBVYB	Limited	Biomarker	[1469]
GINS1	OTVQZMMQ	Limited	Altered Expression	[1470]
GNRH2	OTORRM53	Limited	Altered Expression	[1471]
GOLM1	OTOZSV6O	Limited	Altered Expression	[640]
GOLPH3	OTDLGYM3	Limited	Altered Expression	[1472]
GPR158	OTYOC1RQ	Limited	Biomarker	[1473]
GTF2H1	OTCRXC6B	Limited	Biomarker	[465]
GTF2H2	OTK72L9I	Limited	Altered Expression	[1474]
H1-0	OTRLJK4Z	Limited	Biomarker	[1475]
H1-1	OTSS815G	Limited	Biomarker	[1476]
HCLS1	OTX7WGYN	Limited	Altered Expression	[896]
HERPUD1	OT9EROL6	Limited	Biomarker	[858]
HES5	OTW7JEHV	Limited	Altered Expression	[1477]
HNRNPH1	OTFRWOLM	Limited	Biomarker	[1478]
HOOK3	OT0OE8SX	Limited	Altered Expression	[1479]
HOXA1	OTMSOJ7D	Limited	Biomarker	[1480]
HOXA10	OTB6GQ09	Limited	Biomarker	[1481]
HOXC6	OTBCRAZV	Limited	Altered Expression	[1482]
HPR	OTXSC9UB	Limited	Biomarker	[1483]
HRK	OTR4GWJ0	Limited	Posttranslational Modification	[1484]
HSF2	OTXNJIJ9	Limited	Altered Expression	[1485]
HSPA1A	OTKGIE76	Limited	Biomarker	[1244]
HSPA1L	OTC2V1K6	Limited	Genetic Variation	[1486]
HSPBAP1	OTRYDAZX	Limited	Biomarker	[1487]
ID3	OTUULW5Z	Limited	Altered Expression	[1488]
ID4	OTPMJ39I	Limited	Altered Expression	[1489]
IFI16	OT4SPU0U	Limited	Altered Expression	[1490]
IFNGR1	OTCTQBWW	Limited	Biomarker	[1491]
IGSF8	OTU22IKI	Limited	Genetic Variation	[1492]
IL17RA	OTVVI8ER	Limited	Biomarker	[1493]
IL17RB	OT0KDNSF	Limited	Biomarker	[359]
IL17RD	OTKD9XST	Limited	Biomarker	[1494]
ING4	OT0VVG4V	Limited	Biomarker	[1495]
INHA	OT7HWCO3	Limited	Altered Expression	[1496]
INPP4B	OTLROA7G	Limited	Altered Expression	[1497]
IRF2	OTAZRUW3	Limited	Altered Expression	[1498]
IRF9	OTK4MYQJ	Limited	Biomarker	[1499]
JAG1	OT3LGT6K	Limited	Biomarker	[1500]
JUND	OTNKACJD	Limited	Altered Expression	[825]
KAT8	OT5LPQTR	Limited	Genetic Variation	[1501]
KDM6A	OTZM3MJJ	Limited	Biomarker	[1502]
KHSRP	OTDHZARB	Limited	Altered Expression	[896]
KIF2A	OT2WQ6QD	Limited	Biomarker	[1503]
KIF2B	OTLPAX4N	Limited	Genetic Variation	[1504]
KIF3A	OTMUBSSK	Limited	Altered Expression	[1505]
KLF8	OTUC5CDB	Limited	Biomarker	[1506]
KLK10	OTD573EL	Limited	Altered Expression	[1507]
KLK12	OTNYK59J	Limited	Altered Expression	[1508]
KLK13	OT8LOD2U	Limited	Genetic Variation	[1509]
KLK15	OT7BVG17	Limited	Biomarker	[1510]
KLLN	OTV3FPH0	Limited	Altered Expression	[1511]
KRT8	OTTM4X11	Limited	Altered Expression	[1512]
LAMB1	OT6J9LJR	Limited	Biomarker	[1513]
LAMC1	OTIG527N	Limited	Biomarker	[1514]
LDAH	OTXRU9XQ	Limited	Biomarker	[1515]
LDHB	OT9B1CT3	Limited	Biomarker	[1516]
LGALS7	OTMSVI7R	Limited	Altered Expression	[1517]
LMCD1	OT3AWE8O	Limited	Biomarker	[287]
LMLN	OTQF0JPY	Limited	Biomarker	[1518]
LMTK2	OT93MVIC	Limited	Biomarker	[1519]
LPCAT1	OTCV7AGV	Limited	Altered Expression	[1520]
LPCAT2	OT6NTBAA	Limited	Biomarker	[1476]
LPIN1	OTQ75KF2	Limited	Altered Expression	[1521]
LRP1B	OT4YZG2N	Limited	Genetic Variation	[1522]
LRRC58	OTJ9JMKX	Limited	Biomarker	[287]
LYPD4	OTYNO8BS	Limited	Genetic Variation	[1523]
MAN2C1	OT17VT8D	Limited	Biomarker	[1524]
MAP2K4	OTZPZX11	Limited	Altered Expression	[1525]
MARCKSL1	OT13J2FM	Limited	Altered Expression	[1526]
MARCO	OT0NW2Q0	Limited	Altered Expression	[1527]
MB	OTYWYL2D	Limited	Altered Expression	[1528]
MBD1	OTD19VO6	Limited	Biomarker	[344]
MBD2	OTUQPP0R	Limited	Biomarker	[1529]
MCM2	OTGGORIQ	Limited	Biomarker	[1530]
MDC1	OTEUQH4J	Limited	Biomarker	[1531]
MEAF6	OTAFDRYT	Limited	Altered Expression	[1532]
MED15	OT0D0JVD	Limited	Altered Expression	[1533]
MEIS1	OTH9DKAD	Limited	Biomarker	[1534]
MEP1A	OTY2Z48T	Limited	Altered Expression	[1535]
MEX3D	OTAUWRK7	Limited	Genetic Variation	[1376]
MFN1	OTCBXQZF	Limited	Biomarker	[1536]
MLH1	OTG5XDD8	Limited	Autosomal dominant	[247]
MMP26	OT9O89KU	Limited	Biomarker	[1537]
MMS19	OTAXB34N	Limited	Biomarker	[1538]
MNX1	OTXP9FH1	Limited	Altered Expression	[1082]
MPC2	OT0GHXGG	Limited	Altered Expression	[1539]
MSH6	OT46FP09	Limited	Autosomal dominant	[247]
MSN	OTZJ4J6G	Limited	Biomarker	[333]
MT1B	OTUA4FFH	Limited	Altered Expression	[393]
MT1E	OTXJKU4Y	Limited	Altered Expression	[393]
MT1F	OTZVUYG1	Limited	Altered Expression	[393]
MT1H	OT0MVBM6	Limited	Altered Expression	[393]
MT1M	OTVT8PLU	Limited	Altered Expression	[393]
MUC2	OT3X4QVX	Limited	Biomarker	[1540]
MUC4	OTLT11V1	Limited	Biomarker	[1541]
MUC6	OTPVL723	Limited	Biomarker	[1540]
MYBBP1A	OTIVEMIU	Limited	Biomarker	[344]
MYDGF	OT9HRPL6	Limited	Biomarker	[894]
MYH6	OT3YNCH1	Limited	Biomarker	[1542]
MYL9	OT6B22JB	Limited	Altered Expression	[1543]
MYO6	OTJQYRC7	Limited	Biomarker	[1542]
NBL1	OTT37U4O	Limited	Altered Expression	[1544]
NBN	OT73B5MD	Limited	Autosomal dominant	[247]
NCOA6	OTOMIGTV	Limited	Altered Expression	[1545]
NCOR1	OT04XNOU	Limited	Biomarker	[344]
NCOR2	OTY917X0	Limited	Biomarker	[1546]
NDC80	OTS7D306	Limited	Altered Expression	[1547]
NDRG1	OTVO66BO	Limited	Biomarker	[1144]
NECTIN2	OTIE0W6O	Limited	Altered Expression	[1161]
NEU1	OTH9BY8Y	Limited	Biomarker	[1548]
NEU3	OTQ5PQOW	Limited	Biomarker	[1549]
NEURL1	OT2C4P70	Limited	Biomarker	[1548]
NFIX	OT1DPZAE	Limited	Biomarker	[862]
NHS	OTKE8QAT	Limited	Biomarker	[1550]
NID1	OTKLBLS6	Limited	Biomarker	[1513]
NOL8	OT6RZLH3	Limited	Biomarker	[1551]
NOX5	OTHTH59G	Limited	Altered Expression	[1552]
NPL	OTA7P0TO	Limited	Biomarker	[1553]
NUP62	OTMN63DH	Limited	Biomarker	[465]
NUPR1	OT4FU8C0	Limited	Biomarker	[1554]
NWD1	OT4JMFPH	Limited	Altered Expression	[1555]
OAS1	OT8ZLOCY	Limited	Genetic Variation	[1556]
OPRPN	OT6K1ZD6	Limited	Biomarker	[439]
OSBPL10	OT0TFMBE	Limited	Biomarker	[287]
OSCP1	OTZ4IFGJ	Limited	Biomarker	[1557]
OSR1	OTB19LEQ	Limited	Genetic Variation	[1558]
PAEP	OTQA0NV4	Limited	Biomarker	[1559]
PAGE1	OT7SQGM8	Limited	Biomarker	[1560]
PALB2	OT6DNDBG	Limited	Genetic Variation	[1561]
PARD3	OTH5BPLO	Limited	Biomarker	[1362]
PAX6	OTOC9876	Limited	Biomarker	[344]
PBX1	OTORABGO	Limited	Biomarker	[1562]
PBX3	OT8WMVM4	Limited	Altered Expression	[1563]
PCDH17	OTRK0M05	Limited	Posttranslational Modification	[1564]
PCDH8	OTDDOQM2	Limited	Biomarker	[1565]
PCLAF	OTMVIOUU	Limited	Biomarker	[1566]
PDCD5	OT6T2DDL	Limited	Biomarker	[1567]
PDIA3	OTHPQ0Q3	Limited	Biomarker	[1568]
PENK	OT8P3HMP	Limited	Biomarker	[1569]
PER2	OTU2B1DJ	Limited	Altered Expression	[1570]
PHF21B	OTU5GLCQ	Limited	Altered Expression	[1571]
PIAS3	OT3TWH9R	Limited	Altered Expression	[1201]
PKHD1	OTAH8SMF	Limited	Biomarker	[1572]
PLB1	OTZ6TTYV	Limited	Biomarker	[421]
PLRG1	OTIVZ5LL	Limited	Biomarker	[439]
PLXNA1	OTN0BING	Limited	Altered Expression	[1573]
PMS2	OTNLWTMI	Limited	Autosomal dominant	[247]
POLR2A	OTHJQ1DZ	Limited	Biomarker	[1574]
POTEF	OTV3WXYE	Limited	Biomarker	[1296]
PPFIBP2	OTXQO55Y	Limited	Genetic Variation	[1575]
PPL	OTTM4WDO	Limited	Biomarker	[1576]
PPP1R2	OTNLOUQR	Limited	Biomarker	[1577]
PPP2R2A	OT9297OG	Limited	Biomarker	[1578]
PRDX6	OTS8KC8A	Limited	Altered Expression	[1579]
PRKAA2	OTU1KZPV	Limited	Biomarker	[1580]
PRKAB1	OT1OG4QZ	Limited	Biomarker	[1580]
PRKAR2A	OTZ7P17Z	Limited	Biomarker	[1581]
PRRT2	OTCJUBDO	Limited	Biomarker	[429]
PRY	OTO6GHZU	Limited	Posttranslational Modification	[1392]
PSAP	OTUOEKY7	Limited	Biomarker	[1582]
PSMB1	OTYRFBAH	Limited	Biomarker	[1583]
PSMG1	OTZ5I6UM	Limited	Altered Expression	[248]
PSPH	OTV1PVAX	Limited	Biomarker	[1391]
PSPN	OT54LLZJ	Limited	Biomarker	[1391]
PTHLH	OTI1JF13	Limited	Altered Expression	[1584]
PTOV1	OT94WT5X	Limited	Altered Expression	[1585]
PTPRA	OTZA82J1	Limited	Altered Expression	[1586]
PTPRK	OTAP5AT3	Limited	Altered Expression	[1587]
PTTG1	OTIMYS4W	Limited	Altered Expression	[715]
QKI	OTTAUGLB	Limited	Biomarker	[1588]
RAB27A	OT9SQRWY	Limited	Altered Expression	[1589]
RAB27B	OTPF9D0K	Limited	Altered Expression	[1589]
RAB5A	OTFR2KM4	Limited	Biomarker	[1590]
RAD21	OTQS84ZF	Limited	Altered Expression	[1591]
RAD23B	OT0PGOG3	Limited	Biomarker	[398]
RAG1	OTV131E4	Limited	Biomarker	[344]
RAPGEF4	OT59PSSE	Limited	Autosomal dominant	[247]
RARRES1	OTETUPP5	Limited	Altered Expression	[1592]
RASA2	OTL06RG2	Limited	Biomarker	[1593]
RBBP8	OTRHJ3GI	Limited	Altered Expression	[1594]
RDX	OTNSYUN6	Limited	Biomarker	[1595]
REPS2	OTSE3TRP	Limited	Altered Expression	[1596]
RFX6	OT8H77DL	Limited	Genetic Variation	[1597]
RIDA	OTW4098I	Limited	Biomarker	[1391]
RNASEH2B	OT8KHYFY	Limited	Autosomal dominant	[247]
RNF14	OTWX0D0H	Limited	Biomarker	[1598]
RPL10	OTBHOZGC	Limited	Altered Expression	[1573]
RPS19	OTBKGP48	Limited	Biomarker	[1599]
RPS2	OTSMTZVB	Limited	Altered Expression	[1600]
RPS6	OTT4D1LN	Limited	Biomarker	[1601]
RRAD	OTW2O4GD	Limited	Biomarker	[1602]
SAFB	OTGRV2LW	Limited	Altered Expression	[1603]
SCARB2	OTN929M8	Limited	Altered Expression	[1604]
SEC14L2	OTJST64D	Limited	Biomarker	[1605]
SEC62	OTCWEL5F	Limited	Biomarker	[1606]
SEM1	OTASLBM1	Limited	Biomarker	[1607]
SEMA3C	OTEGUY7F	Limited	Biomarker	[1608]
SEPTIN4	OTD16B30	Limited	Biomarker	[1609]
SERPINA3	OT9BP2S0	Limited	Biomarker	[643]
SERPINB2	OT72QLZB	Limited	Altered Expression	[1610]
SETD5	OTRPAVEO	Limited	Biomarker	[287]
SETDB1	OTWVUA1B	Limited	Biomarker	[344]
SFN	OTLJCZ1U	Limited	Biomarker	[1611]
SFRP5	OTLCVVSH	Limited	Altered Expression	[1612]
SGK3	OTQ6QO99	Limited	Biomarker	[1312]
SGSM3	OTIB1P8A	Limited	Biomarker	[965]
SH3KBP1	OTIUA60B	Limited	Altered Expression	[1613]
SHBG	OTPWU5IW	Limited	Biomarker	[1614]
SIAH1	OT29A838	Limited	Biomarker	[1615]
SIAH2	OTKED2XN	Limited	Altered Expression	[1616]
SIGLEC7	OTNDLURR	Limited	Altered Expression	[896]
SKA3	OTLHEVJD	Limited	Altered Expression	[1617]
SKAP2	OTSF44KP	Limited	Biomarker	[1307]
SKI	OT4KJ8F6	Limited	Altered Expression	[1618]
SKIL	OTNBXH32	Limited	Biomarker	[1619]
SLC2A4RG	OTW3LX8D	Limited	Altered Expression	[1620]
SLC35G1	OTKZUA8O	Limited	Genetic Variation	[1434]
SMUG1	OT2YIOCQ	Limited	Biomarker	[1621]
SMURF2	OT3TRVL7	Limited	Biomarker	[1622]
SNPH	OTL6XBFA	Limited	Biomarker	[1623]
SOAT1	OTB4Y5RJ	Limited	Biomarker	[1624]
SOSTDC1	OTAKDNSM	Limited	Posttranslational Modification	[1625]
SOX7	OTOZOFAG	Limited	Altered Expression	[417]
SPAG11A	OTNQ9UB0	Limited	Biomarker	[434]
SPAG5	OTCLJ56M	Limited	Altered Expression	[1626]
SPEN	OT37A2MD	Limited	Biomarker	[1627]
SPON2	OTE7JLNM	Limited	Altered Expression	[1628]
SPRED1	OTKX7P8G	Limited	Altered Expression	[1629]
SPRED2	OTUX685J	Limited	Altered Expression	[1629]
SPRY2	OTH0CRCZ	Limited	Biomarker	[1630]
SSBP2	OTYG1G80	Limited	Altered Expression	[1631]
ST13	OTNML6UP	Limited	Altered Expression	[1632]
STAP2	OTEB1VVI	Limited	Biomarker	[1633]
STEAP3	OTS9GZK5	Limited	Biomarker	[1634]
STXBP3	OTTTYMAQ	Limited	Biomarker	[1391]
SUMO1	OTJFD4P5	Limited	Biomarker	[1635]
SYNPO2	OTC3U0YH	Limited	Biomarker	[1636]
TAC1	OTM842YW	Limited	Altered Expression	[1051]
TAFA4	OT0RHMNG	Limited	Biomarker	[287]
TBC1D9	OTSSCTB5	Limited	Biomarker	[1637]
TBP	OT6C0S52	Limited	Biomarker	[1638]
TCTN1	OTG5KEV8	Limited	Altered Expression	[1639]
TFDP3	OTI4K6MN	Limited	Biomarker	[1640]
TGM4	OTORRCG6	Limited	Biomarker	[1641]
TLCD3B	OTM6EPUS	Limited	Altered Expression	[1642]
TLK1	OTICTXI8	Limited	Biomarker	[985]
TMEM79	OTEC6EFU	Limited	Biomarker	[1357]
TMF1	OT7JY7UF	Limited	Biomarker	[993]
TMPRSS13	OTMAOAP3	Limited	Biomarker	[1518]
TMSB15A	OTSBWCES	Limited	Biomarker	[1643]
TP63	OT0WOOKQ	Limited	Biomarker	[1644]
TP73	OT0LUO47	Limited	Biomarker	[1645]
TRAF1	OTTLM5RU	Limited	Altered Expression	[1646]
TRIB1	OTPEO17G	Limited	Biomarker	[494]
TRPC4AP	OTNJ9IFS	Limited	Biomarker	[1647]
APBB3	OTNUTR0N	Disputed	Biomarker	[1648]
ARL8B	OTD5TJIN	Disputed	Biomarker	[1649]
ATN1	OTNZFLKY	Disputed	Biomarker	[1650]
C17orf49	OTKPULAA	Disputed	Altered Expression	[1651]
CIP2A	OTVS2GXA	Disputed	Biomarker	[1652]
CXCL6	OTFTCQ4O	Disputed	Altered Expression	[1653]
DUOX1	OTQ2AEW0	Disputed	Biomarker	[1654]
EVX1	OT4A84VD	Disputed	Biomarker	[499]
FLAD1	OTY8R02L	Disputed	Biomarker	[504]
FZD4	OTGLZIE0	Disputed	Biomarker	[502]
GAL3ST2	OTZT1PLE	Disputed	Biomarker	[1655]
GTPBP10	OTS82NCA	Disputed	Biomarker	[1656]
HELLS	OTVVV668	Disputed	Altered Expression	[1657]
IMPACT	OTQ923OB	Disputed	Biomarker	[1658]
ING2	OT6H0EWF	Disputed	Biomarker	[1659]
LEF1	OTWS5I5H	Disputed	Altered Expression	[1660]
MED1	OTOO24C4	Disputed	Biomarker	[1661]
MT1G	OTAV1OCR	Disputed	Altered Expression	[393]
MT1X	OT9AKFVS	Disputed	Altered Expression	[393]
NOLC1	OTKDZU0D	Disputed	Biomarker	[1662]
NOP53	OTA2YKO6	Disputed	Biomarker	[1663]
PAGE4	OT2VLWT0	Disputed	Biomarker	[1664]
PEBP4	OTKDCVC6	Disputed	Biomarker	[1665]
PMEPA1	OTY8Z9UF	Disputed	Biomarker	[1666]
POU2F1	OTK7ELJ0	Disputed	Altered Expression	[508]
PRDX1	OTZ3BEC4	Disputed	Biomarker	[1667]
PRMT6	OT5V3XIN	Disputed	Biomarker	[1668]
RAB3GAP1	OT4DQ8F2	Disputed	Biomarker	[1662]
RAMP1	OT7UT2XB	Disputed	Biomarker	[1669]
RAPSN	OTGMSWDQ	Disputed	Biomarker	[504]
RBAK	OTYJ6EAU	Disputed	Altered Expression	[1254]
RBL2	OTBQSOE6	Disputed	Biomarker	[1662]
RBP1	OTRP1MFC	Disputed	Altered Expression	[1670]
RHOU	OTERIAD4	Disputed	Altered Expression	[1031]
S100A1	OT1F2G4J	Disputed	Altered Expression	[1671]
S100A16	OT3ERKQI	Disputed	Altered Expression	[1672]
SALL4	OTC08PR5	Disputed	Biomarker	[1673]
SELENOF	OT2JFB3S	Disputed	Genetic Variation	[1674]
SERBP1	OTZVSU0X	Disputed	Biomarker	[1675]
SFMBT2	OTZQT61Q	Disputed	Altered Expression	[1676]
SHMT1	OTIINA3J	Disputed	Genetic Variation	[1677]
SMAD2	OTC6VB4K	Disputed	Biomarker	[887]
SNAI1	OTDPYAMC	Disputed	Altered Expression	[801]
STK11	OT1YZSP3	Disputed	Biomarker	[1678]
TDRD1	OT0CBCI3	Disputed	Altered Expression	[1679]
THBS4	OTA1T9KK	Disputed	Altered Expression	[1680]
TSC22D1	OTN4GFWD	Disputed	Altered Expression	[1681]
ADAM15	OTZ7VLTP	moderate	Altered Expression	[1682]
ADGRE2	OTUYJVYG	moderate	Altered Expression	[1683]
ADGRE5	OTTSB84Q	moderate	Altered Expression	[1683]
ADIPOR2	OT2HDTL8	moderate	Genetic Variation	[1684]
AIM2	OT86QUI8	moderate	Biomarker	[1685]
ALDH1A3	OT1C9NKQ	moderate	Altered Expression	[1686]
ALDH7A1	OTV57BZD	moderate	Biomarker	[1687]
AMFR	OTQRX7LC	moderate	Biomarker	[1688]
ARVCF	OT78DKOU	moderate	Biomarker	[1689]
ASS1	OT4ZMG0Q	moderate	Biomarker	[1690]
ASXL1	OTX931AW	moderate	Genetic Variation	[1691]
ASXL2	OTNG4E2M	moderate	Biomarker	[1691]
ATF2	OTNIZPEA	moderate	Biomarker	[1692]
AZU1	OTHXU264	moderate	Altered Expression	[1693]
BAG3	OTVXYUDQ	moderate	Altered Expression	[1694]
BHLHE40	OTITX14U	moderate	Biomarker	[1695]
CAMK2N1	OTKCR5XL	moderate	Altered Expression	[1696]
CAP1	OTYM8A2N	moderate	Biomarker	[937]
CAPG	OTJ86KI6	moderate	Biomarker	[1697]
CBX3	OTOP9RLD	moderate	Biomarker	[1698]
CCDC181	OTPE3H8B	moderate	Biomarker	[1699]
CCN3	OTOW5YL4	moderate	Biomarker	[1700]
CDK20	OTOLNN68	moderate	Biomarker	[532]
CDON	OT81X593	moderate	Altered Expression	[1701]
CFHR3	OTYL8SDO	moderate	Biomarker	[1702]
CHI3L1	OT2Z7VJH	moderate	Biomarker	[893]
CLDN5	OTUX60YO	moderate	Biomarker	[739]
COL4A3	OT6SB8X5	moderate	Biomarker	[1703]
COL4A6	OTUREU5Z	moderate	Altered Expression	[1704]
COX5A	OTP0961M	moderate	Biomarker	[1705]
COX8A	OTU0NR39	moderate	Biomarker	[1705]
CPOX	OTIAY121	moderate	Biomarker	[1705]
CPT2	OTIN6G20	moderate	Biomarker	[1706]
CREBRF	OT2GK1HI	moderate	Altered Expression	[1707]
CTBP1	OTVYH2DH	moderate	Biomarker	[1708]
CTCF	OT8ZB70U	moderate	Biomarker	[1709]
CTTN	OTJRG4ES	moderate	Altered Expression	[1710]
CUL4A	OTTBV70J	moderate	Biomarker	[1711]
CYGB	OTX153DQ	moderate	Biomarker	[1579]
CYP4F8	OT437NB2	moderate	Altered Expression	[547]
CYTH1	OTYH9NRJ	moderate	Biomarker	[1712]
DCD	OTV5PBGJ	moderate	Genetic Variation	[1713]
DEFB1	OT5SV0E4	moderate	Altered Expression	[1714]
DLX1	OT7BH057	moderate	Altered Expression	[1482]
DOHH	OTDRAT3F	moderate	Altered Expression	[544]
DSC2	OTODVH8K	moderate	Biomarker	[1715]
DSC3	OTYG47F8	moderate	Altered Expression	[1715]
DVL2	OTMNYNCM	moderate	Biomarker	[1716]
E2F8	OTQKZGFP	moderate	Biomarker	[1717]
EFEMP1	OTZVUOOB	moderate	Biomarker	[1718]
EHBP1	OTMNUJ15	moderate	Biomarker	[1519]
EIF3B	OTF67VPH	moderate	Altered Expression	[1719]
ELF3	OTUTLEQO	moderate	Biomarker	[1720]
ELP1	OTYEWBF7	moderate	Genetic Variation	[1721]
ERGIC1	OT351FKB	moderate	Biomarker	[1722]
FAM110B	OTLYN2T1	moderate	Altered Expression	[1723]
FBXW11	OT2A6RLR	moderate	Biomarker	[1724]
FEN1	OT6QGG7O	moderate	Altered Expression	[1725]
FOXA2	OTJOCVOY	moderate	Biomarker	[1726]
FRS2	OTDMD800	moderate	Biomarker	[1727]
FRS3	OTTNP6H7	moderate	Biomarker	[1727]
FZD5	OTXFFY56	moderate	Biomarker	[1728]
FZD8	OTZ9IRFL	moderate	Altered Expression	[1729]
G3BP2	OTAWW3KI	moderate	Altered Expression	[1730]
GATM	OTIJ4Z11	moderate	Biomarker	[1390]
GEMIN4	OTX7402E	moderate	Genetic Variation	[1731]
GNA13	OTVDL515	moderate	Altered Expression	[1732]
GNB3	OTA6HYBA	moderate	Genetic Variation	[1733]
GNMT	OT0O2OQO	moderate	Genetic Variation	[1734]
GPRC5A	OTPOCWR7	moderate	Altered Expression	[1735]
H2AX	OT18UX57	moderate	Biomarker	[1736]
HDLBP	OTKDEEYX	moderate	Altered Expression	[1693]
HEBP1	OTR9MPDX	moderate	Altered Expression	[1693]
HEY2	OTU4J3ZI	moderate	Biomarker	[1737]
HEYL	OTN7BH79	moderate	Biomarker	[1737]
HSD17B6	OTSB55D2	moderate	Biomarker	[1568]
HTRA4	OT58M21J	moderate	Altered Expression	[1738]
IQGAP2	OTX2UA7P	moderate	Altered Expression	[1739]
ISG20	OTCWRJJW	moderate	Altered Expression	[1740]
JMJD6	OTILR7E4	moderate	Biomarker	[1741]
KIDINS220	OTLBH2MA	moderate	Genetic Variation	[1742]
KLF13	OTMIKHZ4	moderate	Biomarker	[1743]
KLRG2	OTBLEXSC	moderate	Genetic Variation	[1744]
KMT2B	OTMMAZQX	moderate	Genetic Variation	[1745]
KRT13	OTTYSKGX	moderate	Altered Expression	[1746]
LCOR	OT1K7DKB	moderate	Altered Expression	[1747]
LIG4	OT40DNXU	moderate	Altered Expression	[1748]
LILRA3	OTBNQCOS	moderate	Genetic Variation	[1749]
LPIN2	OTRRTMXX	moderate	Biomarker	[1750]
LRRC26	OTXEFL76	moderate	Biomarker	[1751]
LRRC3B	OT9VDGPR	moderate	Genetic Variation	[1752]
LRWD1	OTHRVJQC	moderate	Biomarker	[1753]
LYPD5	OTGP7UKA	moderate	Altered Expression	[390]
LZTS2	OTQFSQEE	moderate	Altered Expression	[1754]
MAGT1	OTQSAV5C	moderate	Biomarker	[515]
MAP1S	OT5WUD4C	moderate	Biomarker	[1755]
MCCC2	OTQDHSMI	moderate	Altered Expression	[1756]
MED12	OTQZ4D2X	moderate	Biomarker	[344]
MGAT4C	OTQ2R629	moderate	Altered Expression	[1757]
MIB1	OT5C404P	moderate	Altered Expression	[969]
MMRN1	OT7ZNYHT	moderate	Biomarker	[1758]
MRE11	OTGU8TZM	moderate	Altered Expression	[1759]
MRPL41	OTG5URO4	moderate	Biomarker	[1760]
MSH2	OT10H1AB	Moderate	Autosomal dominant	[247]
MSH3	OTD3YPVL	moderate	Genetic Variation	[1761]
MYLIP	OTL0PFGV	moderate	Biomarker	[1762]
NAALADL2	OT2HOGPQ	moderate	Biomarker	[1763]
NANOG	OTUEY1FM	moderate	Altered Expression	[1764]
NEU2	OTW76T35	moderate	Altered Expression	[1765]
NIPSNAP1	OTKXKUT8	moderate	Biomarker	[1750]
NRBP1	OTRWEJ65	moderate	Altered Expression	[1681]
NUCB2	OTHO6JWN	moderate	Altered Expression	[1766]
NUP43	OTDF5K8Y	moderate	Biomarker	[532]
OAS2	OT64CCTM	moderate	Genetic Variation	[1556]
OAZ1	OTPT0PKZ	moderate	Altered Expression	[1767]
OBI1	OTX62ZHW	moderate	Genetic Variation	[1768]
OBP2A	OTBIJ5TI	moderate	Biomarker	[1769]
PCBP1	OTHN0TD7	moderate	Biomarker	[1770]
PEG10	OTWD2278	moderate	Biomarker	[1771]
PHLPP1	OTIFXW8D	moderate	Altered Expression	[1772]
PHLPP2	OTXB1OUI	moderate	Biomarker	[1773]
PIK3R2	OTZSUQK5	moderate	Altered Expression	[1400]
PIP	OTH719AH	moderate	Altered Expression	[1297]
PLAAT1	OTM3M6P4	moderate	Biomarker	[1774]
PLAC8	OT3SYRUJ	moderate	Biomarker	[1775]
PLXNB1	OTCA7JIT	moderate	Biomarker	[1776]
PPARGC1A	OTHCDQ22	moderate	Altered Expression	[1777]
PPP1CB	OTYFTYFR	moderate	Biomarker	[594]
PPP1R12A	OT4AVU95	moderate	Biomarker	[905]
PPP1R12C	OT9Q86JO	moderate	Altered Expression	[1400]
PPP1R13B	OTC88VQO	moderate	Altered Expression	[1400]
PPP1R1A	OTGTAGCV	moderate	Biomarker	[1778]
PPRC1	OT6GB3WR	moderate	Altered Expression	[1779]
PRDX2	OTLWCY9T	moderate	Biomarker	[1780]
PRG2	OT0BCPQG	moderate	Biomarker	[972]
PRKD3	OT987HJI	moderate	Biomarker	[1781]
PRRX2	OT8UR4AU	moderate	Biomarker	[1780]
PRSS3	OTN3S5YB	moderate	Biomarker	[1782]
PSKH1	OTI9K58A	moderate	Biomarker	[1783]
PSMC6	OTG8997V	moderate	Biomarker	[532]
PSMD7	OT7PZZ4K	moderate	Altered Expression	[602]
RAB3B	OTZA4SXL	moderate	Biomarker	[1784]
RACGAP1	OTQE8IEH	moderate	Biomarker	[631]
RAD9A	OTJ3AJQU	moderate	Biomarker	[1785]
RAG2	OTG9UYTW	moderate	Biomarker	[1786]
RAP2A	OT0JB5S4	moderate	Genetic Variation	[1787]
RB1	OT9VMY7B	moderate	Biomarker	[344]
RBM5	OTCBWHHV	moderate	Altered Expression	[1788]
RBM6	OTI99KAZ	moderate	Biomarker	[1789]
RNF40	OTC8SDA3	moderate	Biomarker	[1790]
ROM1	OTE7H0YV	moderate	Altered Expression	[1791]
RPL31	OTV9E1OE	moderate	Biomarker	[1792]
RRAS	OTBBF28C	moderate	Altered Expression	[727]
RRM2B	OTE8GBUR	moderate	Altered Expression	[1793]
SCRIB	OTW4N3FV	moderate	Biomarker	[1794]
SEL1L	OTC0FB7T	moderate	Biomarker	[1795]
SELENOK	OTKM7N7P	moderate	Biomarker	[591]
SEMA3E	OTD4S36H	moderate	Biomarker	[1796]
SHOX2	OTLCZZJW	moderate	Biomarker	[1797]
SLBP	OTVYYQRT	moderate	Altered Expression	[1693]
SMARCA1	OT0Y6PTU	moderate	Biomarker	[344]
SMC4	OTEJE6AG	moderate	Biomarker	[1751]
SMR3B	OTL5HNM8	moderate	Biomarker	[596]
SOX10	OTF25ULQ	moderate	Altered Expression	[1798]
SPAG9	OT45AHMB	moderate	Altered Expression	[1799]
SPANXA1	OTMK3QIS	moderate	Genetic Variation	[1800]
SPATA19	OT47CHQR	moderate	Altered Expression	[1801]
SRA1	OTYOGMTG	moderate	Biomarker	[1478]
SRM	OT4N5MDP	moderate	Biomarker	[1802]
SSX2	OT2Z6RLL	moderate	Altered Expression	[1803]
STAM2	OT9OBWPH	moderate	Altered Expression	[1693]
STEAP4	OTFTLAEZ	moderate	Biomarker	[1804]
STIM1	OT8CLQ1W	moderate	Biomarker	[1805]
SUGP1	OT7W0EB8	moderate	Biomarker	[1080]
SWAP70	OTPHT2QD	moderate	Biomarker	[1806]
TACC2	OTW4M7HI	moderate	Biomarker	[1807]
TBPL1	OT4I143E	moderate	Altered Expression	[616]
TBX5	OT70PISV	moderate	Biomarker	[1724]
TEAD1	OTK6971C	moderate	Altered Expression	[911]
TFG	OT2KJENI	moderate	Altered Expression	[1808]
THBS2	OTXET551	moderate	Biomarker	[1809]
TLK2	OTZ09CG8	moderate	Biomarker	[1810]
TM4SF1	OTY0ECQN	moderate	Altered Expression	[1811]
TMBIM4	OT8712PP	moderate	Biomarker	[1812]
TMED3	OTNOPHHC	moderate	Biomarker	[1722]
TP53I3	OTSCM68G	moderate	Biomarker	[1760]
TRAF2	OT1MEZZN	moderate	Altered Expression	[1813]
TRAP1	OTNG0L8J	moderate	Biomarker	[1814]
TRIM36	OT37JQ8Y	moderate	Biomarker	[1815]
A2M	OTFTX90K	Strong	Biomarker	[1816]
AAAS	OTJT9T23	Strong	Biomarker	[548]
ABCG4	OT2XJIOG	Strong	Biomarker	[1817]
ABI1	OT5H4M62	Strong	Biomarker	[1818]
ACACA	OT5CQPZY	Strong	Altered Expression	[419]
ACCS	OTHIHI9D	Strong	Biomarker	[1328]
ACO1	OT2VUR7L	Strong	Altered Expression	[1545]
ACOX3	OTZEPVGF	Strong	Altered Expression	[1819]
ACP2	OTLPA1LJ	Strong	Altered Expression	[1820]
ACRBP	OT0MK3L1	Strong	Biomarker	[858]
ACSL3	OT3MWER1	Strong	Biomarker	[1821]
ACSL4	OTI71MUJ	Strong	Biomarker	[1822]
ACSM3	OT0AE1IV	Strong	Biomarker	[993]
ACTC1	OTJU04B1	Strong	Altered Expression	[1823]
ACTG2	OTRDWUO0	Strong	Biomarker	[643]
ACTL6A	OT0EC5BQ	Strong	Altered Expression	[1824]
ADAM2	OT62YCDZ	Strong	Biomarker	[551]
ADAM28	OT3GBVHL	Strong	Biomarker	[667]
ADAMTS8	OT2KFY1S	Strong	Biomarker	[344]
ADGRG1	OTQBB8NT	Strong	Biomarker	[1825]
ADIRF	OTTJP8D4	Strong	Biomarker	[1826]
ADRM1	OTOU4EY6	Strong	Genetic Variation	[1827]
AFAP1	OTR473H8	Strong	Altered Expression	[1828]
AFM	OTPOR8IO	Strong	Genetic Variation	[909]
AGFG1	OTI8ZKC4	Strong	Biomarker	[1829]
AGFG2	OTXQZHCR	Strong	Biomarker	[1830]
AGO2	OT4JY32Q	Strong	Biomarker	[1831]
AHCYL2	OTGG9KYG	Strong	Biomarker	[548]
AHSA1	OTC7AFHT	Strong	Altered Expression	[654]
AIRE	OTA7G1Y1	Strong	Biomarker	[1832]
AJUBA	OTNW7YPK	Strong	Biomarker	[1833]
AK6	OT84OHHP	Strong	Biomarker	[1834]
AKAP1	OTIIB2JB	Strong	Biomarker	[1085]
AKIP1	OT7XPG27	Strong	Biomarker	[1835]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[989]
ALKBH1	OTADGU5D	Strong	Biomarker	[1836]
ALKBH3	OTS1CD9Z	Strong	Biomarker	[1837]
ALKBH7	OTJVS8CF	Strong	Genetic Variation	[1836]
ALOX15B	OTWQQ08W	Strong	Altered Expression	[1838]
ALPP	OTZU4G9W	Strong	Biomarker	[678]
AMBRA1	OTY0YGT9	Strong	Biomarker	[1839]
AMELX	OTIN26MM	Strong	Altered Expression	[1840]
AMOTL1	OT40G45S	Strong	Biomarker	[1841]
AMPD1	OTU17BCI	Strong	Biomarker	[1842]
ANKRD22	OT6CRQ67	Strong	Altered Expression	[1843]
ANKRD44	OTUI0WOO	Strong	Genetic Variation	[1844]
ANKS4B	OT1MREUS	Strong	Biomarker	[1329]
ANP32A	OTRHPFO2	Strong	Biomarker	[1845]
ANP32D	OTAGQSQ6	Strong	Biomarker	[1846]
ANXA3	OTDD8OI7	Strong	Biomarker	[1847]
ANXA4	OTUCRYXL	Strong	Altered Expression	[1848]
ANXA6	OT9KIQ0Y	Strong	Altered Expression	[1312]
APBB1IP	OTN02KUV	Strong	Altered Expression	[1849]
APMAP	OT1P2GJA	Strong	Biomarker	[1850]
APOBEC3A	OTYO6F5P	Strong	Genetic Variation	[1851]
APOC1	OTA58CED	Strong	Biomarker	[1852]
APOD	OTT77XW8	Strong	Altered Expression	[1853]
APPBP2	OTLNFV4J	Strong	Genetic Variation	[1119]
APPL1	OT8VR95S	Strong	Altered Expression	[1854]
APPL2	OT9S4C4K	Strong	Biomarker	[858]
AQP5	OT77GBY8	Strong	Altered Expression	[1855]
ARFGAP3	OT2G3KCG	Strong	Genetic Variation	[1856]
ARHGAP21	OT6XY8Y9	Strong	Biomarker	[1857]
ARHGAP24	OTCQCEZS	Strong	Biomarker	[1858]
ARHGEF2	OTBQTFRT	Strong	Altered Expression	[602]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[1663]
ARHGEF7	OT9BPJCL	Strong	Altered Expression	[1400]
ARID1A	OTRWDV3P	Strong	Biomarker	[667]
ARID2	OTIRJXWM	Strong	Biomarker	[344]
ARID4B	OTYLPILE	Strong	Biomarker	[1859]
ARID5B	OTUQ4CQY	Strong	Altered Expression	[1860]
ARL6IP1	OT536XAV	Strong	Biomarker	[1058]
ARMC2	OTMCC01T	Strong	Genetic Variation	[909]
ARMH1	OTTJC0D6	Strong	Altered Expression	[602]
ARRDC3	OTAKW7R9	Strong	Altered Expression	[1861]
ARSG	OTT7TDW7	Strong	Biomarker	[1121]
ASAP1	OT4DLRYY	Strong	Genetic Variation	[1862]
ASB2	OTF9LV7L	Strong	Biomarker	[1863]
ASCC1	OTH4VAP9	Strong	Altered Expression	[1864]
ASCL1	OTI4X44G	Strong	Biomarker	[1865]
ASF1B	OTKXX12I	Strong	Biomarker	[1866]
ASH1L	OTUT5NLJ	Strong	Biomarker	[667]
ASPM	OTKXQMNA	Strong	Biomarker	[1867]
ASZ1	OTLM93UO	Strong	Biomarker	[858]
ATE1	OT3QNM39	Strong	Biomarker	[1868]
ATF5	OT03QCLM	Strong	Biomarker	[1869]
ATF6	OTAFHAVI	Strong	Altered Expression	[1870]
ATG12	OTJRO09Y	Strong	Genetic Variation	[1871]
ATG16L1	OTEOYC5D	Strong	Biomarker	[1871]
ATG4B	OTQ4RNRM	Strong	Biomarker	[1872]
ATL1	OTR2788Y	Strong	Altered Expression	[619]
ATP2A3	OTFYDEES	Strong	Biomarker	[1873]
ATP5F1A	OT3FZDLX	Strong	Altered Expression	[1874]
ATP5F1B	OTLFZUQK	Strong	Biomarker	[1875]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[1876]
ATRNL1	OTY5JUX2	Strong	Biomarker	[678]
AXIN1	OTRGZGZ5	Strong	Genetic Variation	[1877]
AXIN2	OTRMGQNU	Strong	Altered Expression	[1878]
B3GNT2	OTE69HV8	Strong	Genetic Variation	[762]
B4GALT4	OTI5SX62	Strong	Biomarker	[858]
BACH2	OT17GS18	Strong	Biomarker	[1879]
BASP1	OTF4VS5G	Strong	Biomarker	[1525]
BCAS1	OTQKJR81	Strong	Biomarker	[1880]
BCL2L10	OTYXQJ3I	Strong	Altered Expression	[1881]
BCL2L14	OT87E7HW	Strong	Altered Expression	[1882]
BCO2	OTP1L0BZ	Strong	Genetic Variation	[1883]
BEST1	OTWHE1ZC	Strong	Biomarker	[1884]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[1695]
BICRA	OTDTPGW0	Strong	Altered Expression	[1885]
BID	OTOSHSHU	Strong	Altered Expression	[1886]
BIK	OTTH1T3D	Strong	Altered Expression	[1887]
BLM	OTEJOAJX	Strong	Genetic Variation	[1888]
BMP3	OTCTI0UW	Strong	Altered Expression	[1889]
BMPR1A	OTQOA4ZH	Strong	Genetic Variation	[1890]
BMPR1B	OTGFN0OD	Strong	Genetic Variation	[1891]
BMS1	OTEGQ8ZO	Strong	Biomarker	[605]
BOLL	OT5FAEJJ	Strong	Genetic Variation	[1844]
BRF1	OTQC6DMG	Strong	Altered Expression	[1892]
BRMS1	OTV5A6LL	Strong	Altered Expression	[1893]
BRMS1L	OTJIW47U	Strong	Biomarker	[1893]
BST1	OTAV5SE7	Strong	Altered Expression	[1894]
BTF3	OT5ZZFJL	Strong	Biomarker	[1895]
BTG2	OTZF6K1H	Strong	Genetic Variation	[1896]
BUB3	OTU91HAU	Strong	Genetic Variation	[715]
BUD31	OTN3HZYF	Strong	Biomarker	[1897]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[1898]
C1orf116	OTPYEXDM	Strong	Altered Expression	[1899]
C1orf52	OT8RQW3W	Strong	Altered Expression	[1900]
C1QTNF3	OTOJMWW0	Strong	Biomarker	[1901]
CACUL1	OT6P1ZVP	Strong	Biomarker	[1902]
CADM4	OT0TFMFE	Strong	Biomarker	[1903]
CALM2	OTNYA92F	Strong	Altered Expression	[1904]
CAMKMT	OTLJBRUW	Strong	Biomarker	[1905]
CANT1	OT1TPWQR	Strong	Biomarker	[1906]
CAPN3	OTCHG3YK	Strong	Biomarker	[1907]
CAPRIN1	OTEJAMS3	Strong	Genetic Variation	[1908]
CAPZB	OTF1A4N0	Strong	Genetic Variation	[1909]
CASZ1	OTWJ2OR8	Strong	Biomarker	[667]
CAV2	OT1FGRQX	Strong	Biomarker	[1880]
CAVIN1	OTFO915U	Strong	Biomarker	[1910]
CBLIF	OTNE20WU	Strong	Altered Expression	[1911]
CBX5	OT8VYY84	Strong	Altered Expression	[1912]
CCAR2	OTLUDG5T	Strong	Biomarker	[1913]
CCDC115	OT04AZNZ	Strong	Biomarker	[1914]
CCDC6	OTXRQDYG	Strong	Altered Expression	[1915]
CCL25	OTLWJ8CJ	Strong	Biomarker	[1916]
CCL27	OTUZYC61	Strong	Biomarker	[678]
CCN4	OT69BER9	Strong	Biomarker	[1917]
CCN6	OTRFHQ2Z	Strong	Biomarker	[874]
CCNA1	OTX4HD45	Strong	Altered Expression	[1918]
CCNG1	OT17IA9L	Strong	Biomarker	[1919]
CCNH	OTKDU3SR	Strong	Biomarker	[1920]
CCNK	OTZ7JBPK	Strong	Biomarker	[1921]
CCT2	OTW1VV4E	Strong	Biomarker	[883]
CCT3	OTL6EOS1	Strong	Genetic Variation	[1922]
CCT4	OT5D452X	Strong	Biomarker	[1923]
CD164	OTZ7FIU8	Strong	Biomarker	[1924]
CD177	OTS79FNF	Strong	Altered Expression	[1925]
CD1D	OT3ROU4J	Strong	Biomarker	[1926]
CD226	OT4UG0KB	Strong	Biomarker	[1161]
CD48	OT83ZNPP	Strong	Biomarker	[1927]
CD81	OTQFXNAZ	Strong	Biomarker	[1404]
CD99	OTPUZ5DE	Strong	Altered Expression	[1928]
CDC5L	OTTPFUU5	Strong	Biomarker	[1929]
CDC73	OT6JASZ1	Strong	Biomarker	[657]
CDCA7L	OT1FFWKC	Strong	Altered Expression	[1930]
CDCP1	OTD7RRWK	Strong	Biomarker	[1931]
CDH10	OTK3D5WP	Strong	Altered Expression	[1932]
CDH12	OTF2HCGA	Strong	Biomarker	[667]
CDK14	OT385ZH1	Strong	Altered Expression	[1933]
CDK2AP1	OTNFOHDJ	Strong	Altered Expression	[1934]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[1935]
CDKN3	OTBE3H07	Strong	Altered Expression	[1936]
CDY1	OTQVDS8D	Strong	Altered Expression	[1392]
CELF2	OTLJJ4VT	Strong	Biomarker	[1362]
CELSR1	OT7PS8O1	Strong	Genetic Variation	[855]
CELSR3	OT8P6QNJ	Strong	Biomarker	[1085]
CEMIP	OTK80FYN	Strong	Altered Expression	[1937]
CENPA	OT0NEJ4X	Strong	Biomarker	[723]
CENPU	OTQ4TZRS	Strong	Altered Expression	[1938]
CEP55	OTGSG2PA	Strong	Altered Expression	[1939]
CEP70	OTMY5KAE	Strong	Biomarker	[1940]
CETN1	OTGQ8JOZ	Strong	Biomarker	[1941]
CFAP161	OTXT4LBU	Strong	Genetic Variation	[1942]
CFHR1	OT72R16T	Strong	Biomarker	[1943]
CFL1	OTT6D5MH	Strong	Biomarker	[1944]
CFL2	OTE2W0DH	Strong	Altered Expression	[1945]
CHAD	OT7PF813	Strong	Biomarker	[1946]
CHD3	OTDBU4F3	Strong	Biomarker	[344]
CHD5	OTS5EVHH	Strong	Biomarker	[1947]
CHD6	OTEHW1U2	Strong	Biomarker	[344]
CHD7	OTHNIZWZ	Strong	Biomarker	[344]
CHD8	OTS7A6AF	Strong	Biomarker	[1948]
CHMP4C	OT5X8A3O	Strong	Biomarker	[1949]
CHPT1	OT4FJ0K3	Strong	Biomarker	[1706]
CHST14	OT3FLH7U	Strong	Biomarker	[1950]
CIRBP	OTXWTPBL	Strong	Biomarker	[1951]
CISH	OT8T5NYL	Strong	Altered Expression	[520]
CITED2	OT812TV7	Strong	Biomarker	[979]
CIZ1	OT3UKHPI	Strong	Biomarker	[548]
CKS1B	OTNUPLUJ	Strong	Biomarker	[1952]
CKS2	OTPTMHIV	Strong	Altered Expression	[1953]
CLCA2	OTF191LZ	Strong	Biomarker	[1954]
CLDN1	OT27KV99	Strong	Altered Expression	[1955]
CLDN7	OTNE0XHQ	Strong	Altered Expression	[1955]
CLDN8	OT7IIWXG	Strong	Altered Expression	[1956]
CLDN9	OTCKI2IZ	Strong	Biomarker	[858]
CLEC10A	OTD8HQT6	Strong	Altered Expression	[1957]
CLEC3B	OTFD29NF	Strong	Biomarker	[277]
CLGN	OTEWVFQV	Strong	Genetic Variation	[1958]
CLIC4	OT6KTPKD	Strong	Biomarker	[1058]
CLSTN1	OTQN35G2	Strong	Biomarker	[1959]
CMAS	OTFQJG3C	Strong	Biomarker	[928]
CNN3	OTJTAXAP	Strong	Biomarker	[858]
CNNM1	OTHRSSGH	Strong	Altered Expression	[1960]
CNOT3	OT4D5Z9L	Strong	Biomarker	[667]
CNOT8	OT6CMCS0	Strong	Biomarker	[551]
CNPY2	OTGY8ESX	Strong	Biomarker	[1762]
COBLL1	OTQFN1TC	Strong	Altered Expression	[1961]
COL11A2	OT3BQUBH	Strong	Biomarker	[410]
COL12A1	OTHLTV53	Strong	Biomarker	[1962]
COL15A1	OTTFKK18	Strong	Biomarker	[344]
COL5A1	OT24078H	Strong	Biomarker	[344]
COL5A3	OTCGC4DM	Strong	Biomarker	[344]
COMMD1	OT7WUD5R	Strong	Altered Expression	[1963]
COMMD3	OT1UTJH4	Strong	Biomarker	[1964]
COMP	OTS2FPMI	Strong	Biomarker	[1965]
COPB1	OT50CV12	Strong	Biomarker	[1966]
COPB2	OT82JIGC	Strong	Biomarker	[1966]
COPS3	OTZWPJ24	Strong	Biomarker	[654]
CORO1C	OTXDF9T3	Strong	Biomarker	[1967]
COX1	OTG3O9BN	Strong	Genetic Variation	[1968]
COX14	OTQ378WN	Strong	Altered Expression	[1969]
CPNE1	OTH5YKSL	Strong	Altered Expression	[1970]
CPT1A	OTI862QH	Strong	Biomarker	[1706]
CRABP2	OTY01V9G	Strong	Biomarker	[1971]
CRACD	OTII2U6L	Strong	Genetic Variation	[1972]
CREB5	OTJDUJPI	Strong	Biomarker	[1973]
CREG1	OTRHJ8HK	Strong	Biomarker	[858]
CREM	OTJIJ5AL	Strong	Altered Expression	[1974]
CRISP3	OTBSWMPL	Strong	Altered Expression	[1975]
CRKL	OTOYSD1R	Strong	Biomarker	[1976]
CRX	OTH435SV	Strong	Biomarker	[1090]
CRYBG1	OTIPDI15	Strong	Genetic Variation	[1296]
CRYGD	OTW29JC4	Strong	Altered Expression	[817]
CRYL1	OT0SJSJM	Strong	Biomarker	[858]
CSMD1	OTIVDSC4	Strong	Genetic Variation	[855]
CST1	OTE4I83Q	Strong	Biomarker	[993]
CST6	OTZVHJTF	Strong	Posttranslational Modification	[1977]
CTAG1B	OTIQGW6U	Strong	Genetic Variation	[749]
CTHRC1	OTV88X2G	Strong	Biomarker	[1978]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[629]
CTRL	OTB6NA5O	Strong	Biomarker	[1979]
CTSZ	OTSCX2LL	Strong	Biomarker	[1980]
CXCL17	OTRCEVIZ	Strong	Biomarker	[1981]
CXCL3	OTSL94KH	Strong	Biomarker	[1982]
CXCL5	OTZOUPCA	Strong	Altered Expression	[1983]
CYREN	OT5ZL00R	Strong	Biomarker	[1984]
DAB2	OTRMQTMZ	Strong	Biomarker	[1985]
DACH1	OTMKNAGG	Strong	Genetic Variation	[1986]
DACT2	OTNLCC0K	Strong	Altered Expression	[1987]
DAPK1	OTNCNUCO	Strong	Biomarker	[1988]
DAPK2	OTWODUQG	Strong	Altered Expression	[1210]
DBI	OT884QY9	Strong	Biomarker	[1006]
DBN1	OTZVKG8A	Strong	Biomarker	[1989]
DCAF1	OT3ZDVOE	Strong	Biomarker	[1829]
DCAF12	OT24XM7T	Strong	Biomarker	[1990]
DCAF6	OT3EYK1J	Strong	Biomarker	[1711]
DCDC2	OTSUFH1H	Strong	Biomarker	[1991]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[1992]
DCUN1D1	OT8UJLZU	Strong	Altered Expression	[1902]
DDB1	OTTR2L3Z	Strong	Biomarker	[1711]
DDB2	OTO8HVVB	Strong	Biomarker	[1711]
DDIT3	OTI8YKKE	Strong	Altered Expression	[1993]
DDOST	OT39PDMS	Strong	Biomarker	[678]
DDX20	OT6G8YF3	Strong	Altered Expression	[1994]
DDX39A	OT0Z6E1K	Strong	Genetic Variation	[1995]
DDX39B	OTEVCFVU	Strong	Altered Expression	[1995]
DDX3X	OTDO4TRX	Strong	Biomarker	[1996]
DDX52	OTZ7KMEY	Strong	Biomarker	[1997]
DDX56	OTGURA53	Strong	Altered Expression	[1998]
DEFB104A	OTLQZR6K	Strong	Genetic Variation	[1999]
DEGS1	OT4WXPKW	Strong	Biomarker	[858]
DENR	OTXP9HOY	Strong	Altered Expression	[1210]
DEPDC1B	OTMVFOT1	Strong	Altered Expression	[2000]
DESI2	OTHUOKOC	Strong	Biomarker	[2001]
DEUP1	OTXLM86J	Strong	Biomarker	[2002]
DGCR8	OT62LXE4	Strong	Biomarker	[2003]
DHDDS	OTVLYBUS	Strong	Biomarker	[2004]
DHDH	OTKA2AL6	Strong	Biomarker	[299]
DHRS11	OTU3J0ZL	Strong	Biomarker	[876]
DHX15	OT4F98TK	Strong	Altered Expression	[2005]
DHX30	OT7W9CEZ	Strong	Biomarker	[344]
DIDO1	OT9PB547	Strong	Altered Expression	[2006]
DIO2	OTGPNSLH	Strong	Biomarker	[2007]
DIRAS3	OT3XHLQA	Strong	Biomarker	[2008]
DKC1	OTX7DJR6	Strong	Altered Expression	[2009]
DLC1	OTP8LMCR	Strong	Altered Expression	[2010]
DLGAP5	OTWCN39U	Strong	Altered Expression	[2011]
DLST	OTBDF9HJ	Strong	Genetic Variation	[2012]
DMTN	OTDTKPBW	Strong	Biomarker	[2013]
DNAAF3	OT3OHO0O	Strong	Biomarker	[2014]
DNAH5	OTC21RUS	Strong	Biomarker	[2014]
DNAI1	OTF6C65Q	Strong	Biomarker	[2014]
DNAJC10	OTD2EG0R	Strong	Biomarker	[858]
DNAJC3	OT7ROIJF	Strong	Biomarker	[858]
DNASE1L2	OT56VFRL	Strong	Biomarker	[858]
DNER	OT2GH2E5	Strong	Biomarker	[701]
DNM1L	OTXK1Q1G	Strong	Altered Expression	[1210]
DNTT	OTFSEF12	Strong	Genetic Variation	[2015]
DOC2A	OT5G9V94	Strong	Biomarker	[2016]
DPYS	OTLTUIVL	Strong	Biomarker	[2017]
DPYSL5	OT6F9T6F	Strong	Altered Expression	[2018]
DRG1	OTIFYMI3	Strong	Biomarker	[2019]
DSPP	OT1TYNDN	Strong	Biomarker	[2020]
DSTN	OTMXO4YB	Strong	Genetic Variation	[551]
DUSP22	OTEZ3U85	Strong	Altered Expression	[2021]
DVL1	OTD67RF1	Strong	Altered Expression	[2022]
DVL3	OTPRROHJ	Strong	Biomarker	[1867]
DYM	OTQ670WI	Strong	Biomarker	[1981]
DYNLL1	OTR69LHT	Strong	Biomarker	[2023]
E2F4	OTB3JFH4	Strong	Biomarker	[2024]
E2F5	OT1XWING	Strong	Altered Expression	[2025]
EAF1	OTN27MJW	Strong	Altered Expression	[2026]
EAF2	OTSOET5L	Strong	Altered Expression	[2026]
EBAG9	OTTQLQCP	Strong	Biomarker	[2027]
EBF2	OTFWZE51	Strong	Genetic Variation	[909]
EBNA1BP2	OTBRVMZH	Strong	Altered Expression	[602]
ECI2	OT2TP4IX	Strong	Altered Expression	[2028]
ECM1	OT1K65VW	Strong	Biomarker	[2029]
ECT2	OTQDUCT6	Strong	Altered Expression	[2030]
EEF1A1	OT00THXS	Strong	Biomarker	[2031]
EEF1A2	OT9Z23K5	Strong	Altered Expression	[2032]
EEF2	OTZ7SZ39	Strong	Biomarker	[2033]
EEFSEC	OTJ4KKOO	Strong	Genetic Variation	[2034]
EFNA5	OTOH4DRR	Strong	Genetic Variation	[551]
EFNB1	OT7JJW8P	Strong	Biomarker	[2035]
EGR3	OTGPJIRA	Strong	Biomarker	[2036]
EHHADH	OTBAAHL5	Strong	Biomarker	[344]
EI24	OTD4NOYS	Strong	Biomarker	[858]
EIF1	OTB4GZ0V	Strong	Biomarker	[1135]
EIF3L	OTECHRQO	Strong	Biomarker	[2037]
ELF1	OTV5LKIA	Strong	Altered Expression	[2038]
ELF5	OTLRU8YF	Strong	Altered Expression	[2039]
ELL	OTCBN5LF	Strong	Altered Expression	[2040]
ELL2	OTZJRTFM	Strong	Biomarker	[2041]
ELOVL3	OTH70U4Z	Strong	Biomarker	[2042]
ELOVL5	OT375W1Z	Strong	Biomarker	[2043]
ELOVL7	OT89NYVC	Strong	Biomarker	[2044]
EMB	OT67E3Q1	Strong	Biomarker	[450]
EMD	OTR8ZANE	Strong	Biomarker	[2045]
EMP1	OTSZHUHQ	Strong	Biomarker	[2046]
EMP3	OTODMJ1D	Strong	Biomarker	[1880]
EN2	OT7EZCM2	Strong	Biomarker	[2047]
ENDOG	OT5IM7B3	Strong	Biomarker	[2048]
ENO2	OTRODL0T	Strong	Biomarker	[2049]
ENPP5	OTY807N5	Strong	Biomarker	[858]
ENTPD5	OTFH05B9	Strong	Biomarker	[2050]
EPB41L3	OTS6CHG2	Strong	Altered Expression	[2051]
EPB41L4B	OT2K30P7	Strong	Biomarker	[2052]
EPHX3	OTU7LW2F	Strong	Biomarker	[2053]
EPS8L3	OT7XYA2T	Strong	Genetic Variation	[2054]
ERCC1	OTNPYQHI	Strong	Altered Expression	[2055]
ERCC3	OTVAW3P1	Strong	Altered Expression	[2056]
ERCC4	OTFIOPG1	Strong	Genetic Variation	[995]
ERGIC2	OT3MEGIU	Strong	Biomarker	[2057]
ERP29	OTNKANMH	Strong	Biomarker	[858]
ERP44	OT7ZI7AG	Strong	Biomarker	[858]
ESCO1	OTZ9P12A	Strong	Biomarker	[2058]
ESM1	OT331Y8V	Strong	Biomarker	[2059]
ESRP1	OTNCS4SL	Strong	Genetic Variation	[2060]
ESS2	OTZ08VCZ	Strong	Biomarker	[2061]
ETV2	OTP5URZ8	Strong	Biomarker	[2062]
ETV5	OTE2OBM4	Strong	Altered Expression	[2063]
EXO5	OTIN7L7I	Strong	Biomarker	[2064]
FAF2	OTE8CE2E	Strong	Biomarker	[1058]
FAM13C	OTVAGUOV	Strong	Altered Expression	[2065]
FAM3B	OTC2S91N	Strong	Biomarker	[2066]
FAM3C	OTBR6U9G	Strong	Biomarker	[2067]
FAM83F	OTGGJRO7	Strong	Genetic Variation	[2068]
FARP2	OTNRQIMK	Strong	Genetic Variation	[909]
FBL	OTRODIE5	Strong	Altered Expression	[1924]
FBLN5	OTLVNZ8U	Strong	Biomarker	[1442]
FBP1	OTQBANEP	Strong	Biomarker	[2069]
FBXO31	OTF96IC2	Strong	Biomarker	[2070]
FBXO44	OTEUEUTZ	Strong	Biomarker	[1058]
FCGBP	OT63T6XQ	Strong	Altered Expression	[2071]
FERMT2	OTZNPWWX	Strong	Genetic Variation	[909]
FGD4	OTYXJQCW	Strong	Altered Expression	[2072]
FGF13	OTHNNVSG	Strong	Biomarker	[2073]
FGF17	OTAQSFZ2	Strong	Biomarker	[2074]
FGF6	OTRJ679P	Strong	Altered Expression	[2075]
FH	OTEQWU6Q	Strong	Biomarker	[2076]
FHL2	OT0OAYWT	Strong	Altered Expression	[2077]
FHL5	OT6C00Z1	Strong	Biomarker	[643]
FKBP9	OTGRFVKZ	Strong	Altered Expression	[2078]
FLACC1	OTZN9TZV	Strong	Genetic Variation	[2079]
FLI1	OT0EV3LX	Strong	Biomarker	[2080]
FLII	OT7G9JG6	Strong	Altered Expression	[2081]
FLNC	OT3F8J6Y	Strong	Altered Expression	[2082]
FLOT2	OTZ0QR5L	Strong	Biomarker	[2083]
FLT3LG	OTU0YGC4	Strong	Altered Expression	[1842]
FMOD	OT9EJ5H8	Strong	Altered Expression	[2084]
FOSB	OTW6C05J	Strong	Altered Expression	[825]
FOXA3	OTRGT2OT	Strong	Biomarker	[1151]
FOXB2	OTJE3RRR	Strong	Biomarker	[2085]
FOXD1	OT80PRHS	Strong	Altered Expression	[2086]
FOXD2	OTAF63YV	Strong	Altered Expression	[2086]
FOXF1	OT2CJZ5K	Strong	Altered Expression	[2086]
FOXF2	OTV20NGX	Strong	Altered Expression	[2086]
FOXJ1	OT7LLBZ7	Strong	Altered Expression	[2087]
FOXK1	OTLZGS7J	Strong	Biomarker	[2088]
FOXO3	OTHXQG4P	Strong	Biomarker	[2089]
FOXO4	OT90X9LN	Strong	Altered Expression	[2090]
FRG1	OTEJ8HSD	Strong	Biomarker	[2091]
FSTL1	OT6KEZUD	Strong	Altered Expression	[2092]
FTL	OTYQA8A6	Strong	Biomarker	[323]
FUT1	OTODG57A	Strong	Biomarker	[2093]
FUT7	OTJF6BSN	Strong	Altered Expression	[831]
FUT8	OTJJCVG1	Strong	Altered Expression	[2094]
FXR1	OTEMQ1SR	Strong	Biomarker	[1066]
FXYD3	OT9PPRHE	Strong	Altered Expression	[2095]
FZD1	OTZATHVS	Strong	Biomarker	[2096]
FZD2	OT952ML1	Strong	Biomarker	[2097]
FZD6	OTBCPII8	Strong	Altered Expression	[2098]
FZR1	OT0WGWZS	Strong	Genetic Variation	[2099]
GAB1	OTQKE6V4	Strong	Altered Expression	[2100]
GABARAPL1	OT4U7SBG	Strong	Biomarker	[2101]
GABBR1	OTU5A52J	Strong	Biomarker	[2102]
GABPA	OT9YB2SA	Strong	Biomarker	[399]
GADD45A	OTDRV63V	Strong	Genetic Variation	[2103]
GAGE7	OTF8BTR9	Strong	Biomarker	[2104]
GALNT4	OT6WKC13	Strong	Altered Expression	[2105]
GATA1	OTX1R7O1	Strong	Altered Expression	[2106]
GATA2	OTBP2QQ2	Strong	Biomarker	[2107]
GATAD2B	OTJL128N	Strong	Biomarker	[1998]
GBP1	OTUM7RPJ	Strong	Altered Expression	[2108]
GBX1	OTLJ8UR9	Strong	Altered Expression	[2109]
GBX2	OTW0ZI4D	Strong	Biomarker	[2110]
GDF10	OTEVXGJ7	Strong	Biomarker	[480]
GEN1	OT1XFQXF	Strong	Biomarker	[2111]
GFI1	OT9HB9H8	Strong	Biomarker	[2112]
GGNBP2	OT7K9YZV	Strong	Biomarker	[2113]
GGPS1	OTVEHG28	Strong	Biomarker	[2114]
GHRH	OT94U6MO	Strong	Biomarker	[2115]
GIT1	OTHO92S5	Strong	Genetic Variation	[2116]
GKN2	OTR9DOYG	Strong	Biomarker	[2117]
GLYATL1	OTS8JSRY	Strong	Altered Expression	[2118]
GNA12	OT3IRZH3	Strong	Altered Expression	[2119]
GNB2	OT3JPRCQ	Strong	Biomarker	[640]
GNG5	OT5LR7MB	Strong	Biomarker	[858]
GNL3	OTILGYO4	Strong	Altered Expression	[1617]
GNL3L	OTZYEFST	Strong	Altered Expression	[2120]
GOLGA2	OT5S9KYM	Strong	Biomarker	[773]
GOLGA4	OTCMEHNJ	Strong	Biomarker	[858]
GORASP1	OTQS91S7	Strong	Biomarker	[1217]
GPC1	OTQKRSSV	Strong	Altered Expression	[2121]
GPC5	OT8NR7GC	Strong	Biomarker	[2122]
GPLD1	OTUUQOVY	Strong	Altered Expression	[2123]
GPR151	OT7EACU6	Strong	Biomarker	[502]
GPR160	OTMXJT73	Strong	Altered Expression	[1007]
GPR162	OTK4LT3K	Strong	Biomarker	[2124]
GPR42	OTEB0ROY	Strong	Altered Expression	[639]
GPR68	OT1NXSMN	Strong	Biomarker	[2125]
GPSM1	OTA0SJBG	Strong	Altered Expression	[2126]
GPX3	OT6PK94R	Strong	Biomarker	[2127]
GRAP2	OTS5NIZ3	Strong	Altered Expression	[654]
GRB10	OTCKXGRC	Strong	Biomarker	[2128]
GRB7	OTF8Y9XY	Strong	Biomarker	[858]
GRHL1	OTZ4MNEW	Strong	Genetic Variation	[909]
GRHPR	OTLV63QV	Strong	Biomarker	[858]
GRP	OT8JDFNI	Strong	Biomarker	[2129]
GSTCD	OTIIINMT	Strong	Biomarker	[299]
GSTM2	OTG4WT05	Strong	Posttranslational Modification	[2130]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[2131]
GSTM5	OTMMBFY8	Strong	Biomarker	[1576]
GTF2H3	OT87W5QJ	Strong	Altered Expression	[2056]
GTF2H4	OTPD1DIU	Strong	Altered Expression	[2056]
GTF2H5	OTRL219S	Strong	Altered Expression	[2056]
GTF3A	OTVROUVQ	Strong	Altered Expression	[2132]
GUCD1	OTGUB3CM	Strong	Biomarker	[548]
GZMM	OTEC5CWT	Strong	Biomarker	[2133]
H2AZ1	OT3KJJNQ	Strong	Biomarker	[2134]
HACD1	OTEC7EP7	Strong	Biomarker	[937]
HADHA	OTO557N2	Strong	Biomarker	[2135]
HADHB	OT4Y1I62	Strong	Biomarker	[2135]
HARS1	OTHOEOTS	Strong	Genetic Variation	[855]
HAS3	OTPM8IL8	Strong	Altered Expression	[2136]
HAVCR2	OTOL603T	Strong	Altered Expression	[2087]
HBG1	OTVL4NSU	Strong	Biomarker	[993]
HBG2	OT4J48JJ	Strong	Biomarker	[993]
HBP1	OTDPGGDV	Strong	Biomarker	[2137]
HCFC1	OT0UCK62	Strong	Biomarker	[2138]
HEPACAM	OT1MJ51D	Strong	Altered Expression	[2139]
HES6	OTWO5SCF	Strong	Biomarker	[1262]
HHEX	OTLIUVYX	Strong	Altered Expression	[2140]
HHIP	OT77RQYS	Strong	Altered Expression	[1081]
HIC1	OTI9TWY4	Strong	Biomarker	[2141]
HIP1	OT7AKCFQ	Strong	Altered Expression	[2142]
HIPK1	OTSEA8RS	Strong	Biomarker	[740]
HIVEP1	OT7CAG4A	Strong	Biomarker	[1448]
HJURP	OTWMV16B	Strong	Altered Expression	[2143]
HMGB3	OTCJ2EZY	Strong	Altered Expression	[2144]
HMGN5	OTUUAHVQ	Strong	Biomarker	[2145]
HMMR	OT4M0JTZ	Strong	Altered Expression	[2146]
HNRNPAB	OTUKPFOK	Strong	Biomarker	[2147]
HNRNPK	OTNPRM8U	Strong	Biomarker	[2148]
HNRNPL	OT0DJX74	Strong	Biomarker	[2149]
HNRNPM	OTFU3OEZ	Strong	Altered Expression	[2150]
HOPX	OTBSR6C9	Strong	Altered Expression	[1632]
HOXA9	OTKNK5H0	Strong	Biomarker	[2151]
HOXB7	OTC7WYU8	Strong	Biomarker	[2152]
HOXB9	OTMVHQOU	Strong	Biomarker	[2153]
HOXC8	OTJUYU8J	Strong	Biomarker	[2154]
HOXD10	OT0NOWU2	Strong	Biomarker	[2155]
HOXD3	OTBUZ35T	Strong	Biomarker	[2156]
HPS5	OTLO2374	Strong	Biomarker	[1991]
HSDL1	OTPDMCC4	Strong	Altered Expression	[2157]
HSPA14	OTZCA5LK	Strong	Biomarker	[2158]
HSPA2	OTSDET7B	Strong	Biomarker	[1006]
HSPA4	OT5HR0AR	Strong	Altered Expression	[1632]
HSPA6	OTH4S7WB	Strong	Genetic Variation	[2159]
HSPB2	OTS01646	Strong	Altered Expression	[881]
HTRA2	OTC7616F	Strong	Altered Expression	[2160]
HUWE1	OTFH6BJS	Strong	Biomarker	[2161]
HYAL1	OT2SJN0X	Strong	Biomarker	[2162]
HYOU1	OTBGBSOV	Strong	Biomarker	[2163]
ICAM4	OT1BI27E	Strong	Genetic Variation	[2164]
ICAM5	OTDGGAFH	Strong	Genetic Variation	[2164]
IFI44	OTOKSZVA	Strong	Altered Expression	[1474]
IFIT3	OTPGHZB9	Strong	Biomarker	[1663]
IFIT5	OTYTSO77	Strong	Biomarker	[615]
IGFALS	OTTWCZYM	Strong	Biomarker	[2165]
IGFBP4	OT2HZRBD	Strong	Altered Expression	[2166]
IGSF5	OTLIYA15	Strong	Biomarker	[858]
IK	OTWSSXX0	Strong	Genetic Variation	[855]
IKZF5	OTJN51OC	Strong	Genetic Variation	[2167]
IL10RA	OTOX3D1D	Strong	Genetic Variation	[274]
IL17B	OTS86H50	Strong	Biomarker	[2168]
IL17RC	OTEFOBSS	Strong	Altered Expression	[1493]
IL27	OTIS3OF8	Strong	Biomarker	[894]
IL6ST	OT1N9C70	Strong	Biomarker	[667]
ILF3	OTKMZ5K5	Strong	Biomarker	[2169]
IMMT	OTBDSLE7	Strong	Biomarker	[2170]
INCENP	OT9HFRYK	Strong	Genetic Variation	[924]
INF2	OT8ZM13C	Strong	Genetic Variation	[2171]
ING1	OTEZBRKW	Strong	Altered Expression	[2172]
ING3	OTDIJXFP	Strong	Altered Expression	[2173]
ING5	OTRNNSFM	Strong	Biomarker	[2174]
INO80B	OTSHV8JF	Strong	Biomarker	[2175]
INSRR	OT3F75WA	Strong	Genetic Variation	[2176]
INTS4	OT5JQ913	Strong	Biomarker	[548]
INTS7	OT7ZG99E	Strong	Altered Expression	[522]
IREB2	OT747D24	Strong	Biomarker	[2177]
IRF6	OTKJ44EV	Strong	Biomarker	[468]
IRF7	OTC1A2PQ	Strong	Altered Expression	[2178]
IRX5	OT05J514	Strong	Altered Expression	[2179]
ISYNA1	OT49ONSE	Strong	Biomarker	[2180]
ITGA3	OTBCH21D	Strong	Altered Expression	[564]
ITGA9	OTHN1IKA	Strong	Biomarker	[2181]
ITGBL1	OTJDHE17	Strong	Biomarker	[2182]
ITSN1	OT8YF3S5	Strong	Biomarker	[344]
ITSN2	OT8S0OO8	Strong	Biomarker	[344]
IVNS1ABP	OTYHL4I7	Strong	Biomarker	[993]
JADE2	OTVG2MYF	Strong	Biomarker	[344]
JARID2	OT14UM8H	Strong	Biomarker	[2183]
JPT1	OT6CRZEU	Strong	Genetic Variation	[1827]
JTB	OT314JB6	Strong	Altered Expression	[2184]
JUNB	OTG2JXV5	Strong	Altered Expression	[825]
KAT2A	OTN0W2SW	Strong	Biomarker	[2185]
KATNAL1	OTBUZ7KA	Strong	Biomarker	[1917]
KCNH4	OTHJ8WTU	Strong	Altered Expression	[2186]
KCNH8	OT3I5FLB	Strong	Altered Expression	[2186]
KCTD11	OT64DFBU	Strong	Altered Expression	[2187]
KDELR1	OT8YBS5G	Strong	Biomarker	[858]
KDM4B	OT5P1UPY	Strong	Altered Expression	[2188]
KDM4D	OTN6KAE6	Strong	Biomarker	[2062]
KDM5D	OTEKG0KD	Strong	Biomarker	[2189]
KDM8	OTCN5ST8	Strong	Biomarker	[420]
KHDC4	OTBVAMSP	Strong	Altered Expression	[2190]
KIF14	OTXHT4JM	Strong	Altered Expression	[2191]
KIF18A	OTSMBJ24	Strong	Biomarker	[2192]
KIF20A	OTXOQHE0	Strong	Biomarker	[723]
KIF22	OTY6X6BL	Strong	Biomarker	[2193]
KIF4A	OT3UWL7D	Strong	Biomarker	[2194]
KIF7	OT1J6NAW	Strong	Biomarker	[2195]
KIFC1	OTNQDS00	Strong	Biomarker	[2196]
KLF12	OTVH4KD4	Strong	Biomarker	[2197]
KLF15	OTGMQMVR	Strong	Biomarker	[858]
KLF5	OT1ABI9N	Strong	Altered Expression	[2198]
KLF9	OTBFEJRQ	Strong	Biomarker	[2199]
KLK11	OT5PKX7Y	Strong	Biomarker	[2200]
KMT2C	OTC59BCO	Strong	Biomarker	[344]
KMT2D	OTTVHCLY	Strong	Biomarker	[2201]
KPNA1	OTEMVAJ6	Strong	Biomarker	[2202]
KPNA2	OTU7FOE6	Strong	Altered Expression	[2203]
KPNA4	OTP0EX18	Strong	Biomarker	[2204]
KPNA6	OTJ3OX6P	Strong	Biomarker	[2202]
KRIT1	OT58AP1I	Strong	Biomarker	[1905]
KRT16	OTGA0EQN	Strong	Altered Expression	[1013]
KRT18	OTVLQFIP	Strong	Biomarker	[2205]
LAMA3	OTFME7HT	Strong	Biomarker	[2206]
LAMB2	OT71OI2Y	Strong	Biomarker	[858]
LARGE2	OT5BZS3J	Strong	Altered Expression	[2207]
LARP4B	OT2HI0QE	Strong	Altered Expression	[2208]
LARP6	OTUQ9QS9	Strong	Genetic Variation	[2209]
LAT	OTZC1XZ1	Strong	Altered Expression	[2210]
LBH	OT87AT1X	Strong	Altered Expression	[2211]
LBR	OT1HG3HG	Strong	Altered Expression	[1894]
LCE2B	OTA53PGQ	Strong	Biomarker	[667]
LDLRAD1	OTG1GL9H	Strong	Genetic Variation	[805]
LEMD1	OTII3FTO	Strong	Altered Expression	[2212]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[1309]
LGALS4	OTKQCG0H	Strong	Biomarker	[1898]
LGALS8	OT71LJ8T	Strong	Biomarker	[2213]
LGR6	OTPZ1PWR	Strong	Biomarker	[502]
LIMA1	OTONPC9R	Strong	Biomarker	[2214]
LIN28B	OTVWP0FN	Strong	Altered Expression	[2215]
LITAF	OTT5JX1F	Strong	Biomarker	[2216]
LMNB1	OT100T3P	Strong	Biomarker	[631]
LRATD1	OT65IL83	Strong	Biomarker	[2017]
LRATD2	OTEZBUUL	Strong	Biomarker	[1774]
LRIG1	OTY5HZN5	Strong	Biomarker	[2217]
LRIG3	OT6TKZTU	Strong	Biomarker	[2218]
LRRC4	OT7XJ70N	Strong	Altered Expression	[1900]
LSAMP	OTYXVQX2	Strong	Genetic Variation	[2219]
LXN	OTZQ2M6Y	Strong	Biomarker	[2220]
LY6E	OTMG16BZ	Strong	Biomarker	[2221]
LZTS1	OTXXL864	Strong	Biomarker	[1232]
MACIR	OTPSW8Y8	Strong	Biomarker	[1920]
MACROH2A1	OTV2DQDD	Strong	Altered Expression	[2222]
MAEA	OTPA2FDE	Strong	Biomarker	[2223]
MAGEA11	OTLT6Q3G	Strong	Altered Expression	[948]
MAGEB6	OTOTV1FU	Strong	Genetic Variation	[2224]
MAGED1	OT6EOLFC	Strong	Genetic Variation	[2225]
MAGI2	OTXDDKZS	Strong	Altered Expression	[2226]
MAK16	OTD546E5	Strong	Biomarker	[1066]
MAP1LC3B	OTUYHB84	Strong	Biomarker	[2227]
MAP9	OTZD5099	Strong	Biomarker	[2228]
MARCHF1	OTI2EYO6	Strong	Genetic Variation	[2229]
MARCHF6	OTBTA03N	Strong	Biomarker	[2230]
MARCHF8	OTH7PNN2	Strong	Biomarker	[2231]
MASP1	OTWWCNZP	Strong	Biomarker	[2232]
MATN4	OT0CD0VH	Strong	Biomarker	[344]
MAX	OTKZ0YKM	Strong	Biomarker	[2233]
MBTD1	OT2P6943	Strong	Altered Expression	[2234]
MCC	OTQVI1EM	Strong	Genetic Variation	[2235]
MCF2L	OTEURA8N	Strong	Biomarker	[678]
MCM10	OTV0O3JN	Strong	Altered Expression	[2236]
MCM3	OTOOHQPM	Strong	Altered Expression	[2237]
MCM5	OTAHLB62	Strong	Altered Expression	[2238]
MCM8	OTC93H3S	Strong	Altered Expression	[2239]
MDH2	OT7364GY	Strong	Biomarker	[2076]
MED19	OTT9RT5N	Strong	Biomarker	[2240]
MED28	OTEDM1L5	Strong	Altered Expression	[2241]
MED9	OT59OKEJ	Strong	Biomarker	[2242]
MEIS2	OTG4ADLM	Strong	Biomarker	[2243]
MEOX1	OTJEMT2D	Strong	Altered Expression	[2244]
METTL3	OTSXP1M3	Strong	Altered Expression	[2245]
MGA	OTTLB216	Strong	Biomarker	[344]
MGAT5	OTU4DD4G	Strong	Biomarker	[2246]
MICA	OTPEIEAR	Strong	Biomarker	[2247]
MICAL2	OT04OQQJ	Strong	Biomarker	[2248]
MID1	OTWN1PGU	Strong	Biomarker	[2249]
MIIP	OT79EXZ7	Strong	Biomarker	[2250]
MINDY4	OTBZ2SZB	Strong	Altered Expression	[672]
MLC1	OTCNZLSP	Strong	Biomarker	[2251]
MLH3	OT91PPBI	Strong	Genetic Variation	[2252]
MLIP	OTMT7AII	Strong	Biomarker	[1834]
MLXIP	OT30UNI7	Strong	Biomarker	[2231]
MNAT1	OTXLOYCB	Strong	Genetic Variation	[2253]
MOAP1	OTVF3LUG	Strong	Biomarker	[2232]
MPC1	OT6DYFUO	Strong	Biomarker	[2254]
MRGPRX3	OTRKCCDS	Strong	Biomarker	[502]
MRGPRX4	OTOBHZVA	Strong	Biomarker	[502]
MRI1	OTOP49DM	Strong	Genetic Variation	[2255]
MRPL28	OT4LUTZU	Strong	Genetic Variation	[2256]
MRTFA	OTCVXASM	Strong	Biomarker	[2257]
MSMP	OT20VCWP	Strong	Biomarker	[2258]
MST1	OTOC4UNG	Strong	Biomarker	[1518]
MTFMT	OT1OIVJL	Strong	Biomarker	[2259]
MTO1	OT7HCZ1D	Strong	Altered Expression	[2260]
MTUS1	OTBPALMU	Strong	Biomarker	[664]
MUC5B	OTPW6K5C	Strong	Altered Expression	[2261]
MVP	OTJGHJRB	Strong	Genetic Variation	[2262]
MXD1	OTS5CTHX	Strong	Biomarker	[1842]
MXI1	OTUQ9E0D	Strong	Biomarker	[2263]
MYCL	OT1MFQ5U	Strong	Biomarker	[2264]
MYH11	OTVNVWY3	Strong	Genetic Variation	[2265]
MYH14	OT1TZEJK	Strong	Biomarker	[858]
MYO1B	OTGZUJ0I	Strong	Biomarker	[2266]
MYO1C	OT69L39Y	Strong	Altered Expression	[2267]
MYO1E	OTM9YSIZ	Strong	Altered Expression	[2267]
MYO5A	OTMWLP3E	Strong	Altered Expression	[2268]
MYRF	OTKF6AEB	Strong	Biomarker	[2269]
MYSM1	OTO73N00	Strong	Biomarker	[2270]
MZB1	OT071TET	Strong	Altered Expression	[248]
MZF1	OTMVZCPW	Strong	Biomarker	[529]
NAA10	OTYB9R6I	Strong	Biomarker	[2271]
NAA16	OTWMA7LK	Strong	Genetic Variation	[1120]
NAGK	OTR4H8SJ	Strong	Biomarker	[858]
NAIP	OTLA925F	Strong	Altered Expression	[2272]
NAP1L1	OTI7WBZV	Strong	Biomarker	[2273]
NBEAL2	OTMCAXWR	Strong	Biomarker	[2274]
NCAM2	OT8LBJN8	Strong	Genetic Variation	[551]
NCAPD3	OTOZY2UL	Strong	Altered Expression	[2275]
NCAPH	OTXOS97C	Strong	Biomarker	[2276]
NCOA7	OT2CNBOG	Strong	Biomarker	[667]
ND6	OTG47B7B	Strong	Biomarker	[2277]
NDRG2	OT5L6KD7	Strong	Altered Expression	[2278]
NDRG3	OTJTJCHD	Strong	Biomarker	[2279]
NDRG4	OTJBOTD8	Strong	Genetic Variation	[1219]
NDST2	OT21PY3J	Strong	Biomarker	[344]
NDST4	OTEKG7JJ	Strong	Biomarker	[667]
NEK3	OTKWD5FY	Strong	Biomarker	[2280]
NELFB	OTCFH88S	Strong	Biomarker	[2281]
NELL2	OTS4MJZ7	Strong	Altered Expression	[2282]
NEUROD1	OTZQ7QJ2	Strong	Altered Expression	[2283]
NFATC1	OT4TMERS	Strong	Altered Expression	[2284]
NFIC	OTLMCUIB	Strong	Biomarker	[1058]
NIBAN1	OTYOLI12	Strong	Biomarker	[679]
NIPAL3	OTI858LL	Strong	Biomarker	[2285]
NKX2-1	OTCMEJTA	Strong	Biomarker	[2286]
NKX2-5	OTS1SAWM	Strong	Altered Expression	[2287]
NLK	OT2LETFS	Strong	Altered Expression	[999]
NLRP12	OTGR132Z	Strong	Biomarker	[2288]
NLRP2	OTJA81JU	Strong	Altered Expression	[2289]
NOB1	OTW0YNSL	Strong	Altered Expression	[2290]
NOC2L	OTNT7R33	Strong	Biomarker	[2291]
NOG	OTGRHHPG	Strong	Biomarker	[2292]
NOL3	OT1K0L0D	Strong	Genetic Variation	[2293]
NOX1	OTZPJQCC	Strong	Genetic Variation	[1654]
NOX3	OT0FFJH8	Strong	Biomarker	[344]
NPAS2	OTMRT2TS	Strong	Genetic Variation	[2294]
NPBWR1	OTN8NRXK	Strong	Biomarker	[2053]
NPPA	OTMQNTNX	Strong	Therapeutic	[2295]
NPRL2	OTOB10MO	Strong	Altered Expression	[2296]
NR2C1	OTJEL7WT	Strong	Biomarker	[2297]
NR2C2	OTDZWVOJ	Strong	Biomarker	[2298]
NR2E1	OTW47GKM	Strong	Altered Expression	[315]
NR2F2	OTJFS67N	Strong	Biomarker	[2299]
NR6A1	OTFZOOQ9	Strong	Altered Expression	[2300]
NSD2	OTQ6SW4R	Strong	Altered Expression	[243]
NSMCE1	OTZJTA5X	Strong	Biomarker	[2017]
NSUN4	OTY6O37Z	Strong	Genetic Variation	[924]
NT5C3A	OT67KZJA	Strong	Genetic Variation	[2253]
NTS	OTPGDNQS	Strong	Biomarker	[404]
NUDCD1	OT8DS3CX	Strong	Biomarker	[2301]
NUMB	OTMB586Q	Strong	Altered Expression	[2302]
NUP153	OTCAS0AR	Strong	Biomarker	[2303]
NUSAP1	OT85HIJ5	Strong	Biomarker	[2304]
NXF1	OTEFHXG6	Strong	Biomarker	[1605]
NXT1	OT0VO6AY	Strong	Genetic Variation	[2256]
ODF4	OTP9AMYG	Strong	Biomarker	[2305]
OLFM1	OTOYPEWW	Strong	Biomarker	[993]
OMP	OT7JH0DY	Strong	Biomarker	[2306]
ONECUT2	OTHUE5YY	Strong	Biomarker	[2307]
OPN1LW	OTFNUZ7O	Strong	Biomarker	[291]
OPTN	OT2UXWH9	Strong	Biomarker	[2273]
OR51E1	OTB7Q65H	Strong	Biomarker	[2308]
ORAI3	OTUP3OH3	Strong	Biomarker	[2309]
OVOL2	OTFM1GKF	Strong	Altered Expression	[2310]
P2RX5	OTLBR20R	Strong	Altered Expression	[1000]
P3H4	OTZPXYSH	Strong	Biomarker	[2311]
P4HB	OTTYNYPF	Strong	Biomarker	[858]
PA2G4	OT7IG7HT	Strong	Biomarker	[2312]
PACC1	OTKBS8CC	Strong	Altered Expression	[2313]
PADI2	OTT40K94	Strong	Biomarker	[2314]
PAG1	OTFOJUIQ	Strong	Biomarker	[291]
PAGR1	OTXR5PQ8	Strong	Altered Expression	[836]
PAICS	OTMZN747	Strong	Genetic Variation	[2315]
PAK3	OT80M3BV	Strong	Biomarker	[1283]
PAK6	OTAHPZTT	Strong	Biomarker	[377]
PANK2	OTFBW889	Strong	Biomarker	[1329]
PAQR3	OTTKJ9Y4	Strong	Posttranslational Modification	[2316]
PAQR4	OTNO659U	Strong	Biomarker	[1950]
PAQR7	OTIWX5AM	Strong	Genetic Variation	[2317]
PARM1	OTDNK7EX	Strong	Biomarker	[2318]
PARP9	OT7K4494	Strong	Biomarker	[2319]
PATE1	OTTTPGG2	Strong	Altered Expression	[2320]
PAX2	OTKP1N8F	Strong	Altered Expression	[2321]
PBOV1	OT67PERT	Strong	Altered Expression	[2322]
PCBD1	OTDSRUD5	Strong	Biomarker	[2014]
PCBP4	OTDLL4NB	Strong	Biomarker	[291]
PCDH11Y	OTI2D7DR	Strong	Biomarker	[2323]
PCDH7	OTP091X8	Strong	Biomarker	[2324]
PCDH9	OTX3BFV4	Strong	Biomarker	[2325]
PCDHA1	OT65E2NU	Strong	Genetic Variation	[855]
PCDHA2	OTAV93M9	Strong	Genetic Variation	[855]
PCDHA3	OT7UREAI	Strong	Genetic Variation	[855]
PCDHA4	OTJH4515	Strong	Genetic Variation	[855]
PCDHA5	OTHZT1GR	Strong	Genetic Variation	[855]
PCDHA6	OTMAD36Z	Strong	Genetic Variation	[855]
PCDHA7	OTOPXHMA	Strong	Genetic Variation	[855]
PCDHA8	OTH6A6BV	Strong	Biomarker	[1841]
PCDHB9	OT9S1QXZ	Strong	Biomarker	[2326]
PCDHGA1	OTR1U1LI	Strong	Genetic Variation	[855]
PCDHGA2	OTGUFD36	Strong	Genetic Variation	[855]
PCGF2	OTIY1J5L	Strong	Altered Expression	[2327]
PCK2	OTJ8LX4N	Strong	Altered Expression	[2328]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[2329]
PDGFRL	OTJPRECT	Strong	Genetic Variation	[2330]
PDHA1	OTGEU8IK	Strong	Biomarker	[2331]
PDIK1L	OTISF4KG	Strong	Altered Expression	[2332]
PDK4	OTCMHMBZ	Strong	Biomarker	[2333]
PDLIM3	OTVXQC81	Strong	Biomarker	[678]
PDLIM4	OT23LZYY	Strong	Altered Expression	[2334]
PDLIM5	OTLQVV22	Strong	Biomarker	[2335]
PDP1	OT82RTMT	Strong	Biomarker	[2331]
PDS5A	OT34P56Z	Strong	Biomarker	[344]
PDS5B	OT3U3X8Z	Strong	Biomarker	[2336]
PDZD2	OTPPVRGY	Strong	Biomarker	[2337]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[858]
PELI1	OTMLBCLC	Strong	Biomarker	[1802]
PELP1	OTVXQNOT	Strong	Genetic Variation	[2338]
PER3	OTVKYVJA	Strong	Altered Expression	[2339]
PF4V1	OT2CXM6L	Strong	Biomarker	[2340]
PGAM1	OTZ5DB06	Strong	Biomarker	[2341]
PGAM2	OT9BE03I	Strong	Biomarker	[858]
PGK1	OT6V1ICH	Strong	Biomarker	[2342]
PHB2	OTCAX3AW	Strong	Altered Expression	[2343]
PHF21A	OTU3FFG4	Strong	Altered Expression	[2344]
PI16	OTJY2N6U	Strong	Altered Expression	[2345]
PIAS1	OTZVAHZI	Strong	Biomarker	[2346]
PICK1	OT8QE6EU	Strong	Biomarker	[2347]
PIEZO1	OTBG1FU4	Strong	Biomarker	[2348]
PIF1	OTUHKKVP	Strong	Biomarker	[2349]
PIGP	OTGYAH4X	Strong	Biomarker	[548]
PIK3C2B	OTY2PROB	Strong	Altered Expression	[2350]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[2351]
PITX1	OTA0UN4C	Strong	Biomarker	[2057]
PITX2	OTWMXAOY	Strong	Posttranslational Modification	[2352]
PITX3	OTE2KT8P	Strong	Biomarker	[1950]
PKD1	OT5ALRZ5	Strong	Altered Expression	[2353]
PKD2	OTIXBU8H	Strong	Biomarker	[1054]
PKIB	OT7C8GFN	Strong	Biomarker	[1052]
PKP3	OTPL1HRB	Strong	Biomarker	[858]
PLA2G10	OTRZ2L5A	Strong	Genetic Variation	[1029]
PLA2G15	OT6VJTPA	Strong	Biomarker	[1328]
PLA2G6	OT5FL0WU	Strong	Altered Expression	[2354]
PLAAT3	OTVXXJ5K	Strong	Posttranslational Modification	[2355]
PLCL1	OTJL2C79	Strong	Biomarker	[2356]
PLEK2	OTUBWUUK	Strong	Biomarker	[858]
PLEKHF1	OT9OL16U	Strong	Altered Expression	[2357]
PLIN5	OTV8G50L	Strong	Genetic Variation	[1119]
PLK3	OT19CT2Z	Strong	Biomarker	[2358]
PMAIP1	OTXEE550	Strong	Biomarker	[1252]
PNO1	OT010GIS	Strong	Biomarker	[1066]
PNPLA2	OTR3ERMR	Strong	Biomarker	[2359]
PODXL	OTPNQXF3	Strong	Altered Expression	[2360]
POLD3	OTEQEFQ2	Strong	Biomarker	[1998]
POLDIP2	OT8SZSJ6	Strong	Altered Expression	[654]
POLI	OTBA4DCE	Strong	Genetic Variation	[2058]
POLK	OTKZ38JH	Strong	Biomarker	[2361]
POLL	OTZ24QGM	Strong	Biomarker	[2362]
POLR2E	OTH5IL2A	Strong	Genetic Variation	[2363]
POLR3G	OTU3TGQ9	Strong	Biomarker	[2364]
POM121	OTIA7ZOQ	Strong	Biomarker	[1830]
POP4	OTN0XJZJ	Strong	Biomarker	[551]
POP5	OTCZTDJC	Strong	Genetic Variation	[551]
POP7	OTKC7SG5	Strong	Genetic Variation	[551]
POPDC2	OTDAZSY5	Strong	Biomarker	[551]
POPDC3	OTN4FJ5J	Strong	Genetic Variation	[551]
POTED	OTAUSTUK	Strong	Biomarker	[2365]
POU3F2	OT30NFOC	Strong	Biomarker	[2366]
POU4F1	OTMHYGWQ	Strong	Altered Expression	[2367]
POU4F3	OTILD0XS	Strong	Altered Expression	[2367]
POU5F1	OTDHHN7O	Strong	Biomarker	[2368]
POU5F1B	OT0FKQ51	Strong	Genetic Variation	[2369]
PPFIA2	OT34BLXJ	Strong	Altered Expression	[2370]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[2371]
PPP1R14A	OTQODWZB	Strong	Genetic Variation	[2372]
PPP1R3A	OTJL9VYP	Strong	Altered Expression	[2373]
PPP1R8	OTH5KB2P	Strong	Biomarker	[2271]
PPP2R2C	OTXK0SDM	Strong	Biomarker	[2374]
PRAC1	OT7MCG86	Strong	Genetic Variation	[1726]
PRAC2	OT56IBFQ	Strong	Genetic Variation	[1726]
PRAP1	OT48QD82	Strong	Genetic Variation	[2375]
PRDM2	OT8L7CGX	Strong	Biomarker	[2376]
PRDM6	OTKY12D9	Strong	Biomarker	[1802]
PRDX3	OTLB2WEU	Strong	Biomarker	[428]
PREX1	OTUTPVA9	Strong	Altered Expression	[2377]
PRKAA1	OT7TNF0L	Strong	Biomarker	[1580]
PRKACB	OT6RMDCE	Strong	Biomarker	[2378]
PRLH	OTJBP360	Strong	Altered Expression	[2140]
PRM3	OT6574BF	Strong	Genetic Variation	[2379]
PROK1	OT8S7RUG	Strong	Biomarker	[2380]
PROM2	OTT8IVS7	Strong	Biomarker	[2381]
PRPF8	OTU39JZI	Strong	Biomarker	[2382]
PRRX1	OTTZK5G8	Strong	Biomarker	[993]
PRUNE2	OTGW2974	Strong	Biomarker	[2383]
PSG1	OT1U4ZZW	Strong	Biomarker	[2384]
PSG2	OT2EIXAI	Strong	Biomarker	[2384]
PSG7	OT1IXGBX	Strong	Biomarker	[2384]
PSG8	OT00UZBM	Strong	Biomarker	[2384]
PSMA1	OTNBVM2U	Strong	Biomarker	[1268]
PSMA5	OT38E6Y1	Strong	Biomarker	[2385]
PSMC3IP	OT9UB5UO	Strong	Biomarker	[858]
PSMD14	OTJWHMZ5	Strong	Altered Expression	[2386]
PSME3	OTSTC4YY	Strong	Biomarker	[2387]
PTCD3	OTHTOLE0	Strong	Altered Expression	[2388]
PTGES3	OTPPQWI0	Strong	Altered Expression	[727]
PTMA	OT2W4T1M	Strong	Altered Expression	[2389]
PTPA	OTRGFOI7	Strong	Biomarker	[1578]
PTPN12	OT5WA666	Strong	Biomarker	[2390]
PTPRN2	OTL6SH28	Strong	Genetic Variation	[2391]
PTPRT	OTV5TXNN	Strong	Biomarker	[2392]
PTRH2	OTBU39Q1	Strong	Biomarker	[1058]
PVR	OT3N91T7	Strong	Biomarker	[2393]
PXDN	OTFGGM9R	Strong	Biomarker	[2394]
PXMP4	OTNDYSHU	Strong	Posttranslational Modification	[2395]
PXN	OTVMMUOF	Strong	Biomarker	[2396]
PYCR1	OTQHB52T	Strong	Altered Expression	[2397]
PYDC2	OTRWKIYY	Strong	Biomarker	[551]
PYGO2	OTZHB2OI	Strong	Altered Expression	[2398]
PYHIN1	OT30GD05	Strong	Biomarker	[344]
QRFPR	OT31N14I	Strong	Altered Expression	[2399]
QRSL1	OTJDU2UG	Strong	Altered Expression	[2400]
RAB11FIP5	OTNA33DE	Strong	Biomarker	[2401]
RAB23	OTBAKFBR	Strong	Altered Expression	[2402]
RAB25	OTW0W6NP	Strong	Altered Expression	[2403]
RAB40B	OTCA9ZF5	Strong	Biomarker	[2404]
RAB4B	OTTT4DY3	Strong	Biomarker	[858]
RAB6A	OTLS86J5	Strong	Biomarker	[2405]
RABEPK	OTCZSREH	Strong	Altered Expression	[602]
RABGAP1L	OT7QO47I	Strong	Altered Expression	[2406]
RAC2	OTAOHFNH	Strong	Biomarker	[520]
RALA	OT734R7X	Strong	Biomarker	[2407]
RALGDS	OTG36NI7	Strong	Biomarker	[385]
RAN	OT2TER5M	Strong	Genetic Variation	[2408]
RAP1A	OT5RH6TI	Strong	Biomarker	[1962]
RAP1GDS1	OTH70UHD	Strong	Altered Expression	[2409]
RARRES2	OT1BJE8K	Strong	Biomarker	[2410]
RASAL3	OTPALJBY	Strong	Altered Expression	[2411]
RASD1	OT2BAJHK	Strong	Biomarker	[858]
RASGRF1	OTNWJ7EN	Strong	Biomarker	[722]
RASSF1	OTEZIPB7	Strong	Biomarker	[2412]
RBM25	OTVOUOAG	Strong	Biomarker	[1841]
RBM3	OTAJ7R31	Strong	Biomarker	[2413]
RBMS3	OTFSC9MR	Strong	Biomarker	[1066]
RCBTB2	OTECBF4R	Strong	Biomarker	[2414]
RCC1	OT25AGMB	Strong	Altered Expression	[2414]
RCCD1	OT60N06L	Strong	Genetic Variation	[924]
RCHY1	OTAE7504	Strong	Altered Expression	[2415]
RCN1	OT3JBGAG	Strong	Altered Expression	[2416]
REC8	OT6JAVXE	Strong	Biomarker	[858]
RECQL4	OT59LSW7	Strong	Genetic Variation	[2417]
REST	OTLL92LQ	Strong	Altered Expression	[2418]
RFK	OT77IYIS	Strong	Biomarker	[2419]
RGMB	OT2DROYU	Strong	Biomarker	[667]
RGN	OTD04KB1	Strong	Biomarker	[2420]
RGPD2	OTMUZ0HX	Strong	Biomarker	[1830]
RGS17	OT5RVUDS	Strong	Biomarker	[2421]
RHBDL1	OTSCUCQV	Strong	Biomarker	[2422]
RHEB	OTFLTSEC	Strong	Altered Expression	[2423]
RHOBTB1	OTGE8K45	Strong	Biomarker	[2424]
RHPN2	OTTYWMF6	Strong	Biomarker	[2425]
RING1	OTCWTAX0	Strong	Biomarker	[2426]
RIT1	OTVNOGOH	Strong	Biomarker	[2427]
RLIM	OTEBRNHJ	Strong	Biomarker	[993]
RMC1	OT7K8MTJ	Strong	Altered Expression	[2428]
RMDN1	OTE1NB6U	Strong	Biomarker	[2232]
RMDN2	OTK5WSFI	Strong	Biomarker	[2232]
RMDN3	OTKO7AUM	Strong	Biomarker	[2232]
RMI1	OT1ZVTFL	Strong	Genetic Variation	[2058]
RNASE4	OTA5SZLC	Strong	Biomarker	[858]
RNASEH2C	OTJL9ZRN	Strong	Altered Expression	[2126]
RNASEK	OT1QS1KM	Strong	Biomarker	[2429]
RNF130	OT7DWTFH	Strong	Biomarker	[858]
RNF149	OT6SBKQV	Strong	Altered Expression	[1914]
RNF19A	OTKWCV80	Strong	Altered Expression	[654]
RNF2	OTFPLOIN	Strong	Biomarker	[2430]
RNF20	OT9NK6ZT	Strong	Biomarker	[2431]
RNF31	OT4BZONL	Strong	Biomarker	[344]
RNGTT	OT59E0KX	Strong	Biomarker	[2432]
RNPS1	OT7G4COD	Strong	Altered Expression	[614]
ROBO2	OTFJ9FQW	Strong	Biomarker	[667]
RPAIN	OTBMXAYK	Strong	Biomarker	[1829]
RPL11	OT3VZ6OE	Strong	Biomarker	[667]
RPL12	OTIUAQDN	Strong	Biomarker	[858]
RPL13	OTFKNTD6	Strong	Biomarker	[2433]
RPL19	OT33LM66	Strong	Biomarker	[2434]
RPL22	OTVCN8K0	Strong	Biomarker	[2435]
RPL22L1	OTNWGF5C	Strong	Biomarker	[2435]
RPL29	OTUFIBJL	Strong	Altered Expression	[1081]
RPN2	OTJ1SKOA	Strong	Biomarker	[858]
RPRD2	OTPPH601	Strong	Biomarker	[344]
RPS21	OT6P58W6	Strong	Biomarker	[2435]
RPS24	OTSNKIL5	Strong	Biomarker	[1599]
RPS27A	OTIIGGZ2	Strong	Biomarker	[1202]
RPS7	OTIK25WI	Strong	Altered Expression	[2436]
RRBP1	OT4ZTPTM	Strong	Biomarker	[2422]
RREB1	OT62460U	Strong	Altered Expression	[2437]
RRS1	OTTNCZN6	Strong	Biomarker	[2438]
RTL10	OTHGB81W	Strong	Biomarker	[2439]
RWDD4	OTH18ZIC	Strong	Altered Expression	[1938]
S100A11	OTI57KDN	Strong	Altered Expression	[2440]
S100A2	OTTGHJ1H	Strong	Biomarker	[1095]
S100A7	OTJFVJRF	Strong	Altered Expression	[2441]
SAG	OTDNS3ZQ	Strong	Biomarker	[2442]
SALL1	OTYYZGLH	Strong	Biomarker	[2443]
SAMD5	OT95NRVS	Strong	Altered Expression	[2444]
SAMD9	OTDG48P0	Strong	Biomarker	[344]
SAP30L	OTI15CY4	Strong	Biomarker	[2445]
SARAF	OTH5JIFE	Strong	Biomarker	[551]
SARDH	OTQ49Q27	Strong	Biomarker	[997]
SARM1	OTEP4I5O	Strong	Biomarker	[2446]
SARS1	OTFKXQ1O	Strong	Biomarker	[2447]
SARS2	OTU4T99W	Strong	Biomarker	[2447]
SART3	OTC1AM7S	Strong	Biomarker	[2448]
SCAND1	OTRG0AGH	Strong	Biomarker	[529]
SCARA3	OT46I38Y	Strong	Biomarker	[2449]
SCGN	OTGD7SKH	Strong	Biomarker	[2450]
SCIN	OT6U09OL	Strong	Biomarker	[2451]
SCTR	OTC80IMR	Strong	Biomarker	[2452]
SDCBP	OTS3NCC5	Strong	Biomarker	[2453]
SDF2L1	OTE7JIO2	Strong	Biomarker	[858]
SDF4	OTQ7WFYW	Strong	Biomarker	[1941]
SDHC	OTC8G2MX	Strong	Biomarker	[2454]
SEC14L1	OTA75FET	Strong	Biomarker	[2455]
SELENOP	OT02B8IR	Strong	Altered Expression	[2456]
SELENOS	OTUEWIU9	Strong	Biomarker	[858]
SEMA3B	OTCZCPMS	Strong	Genetic Variation	[2457]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[2458]
SEMA4B	OT1Y3YZD	Strong	Altered Expression	[907]
SEMA4F	OTVP97ZV	Strong	Biomarker	[2459]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[2460]
SEMG1	OT6Z4BPQ	Strong	Biomarker	[2461]
SENP6	OT05LLF4	Strong	Biomarker	[667]
SEPTIN9	OT1VMRFQ	Strong	Biomarker	[2202]
SERINC3	OTQ1LAJ1	Strong	Biomarker	[858]
SERPINA2	OT7UW9HA	Strong	Biomarker	[2462]
SERPINA5	OTTZXPGD	Strong	Altered Expression	[2463]
SERPINB1	OT5RDUFO	Strong	Biomarker	[2464]
SERPINB10	OT5ZM0X6	Strong	Biomarker	[2465]
SERPINB6	OT7G55IK	Strong	Biomarker	[937]
SERPINI1	OTUJHIJW	Strong	Altered Expression	[2466]
SERTAD1	OTBHKZQP	Strong	Biomarker	[2467]
SESN2	OT889IXY	Strong	Biomarker	[2468]
SESN3	OTJRY1Y5	Strong	Biomarker	[548]
SET	OTGYYQJO	Strong	Biomarker	[2469]
SETX	OTG3JNOQ	Strong	Biomarker	[1906]
SF3B2	OTNW2U4Y	Strong	Altered Expression	[2470]
SFRP1	OT0U9G41	Strong	Biomarker	[2471]
SFRP2	OT8GZ0CA	Strong	Biomarker	[1571]
SFTPA2	OT6SFOMU	Strong	Biomarker	[2472]
SFXN1	OTL66767	Strong	Genetic Variation	[2473]
SH2B1	OTJZO2CI	Strong	Biomarker	[1309]
SH2B2	OTEDHHDH	Strong	Genetic Variation	[2474]
SH3BGRL	OTUOCTMT	Strong	Altered Expression	[522]
SH3BP4	OTVIRKW7	Strong	Biomarker	[2475]
SH3GLB1	OTAZ5OP8	Strong	Genetic Variation	[2476]
SH3GLB2	OTF7BB9S	Strong	Altered Expression	[2477]
SHARPIN	OTU1J2KH	Strong	Biomarker	[2478]
SHC1	OT1J5IRN	Strong	Altered Expression	[2479]
SHLD2	OTMLERXL	Strong	Altered Expression	[2480]
SHROOM2	OTZ2FJ7Q	Strong	Genetic Variation	[909]
SIDT1	OTJM5S74	Strong	Genetic Variation	[909]
SIGLEC1	OTNWSQA9	Strong	Altered Expression	[2481]
SIL1	OTDI85I5	Strong	Biomarker	[858]
SIM2	OT0QWHK4	Strong	Biomarker	[2482]
SIN3B	OTFB59FK	Strong	Biomarker	[2483]
SIPA1	OTXY5RXC	Strong	Biomarker	[2484]
SIRT7	OT5M4OT4	Strong	Biomarker	[2485]
SIT1	OT7MDF09	Strong	Genetic Variation	[2486]
SIX1	OT70YYWM	Strong	Posttranslational Modification	[2487]
SKA1	OTDYJ12A	Strong	Biomarker	[2488]
SLC12A9	OTR7VRAK	Strong	Biomarker	[1653]
SLC16A4	OT1YXBKC	Strong	Biomarker	[1114]
SLC26A8	OTNCW8RJ	Strong	Biomarker	[1285]
SLPI	OTUNFUU8	Strong	Biomarker	[862]
SMAD4	OTWQWCKG	Strong	Biomarker	[2489]
SMARCA2	OTSGJ8SV	Strong	Altered Expression	[2490]
SMARCA5	OT5GR4Z2	Strong	Biomarker	[2491]
SMARCAD1	OT90AZTX	Strong	Biomarker	[344]
SMARCAL1	OTTKXLUZ	Strong	Biomarker	[1329]
SMARCE1	OTAX4ITH	Strong	Altered Expression	[2492]
SMC1A	OT9ZMRK9	Strong	Biomarker	[2493]
SMC3	OTWGFRHD	Strong	Biomarker	[1333]
SMS	OT8JYKNH	Strong	Biomarker	[2494]
SNRNP70	OTP52YZ3	Strong	Genetic Variation	[2495]
SNRPN	OTQB1ID1	Strong	Biomarker	[636]
SNW1	OTKWG3PS	Strong	Altered Expression	[2496]
SOCS2	OTBPNKJQ	Strong	Altered Expression	[2497]
SOCS6	OT2O5ZBK	Strong	Altered Expression	[2498]
SOD3	OTIOZQAB	Strong	Biomarker	[2499]
SORBS1	OTWH8762	Strong	Biomarker	[937]
SOS1	OTTCWXC3	Strong	Altered Expression	[1620]
SOX1	OTVI1RAR	Strong	Altered Expression	[2500]
SOX11	OT4LG7LA	Strong	Posttranslational Modification	[2501]
SOX15	OTTB37I1	Strong	Genetic Variation	[2502]
SOX18	OTPUMHWA	Strong	Altered Expression	[559]
SOX4	OTSS40SS	Strong	Biomarker	[2503]
SOX6	OTT0W0LE	Strong	Biomarker	[2504]
SOX9	OTVDJFGN	Strong	Biomarker	[2505]
SP5	OT4HUP9B	Strong	Biomarker	[858]
SPACA9	OTVRFX49	Strong	Biomarker	[2506]
SPAM1	OTMPOB4E	Strong	Biomarker	[2507]
SPANXB1	OTLMGC9T	Strong	Genetic Variation	[1800]
SPARCL1	OT74DWMV	Strong	Biomarker	[2508]
SPATA18	OTOEHTHU	Strong	Biomarker	[344]
SPATA2	OTOA45GL	Strong	Biomarker	[2509]
SPC25	OTCAS0OH	Strong	Altered Expression	[2510]
SPG21	OTMKJSYS	Strong	Biomarker	[2506]
SPINK5	OT61IIAO	Strong	Biomarker	[858]
SPINT2	OTQV7BKQ	Strong	Genetic Variation	[2511]
SPOCK2	OTXSVTSA	Strong	Biomarker	[972]
SRCAP	OT82P6CN	Strong	Altered Expression	[2512]
SRF	OTW18FQN	Strong	Biomarker	[506]
SRL	OT7IEBWZ	Strong	Biomarker	[997]
SRPX	OT5B9LXS	Strong	Altered Expression	[1863]
SRPX2	OT6A63TX	Strong	Biomarker	[2513]
SRRM2	OTSIMMC9	Strong	Biomarker	[1066]
SRRM4	OTALUISN	Strong	Altered Expression	[2514]
SRSF5	OTC5WP98	Strong	Genetic Variation	[2515]
SRY	OT516T6D	Strong	Biomarker	[988]
SSR2	OTQJSL7M	Strong	Biomarker	[858]
ST3GAL1	OTFCO8QX	Strong	Biomarker	[1898]
ST3GAL3	OTOORKUE	Strong	Biomarker	[2516]
ST6GAL1	OT7US3NO	Strong	Biomarker	[2517]
ST6GALNAC3	OTLAQ14Q	Strong	Biomarker	[1699]
STAG1	OT564IX4	Strong	Altered Expression	[2518]
STAMBPL1	OTI4CYTF	Strong	Biomarker	[1221]
STARD10	OTWVNFV4	Strong	Biomarker	[858]
STARD13	OTB4U1HY	Strong	Biomarker	[2519]
STARD8	OTY9IAKW	Strong	Altered Expression	[2520]
STAT5A	OTBSJGN3	Strong	Biomarker	[2521]
STAT5B	OTZVPEBT	Strong	Biomarker	[2521]
STIL	OT9799VN	Strong	Biomarker	[1580]
STING1	OTDAP4G0	Strong	Biomarker	[1173]
STIP1	OT7TXLOX	Strong	Altered Expression	[1632]
STK24	OTGUHOIL	Strong	Biomarker	[2522]
STK26	OTW4QE0D	Strong	Biomarker	[2522]
STUB1	OTSUYI9A	Strong	Biomarker	[2523]
STX1A	OTSBUZB4	Strong	Biomarker	[2524]
STX4	OTQ7YUX1	Strong	Biomarker	[858]
STX6	OTC5F5M6	Strong	Biomarker	[2525]
SUN2	OT2IQJUC	Strong	Genetic Variation	[2526]
SUOX	OTEJQ9FC	Strong	Altered Expression	[2527]
SURF4	OTCSXJ9C	Strong	Biomarker	[858]
SV2B	OTAO5WIU	Strong	Altered Expression	[2528]
SYBU	OT3FQV7N	Strong	Biomarker	[2232]
SYNE1	OTSBSLUH	Strong	Biomarker	[2529]
SYNPO	OTICDJAB	Strong	Biomarker	[2530]
SYP	OTFJKMO4	Strong	Altered Expression	[2531]
SYT1	OTVTPOI6	Strong	Biomarker	[1217]
SYT7	OTBWAOWY	Strong	Altered Expression	[2532]
TAF1	OTDYS5G4	Strong	Altered Expression	[2533]
TAF1L	OT9Z7EVA	Strong	Biomarker	[344]
TAL1	OTX4K6QZ	Strong	Altered Expression	[1231]
TANGO2	OTT9UI89	Strong	Genetic Variation	[1946]
TARBP2	OT1QQ8H3	Strong	Altered Expression	[1545]
TAT	OT2CJ91O	Strong	Biomarker	[2534]
TBATA	OTGDMAAL	Strong	Biomarker	[2535]
TBC1D2	OTSGHPD0	Strong	Biomarker	[344]
TBC1D3	OT1GW0K2	Strong	Altered Expression	[2405]
TBC1D3B	OTIXDB15	Strong	Biomarker	[2405]
TBC1D3D	OTIOU5HX	Strong	Biomarker	[2405]
TBC1D3E	OTNBQN47	Strong	Biomarker	[2405]
TBX15	OTAZ9QDX	Strong	Altered Expression	[2536]
TBX2	OTTOT7A9	Strong	Biomarker	[2537]
TBX3	OTM64N7K	Strong	Biomarker	[667]
TCAF1	OTSQQ37P	Strong	Biomarker	[1084]
TCEAL7	OTNPDZCN	Strong	Biomarker	[993]
TCF12	OTZVONNU	Strong	Altered Expression	[2538]
TCF21	OT393IMA	Strong	Posttranslational Modification	[2539]
TCF7	OT1ID822	Strong	Biomarker	[2540]
TCN1	OTW6A49Y	Strong	Biomarker	[2541]
TCN2	OT41D0L3	Strong	Biomarker	[858]
TCP1	OT1MGUX9	Strong	Biomarker	[878]
TENT5B	OTO2P28B	Strong	Altered Expression	[2542]
TERF2IP	OT3M5P3G	Strong	Altered Expression	[1849]
TES	OTL8PP6V	Strong	Genetic Variation	[2543]
TFAM	OTXXV5V7	Strong	Genetic Variation	[2544]
TFEB	OTJUJJQY	Strong	Altered Expression	[1205]
TFIP11	OT7NVSWU	Strong	Biomarker	[2545]
TGFBR3	OTQOOUC4	Strong	Altered Expression	[2546]
TGIF2LX	OTLBWKZA	Strong	Altered Expression	[2547]
THADA	OTYZQX0F	Strong	Genetic Variation	[2548]
THY1	OTVONVTB	Strong	Biomarker	[2549]
THYN1	OTMRKMPD	Strong	Biomarker	[1058]
TIMM8A	OTDX9687	Strong	Biomarker	[1036]
TJP3	OTC1K8HC	Strong	Biomarker	[858]
TLE3	OTR9PH95	Strong	Biomarker	[2550]
TLE5	OTEH0BFG	Strong	Biomarker	[2551]
TLR10	OTQ1KVJO	Strong	Genetic Variation	[1165]
TM7SF2	OTILU5S7	Strong	Altered Expression	[663]
TMC5	OTO5D86M	Strong	Altered Expression	[2552]
TMED10	OTUXSHH7	Strong	Biomarker	[2553]
TMED9	OTYGAQS0	Strong	Biomarker	[2554]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[2555]
TMEM135	OT63ZT3X	Strong	Biomarker	[2002]
TMEM17	OTEU00OH	Strong	Genetic Variation	[2526]
TMEM30A	OTR6N5J2	Strong	Biomarker	[551]
TMEM41B	OTW0B0KS	Strong	Biomarker	[1298]
TMEM45B	OTVQCO8N	Strong	Biomarker	[2556]
TMOD1	OTTRYF9Y	Strong	Biomarker	[1058]
TMPO	OTL68EL4	Strong	Biomarker	[2135]
TMPRSS4	OTCCGY2K	Strong	Altered Expression	[2557]
TNFAIP8	OT1G9297	Strong	Altered Expression	[2558]
TNFRSF10C	OTVHOL9B	Strong	Altered Expression	[2559]
TNFRSF10D	OTOSRDJT	Strong	Altered Expression	[2560]
TNFSF9	OTV9L89D	Strong	Altered Expression	[2561]
TNIP1	OTRAOTEW	Strong	Altered Expression	[2562]
TNRC6B	OTGVT0SH	Strong	Biomarker	[2563]
TOM1L1	OT37NXR0	Strong	Biomarker	[858]
TOPORS	OT1ERFFQ	Strong	Biomarker	[2564]
TPD52	OTPKSK43	Strong	Biomarker	[2565]
TPD52L1	OTSA6U0I	Strong	Biomarker	[858]
TPD52L2	OTTOG0NK	Strong	Biomarker	[2566]
TPM2	OTA1L0P8	Strong	Genetic Variation	[2567]
TPPP	OTCFMSUF	Strong	Biomarker	[2554]
TRA2B	OTZYQW52	Strong	Altered Expression	[614]
TRAF4	OTJLRVMC	Strong	Biomarker	[1257]
TRIB2	OTHSX3MX	Strong	Altered Expression	[2568]
TRIM11	OTMD6IM2	Strong	Biomarker	[2569]
TRIM16	OTLRXYOZ	Strong	Biomarker	[2570]
TRIM23	OTVIGJ4T	Strong	Biomarker	[2271]
TRIM25	OT35SG1R	Strong	Altered Expression	[1730]
TRIM44	OT0B1T2B	Strong	Biomarker	[2571]
TRIM68	OTHMDMOG	Strong	Altered Expression	[2572]
TRIM8	OTS6JFR0	Strong	Genetic Variation	[909]
TRIP13	OTFM3TI9	Strong	Biomarker	[2573]
TROAP	OTC8CE0R	Strong	Altered Expression	[2574]
TRPS1	OT7XPPEL	Strong	Altered Expression	[2575]
TSGA10	OTIF1O1T	Strong	Altered Expression	[2576]
TSHZ2	OTZWBXXY	Strong	Altered Expression	[2577]
TSHZ3	OTAN7RY5	Strong	Posttranslational Modification	[2577]
TSPAN1	OTZQPIYK	Strong	Biomarker	[2578]
TSPY1	OTPY57X4	Strong	Biomarker	[2579]
TSPY3	OTQK3AKI	Strong	Biomarker	[2579]
TSPYL5	OT7QEI2X	Strong	Biomarker	[2580]
TTC9C	OTMOWK6Z	Strong	Biomarker	[858]
TTLL12	OTJQ8RF4	Strong	Biomarker	[2581]
ABHD2	OTCRUOCS	Definitive	Altered Expression	[2582]
ACOT7	OT7C68YV	Definitive	Biomarker	[643]
ACTBL2	OTD6B81U	Definitive	Biomarker	[643]
ADAM19	OTH88TXU	Definitive	Altered Expression	[2583]
ADGRA2	OTBT4W36	Definitive	Genetic Variation	[1338]
AFAP1L2	OTJBI0VN	Definitive	Biomarker	[2584]
ANGPTL2	OTB6JG41	Definitive	Altered Expression	[1358]
ANXA7	OTLMD0TK	Definitive	Altered Expression	[2585]
AP1S2	OTZHJFYI	Definitive	Biomarker	[2586]
ARSF	OTC0L12N	Definitive	Altered Expression	[2587]
ATOX1	OT05LF59	Definitive	Altered Expression	[2588]
ATRIP	OT78O9LF	Definitive	Biomarker	[1338]
BHLHE22	OTZUQY5L	Definitive	Altered Expression	[2589]
BIRC6	OTCQJAB0	Definitive	Altered Expression	[264]
BRD8	OTIKS3PC	Definitive	Biomarker	[2590]
BTNL2	OTTTEMZA	Definitive	Genetic Variation	[2591]
CAPS	OTC9GZ2M	Definitive	Genetic Variation	[2592]
CBX2	OTOQ5WS4	Definitive	Biomarker	[2593]
CCL18	OT7JYSK9	Definitive	Altered Expression	[2594]
CCL19	OTQ2UJMH	Definitive	Altered Expression	[2595]
CCS	OTXHT3QO	Definitive	Altered Expression	[2588]
CDO1	OTLG1P77	Definitive	Posttranslational Modification	[2596]
CEBPD	OTNBIPMY	Definitive	Altered Expression	[2597]
CERS2	OTRAHYYP	Definitive	Altered Expression	[1375]
CLEC2D	OTVRLKPM	Definitive	Biomarker	[2598]
CSH1	OT33HTRR	Definitive	Genetic Variation	[1538]
CSH2	OTW8JVAN	Definitive	Genetic Variation	[1538]
CTBS	OT135K92	Definitive	Altered Expression	[1259]
CTDSPL	OTZJ0CZK	Definitive	Biomarker	[287]
DIXDC1	OT87DXEG	Definitive	Altered Expression	[2599]
DLD	OT378CU9	Definitive	Biomarker	[2600]
DLEC1	OTMKKBUW	Definitive	Altered Expression	[2601]
DNAJB7	OT4BOECZ	Definitive	Biomarker	[2602]
DSG2	OTJPB2TO	Definitive	Biomarker	[2603]
DSP	OTB2MOP8	Definitive	Biomarker	[2604]
EFNA2	OTEAUKRX	Definitive	Biomarker	[2605]
EIF3A	OTFABY9G	Definitive	Biomarker	[425]
ERCC6	OT2QZKSF	Definitive	Genetic Variation	[1538]
FABP9	OTTAEGAN	Definitive	Biomarker	[2606]
FLRT2	OTGD8TID	Definitive	Biomarker	[2607]
FRK	OTEKV1SC	Definitive	Genetic Variation	[1451]
GLCE	OTPRSHX5	Definitive	Altered Expression	[2608]
GLUD1	OTXKOCUH	Definitive	Altered Expression	[2609]
GPR4	OTIBF32I	Definitive	Altered Expression	[2610]
GPX2	OTXI2NTI	Definitive	Biomarker	[2611]
GPX4	OTRAFFX2	Definitive	Genetic Variation	[2612]
GREB1	OTU6ZA26	Definitive	Biomarker	[2613]
HEY1	OTJQL0I3	Definitive	Biomarker	[2614]
HIP1R	OTIPKEJC	Definitive	Altered Expression	[2615]
HNRNPC	OT47AK4C	Definitive	Biomarker	[1478]
HNRNPDL	OTB3BFCV	Definitive	Biomarker	[1478]
HOXB13	OTRMYHI9	Definitive	Autosomal dominant	[1243]
IARS1	OT9WXH5N	Definitive	Altered Expression	[2616]
INTS6	OT6GDV46	Definitive	Biomarker	[2617]
IRX4	OT0TV6WK	Definitive	Altered Expression	[2618]
KLRB1	OTQ2959Y	Definitive	Biomarker	[2598]
LCP1	OTK61F2A	Definitive	Genetic Variation	[2619]
LPXN	OTUNV3CK	Definitive	Posttranslational Modification	[1396]
MAD2L2	OT24ZO59	Definitive	Biomarker	[1247]
MAL	OTBM30SW	Definitive	Biomarker	[2620]
MCAT	OTH07FIW	Definitive	Altered Expression	[1233]
MCTS1	OT7SAOJP	Definitive	Altered Expression	[1233]
MLPH	OT7ADCXL	Definitive	Genetic Variation	[2621]
MLST8	OT8DNJSD	Definitive	Altered Expression	[2622]
MSC	OTBRPZL5	Definitive	Biomarker	[2623]
MSH5	OTDARQT3	Definitive	Genetic Variation	[2624]
MX1	OT6X8G5T	Definitive	Altered Expression	[2625]
NAB2	OTG4BDF3	Definitive	Posttranslational Modification	[2626]
NANS	OTMQ2FUH	Definitive	Biomarker	[2602]
NKAIN2	OTI4H30Z	Definitive	Altered Expression	[2627]
NLGN4Y	OT7E1S57	Definitive	Biomarker	[2628]
OPCML	OT93PQ6Y	Definitive	Biomarker	[2607]
PCDH10	OT2GIT0E	Definitive	Posttranslational Modification	[2629]
PDCD10	OTCHJTSF	Definitive	Biomarker	[2630]
PDLIM2	OTEURRPD	Definitive	Biomarker	[2631]
PEX6	OTFAK5EF	Definitive	Genetic Variation	[2632]
PFKFB4	OTQYEXL2	Definitive	Altered Expression	[2633]
PFN1	OTHTGA1H	Definitive	Altered Expression	[2634]
PIK3R1	OT5BZ1J9	Definitive	Altered Expression	[1400]
PKP1	OT9HSQ8F	Definitive	Altered Expression	[2635]
PLEKHH3	OTREOQBO	Definitive	Biomarker	[1338]
POTEM	OT7L2HGH	Definitive	Biomarker	[643]
PPP1R13L	OTNCPLWE	Definitive	Altered Expression	[2636]
PRC1	OTHD0XS0	Definitive	Altered Expression	[2637]
PRIMA1	OT9ITT3P	Definitive	Genetic Variation	[2638]
PROX1	OT68R6IO	Definitive	Biomarker	[2639]
PSMD4	OTH1VZTM	Definitive	Altered Expression	[2587]
RABGEF1	OTWC3Z3R	Definitive	Altered Expression	[2640]
RAD50	OTYMU9G1	Definitive	Biomarker	[2641]
RAD51B	OTCJVRMY	Definitive	Genetic Variation	[2624]
RASGRP3	OTEMEV3P	Definitive	Altered Expression	[2642]
RB1CC1	OTZK8PFX	Definitive	Altered Expression	[1838]
RBBP5	OT12W2MK	Definitive	Biomarker	[2643]
RBL1	OTDEBFYC	Definitive	Altered Expression	[2644]
RLN1	OTL6QNHG	Definitive	Altered Expression	[2645]
RLN2	OTY3OG71	Definitive	Biomarker	[2646]
RNASE3	OTVE2XD1	Definitive	Altered Expression	[2647]
RNF41	OTN1DQOY	Definitive	Biomarker	[2648]
SEC23A	OTBRNIJ3	Definitive	Altered Expression	[2649]
SGTA	OTKOJ3JB	Definitive	Altered Expression	[2650]
SHISA2	OT4GMTML	Definitive	Biomarker	[2651]
SMURF1	OT5UIZR8	Definitive	Altered Expression	[2652]
SND1	OTT734JN	Definitive	Biomarker	[2653]
SPINT1	OT1CLR5L	Definitive	Altered Expression	[1242]
SRSF1	OTF61HOV	Definitive	Altered Expression	[2587]
STARD3	OTSTC5B5	Definitive	Altered Expression	[2654]
TET1	OTZDHT1D	Definitive	Altered Expression	[2655]
THOC1	OTVABJ4Z	Definitive	Biomarker	[875]
TIMP4	OT8A68SW	Definitive	Altered Expression	[2656]
TMOD4	OTXLGJ4R	Definitive	Biomarker	[2657]
TNFAIP8L2	OTII0RM0	Definitive	Biomarker	[2658]
TP53AIP1	OT1XVNDP	Definitive	Genetic Variation	[2659]
TP53INP1	OT2363Z9	Definitive	Biomarker	[2660]
TPR	OTUBBA4W	Definitive	Genetic Variation	[2661]
TRIM29	OT2DNESG	Definitive	Biomarker	[2662]
TRRAP	OT68OI2Y	Definitive	Genetic Variation	[2663]
TSPAN13	OTCS9BZY	Definitive	Biomarker	[2664]
TSPAN31	OT8WQ83R	Definitive	Biomarker	[2602]
TSPAN8	OT1F68WQ	Definitive	Biomarker	[2665]
TTF1	OT4K90WD	Definitive	Biomarker	[2600]

This Disease Is Related to 1146 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADCYAP1R1	TT5OREU	Limited	Genetic Variation	[248]
ADRA1D	TT34BHT	Limited	Altered Expression	[249]
AGK	TTJETQC	Limited	Biomarker	[250]
AGR2	TT9K86S	Limited	Altered Expression	[251]
AHR	TT037IE	Limited	Altered Expression	[252]
AKR1C3	TT5ZWB6	Limited	Biomarker	[253]
ALOX12	TT12ABZ	Limited	Altered Expression	[254]
ALOX12B	TTQ4QQH	Limited	Biomarker	[255]
AMHR2	TTZDCPK	Limited	Altered Expression	[256]
ANG	TTURHFP	Limited	Altered Expression	[257]
APEX1	TTHGL48	Limited	Genetic Variation	[258]
AREG	TT76B3W	Limited	Altered Expression	[259]
ATM	TTKBM7V	Limited	Autosomal dominant	[247]
ATR	TT8ZYBQ	Limited	Biomarker	[260]
AURKB	TT9RTBL	Limited	Biomarker	[261]
BAP1	TT47RXJ	Limited	Genetic Variation	[262]
BCL2	TTFOUV4	Limited	Altered Expression	[263]
BIRC3	TTAIWZN	Limited	Altered Expression	[264]
BMP2	TTP3IGX	Limited	Altered Expression	[265]
CACNA2D2	TTU8P3M	Limited	Biomarker	[266]
CALCA	TTVSFJW	Limited	Altered Expression	[267]
CBR1	TTVG0SN	Limited	Genetic Variation	[268]
CCK	TT90CMU	Limited	Genetic Variation	[269]
CCKBR	TTVFO0U	Limited	Biomarker	[270]
CCL5	TT9DWLC	Limited	Biomarker	[271]
CCN1	TTPK79J	Limited	Altered Expression	[272]
CCR4	TT7HQD0	Limited	Biomarker	[273]
CCR6	TTFDB30	Limited	Genetic Variation	[274]
CCR7	TT2GIDQ	Limited	Biomarker	[275]
CD33	TTJVYO3	Limited	Biomarker	[276]
CD59	TTBGTEJ	Limited	Biomarker	[277]
CD9	TTZEIBV	Limited	Altered Expression	[278]
CDC20	TTBKFDV	Limited	Biomarker	[279]
CDK5	TTL4Q97	Limited	Biomarker	[280]
CDK8	TTBJR4L	Limited	Altered Expression	[281]
CEBPB	TTUI35N	Limited	Biomarker	[282]
CFD	TT8D13I	Limited	Altered Expression	[283]
CFLAR	TTJZQYH	Limited	Genetic Variation	[284]
CGA	TTFC29G	Limited	Biomarker	[285]
CHUK	TT1F8OQ	Limited	Posttranslational Modification	[286]
CLCN2	TT30NW6	Limited	Biomarker	[287]
CLIC1	TT8KZG6	Limited	Biomarker	[288]
CNTN1	TTPR8FK	Limited	Biomarker	[289]
CREB1	TTH4AN3	Limited	Biomarker	[290]
CREBBP	TTFRCTK	Limited	Biomarker	[291]
CRY2	TTAO58M	Limited	Genetic Variation	[292]
CRYAB	TT7RUHB	Limited	Biomarker	[293]
CRYZ	TTP6UO8	Limited	Genetic Variation	[294]
CSNK2A2	TT7GR5W	Limited	Biomarker	[295]
CTSD	TTPT2QI	Limited	Biomarker	[296]
CXXC5	TTVS4C3	Limited	Altered Expression	[297]
CYP2B6	TTMH124	Limited	Genetic Variation	[298]
CYP2C19	TTZ58XG	Limited	Biomarker	[299]
DDR2	TTU98HG	Limited	Biomarker	[300]
DKK1	TTE3RAC	Limited	Altered Expression	[301]
DNM2	TTVRA5G	Limited	Biomarker	[302]
DNMT1	TT6S2FE	Limited	Posttranslational Modification	[303]
DYRK1B	TTYGQ8A	Limited	Biomarker	[304]
E2F3	TTWIJYH	Limited	Altered Expression	[305]
EDNRB	TT3ZTGU	Limited	Biomarker	[306]
EGR1	TTE8LGD	Limited	Altered Expression	[307]
EIF2AK2	TTXEZJ4	Limited	Biomarker	[308]
EIF4EBP1	TTKGEBL	Limited	Biomarker	[309]
EML4	TT92GY4	Limited	Biomarker	[310]
EPCAM	TTZ8WH4	Limited	Biomarker	[311]
EPHA1	TTLFZVU	Limited	Altered Expression	[312]
EPHA5	TTV9KOD	Limited	Posttranslational Modification	[313]
EPHA6	TTFAHWI	Limited	Biomarker	[314]
ESRRB	TTKF0XS	Limited	Altered Expression	[315]
F3	TT38MDJ	Limited	Altered Expression	[316]
FANCA	TTV5HJS	Limited	Genetic Variation	[317]
FDPS	TTIKWV4	Limited	Biomarker	[318]
FGF19	TTGCH11	Limited	Biomarker	[319]
FKBP4	TTHY0FT	Limited	Biomarker	[320]
FLT4	TTDCBX5	Limited	Biomarker	[321]
FOXP1	TT0MUCI	Limited	Biomarker	[322]
FTH1	TT975ZT	Limited	Biomarker	[323]
FUS	TTKGYZ9	Limited	Biomarker	[324]
GAS6	TT69QD2	Limited	Biomarker	[325]
GDF15	TT4MXVG	Limited	Biomarker	[326]
GGT1	TTZVT7O	Limited	Altered Expression	[327]
GHRL	TT1OCL0	Limited	Biomarker	[328]
GHSR	TTWDC17	Limited	Biomarker	[329]
GJA1	TT4F7SL	Limited	Biomarker	[330]
GLIPR1	TTEQF1O	Limited	Altered Expression	[331]
GNRHR	TT8R70G	Limited	Biomarker	[332]
GRK5	TTTCXO0	Limited	Biomarker	[333]
GSK3B	TTRSMW9	Limited	Biomarker	[334]
GSR	TTEP6RV	Limited	Altered Expression	[335]
HAAO	TTWON83	Limited	Posttranslational Modification	[336]
HAMP	TTRV5YJ	Limited	Biomarker	[337]
HCRTR1	TT60Q8D	Limited	Biomarker	[338]
HCRTR2	TT9N02I	Limited	Biomarker	[338]
HEXIM1	TTFOKAH	Limited	Altered Expression	[339]
HMGA1	TTBA219	Limited	Altered Expression	[340]
HMGB2	TTA78JQ	Limited	Biomarker	[341]
HMOX1	TTI6V2A	Limited	Biomarker	[342]
HNRNPA2B1	TT8UPW6	Limited	Biomarker	[343]
HRAS	TT28ZON	Limited	Biomarker	[344]
HSD11B1	TTN7BL9	Limited	Biomarker	[345]
HSD17B1	TTIWB6L	Limited	Biomarker	[346]
HTATIP2	TTC6IX5	Limited	Altered Expression	[347]
ICA1	TTMX06B	Limited	Biomarker	[348]
ID1	TTBXVDE	Limited	Altered Expression	[349]
IDO1	TTZJYKH	Limited	Altered Expression	[350]
IFNB1	TT4TZ8J	Limited	Biomarker	[351]
IGFBP1	TTCJTWF	Limited	Genetic Variation	[352]
IGFBP5	TTDWEA8	Limited	Biomarker	[353]
IL11RA	TTZPLJS	Limited	Biomarker	[354]
IL15	TTJFA35	Limited	Biomarker	[355]
IL15RA	TTGN89I	Limited	Biomarker	[356]
IL1RN	TT6GSR3	Limited	Genetic Variation	[357]
IL24	TT1EPXZ	Limited	Biomarker	[358]
IL25	TTVMO5W	Limited	Biomarker	[359]
IL7R	TTAWI51	Limited	Altered Expression	[360]
IMP3	TTEJA2R	Limited	Altered Expression	[361]
INHBA	TTVB30D	Limited	Biomarker	[362]
INSR	TTCBFJO	Limited	Altered Expression	[363]
ITCH	TT5SEWD	Limited	Altered Expression	[364]
ITGA4	TTJMF9P	Limited	Posttranslational Modification	[365]
ITGB3	TTJA1ZO	Limited	Altered Expression	[366]
ITK	TT3C80U	Limited	Biomarker	[367]
ITPR1	TT5HWAT	Limited	Biomarker	[368]
ITPR2	TTK9OV3	Limited	Biomarker	[368]
JAK1	TT6DM01	Limited	Biomarker	[344]
KAT6B	TTH4VJL	Limited	Altered Expression	[369]
KDM1A	TTNR0UQ	Limited	Biomarker	[370]
KDM4A	TTZHPB8	Limited	Biomarker	[371]
LAMP2	TTULDG7	Limited	Biomarker	[372]
LAPTM4B	TTEJQT0	Limited	Biomarker	[373]
LARP1	TTSN1YP	Limited	Biomarker	[374]
LGALS1	TTO3NYT	Limited	Altered Expression	[375]
LHCGR	TT2O4W9	Limited	Biomarker	[376]
LIMK1	TTWL9TY	Limited	Biomarker	[377]
LYN	TT1RWNJ	Limited	Biomarker	[378]
M6PR	TT95ICL	Limited	Biomarker	[379]
MAGEA3	TTWSKHD	Limited	Biomarker	[380]
MAP2K7	TT6QY3J	Limited	Altered Expression	[381]
MAP3K11	TTETX6Q	Limited	Altered Expression	[382]
MAP4	TT0VFPN	Limited	Biomarker	[287]
MAPK3	TT1MG9E	Limited	Biomarker	[383]
MARK2	TTAJ45Y	Limited	Altered Expression	[384]
MAZ	TT059DA	Limited	Altered Expression	[385]
MBTPS1	TTNSM2I	Limited	Biomarker	[386]
MC1R	TT0MV2T	Limited	Genetic Variation	[387]
MET	TTNDSF4	Limited	Biomarker	[388]
MLH1	TTISG27	Limited	Autosomal dominant	[247]
MRC2	TTYVR8M	Limited	Biomarker	[389]
MTA1	TTO4HUS	Limited	Biomarker	[390]
MTAP	TTDBX7N	Limited	Biomarker	[391]
MTDH	TTH6SA5	Limited	Biomarker	[392]
MTNR1A	TT0WAIE	Limited	Altered Expression	[393]
MTR	TTUTO39	Limited	Genetic Variation	[394]
MVD	TTE5J6X	Limited	Biomarker	[395]
NAAA	TTMN4HY	Limited	Biomarker	[396]
NCOA3	TT124R0	Limited	Biomarker	[397]
NDUFA13	TTRU1NG	Limited	Biomarker	[398]
NFE2L2	TTA6ZN2	Limited	Biomarker	[399]
NGF	TTDN3LF	Limited	Biomarker	[400]
NPPC	TTRK0B9	Limited	Biomarker	[401]
NR3C1	TTOZRK6	Limited	Altered Expression	[402]
NRG4	TTWAGKJ	Limited	Altered Expression	[403]
NTSR1	TTTUMEP	Limited	Altered Expression	[404]
OLFM4	TTK1CX7	Limited	Biomarker	[405]
OPHN1	TTU7HRD	Limited	Biomarker	[406]
P2RY2	TTOZHQC	Limited	Biomarker	[407]
PAK1	TTFN95D	Limited	Altered Expression	[408]
PAOX	TTNQ760	Limited	Biomarker	[409]
PARP1	TTVDSZ0	Limited	Biomarker	[410]
PAWR	TT3I4WV	Limited	Biomarker	[411]
PCSK9	TTNIZ2B	Limited	Altered Expression	[412]
PDE4A	TTZ97H5	Limited	Biomarker	[413]
PDGFB	TTQA6SX	Limited	Biomarker	[414]
PGR	TTUV8G9	Limited	Biomarker	[402]
PGRMC1	TTY3LAZ	Limited	Biomarker	[415]
PHB	TT6U071	Limited	Altered Expression	[416]
PHGDH	TT8DRCK	Limited	Altered Expression	[417]
PI4KA	TTCUS9F	Limited	Biomarker	[418]
PIN1	TTJNTSI	Limited	Altered Expression	[419]
PKM	TT4LOT8	Limited	Biomarker	[420]
PLA2G1B	TT9V5JH	Limited	Biomarker	[421]
PLA2R1	TTHKW7D	Limited	Altered Expression	[422]
PLG	TTP86E2	Limited	Biomarker	[423]
PLK4	TTGPNZQ	Limited	Biomarker	[424]
PMS1	TTX1ISF	Limited	Biomarker	[344]
POLA1	TTGPJ0U	Limited	Biomarker	[425]
PPP3CA	TTA4LDE	Limited	Altered Expression	[426]
PPP5C	TTTW7FJ	Limited	Altered Expression	[427]
PRDX4	TTPBL9I	Limited	Biomarker	[428]
PRKCA	TTFJ8Q1	Limited	Biomarker	[429]
PRKCB	TTYPXQF	Limited	Biomarker	[429]
PRKCE	TT57MT2	Limited	Biomarker	[430]
PRSS8	TTT4N0Q	Limited	Biomarker	[431]
PSIP1	TTH9LDP	Limited	Biomarker	[432]
PTGER1	TTG1QMU	Limited	Altered Expression	[433]
PTGER2	TT1ZAVI	Limited	Biomarker	[434]
PTGER3	TTPNGDE	Limited	Altered Expression	[435]
PTGS1	TT8NGED	Limited	Genetic Variation	[436]
PTK7	TTXH2ZN	Limited	Biomarker	[437]
PTN	TTA9EJK	Limited	Altered Expression	[438]
PTP4A1	TTA8GFO	Limited	Altered Expression	[439]
PTPN6	TT369M5	Limited	Biomarker	[440]
PTPN7	TT2C1DT	Limited	Biomarker	[441]
RAD51	TTC0G1L	Limited	Altered Expression	[442]
RAPGEF4	TTOS63B	Limited	Autosomal dominant	[247]
RARA	TTW38KT	Limited	Biomarker	[443]
RGMA	TTURJV4	Limited	Altered Expression	[444]
RNF43	TTD91BL	Limited	Biomarker	[344]
RNF6	TT4S09X	Limited	Biomarker	[445]
ROCK1	TTZN7RP	Limited	Altered Expression	[446]
ROS1	TTSZ6Y3	Limited	Biomarker	[447]
RPS6KA1	TTIXKA4	Limited	Biomarker	[448]
RPS6KA2	TT0ZW9O	Limited	Biomarker	[448]
RRM2	TT1S4LJ	Limited	Altered Expression	[449]
S100A4	TTPR5SX	Limited	Biomarker	[450]
S100A8	TT4AF6N	Limited	Biomarker	[451]
S1PR5	TTDZCKV	Limited	Biomarker	[452]
SATB1	TTLFRIC	Limited	Altered Expression	[453]
SCARB1	TTRE324	Limited	Altered Expression	[345]
SCGB1A1	TTONPVW	Limited	Biomarker	[454]
SDC1	TTYDSVG	Limited	Biomarker	[455]
SEPTIN6	TTAGE7U	Limited	Altered Expression	[456]
SF3B1	TTL2WUI	Limited	Biomarker	[457]
SGK1	TTTV8EJ	Limited	Altered Expression	[458]
SIK2	TTCUGZR	Limited	Altered Expression	[459]
SIRT1	TTUF2HO	Limited	Biomarker	[460]
SLC22A3	TTG2UMS	Limited	Biomarker	[367]
SLC5A5	TTW7HI9	Limited	Biomarker	[461]
SORT1	TTRX9AV	Limited	Altered Expression	[404]
SOST	TTYRO4F	Limited	Altered Expression	[462]
SPHK1	TTOHFIY	Limited	Biomarker	[463]
SPHK2	TTCN0M9	Limited	Biomarker	[464]
SQSTM1	TTOT2RY	Limited	Biomarker	[465]
SRPK2	TTCZEJ9	Limited	Altered Expression	[466]
SSTR3	TTJX3UE	Limited	Biomarker	[467]
ST14	TTPRO7W	Limited	Biomarker	[468]
STAR	TTEI40H	Limited	Altered Expression	[469]
STC1	TTDLUER	Limited	Altered Expression	[470]
SULF2	TTLQTHB	Limited	Altered Expression	[471]
TACSTD2	TTP2HE5	Limited	Biomarker	[472]
TAGLN	TTDRZ9H	Limited	Altered Expression	[473]
TAP1	TT7JZI8	Limited	Biomarker	[344]
TBK1	TTMP03S	Limited	Biomarker	[474]
TCF7L2	TT80QAL	Limited	Biomarker	[475]
TDGF1	TTN7HMG	Limited	Biomarker	[476]
TEK	TT9VGXW	Limited	Biomarker	[477]
TEP1	TTQGAVX	Limited	Altered Expression	[478]
TF	TT8WXAV	Limited	Altered Expression	[479]
TGFB2	TTI0KH6	Limited	Biomarker	[480]
TLR9	TTSHG0T	Limited	Altered Expression	[481]
TNFRSF10B	TTW20TU	Limited	Biomarker	[482]
UCHL1	TTX9IFP	Limited	Biomarker	[483]
UGT1A1	TT34ZAF	Limited	Genetic Variation	[484]
VDAC1	TTAMKGB	Limited	Biomarker	[485]
VIP	TTGTWLF	Limited	Altered Expression	[486]
WWP2	TT6TU05	Limited	Altered Expression	[487]
XRCC5	TTCB9KW	Limited	Altered Expression	[488]
ZEB2	TTT2WK4	Limited	Biomarker	[489]
AGTR1	TT8DBY3	Disputed	Biomarker	[490]
ATAD2	TT9A0HI	Disputed	Biomarker	[491]
BUB1	TT78309	Disputed	Biomarker	[492]
CBS	TTVZJ7G	Disputed	Altered Expression	[493]
CD163	TTTZ9DE	Disputed	Biomarker	[494]
DGAT2	TTRHEQ4	Disputed	Genetic Variation	[495]
DUSP1	TTG8HIM	Disputed	Biomarker	[441]
EPHA3	TTHS2LR	Disputed	Altered Expression	[496]
FABP5	TTNT2S6	Disputed	Altered Expression	[497]
FCGR3A	TTIFOC0	Disputed	Genetic Variation	[498]
FGF1	TTMY81X	Disputed	Biomarker	[499]
IL11	TTGUYTR	Disputed	Biomarker	[500]
KNG1	TTDJ4MY	Disputed	Altered Expression	[501]
LPAR3	TTE2YJR	Disputed	Biomarker	[502]
LTB4R2	TTVJX54	Disputed	Biomarker	[503]
MUSK	TT6SA0X	Disputed	Biomarker	[504]
NPR1	TTM9IYA	Disputed	Altered Expression	[505]
PKN1	TTSL41O	Disputed	Altered Expression	[506]
REG4	TTVZEHU	Disputed	Altered Expression	[507]
SLC22A1	TTM5Q4V	Disputed	Altered Expression	[508]
SMAD9	TTX8EBV	Disputed	Altered Expression	[509]
SMARCA4	TTVQEZS	Disputed	Altered Expression	[510]
ABCC4	TTUEAFL	moderate	Biomarker	[511]
ABCG1	TTMWDGU	moderate	Altered Expression	[512]
AKT3	TTO6SGY	moderate	Altered Expression	[513]
ALCAM	TT2AFT6	moderate	Biomarker	[514]
ALPI	TTHYMUV	moderate	Biomarker	[515]
ANO1	TTOJI4S	moderate	Altered Expression	[516]
AOX1	TT3MOS2	moderate	Genetic Variation	[517]
ARG2	TTV1AG6	moderate	Biomarker	[518]
AXL	TTZPY6J	moderate	Biomarker	[519]
BCL2L1	TTRE6AX	moderate	Biomarker	[520]
BTK	TTGM6VW	moderate	Biomarker	[521]
CAPN2	TTG5QB7	moderate	Genetic Variation	[522]
CASP5	TTWR48J	moderate	Genetic Variation	[523]
CCNA2	TTAMQ62	moderate	Biomarker	[524]
CCR1	TTC24WT	moderate	Biomarker	[525]
CCR3	TTD3XFU	moderate	Biomarker	[526]
CD38	TTPURFN	moderate	Biomarker	[527]
CD3E	TTZAT79	moderate	Biomarker	[528]
CD47	TT28S46	moderate	Biomarker	[515]
CDC37	TT5SOEU	moderate	Biomarker	[529]
CDK1	TTH6V3D	moderate	Altered Expression	[530]
CDK7	TTQYF7G	moderate	Biomarker	[531]
CDKL1	TTBTI6P	moderate	Biomarker	[532]
CRBN	TTDKGTC	moderate	Altered Expression	[533]
CX3CL1	TT1OFBQ	moderate	Altered Expression	[534]
CX3CR1	TT2T98G	moderate	Altered Expression	[535]
CXCL1	TTLK1RW	moderate	Biomarker	[536]
CXCR5	TTIW59R	moderate	Altered Expression	[537]
CYP2E1	TTWVHQ5	moderate	Genetic Variation	[538]
DAPK3	TTERVQN	moderate	Altered Expression	[539]
DNASE1	TTYWGOJ	moderate	Biomarker	[540]
DPEP1	TTYUENF	moderate	Biomarker	[541]
DPP4	TTDIGC1	moderate	Biomarker	[542]
DUSP10	TTF3RJ0	moderate	Biomarker	[543]
EIF5A	TTIVCNR	moderate	Altered Expression	[544]
EPAS1	TTWPA54	moderate	Biomarker	[545]
EPHA2	TTRJB2G	moderate	Biomarker	[546]
EPHX2	TT7WVHI	moderate	Altered Expression	[547]
EZR	TTE47YC	moderate	Biomarker	[548]
F2RL2	TTVSEBF	moderate	Biomarker	[549]
FDFT1	TTFQEO5	moderate	Biomarker	[550]
FHIT	TTMS54D	moderate	Genetic Variation	[551]
FOXC2	TTLBAP1	moderate	Biomarker	[552]
FSCN1	TTTRS9B	moderate	Biomarker	[553]
FTO	TTFW3BT	moderate	Genetic Variation	[554]
GABRE	TTBY4OD	moderate	Altered Expression	[555]
GPNMB	TT7315J	moderate	Biomarker	[556]
GSK3A	TTQWAU1	moderate	Altered Expression	[557]
HMGCR	TTPADOQ	moderate	Biomarker	[558]
HNF1A	TT01M3K	moderate	Altered Expression	[559]
HOXA13	TTN26OM	moderate	Altered Expression	[560]
HSF1	TTN6STZ	moderate	Biomarker	[561]
HTR1B	TTK8CXU	moderate	Genetic Variation	[562]
IAPP	TTHN8EM	moderate	Biomarker	[515]
ITGA5	TTHIZP9	moderate	Biomarker	[563]
ITGA6	TT165T3	moderate	Altered Expression	[564]
KDM4C	TTV8CRH	moderate	Biomarker	[565]
KISS1	TTU2O6T	moderate	Biomarker	[566]
KLK14	TTDA81R	moderate	Biomarker	[567]
KLK6	TTLPF4X	moderate	Genetic Variation	[568]
KMT5A	TTGC95K	moderate	Genetic Variation	[569]
KRT19	TT3JF9E	moderate	Biomarker	[570]
LANCL1	TTZW8NS	moderate	Altered Expression	[571]
LASP1	TTZJA87	moderate	Altered Expression	[572]
LATS2	TTML7FG	moderate	Altered Expression	[573]
LILRB1	TTC0QRJ	moderate	Biomarker	[574]
LMO2	TTFX379	moderate	Altered Expression	[575]
LPA	TTU9LGY	moderate	Biomarker	[576]
LPAR1	TTQ6S1K	moderate	Biomarker	[432]
LPL	TTOF3WZ	moderate	Posttranslational Modification	[577]
LTA4H	TTXZEAJ	moderate	Genetic Variation	[578]
MELK	TTBZOTY	moderate	Altered Expression	[579]
MGAT1	TTYJRN5	moderate	Biomarker	[580]
MMP13	TTHY57M	moderate	Altered Expression	[481]
MSH2	TTCAWRT	Moderate	Autosomal dominant	[247]
NCF1	TTZ4JC3	moderate	Altered Expression	[581]
NLRP1	TTQX29T	moderate	Genetic Variation	[582]
NR4A1	TTMXE2Q	moderate	Altered Expression	[583]
NUF2	TTIXBFP	moderate	Altered Expression	[584]
OLR1	TTKSND3	moderate	Biomarker	[585]
OSM	TTIVXSE	moderate	Biomarker	[586]
OXER1	TT7WBSV	moderate	Altered Expression	[587]
PARP2	TTQ4V96	moderate	Biomarker	[588]
PDE11A	TTTWC79	moderate	Genetic Variation	[589]
PLAC1	TTM18HX	moderate	Altered Expression	[590]
PRDX5	TTLPJWH	moderate	Genetic Variation	[591]
PRKAR2B	TTW4Y2M	moderate	Altered Expression	[592]
PRKCZ	TTBSN0L	moderate	Biomarker	[593]
PSMB6	TT8EPLT	moderate	Biomarker	[594]
PSMB9	TTOUSTQ	moderate	Biomarker	[595]
PTGES2	TTWU04I	moderate	Genetic Variation	[578]
PTP4A3	TT7YM8D	moderate	Biomarker	[596]
RACK1	TTJ10AL	moderate	Biomarker	[597]
RAPGEF3	TTOE7I0	moderate	Biomarker	[598]
REN	TTB2MXP	moderate	Biomarker	[599]
RICTOR	TT143WL	moderate	Biomarker	[600]
RIPK1	TTVJHX8	moderate	Biomarker	[601]
RPSA	TTLUW5B	moderate	Altered Expression	[602]
RUNX1	TTWIN3H	moderate	Biomarker	[603]
RXFP1	TTMAHD1	moderate	Biomarker	[604]
SCD	TT6RIOV	moderate	Biomarker	[605]
SLC18A2	TTNZRI3	moderate	Altered Expression	[606]
SLC2A12	TTZO36H	moderate	Biomarker	[607]
SLC39A6	TTZN1CF	moderate	Altered Expression	[608]
SLC7A5	TTPH2JB	moderate	Biomarker	[609]
SLCO2B1	TTDL3UZ	moderate	Altered Expression	[610]
SMAD1	TT9GR53	moderate	Biomarker	[611]
SMYD3	TTKLJYX	moderate	Altered Expression	[612]
SQLE	TTE14XG	moderate	Biomarker	[613]
SRPK1	TTU3WV6	moderate	Altered Expression	[614]
STAT1	TTN7R6K	moderate	Biomarker	[615]
TERF1	TT1Y6J2	moderate	Altered Expression	[616]
TMPRSS11D	TTWHYC8	moderate	Biomarker	[617]
TMPRSS6	TTL9KE7	moderate	Biomarker	[618]
TNC	TTUCPMY	moderate	Altered Expression	[619]
TNFSF15	TTEST6I	moderate	Biomarker	[620]
TPX2	TT0PHL4	moderate	Biomarker	[621]
TRIM59	TT613U4	moderate	Biomarker	[622]
TXNRD1	TTR7UJ3	moderate	Altered Expression	[623]
TXNRD3	TTDYFVB	moderate	Biomarker	[624]
USP1	TTG9MT5	moderate	Biomarker	[625]
USP2	TTUEQ1W	moderate	Altered Expression	[626]
USP7	TTXU3EQ	moderate	Biomarker	[344]
VIPR1	TTCL30I	moderate	Altered Expression	[627]
WDR5	TT7OFWB	moderate	Altered Expression	[628]
XPO1	TTCJUR4	moderate	Altered Expression	[629]
ZNF217	TTY3BRA	moderate	Altered Expression	[630]
ZWINT	TTWY768	moderate	Biomarker	[631]
ABCA1	TTJW1GN	Strong	Biomarker	[632]
ABCB1	TT3OT40	Strong	Biomarker	[633]
ABCC1	TTOI92F	Strong	Genetic Variation	[634]
ABCG2	TTIMJ02	Strong	Genetic Variation	[635]
ABCG5	TTKZ7WY	Strong	Altered Expression	[636]
ACAT1	TTK3C21	Strong	Biomarker	[637]
ACHE	TT1RS9F	Strong	Biomarker	[638]
ACKR3	TTRQJTC	Strong	Altered Expression	[639]
ACLY	TT0Z6Y2	Strong	Altered Expression	[640]
ACO2	TTMTF2P	Strong	Biomarker	[641]
ACR	TTAHE2N	Strong	Biomarker	[642]
ACTG1	TTGAZF9	Strong	Biomarker	[643]
ACVR1	TTJNBQA	Strong	Biomarker	[644]
ACVR2A	TTX2DRI	Strong	Altered Expression	[645]
ACVRL1	TTGYPTC	Strong	Biomarker	[646]
ADAM10	TTVXEGU	Strong	Biomarker	[647]
ADAM17	TT6AZXG	Strong	Altered Expression	[648]
ADAM8	TTQWYMD	Strong	Biomarker	[649]
ADAM9	TTTYQNS	Strong	Altered Expression	[650]
ADCYAP1	TTW4LYC	Strong	Altered Expression	[248]
ADIPOQ	TTXKA7D	Strong	Altered Expression	[651]
ADM	TTV14YH	Strong	Altered Expression	[652]
ADRA1A	TTNGILX	Strong	Altered Expression	[639]
ADRA2B	TTWM4TY	Strong	Altered Expression	[639]
AGTR2	TTQVOEI	Strong	Biomarker	[653]
AIMP2	TTXWHGF	Strong	Altered Expression	[654]
AKT2	TTH24WI	Strong	Biomarker	[655]
ALAD	TTJHKYD	Strong	Biomarker	[656]
ALAS1	TTG1FXO	Strong	Biomarker	[657]
ALKBH5	TTOHB1M	Strong	Biomarker	[658]
ALOX15	TTN9T81	Strong	Altered Expression	[659]
ALPL	TTMR5UV	Strong	Biomarker	[660]
AMD1	TTBFROQ	Strong	Biomarker	[661]
AMOT	TTI48OS	Strong	Biomarker	[662]
ANGPT1	TTWNQ1T	Strong	Altered Expression	[663]
ANGPT2	TTKLQTJ	Strong	Biomarker	[664]
ANGPTL4	TTWALY5	Strong	Altered Expression	[665]
ANO7	TT2X79I	Strong	Biomarker	[666]
ANTXR2	TTOD34I	Strong	Biomarker	[667]
ANXA1	TTUCK4B	Strong	Altered Expression	[668]
ANXA10	TT0NL6U	Strong	Altered Expression	[669]
ANXA2	TT4YANI	Strong	Biomarker	[670]
ANXA5	TT2Z83I	Strong	Biomarker	[671]
AQP1	TTSF1KH	Strong	Altered Expression	[672]
AQP3	TTLDNMQ	Strong	Biomarker	[673]
AQP7	TTNGCRK	Strong	Altered Expression	[674]
AQP9	TTQEI32	Strong	Altered Expression	[674]
ARF1	TT70KXY	Strong	Altered Expression	[675]
ARRB2	TT8SO2I	Strong	Altered Expression	[676]
ARSB	TTESQTG	Strong	Biomarker	[677]
ASRGL1	TT4WT91	Strong	Biomarker	[678]
ATF4	TTQCKWT	Strong	Biomarker	[679]
ATG7	TTLVB9Z	Strong	Biomarker	[680]
ATP7B	TTOPO51	Strong	Biomarker	[681]
AVPR2	TTK8R02	Strong	Biomarker	[682]
AZGP1	TTUPYLV	Strong	Biomarker	[683]
B2M	TTY7FKA	Strong	Biomarker	[684]
BACH1	TT2ME4S	Strong	Altered Expression	[685]
BAX	TTQ57WJ	Strong	Altered Expression	[686]
BAZ2A	TT2MV0R	Strong	Biomarker	[687]
BAZ2B	TT6K8YG	Strong	Biomarker	[687]
BBC3	TT7JUKC	Strong	Altered Expression	[688]
BCAT1	TTES57P	Strong	Biomarker	[689]
BCL2A1	TTGT9C7	Strong	Biomarker	[690]
BGN	TT0JPVF	Strong	Altered Expression	[691]
BIRC2	TTQ5LRD	Strong	Biomarker	[692]
BIRC5	TTTPU1G	Strong	Biomarker	[693]
BIRC7	TTHZ8TA	Strong	Altered Expression	[694]
BMI1	TTIPNSR	Strong	Biomarker	[695]
BMP1	TT0L58T	Strong	Biomarker	[696]
BMP10	TTTG6H1	Strong	Biomarker	[697]
BMP7	TTKOBRA	Strong	Biomarker	[698]
BMPR2	TTGKF90	Strong	Biomarker	[699]
BMX	TTN2I9E	Strong	Biomarker	[521]
BRAF	TT0EOB8	Strong	Biomarker	[700]
BRD4	TTSRAOU	Strong	Biomarker	[701]
BRD7	TT07ZS1	Strong	Altered Expression	[702]
BRIP1	TTZV7LJ	Strong	Genetic Variation	[703]
BRPF1	TTT46BN	Strong	Biomarker	[344]
BRS3	TTKYEPM	Strong	Altered Expression	[639]
BSG	TT5UJWD	Strong	Biomarker	[704]
BTG1	TTL7N2W	Strong	Biomarker	[705]
CACNA1D	TT7RGTM	Strong	Biomarker	[706]
CAD	TT2YT1K	Strong	Biomarker	[707]
CAMKK2	TTV298Y	Strong	Biomarker	[708]
CARM1	TTIZQFJ	Strong	Biomarker	[709]
CASP1	TTCQIBE	Strong	Biomarker	[710]
CASP2	TT12VNG	Strong	Biomarker	[711]
CASP7	TTM7Y45	Strong	Biomarker	[712]
CCL11	TTCF05Y	Strong	Altered Expression	[534]
CCL20	TT2XAZY	Strong	Altered Expression	[713]
CCL21	TTLZK1U	Strong	Biomarker	[714]
CCL22	TTBTWI1	Strong	Biomarker	[273]
CCNB1	TT9P6OW	Strong	Genetic Variation	[715]
CCNE1	TTCEJ4F	Strong	Altered Expression	[716]
CCNE2	TTLDRGX	Strong	Altered Expression	[717]
CCR2	TTFZYTO	Strong	Biomarker	[273]
CCR5	TTJIH8Q	Strong	Altered Expression	[526]
CCR9	TTIPS8B	Strong	Genetic Variation	[274]
CD24	TTCTYNP	Strong	Altered Expression	[718]
CD46	TTMS7DF	Strong	Altered Expression	[315]
CD69	TTPQE9F	Strong	Biomarker	[719]
CDC25A	TTLZS4Q	Strong	Altered Expression	[720]
CDC25B	TTR0SWN	Strong	Biomarker	[721]
CDC25C	TTESBNC	Strong	Biomarker	[722]
CDCA8	TT04YCM	Strong	Biomarker	[723]
CDH11	TTRGWZC	Strong	Biomarker	[724]
CDH2	TT1WS0T	Strong	Genetic Variation	[725]
CDK12	TTJ21A9	Strong	Genetic Variation	[726]
CDK19	TTNABU9	Strong	Altered Expression	[281]
CDK5R1	TTBYM6V	Strong	Altered Expression	[727]
CDK6	TTO0FDJ	Strong	Biomarker	[728]
CDK9	TT1LVF2	Strong	Biomarker	[729]
CEACAM5	TTY6DTE	Strong	Altered Expression	[730]
CEACAM6	TTIGH2W	Strong	Altered Expression	[731]
CEBPA	TT5LWG1	Strong	Biomarker	[732]
CENPE	TTZD5QR	Strong	Altered Expression	[733]
CGB3	TTUH273	Strong	Altered Expression	[734]
CHKA	TT10AWB	Strong	Altered Expression	[735]
CHRM1	TTZ9SOR	Strong	Biomarker	[736]
CHRM3	TTQ13Z5	Strong	Altered Expression	[737]
CLCN3	TT8XNZ7	Strong	Altered Expression	[738]
CLDN4	TTMTS9H	Strong	Biomarker	[739]
CLK2	TT85TPS	Strong	Biomarker	[740]
CNR1	TT6OEDT	Strong	Biomarker	[741]
CRAT	TTC8M31	Strong	Biomarker	[742]
CRK	TTFEUYR	Strong	Altered Expression	[654]
CRTC1	TT4GO0F	Strong	Biomarker	[743]
CRTC2	TTFWETR	Strong	Biomarker	[744]
CSF1	TT0IQER	Strong	Biomarker	[745]
CSF1R	TT7MRDV	Strong	Biomarker	[746]
CSNK1E	TTA8PLI	Strong	Biomarker	[747]
CSNK2A1	TTER6YH	Strong	Biomarker	[748]
CTAG1A	TTE5ITK	Strong	Genetic Variation	[749]
CTH	TTLQUZS	Strong	Altered Expression	[750]
CTSB	TTF2LRI	Strong	Biomarker	[751]
CTSE	TTLXC4Q	Strong	Biomarker	[752]
CTSK	TTDZN01	Strong	Biomarker	[753]
CTSL	TT36ETB	Strong	Biomarker	[754]
CUL3	TTPCU0Q	Strong	Biomarker	[344]
CXCL11	TTWG0RE	Strong	Altered Expression	[755]
CXCL13	TT0NIZ1	Strong	Altered Expression	[537]
CXCL9	TTWE5PB	Strong	Biomarker	[756]
CXCR3	TT1UCIJ	Strong	Altered Expression	[757]
CXCR6	TT2BVUA	Strong	Altered Expression	[639]
CYP11A1	TTSYVO6	Strong	Biomarker	[758]
CYP11B2	TT9MNE2	Strong	Biomarker	[759]
CYP19A1	TTSZLWK	Strong	Biomarker	[760]
CYP1A2	TTS1DTU	Strong	Genetic Variation	[761]
CYP2A6	TTAQ6ZW	Strong	Biomarker	[299]
DAG1	TT4X7PG	Strong	Altered Expression	[762]
DCK	TTJOCE4	Strong	Biomarker	[763]
DCLK1	TTOHTCY	Strong	Altered Expression	[764]
DCN	TTB3XAN	Strong	Biomarker	[765]
DCTPP1	TTZ1YIS	Strong	Biomarker	[766]
DDC	TTN451K	Strong	Biomarker	[767]
DDIT4	TTVEOY6	Strong	Biomarker	[768]
DDX5	TTZKPVC	Strong	Biomarker	[769]
DEK	TT1NMGV	Strong	Biomarker	[770]
DEPDC1	TT8S9CM	Strong	Biomarker	[771]
DEPTOR	TTLYP6D	Strong	Biomarker	[772]
DGAT1	TT0GV3R	Strong	Altered Expression	[773]
DHCR24	TTTK0NH	Strong	Biomarker	[774]
DIABLO	TTN74LE	Strong	Therapeutic	[775]
DLL3	TT1C9K6	Strong	Biomarker	[776]
DLL4	TTV23LH	Strong	Altered Expression	[777]
DNAJB1	TTPXAWS	Strong	Biomarker	[778]
DRD1	TTZFYLI	Strong	Altered Expression	[779]
DUSP3	TTIFAYS	Strong	Biomarker	[780]
DUSP5	TTZN92A	Strong	Altered Expression	[781]
E2F2	TT5FYX0	Strong	Biomarker	[782]
ECE1	TTQ9RYT	Strong	Biomarker	[783]
EDNRA	TTKRD0G	Strong	Altered Expression	[639]
EGLN1	TT9ISBX	Strong	Biomarker	[784]
EHMT2	TTS6RZT	Strong	Altered Expression	[785]
EIF4E	TTZGCP6	Strong	Biomarker	[309]
EIF4EBP2	TTNBTCW	Strong	Biomarker	[786]
EIF5A2	TTH53G9	Strong	Altered Expression	[787]
ENG	TTB30LE	Strong	Biomarker	[788]
ENPEP	TT9PBIL	Strong	Biomarker	[789]
ENPP1	TTZTIWS	Strong	Biomarker	[790]
ENPP2	TTSCIM2	Strong	Altered Expression	[791]
EPHA7	TTAHTVG	Strong	Altered Expression	[792]
EPHB2	TTKPV6O	Strong	Biomarker	[793]
EPHB4	TTI4ZX2	Strong	Biomarker	[794]
EPHB6	TTZEMUY	Strong	Altered Expression	[795]
EPOR	TTAUX24	Strong	Biomarker	[796]
EREG	TTYSB89	Strong	Genetic Variation	[797]
ERF	TTGXULC	Strong	Biomarker	[344]
ERN1	TTKIAT3	Strong	Biomarker	[798]
ESRRA	TTPNQAC	Strong	Biomarker	[799]
ESRRG	TT9ZRHB	Strong	Biomarker	[800]
ETS1	TTTGPSD	Strong	Biomarker	[801]
ETS2	TT9AH0M	Strong	Biomarker	[390]
EYA2	TTUY9C6	Strong	Altered Expression	[802]
EZH1	TTNJA0C	Strong	Biomarker	[803]
F11R	TT3C8EG	Strong	Genetic Variation	[804]
F13A1	TTXI2RA	Strong	Genetic Variation	[805]
F13B	TTAXGIP	Strong	Altered Expression	[806]
F2R	TTL935N	Strong	Biomarker	[807]
F2RL1	TTQR74A	Strong	Altered Expression	[808]
F2RL3	TTD0652	Strong	Biomarker	[411]
FABP4	TTHWMFZ	Strong	Biomarker	[809]
FAP	TTGPQ0F	Strong	Biomarker	[810]
FASLG	TTO7014	Strong	Genetic Variation	[811]
FASN	TT7AOUD	Strong	Biomarker	[812]
FAT1	TTGUJYV	Strong	Biomarker	[813]
FECH	TTQ6VF4	Strong	Biomarker	[814]
FER	TTRA9G0	Strong	Altered Expression	[815]
FFAR1	TTB8FUC	Strong	Altered Expression	[816]
FFAR4	TT08JVB	Strong	Altered Expression	[817]
FGF10	TTNPEFX	Strong	Biomarker	[818]
FGF23	TT2IZ4K	Strong	Altered Expression	[819]
FGF7	TTFY134	Strong	Biomarker	[818]
FGF8	TTIUF3J	Strong	Altered Expression	[820]
FKBP1A	TTMW94E	Strong	Biomarker	[821]
FKBP5	TT0J5KQ	Strong	Biomarker	[821]
FKBP7	TTO1ENI	Strong	Altered Expression	[822]
FLNA	TTSTRZY	Strong	Altered Expression	[823]
FN1	TTPJ921	Strong	Biomarker	[824]
FOS	TTOM5AU	Strong	Altered Expression	[825]
FOSL1	TTY8LZG	Strong	Biomarker	[826]
FOXC1	TTNT3YA	Strong	Biomarker	[827]
FOXM1	TTD3KOX	Strong	Altered Expression	[828]
FOXP3	TT1X3QF	Strong	Biomarker	[829]
FST	TTDNM9W	Strong	Altered Expression	[830]
FUT3	TTUPAD7	Strong	Altered Expression	[831]
FUT4	TTNV1KZ	Strong	Biomarker	[276]
FYN	TT2B9KF	Strong	Altered Expression	[832]
G3BP1	TTG0R8Z	Strong	Altered Expression	[833]
GAD2	TT7UY6K	Strong	Genetic Variation	[834]
GADD45B	TTMDW9L	Strong	Altered Expression	[835]
GALNS	TTT9YPO	Strong	Altered Expression	[836]
GAN	TT6WNG2	Strong	Genetic Variation	[837]
GATA3	TT45KOB	Strong	Biomarker	[838]
GCK	TTDLNGZ	Strong	Biomarker	[607]
GDF2	TTAP4T1	Strong	Biomarker	[644]
GGH	TTZJRL0	Strong	Biomarker	[839]
GHRHR	TTG4R8V	Strong	Genetic Variation	[840]
GJB1	TTSJIRP	Strong	Altered Expression	[841]
GLI1	TTJOMH6	Strong	Biomarker	[842]
GLO1	TTV9A7R	Strong	Biomarker	[843]
GLP1R	TTVIMDE	Strong	Biomarker	[844]
GLUL	TTURQ2G	Strong	Biomarker	[845]
GNRH1	TT0ID4A	Strong	Biomarker	[846]
GPC3	TTJTSX4	Strong	Altered Expression	[847]
GPER1	TTDSB34	Strong	Biomarker	[848]
GPR39	TTTPCNU	Strong	Altered Expression	[849]
GPRC6A	TTI1PRE	Strong	Biomarker	[502]
GREM1	TTOUZN5	Strong	Posttranslational Modification	[850]
GRHL2	TTUGH4C	Strong	Altered Expression	[851]
GRK2	TTAZ3MN	Strong	Biomarker	[852]
GRK3	TT5A4DX	Strong	Biomarker	[853]
GRM1	TTVBPDM	Strong	Biomarker	[854]
GRM7	TT0I76D	Strong	Genetic Variation	[855]
GSN	TTUH7OM	Strong	Altered Expression	[856]
GSTA2	TTNLFBE	Strong	Genetic Variation	[857]
GSTO1	TTWO3SH	Strong	Biomarker	[858]
GUSB	TTHS7CM	Strong	Biomarker	[859]
HAO1	TTS58YO	Strong	Biomarker	[858]
HBEGF	TT15SL0	Strong	Biomarker	[860]
HDAC1	TT6R7JZ	Strong	Biomarker	[861]
HDAC2	TTSHTOI	Strong	Biomarker	[862]
HDAC3	TT4YWTO	Strong	Biomarker	[863]
HDAC4	TTTQGH8	Strong	Genetic Variation	[864]
HDAC9	TT8M4E1	Strong	Altered Expression	[865]
HGF	TT4V2JM	Strong	Biomarker	[388]
HK2	TTK02H8	Strong	Biomarker	[866]
HMGA2	TTSTVM0	Strong	Biomarker	[867]
HMGB1	TTWQYB7	Strong	Biomarker	[868]
HMGCS1	TTQF4TK	Strong	Biomarker	[869]
HMGCS2	TTS0EZJ	Strong	Altered Expression	[870]
HNF4A	TT2F3CD	Strong	Biomarker	[871]
HNMT	TT2B6EV	Strong	Biomarker	[872]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[873]
HPD	TT8DSFC	Strong	Biomarker	[874]
HPSE	TTR7GJO	Strong	Biomarker	[875]
HSD17B13	TTDJYZR	Strong	Biomarker	[876]
HSD17B2	TT0PT1R	Strong	Biomarker	[877]
HSP90AB1	TTH5YN2	Strong	Biomarker	[878]
HSP90B1	TTFPKXQ	Strong	Biomarker	[878]
HSPA5	TTW26OG	Strong	Biomarker	[879]
HSPA9	TTMTPG3	Strong	Biomarker	[880]
HSPB1	TT9AZWY	Strong	Altered Expression	[881]
HSPB3	TTLH8WG	Strong	Altered Expression	[881]
HSPB8	TTY0OJN	Strong	Altered Expression	[882]
HSPD1	TT9HL5R	Strong	Biomarker	[883]
HSPG2	TT5UM29	Strong	Biomarker	[884]
ICAM1	TTA1L39	Strong	Altered Expression	[885]
ID2	TTW8A5N	Strong	Biomarker	[886]
IDH1	TTV2A1R	Strong	Genetic Variation	[887]
IFNL3	TTRF4Q2	Strong	Biomarker	[888]
IGF2R	TTPNE41	Strong	Altered Expression	[889]
IGFBP2	TTU4QSN	Strong	Biomarker	[352]
IGFBP6	TTLAYV8	Strong	Biomarker	[890]
IGFBP7	TTUQ01B	Strong	Posttranslational Modification	[891]
IKBKB	TTJ3E9X	Strong	Biomarker	[286]
IL12A	TTRTK6Y	Strong	Biomarker	[892]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[893]
IL17D	TTC5LTG	Strong	Biomarker	[894]
IL18	TTRICUF	Strong	Genetic Variation	[895]
IL2RB	TT9721Y	Strong	Altered Expression	[896]
IL4R	TTDWHC3	Strong	Biomarker	[897]
IL7	TT8FRMO	Strong	Altered Expression	[360]
IL9	TT0JTFD	Strong	Altered Expression	[602]
IMPDH2	TTTB4UP	Strong	Altered Expression	[898]
INS	TTZOPHG	Strong	Biomarker	[899]
IRS2	TTF95B8	Strong	Posttranslational Modification	[900]
ITGAM	TTB69FJ	Strong	Biomarker	[901]
ITGAV	TTT1R2L	Strong	Biomarker	[563]
ITGB1	TTBVIQC	Strong	Altered Expression	[902]
ITPR3	TTH1769	Strong	Altered Expression	[903]
JAK2	TTRMX3V	Strong	Biomarker	[904]
JUN	TTS7IR5	Strong	Biomarker	[905]
JUP	TTREN0G	Strong	Biomarker	[858]
KAT2B	TTVK7SB	Strong	Altered Expression	[906]
KAT6A	TT6O1J0	Strong	Biomarker	[667]
KCNH2	TTQ6VDM	Strong	Altered Expression	[907]
KCNMA1	TTE87WJ	Strong	Biomarker	[908]
KCNN3	TT9JH25	Strong	Genetic Variation	[909]
KCNN4	TT7M9I6	Strong	Biomarker	[910]
KDM3A	TTKXS4A	Strong	Biomarker	[911]
KDM5C	TT94UCF	Strong	Altered Expression	[912]
KDM6B	TTDIJUQ	Strong	Biomarker	[913]
KDM7A	TT0NYMP	Strong	Biomarker	[914]
KDR	TTUTJGQ	Strong	Biomarker	[915]
KEAP1	TT3Z6Y9	Strong	Biomarker	[344]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[916]
KIF11	TTBGTCW	Strong	Biomarker	[917]
KLB	TTARBVH	Strong	Altered Expression	[918]
KLF4	TTTI53X	Strong	Biomarker	[919]
KLK1	TT5T3P6	Strong	Biomarker	[920]
KLK4	TT4319X	Strong	Biomarker	[921]
KLK7	TTE6GTB	Strong	Altered Expression	[922]
KMT2A	TT1GNDM	Strong	Biomarker	[344]
KPNB1	TTHOJ5F	Strong	Altered Expression	[923]
KRAS	TTM8FR7	Strong	Genetic Variation	[700]
L3MBTL3	TTQDMJN	Strong	Genetic Variation	[924]
LAMP1	TTC214J	Strong	Biomarker	[925]
LBP	TTVQJLY	Strong	Biomarker	[926]
LCK	TT860QF	Strong	Biomarker	[927]
LDHA	TTW76JE	Strong	Biomarker	[928]
LDLR	TTH0DUS	Strong	Altered Expression	[929]
LGMN	TTPTWV5	Strong	Biomarker	[930]
LGR4	TTY6C71	Strong	Biomarker	[931]
LIF	TTGZ5WN	Strong	Biomarker	[932]
LIFR	TTID542	Strong	Biomarker	[933]
LIMK2	TTASMD8	Strong	Biomarker	[934]
LIN28A	TTO50LN	Strong	Biomarker	[935]
LIPA	TTS8T1M	Strong	Biomarker	[936]
LNPEP	TTY2KP7	Strong	Biomarker	[937]
LOX	TTQHNAM	Strong	Biomarker	[938]
LOXL2	TTFSUHX	Strong	Altered Expression	[939]
LPAR2	TTB7Y8I	Strong	Altered Expression	[639]
LRP5	TT7VMG4	Strong	Biomarker	[940]
LRP6	TTSXOWE	Strong	Biomarker	[941]
LSM1	TT2KHSC	Strong	Altered Expression	[942]
LTBR	TTFO0PM	Strong	Biomarker	[943]
LTF	TTSZDQU	Strong	Altered Expression	[944]
LY6D	TTINE9B	Strong	Biomarker	[945]
MAG	TT9XFON	Strong	Biomarker	[946]
MAGEA2	TTOZT28	Strong	Biomarker	[947]
MAGEA6	TTJIWMO	Strong	Altered Expression	[948]
MAGEC1	TT9M6NA	Strong	Genetic Variation	[949]
MAGEC2	TTKGUEB	Strong	Biomarker	[950]
MAN2A1	TT34DCN	Strong	Altered Expression	[815]
MAOA	TT3WG5C	Strong	Altered Expression	[951]
MAP2K5	TTV3O87	Strong	Biomarker	[952]
MAP3K1	TTW8TJI	Strong	Biomarker	[667]
MAP3K3	TTJZNIG	Strong	Altered Expression	[953]
MAP3K8	TTGECUM	Strong	Genetic Variation	[954]
MAP4K4	TT6NI13	Strong	Biomarker	[955]
MAPK14	TTQBR95	Strong	Altered Expression	[654]
MAPK8	TT0K6EO	Strong	Biomarker	[290]
MAPK9	TT3IVG2	Strong	Biomarker	[956]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[957]
MARCKS	TTHRM39	Strong	Biomarker	[958]
MAT2A	TTSMPXQ	Strong	Altered Expression	[959]
MBOAT4	TTSYOWR	Strong	Biomarker	[960]
MC2R	TTPWFDX	Strong	Biomarker	[858]
MCAM	TTHRE05	Strong	Biomarker	[961]
MCL1	TTL53M6	Strong	Altered Expression	[962]
MCM7	TT1RM3F	Strong	Biomarker	[963]
MECP2	TTTAU9R	Strong	Biomarker	[964]
MERTK	TTO7LKR	Strong	Biomarker	[965]
METAP2	TTZL0OI	Strong	Altered Expression	[966]
MGLL	TTZ963I	Strong	Biomarker	[967]
MIF	TT6804T	Strong	Biomarker	[968]
MKI67	TTB4UNG	Strong	Altered Expression	[969]
MLH1	TTISG27	Strong	Biomarker	[970]
MME	TT5TKPM	Strong	Biomarker	[971]
MMP14	TTJ4QE7	Strong	Altered Expression	[972]
MMP16	TTNP4CU	Strong	Biomarker	[973]
MRGPRX1	TTIX6PK	Strong	Biomarker	[502]
MSI2	TTTXQF6	Strong	Biomarker	[974]
MST1R	TTBQ3OC	Strong	Biomarker	[975]
MYCN	TT9JBY5	Strong	Biomarker	[976]
MYLK	TT18ETS	Strong	Altered Expression	[977]
NACC1	TT4AQ5F	Strong	Biomarker	[351]
NAGLU	TTDM6HZ	Strong	Biomarker	[858]
NCK1	TTMA3VF	Strong	Biomarker	[978]
NCL	TTK1V5Q	Strong	Biomarker	[979]
NCOA4	TT8OY02	Strong	Genetic Variation	[980]
NCR1	TTQNRJM	Strong	Biomarker	[981]
NEDD4	TT1QU6G	Strong	Altered Expression	[982]
NEDD8	TTNDC4K	Strong	Biomarker	[983]
NEDD9	TT1UREA	Strong	Biomarker	[984]
NEK1	TTO5QT2	Strong	Biomarker	[985]
NEK6	TT8I2M7	Strong	Altered Expression	[986]
NKX3-1	TT1E0JK	Strong	Biomarker	[987]
NME1	TTDY8JH	Strong	Genetic Variation	[988]
NODAL	TTK2O1Q	Strong	Posttranslational Modification	[989]
NOTCH4	TTXDIK2	Strong	Altered Expression	[990]
NOX4	TTQRBSJ	Strong	Biomarker	[991]
NPM1	TTHBS98	Strong	Biomarker	[992]
NPR3	TTWVLS6	Strong	Biomarker	[993]
NR0B2	TT25A9Q	Strong	Altered Expression	[994]
NR1H2	TTXA6PH	Strong	Genetic Variation	[995]
NR1H3	TTECBXN	Strong	Biomarker	[996]
NR1I2	TT7LCTF	Strong	Biomarker	[997]
NR3C2	TT26PHO	Strong	Biomarker	[998]
NR4A2	TT9HKN3	Strong	Altered Expression	[999]
NR5A2	TTAU3SY	Strong	Altered Expression	[1000]
NRP1	TTIPJCB	Strong	Altered Expression	[1001]
NRP2	TTRXUVC	Strong	Biomarker	[1002]
NT5E	TTK0O6Y	Strong	Altered Expression	[1003]
NTSR2	TT31Q0V	Strong	Altered Expression	[404]
OR51E2	TTZRE3C	Strong	Biomarker	[502]
ORAI1	TTE76YK	Strong	Biomarker	[1004]
P2RX7	TT473XN	Strong	Genetic Variation	[1005]
P2RY1	TTA93TL	Strong	Biomarker	[1006]
P2RY12	TTZ1DT0	Strong	Altered Expression	[1007]
P4HA1	TTNH25W	Strong	Altered Expression	[1008]
PAK4	TT7Y3BZ	Strong	Genetic Variation	[520]
PAX5	TTA4REJ	Strong	Altered Expression	[1009]
PBK	TTMY6BZ	Strong	Biomarker	[1010]
PBRM1	TTH8ZRL	Strong	Biomarker	[1011]
PCNA	TTLG1PD	Strong	Altered Expression	[1012]
PCSK1	TTED9LZ	Strong	Altered Expression	[1013]
PCSK6	TT75LN9	Strong	Biomarker	[1014]
PDCD1LG2	TTW14O3	Strong	Biomarker	[1015]
PDGFD	TTSN0GA	Strong	Biomarker	[1016]
PDK1	TTCZOF2	Strong	Posttranslational Modification	[1017]
PDZK1	TTDTBLM	Strong	Biomarker	[858]
PEBP1	TT1BGU8	Strong	Altered Expression	[1018]
PECAM1	TT4EZB2	Strong	Altered Expression	[1019]
PF4	TTSG7Q5	Strong	Biomarker	[1020]
PFKFB3	TTTHMQJ	Strong	Biomarker	[1021]
PGF	TT48I1Y	Strong	Altered Expression	[1022]
PHF8	TT81PFE	Strong	Biomarker	[1023]
PIM2	TT69J2Z	Strong	Biomarker	[1024]
PINX1	TT4FJ3A	Strong	Genetic Variation	[1025]
PIP5K1A	TTA7DU1	Strong	Biomarker	[1026]
PKLR	TT31N4S	Strong	Altered Expression	[1027]
PKN2	TTTHO0M	Strong	Biomarker	[1028]
PLA2G2A	TTO8QRU	Strong	Genetic Variation	[1029]
PLA2G4A	TTT1JVS	Strong	Altered Expression	[1030]
PLA2G7	TTDNFMT	Strong	Altered Expression	[1031]
PLAU	TTGY7WI	Strong	Biomarker	[1032]
PLAUR	TTNOSTX	Strong	Biomarker	[1033]
PLCG1	TT6T4JI	Strong	Altered Expression	[1034]
PLD1	TT3T17P	Strong	Altered Expression	[1035]
PLD2	TTRLMKF	Strong	Altered Expression	[1036]
PLK1	TTH4IP0	Strong	Biomarker	[1037]
PLN	TTMCVJF	Strong	Genetic Variation	[1038]
PML	TTLH9NY	Strong	Biomarker	[1039]
PNP	TTMCF1Y	Strong	Biomarker	[1040]
POLB	TTA0XPV	Strong	Genetic Variation	[1041]
PON1	TT9LX82	Strong	Genetic Variation	[1042]
POSTN	TT8ALTZ	Strong	Altered Expression	[1043]
PPARA	TTJ584C	Strong	Altered Expression	[1044]
PPARD	TT2JWF6	Strong	Altered Expression	[1045]
PPARGC1B	TTKSQ3W	Strong	Biomarker	[1046]
PPIA	TTL2ADK	Strong	Biomarker	[1047]
PPID	TTNAFOU	Strong	Biomarker	[1048]
PPM1A	TTLA7IX	Strong	Altered Expression	[1049]
PPP2CA	TTHTKNY	Strong	Altered Expression	[1050]
PPT1	TTSQC14	Strong	Altered Expression	[1051]
PRCP	TTTJZ4M	Strong	Biomarker	[696]
PRKACA	TT5U49F	Strong	Biomarker	[1052]
PRKCI	TTWJTHX	Strong	Biomarker	[1053]
PRKD1	TTSLUMT	Strong	Altered Expression	[1054]
PRKDC	TTK3PY9	Strong	Altered Expression	[1055]
PRL	TTJ2TSA	Strong	Altered Expression	[1056]
PRMT5	TTR1D7X	Strong	Biomarker	[1057]
PRNP	TTY5F9C	Strong	Biomarker	[1058]
PROM1	TTXMZ81	Strong	Biomarker	[1059]
PRTN3	TT5MLC4	Strong	Biomarker	[1060]
PSCA	TT9T4AV	Strong	Biomarker	[1061]
PSEN2	TTWN3F4	Strong	Biomarker	[1062]
PSMB5	TT68GPI	Strong	Biomarker	[1063]
PSMD10	TT2H4LN	Strong	Biomarker	[1064]
PTAFR	TTQL5VC	Strong	Biomarker	[1065]
PTBP1	TTWMX0U	Strong	Biomarker	[1066]
PTGER4	TT79WV3	Strong	Biomarker	[1067]
PTGES	TTYLQ8V	Strong	Biomarker	[1068]
PTK2B	TTTEFBV	Strong	Biomarker	[1069]
PTK6	TT6TH8V	Strong	Biomarker	[1070]
PTP4A2	TT1MHKD	Strong	Biomarker	[1071]
PTPN1	TTELIN2	Strong	Biomarker	[1072]
PTPN13	TT405FP	Strong	Altered Expression	[1073]
RAC1	TT2M9CG	Strong	Biomarker	[1074]
RAC3	TT9BQ50	Strong	Altered Expression	[1075]
RAF1	TTAN5W2	Strong	Genetic Variation	[1076]
RALBP1	TTVSRUA	Strong	Biomarker	[1077]
RARB	TTISP28	Strong	Posttranslational Modification	[1078]
RARG	TT1Q3IE	Strong	Biomarker	[1079]
RBP4	TT0C8BY	Strong	Biomarker	[1080]
REG3A	TTL4H8N	Strong	Altered Expression	[1081]
RENBP	TTZCG0Q	Strong	Biomarker	[1080]
RGS12	TTP9AV7	Strong	Biomarker	[1082]
RGS2	TTKB7T3	Strong	Altered Expression	[1083]
RHCG	TTN5MZ3	Strong	Biomarker	[1084]
RHO	TTH0KSX	Strong	Biomarker	[1085]
RNF7	TTODWGT	Strong	Biomarker	[1086]
ROBO1	TTND1YP	Strong	Biomarker	[667]
ROBO4	TT3S9TY	Strong	Altered Expression	[1087]
ROCK2	TTGWKQJ	Strong	Altered Expression	[446]
ROR2	TTUDPCI	Strong	Altered Expression	[1088]
RORA	TT1TYN7	Strong	Genetic Variation	[1089]
RPGR	TTHBDA9	Strong	Biomarker	[1090]
RPS6KB1	TTG0U4H	Strong	Altered Expression	[1091]
RSF1	TTMP86V	Strong	Biomarker	[1092]
RSPO3	TT7HJTF	Strong	Altered Expression	[1093]
RTN4	TT7GXMU	Strong	Biomarker	[1094]
S100A6	TT716MY	Strong	Biomarker	[1095]
SAA1	TTY0DN9	Strong	Biomarker	[1096]
SCN11A	TTN9VTF	Strong	Biomarker	[1097]
SCN1A	TTANOZH	Strong	Biomarker	[351]
SCN9A	TT4G2JS	Strong	Altered Expression	[1098]
SELE	TT1PL7M	Strong	Biomarker	[1099]
SEMA3A	TTVKD3S	Strong	Altered Expression	[1100]
SENP1	TTW9HY5	Strong	Biomarker	[1101]
SERPINB3	TT6QLPX	Strong	Biomarker	[1102]
SERPINF1	TTR59S1	Strong	Altered Expression	[1103]
SERPING1	TTVQ6R9	Strong	Altered Expression	[1104]
SETD7	TTJ0FSU	Strong	Biomarker	[1105]
SFRP4	TTX8I1Y	Strong	Biomarker	[1106]
SFTPD	TTGLMU7	Strong	Altered Expression	[1107]
SGO1	TTBPKGD	Strong	Altered Expression	[1108]
SHH	TTIENCJ	Strong	Altered Expression	[1109]
SIGMAR1	TT5TPI6	Strong	Biomarker	[1110]
SIRT2	TTLKF5M	Strong	Biomarker	[1111]
SIRT3	TTVZLIJ	Strong	Altered Expression	[1112]
SKP2	TT5B2EO	Strong	Altered Expression	[1113]
SLC16A3	TTG6VD5	Strong	Biomarker	[1114]
SLC19A1	TT09I7D	Strong	Biomarker	[1115]
SLC1A5	TTF7WRM	Strong	Biomarker	[609]
SLC26A4	TT7X02I	Strong	Biomarker	[858]
SLC2A1	TT79TKF	Strong	Altered Expression	[1116]
SLC2A4	TTP6MT5	Strong	Biomarker	[1117]
SLC33A1	TTL69WB	Strong	Biomarker	[1118]
SLC36A1	TTUYIZW	Strong	Genetic Variation	[1119]
SLC38A1	TT1YE9Z	Strong	Genetic Variation	[1120]
SLC44A4	TT0NYDG	Strong	Altered Expression	[1121]
SLC52A2	TT6TKEN	Strong	Altered Expression	[384]
SLC5A7	TTRV7W3	Strong	Biomarker	[1122]
SLC7A1	TT4S150	Strong	Biomarker	[742]
SLC7A11	TTBZMIO	Strong	Biomarker	[1123]
SLCO1A2	TTUGD21	Strong	Altered Expression	[610]
SLCO4C1	TTACFNR	Strong	Genetic Variation	[1124]
SLIT2	TTDWK85	Strong	Biomarker	[1125]
SMAD7	TT0J32Z	Strong	Altered Expression	[1126]
SMC2	TTS8D17	Strong	Genetic Variation	[924]
SMPD1	TTJTM88	Strong	Genetic Variation	[1127]
SOCS1	TT8COJM	Strong	Altered Expression	[1128]
SOCS3	TTI0ME6	Strong	Altered Expression	[1129]
SORD	TTLSRBZ	Strong	Altered Expression	[1130]
SPARC	TTBQFM7	Strong	Altered Expression	[1131]
SPDEF	TT2ZUPY	Strong	Biomarker	[436]
SPRY1	TT0PSN6	Strong	Altered Expression	[1132]
SRD5A1	TTTU72V	Strong	Altered Expression	[1133]
SREBF1	TTER0UB	Strong	Altered Expression	[1134]
SRR	TTZFUY6	Strong	Biomarker	[1135]
SSRP1	TTETDKQ	Strong	Altered Expression	[1136]
SST	TTWF7UG	Strong	Biomarker	[1137]
SSTR1	TTIND6G	Strong	Altered Expression	[1138]
SSTR2	TTZ6T9E	Strong	Biomarker	[1139]
SSTR4	TTAE1BR	Strong	Altered Expression	[639]
ST8SIA4	TTDP8YM	Strong	Genetic Variation	[1140]
STAB2	TTM3DAY	Strong	Biomarker	[344]
STC2	TT4EFTR	Strong	Biomarker	[1141]
STEAP1	TT9E64S	Strong	Biomarker	[1142]
STEAP2	TTOXF5J	Strong	Biomarker	[1143]
STK38	TT27XFN	Strong	Biomarker	[1144]
STK39	TTYQTIU	Strong	Altered Expression	[1145]
STK4	TTCPLVN	Strong	Biomarker	[1146]
STMN1	TT7W5OT	Strong	Biomarker	[1147]
STYK1	TTRMCYJ	Strong	Altered Expression	[1148]
SUV39H1	TTUWQTK	Strong	Altered Expression	[1149]
TACC3	TTQ4UFD	Strong	Biomarker	[1150]
TBXAS1	TTKNWZ4	Strong	Biomarker	[1151]
TCF3	TTULOD8	Strong	Altered Expression	[1152]
TERF2	TT5XSLT	Strong	Altered Expression	[616]
TFAP2A	TTDY4BS	Strong	Biomarker	[1153]
TFF1	TTNOJIZ	Strong	Biomarker	[1154]
TFPI	TT068JH	Strong	Biomarker	[1155]
TGFA	TTTLQFR	Strong	Biomarker	[1156]
TGFB3	TTWOMY8	Strong	Altered Expression	[1157]
TGFBR2	TTZE3P7	Strong	Altered Expression	[1158]
TGM1	TT7A949	Strong	Altered Expression	[806]
TGM2	TT2F4OL	Strong	Altered Expression	[1159]
THRB	TTGER3L	Strong	Genetic Variation	[1160]
TIGIT	TTWNL74	Strong	Biomarker	[1161]
TIRAP	TTKU0LS	Strong	Biomarker	[1162]
TK1	TTP3QRF	Strong	Altered Expression	[1163]
TKTL1	TTNQ1J3	Strong	Altered Expression	[1164]
TLR1	TTW14D0	Strong	Genetic Variation	[1165]
TLR5	TTCXP8J	Strong	Biomarker	[1162]
TLR8	TT8CWFK	Strong	Biomarker	[1166]
TMBIM6	TT7QSMG	Strong	Altered Expression	[1167]
TMEM219	TTY078U	Strong	Biomarker	[1168]
TMSB4X	TTMVAIU	Strong	Biomarker	[1169]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[1170]
TNFRSF12A	TTKPS7V	Strong	Biomarker	[1171]
TNFRSF21	TT8UA0T	Strong	Biomarker	[1172]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[1173]
TNK2	TTIET93	Strong	Altered Expression	[1174]
TNKS	TTVUSO7	Strong	Biomarker	[1175]
TNS4	TT1K65C	Strong	Altered Expression	[1176]
TOP1	TTGTQHC	Strong	Biomarker	[1177]
TOP2A	TTCGY2K	Strong	Altered Expression	[1178]
TOP2B	TT4NVEM	Strong	Biomarker	[1179]
TP53BP1	TTX4UE9	Strong	Altered Expression	[1180]
TPBG	TT70MLA	Strong	Biomarker	[858]
TPP1	TTOVYPT	Strong	Biomarker	[858]
TRIM24	TT9Q7AE	Strong	Altered Expression	[1181]
TRIM28	TTQ2BKV	Strong	Altered Expression	[1182]
TRIM37	TTAMCSL	Strong	Biomarker	[1183]
TRIP10	TTKHTGE	Strong	Genetic Variation	[1184]
TRPA1	TTELV3W	Strong	Biomarker	[1185]
TRPC1	TTA76X0	Strong	Biomarker	[1186]
TRPC3	TTNVC34	Strong	Biomarker	[1185]
TRPM2	TTEBMN7	Strong	Biomarker	[1187]
TRPM4	TTJ2HKA	Strong	Biomarker	[1188]
TRPM7	TTFPVZO	Strong	Altered Expression	[1189]
TRPM8	TTXDKTO	Strong	Biomarker	[1190]
TRPV1	TTMI6F5	Strong	Genetic Variation	[1191]
TRPV2	TTBECWA	Strong	Biomarker	[1192]
TSG101	TTHU7JA	Strong	Biomarker	[1193]
TSPO	TTPTXIN	Strong	Genetic Variation	[453]
TST	TT51OTS	Strong	Biomarker	[858]
TTK	TTP7EGM	Strong	Altered Expression	[1194]
TWIST1	TTX1MY7	Strong	Altered Expression	[1195]
TXN	TTZJ5U9	Strong	Genetic Variation	[1196]
TXNIP	TTTLDZK	Strong	Biomarker	[1197]
TYMS	TTP1UKZ	Strong	Biomarker	[1198]
TYR	TTULVH8	Strong	Biomarker	[1199]
TYRO3	TTIEMFN	Strong	Altered Expression	[1200]
TYRP1	TTFRV98	Strong	Biomarker	[1201]
UBC	TTBP3XA	Strong	Biomarker	[1202]
UBE2T	TT0A1R8	Strong	Biomarker	[1203]
UBE3A	TTUZX6V	Strong	Altered Expression	[1204]
UCP3	TT12RJK	Strong	Biomarker	[1151]
ULK1	TT4D7MJ	Strong	Altered Expression	[1205]
UMPS	TTAFJUD	Strong	Biomarker	[1206]
USP10	TT5IH09	Strong	Altered Expression	[1207]
USP14	TTVSYP9	Strong	Biomarker	[1208]
USP44	TTJLTNM	Strong	Biomarker	[1209]
UTRN	TTNO1VA	Strong	Altered Expression	[1210]
UTS2R	TTW5UDX	Strong	Altered Expression	[1211]
VEGFB	TTPJQHE	Strong	Biomarker	[1212]
VEGFC	TT0QUFV	Strong	Altered Expression	[1213]
VIPR2	TT4O5P0	Strong	Biomarker	[1214]
VSIR	TT51SK8	Strong	Altered Expression	[1215]
WEE1	TTJFOAL	Strong	Altered Expression	[1216]
WNK1	TTJ9UMX	Strong	Biomarker	[1217]
WNT5A	TTKG7F8	Strong	Biomarker	[1218]
WNT7A	TT8NARC	Strong	Biomarker	[1219]
WWP1	TTBWMKT	Strong	Biomarker	[1220]
XIAP	TTK3WBU	Strong	Biomarker	[1221]
XPNPEP2	TTI9MBZ	Strong	Altered Expression	[1222]
YAP1	TT8UN2D	Strong	Biomarker	[1223]
YES1	TT0SQ8J	Strong	Biomarker	[1224]
ZFAND5	TTLFY3S	Strong	Biomarker	[1058]
ZUP1	TTZC0KV	Strong	Biomarker	[1202]
ADRB2	TTG8ZWP	Definitive	Biomarker	[1225]
ALOX5	TTSJ6Q4	Definitive	Biomarker	[1226]
ATF3	TTCE793	Definitive	Biomarker	[1227]
BACE2	TT69DB8	Definitive	Altered Expression	[1228]
BCL11A	TTR61MW	Definitive	Altered Expression	[1229]
CBX7	TTBN3HC	Definitive	Biomarker	[1230]
CCND3	TT1JXNR	Definitive	Altered Expression	[1231]
CD276	TT6CQUM	Definitive	Biomarker	[1161]
CHEK1	TTTU902	Definitive	Biomarker	[1232]
CMA1	TT8VUE0	Definitive	Altered Expression	[1233]
CRY1	TT5MLZR	Definitive	Genetic Variation	[1234]
DGKZ	TTSBBXL	Definitive	Biomarker	[1235]
ELAVL1	TTPC9D0	Definitive	Biomarker	[1236]
FNDC1	TTQJCV8	Definitive	Altered Expression	[1237]
FOXQ1	TTEJZOL	Definitive	Biomarker	[1229]
FZD7	TTUQMO5	Definitive	Altered Expression	[1238]
GPR137	TTATO6X	Definitive	Biomarker	[1239]
GPR31	TT71ZLK	Definitive	Biomarker	[1240]
GRN	TT0LWE3	Definitive	Biomarker	[1061]
GZMB	TTKEPHX	Definitive	Biomarker	[276]
HCRT	TTU5HJP	Definitive	Altered Expression	[1241]
HGFAC	TTD96RW	Definitive	Altered Expression	[1242]
HOXB13	TTZ6I58	Definitive	Autosomal dominant	[1243]
HSPA8	TTMQL3K	Definitive	Biomarker	[1244]
ILK	TT7ALZG	Definitive	Altered Expression	[1245]
ITGA2	TTSJ542	Definitive	Posttranslational Modification	[1246]
JMJD1C	TTBISK4	Definitive	Biomarker	[1247]
KDM5B	TTCLI75	Definitive	Biomarker	[1248]
KLK5	TTULSEW	Definitive	Altered Expression	[1249]
LCN2	TTKTLAI	Definitive	Biomarker	[1250]
LGALS3	TTFPQV7	Definitive	Biomarker	[1251]
LRP1	TTF2V7I	Definitive	Biomarker	[1252]
LRP2	TTPH1AJ	Definitive	Altered Expression	[1253]
MMP11	TTZW4MV	Definitive	Altered Expression	[1254]
MUTYH	TTNB0ZK	Definitive	Altered Expression	[1255]
NES	TTHZ752	Definitive	Altered Expression	[1256]
NGFR	TTEDJN4	Definitive	Biomarker	[1257]
NQO2	TTJLP0R	Definitive	Biomarker	[877]
NTN1	TT0AH4L	Definitive	Altered Expression	[1258]
PCYT1B	TTUAIKM	Definitive	Altered Expression	[1259]
PDE4D	TTSKMI8	Definitive	Biomarker	[667]
PGC	TT7K6AD	Definitive	Altered Expression	[1260]
PIM3	TTCGOIN	Definitive	Altered Expression	[1261]
PKD2L1	TTAHD89	Definitive	Biomarker	[321]
PTK2	TTON5IT	Definitive	Biomarker	[535]
RBPJ	TT72D4Z	Definitive	Altered Expression	[1262]
RCE1	TT2AP5B	Definitive	Altered Expression	[1263]
RPS6KA3	TTUM2ZR	Definitive	Biomarker	[448]
RUNX2	TTD6SZ8	Definitive	Biomarker	[1264]
RXRA	TT6PEUO	Definitive	Altered Expression	[1265]
SLC16A1	TTN1J82	Definitive	Altered Expression	[1233]
SLC2A9	TTIF3GB	Definitive	Altered Expression	[1266]
SOX2	TTCNOT6	Definitive	Biomarker	[1267]
TBL1XR1	TTYXT16	Definitive	Biomarker	[667]
TBX21	TTNF9PH	Definitive	Biomarker	[1268]
TBXA2R	TT2O84V	Definitive	Altered Expression	[1269]
TLN1	TTQSMFG	Definitive	Biomarker	[1270]
TNFSF11	TT9E8HR	Definitive	Biomarker	[1264]
TNFSF12	TTBTDM1	Definitive	Biomarker	[1271]
TPT1	TT3PTB6	Definitive	Altered Expression	[727]
TRPC6	TTRBT3W	Definitive	Altered Expression	[1272]
YWHAH	TTADIOY	Definitive	Genetic Variation	[1273]

This Disease Is Related to 37 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A7	DTLT3UG	Limited	Biomarker	[1274]
SLC25A21	DT2UQYR	Limited	Biomarker	[1275]
SLC52A1	DT7NOKR	Limited	Altered Expression	[384]
SLC5A8	DTE3TAW	Limited	Biomarker	[1276]
SLC14A2	DT8QC7K	Disputed	Genetic Variation	[1277]
ATP12A	DT5NLZA	moderate	Altered Expression	[1278]
SLC2A11	DTJK135	moderate	Biomarker	[1279]
SLC2A5	DTOR02F	moderate	Biomarker	[1279]
SLC31A1	DTP8L4F	moderate	Biomarker	[681]
SLC7A6	DTTBSQG	moderate	Altered Expression	[1280]
SLC7A7	DTE4HJ8	moderate	Altered Expression	[1280]
ABCC10	DTPS120	Strong	Altered Expression	[1281]
ABCC5	DTYVM24	Strong	Altered Expression	[1282]
ABCC6	DT582KR	Strong	Biomarker	[1283]
SLC12A2	DTHKL3Q	Strong	Biomarker	[858]
SLC13A3	DTKXTPW	Strong	Biomarker	[1284]
SLC16A10	DTPAQJO	Strong	Biomarker	[1285]
SLC1A4	DTC54PX	Strong	Biomarker	[1286]
SLC25A16	DTNU9EW	Strong	Genetic Variation	[1287]
SLC25A20	DTQOUM4	Strong	Biomarker	[1288]
SLC2A3	DT9SQ3L	Strong	Altered Expression	[1289]
SLC30A1	DT1BO38	Strong	Altered Expression	[1290]
SLC30A4	DT280XI	Strong	Biomarker	[1291]
SLC35B4	DTMALXP	Strong	Altered Expression	[1292]
SLC39A1	DTLWPXS	Strong	Biomarker	[1293]
SLC39A9	DTJH79E	Strong	Altered Expression	[1294]
SLC3A1	DTBCKVM	Strong	Biomarker	[1295]
SLC43A1	DTBMSWG	Strong	Altered Expression	[1280]
SLC45A2	DTNCJAT	Strong	Genetic Variation	[1296]
SLC45A3	DTGEFXH	Strong	Biomarker	[1297]
SLC4A2	DTF7GAL	Strong	Biomarker	[344]
SLC4A7	DT03V27	Strong	Biomarker	[1298]
SLC50A1	DTI9CQU	Strong	Biomarker	[1299]
KCNK2	DTENHUP	Definitive	Biomarker	[1300]
SLC2A6	DTS4MKQ	Definitive	Altered Expression	[1266]
SLC30A6	DTKPRIL	Definitive	Altered Expression	[1301]
SLC35A2	DT0567K	Definitive	Genetic Variation	[1302]

This Disease Is Related to 79 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ALDH1A2	DEKN1H4	Limited	Genetic Variation	[1303]
CYP2R1	DEBIHM3	Limited	Biomarker	[1304]
DCXR	DE3FEV8	Limited	Biomarker	[858]
DTYMK	DEOTVYU	Limited	Altered Expression	[1305]
GCLC	DESYL1F	Limited	Genetic Variation	[299]
HIF1AN	DEY1CBW	Limited	Biomarker	[1306]
HPGD	DEHKSC6	Limited	Genetic Variation	[268]
HSD17B7	DEDMWFX	Limited	Biomarker	[1307]
HSD3B1	DERDQWN	Limited	Biomarker	[1308]
LDHC	DEQG7F9	Limited	Biomarker	[1309]
PER1	DE9HF0I	Limited	Biomarker	[1310]
SAT1	DEMWO83	Limited	Biomarker	[1311]
SULT2B1	DEZBN53	Limited	Biomarker	[877]
UBASH3B	DE10BJ5	Limited	Altered Expression	[1312]
UGT1A3	DEF2WXN	Limited	Genetic Variation	[1302]
UGT1A5	DEPF954	Limited	Genetic Variation	[1302]
UGT1A9	DE85D2P	Limited	Genetic Variation	[1302]
AKR1C2	DEOY5ZM	Disputed	Altered Expression	[402]
CYP4F3	DEFCMPI	Disputed	Genetic Variation	[1313]
PTGR1	DE4Q2OE	Disputed	Biomarker	[1314]
SRD5A3	DEZGVDW	Disputed	Altered Expression	[1315]
AKR1A1	DED2FW3	moderate	Biomarker	[1316]
EGLN3	DEMQTKH	moderate	Altered Expression	[1317]
HSD17B11	DEPFD73	moderate	Altered Expression	[1318]
HSD17B12	DE915QP	moderate	Biomarker	[1319]
MMEL1	DEYCUQ2	moderate	Altered Expression	[1320]
MT2A	DEFKGT7	moderate	Genetic Variation	[1321]
PCYT1A	DEQYXD4	moderate	Genetic Variation	[1322]
PTGDS	DER3H9C	moderate	Altered Expression	[1323]
RDH5	DESI4OK	moderate	Altered Expression	[1324]
THOP1	DE95LJC	moderate	Altered Expression	[1325]
ACP3	DEDW5H6	Strong	Biomarker	[1326]
ACP4	DE3OZT4	Strong	Altered Expression	[1327]
ACSS2	DEE76VW	Strong	Biomarker	[1328]
ADH1C	DEM1HNL	Strong	Altered Expression	[1316]
ADH5	DEIOH6A	Strong	Altered Expression	[1316]
AKR1B10	DEP6GT1	Strong	Biomarker	[1329]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[1330]
ALDH1B1	DEXI4UQ	Strong	Genetic Variation	[1303]
BAAT	DERA3OF	Strong	Biomarker	[1331]
BCO1	DE6BOK3	Strong	Genetic Variation	[1332]
BLMH	DECH1VP	Strong	Biomarker	[1333]
CPA4	DEXKD7J	Strong	Genetic Variation	[1334]
CRMP1	DE0EUXB	Strong	Altered Expression	[1210]
CYP27A1	DEBS639	Strong	Altered Expression	[1335]
CYP2C18	DEZMWRE	Strong	Biomarker	[299]
CYP2C8	DES5XRU	Strong	Biomarker	[1336]
CYP39A1	DEEG96X	Strong	Biomarker	[1337]
CYP3A43	DEO1IE3	Strong	Genetic Variation	[1338]
CYP7B1	DE36TMY	Strong	Biomarker	[1339]
DDAH1	DEY0TQC	Strong	Altered Expression	[1340]
DHRS7	DEEXSKI	Strong	Biomarker	[1341]
DHRS9	DEGTU5I	Strong	Biomarker	[1342]
DIO3	DET89OV	Strong	Biomarker	[1343]
FAAH	DEUM1EX	Strong	Altered Expression	[1344]
GLS	DE3E0VT	Strong	Biomarker	[1345]
HAGH	DE05IKP	Strong	Altered Expression	[1346]
HPRT1	DEVXTP5	Strong	Altered Expression	[1347]
HSD17B3	DEX8J7E	Strong	Biomarker	[1348]
HSD3B2	DEN0GVQ	Strong	Biomarker	[758]
MAT1A	DEQ6NC9	Strong	Biomarker	[637]
MAT2B	DEKF1OH	Strong	Altered Expression	[959]
MT1A	DE5ME8A	Strong	Biomarker	[1349]
NAT10	DEZV4AP	Strong	Biomarker	[678]
NNMT	DECVGJ3	Strong	Altered Expression	[1350]
PARK7	DEPOVCH	Strong	Biomarker	[1351]
PGPEP1	DEVDR46	Strong	Biomarker	[696]
UCK2	DETN1O0	Strong	Biomarker	[548]
UGT2B10	DEI8NGH	Strong	Biomarker	[693]
UGT2B11	DE7TIN4	Strong	Biomarker	[693]
GLDC	DEIN8FB	Definitive	Biomarker	[1352]
MTRR	DE6NIY9	Definitive	Genetic Variation	[1353]
SULT1E1	DESTKG6	Definitive	Genetic Variation	[1354]
SULT2A1	DE0P6LK	Definitive	Biomarker	[610]
UGT1A10	DEL5N6Y	Definitive	Genetic Variation	[1302]
UGT1A4	DELOY3P	Definitive	Genetic Variation	[1302]
UGT1A6	DESD26P	Definitive	Genetic Variation	[1302]
UGT1A7	DEZO4N3	Definitive	Genetic Variation	[1302]
UGT1A8	DE2GB8N	Definitive	Genetic Variation	[1302]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1188).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] ClinicalTrials.gov (NCT01946204) A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6878).
• [8] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [9] Drug information of Cyproterone, 2008. eduDrugs.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5585).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6886).
• [13] Docetaxel FDA Label
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457).
• [15] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [16] Everolimus FDA Label
• [17] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6943).
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2862).
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [22] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215833.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4265).
• [24] ClinicalTrials.gov (NCT01272830) Double-Blinded Clinical Trial Using ApatoneB for Symptomatic Postoperative Total Joint Replacements. U.S. National Institutes of Health.
• [25] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2864).
• [27] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [30] Sirolimus FDA Label
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7957).
• [32] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [33] ClinicalTrials.gov (NCT00633347) Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation. U.S. National Institutes of Health.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031375)
• [35] ClinicalTrials.gov (NCT03511664) Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION). U.S. National Institutes of Health.
• [36] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT01964170) A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3487).
• [39] ClinicalTrials.gov (NCT05204927) A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [40] ClinicalTrials.gov (NCT00810849) A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis. U.S. National Institutes of Health.
• [41] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016680)
• [42] ClinicalTrials.gov (NCT00043212) Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.. U.S. National Institutes of Health.
• [43] ClinicalTrials.gov (NCT00090103) Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment. U.S. National Institutes of Health.
• [44] Clinical pipeline report, company report or official report of Roche.
• [45] ClinicalTrials.gov (NCT01436968) Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
• [46] ClinicalTrials.gov (NCT03850795) HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.
• [47] Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study. Dis Colon Rectum. 1998 Aug;41(8):953-62.
• [48] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [49] ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT04647526) A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH). U.S.National Institutes of Health.
• [51] ClinicalTrials.gov (NCT01913353) A Non-inferiority Trial to Compare MVA-BN Smallpox Vaccine to ACAM2000. U.S. National Institutes of Health.
• [52] Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
• [53] ClinicalTrials.gov (NCT01322490) A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect). U.S. National Institutes of Health.
• [54] ClinicalTrials.gov (NCT01966614) Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH. U.S. National Institutes of Health.
• [55] Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105.
• [56] Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
• [57] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8098).
• [58] ClinicalTrials.gov (NCT04887506) Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC. U.S.National Institutes of Health.
• [59] ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
• [60] ClinicalTrials.gov (NCT00397345) TroVax Renal Immunotherapy Survival Trial. U.S. National Institutes of Health.
• [61] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2826).
• [62] ClinicalTrials.gov (NCT00351416) Letrozole Treatment in Normal and GnRH Deficient Women. U.S. National Institutes of Health.
• [63] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [64] ClinicalTrials.gov (NCT01667536) A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology. U.S. National Institutes of Health.
• [65] ClinicalTrials.gov (NCT02147964) ITT-5 Mechanisms of Spermatogenesis. U.S. National Institutes of Health.
• [66] ClinicalTrials.gov (NCT00583752) Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21. U.S. National Institutes of Health.
• [67] ClinicalTrials.gov (NCT00849290) Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442). U.S. National Institutes of Health.
• [68] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019429)
• [69] ClinicalTrials.gov (NCT04089553) An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [70] ClinicalTrials.gov (NCT05367440) A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA). U.S.National Institutes of Health.
• [71] ClinicalTrials.gov (NCT04382898) First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer. U.S.National Institutes of Health.
• [72] ClinicalTrials.gov (NCT00585416) Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
• [73] Clinical pipeline report, company report or official report of Corcept.
• [74] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [75] ClinicalTrials.gov (NCT03837353) A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. U.S. National Institutes of Health.
• [76] ClinicalTrials.gov (NCT02923180) Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer. U.S. National Institutes of Health.
• [77] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4204).
• [78] ClinicalTrials.gov (NCT01326312) Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer. U.S. National Institutes of Health.
• [79] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7747).
• [80] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [81] ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
• [82] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [83] Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
• [84] ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT05848011) A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [86] ClinicalTrials.gov (NCT00195039) Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT00866944) Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases. U.S. National Institutes of Health.
• [88] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039703)
• [89] ClinicalTrials.gov (NCT03592264) This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
• [91] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012441)
• [92] ClinicalTrials.gov (NCT03414034) Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT00691132) Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers. U.S. National Institutes of Health.
• [94] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7937).
• [95] ClinicalTrials.gov (NCT00078585) PROSTVAC-VF/TRICOM Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy. U.S. National Institutes of Health.
• [96] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022683)
• [97] J Clin Oncol 32, 2014 (suppl 4; abstr 83).
• [98] ClinicalTrials.gov (NCT04114825) Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac). U.S. National Institutes of Health.
• [99] ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.
• [100] Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6 Suppl 10:S3-S12.
• [101] ClinicalTrials.gov (NCT02381288) Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone. U.S. National Institutes of Health.
• [102] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
• [103] ClinicalTrials.gov (NCT05005728) Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb?20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [104] ClinicalTrials.gov (NCT00050297) YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
• [105] ClinicalTrials.gov (NCT04471974) ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [106] ClinicalTrials.gov (NCT05156905) A Phase 1b Trial Investigating Docetaxel Combined With Cirmtuzumab in Patients With Metastatic Castration Resistant Prostate Cancer. U.S.National Institutes of Health.
• [107] ClinicalTrials.gov (NCT03490838) 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (PROter). U.S. National Institutes of Health.
• [108] ClinicalTrials.gov (NCT05249127) 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer. U.S.National Institutes of Health.
• [109] ClinicalTrials.gov (NCT04868604) A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer. U.S.National Institutes of Health.
• [110] ClinicalTrials.gov (NCT04631601) A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC). U.S.National Institutes of Health.
• [111] ClinicalTrials.gov (NCT01862900) Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions. U.S. National Institutes of Health.
• [112] 2011 Pipeline of Adamis Pharmaceuticals.
• [113] ClinicalTrials.gov (NCT03888612) Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.
• [114] ClinicalTrials.gov (NCT05067140) A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer. U.S.National Institutes of Health.
• [115] ClinicalTrials.gov (NCT01352208) Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
• [117] ClinicalTrials.gov (NCT03910660) Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. U.S.National Institutes of Health.
• [118] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [119] ClinicalTrials.gov (NCT01225471) Novel Peptide Vaccination for Patients With Advanced Prostate Cancer. U.S. National Institutes of Health.
• [120] Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
• [121] ClinicalTrials.gov (NCT01171729) Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer. U.S. National Institutes of Health.
• [122] VC-01's Path to the Clinic. Viacyte. 2015.
• [123] Clinical pipeline report, company report or official report of Genovax Srl.
• [124] ClinicalTrials.gov (NCT03300505) ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer. U.S.National Institutes of Health.
• [125] ClinicalTrials.gov (NCT05369000) Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific gamma-delta-T Cell Engager, in Patients With Therapy Refractory mCRPC. U.S.National Institutes of Health.
• [126] ClinicalTrials.gov (NCT03436485) Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer. U.S.National Institutes of Health.
• [127] ClinicalTrials.gov (NCT00070837) MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer. U.S. National Institutes of Health.
• [128] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039208)
• [129] Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results in Osteosarcoma Patients After Intensive Chemotherapy. Onyvax vaccines therapies. April 19, 2005.
• [130] Clinical pipeline report, company report or official report of Weizmann Institute of Science.
• [131] ClinicalTrials.gov (NCT00895466) Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients. U.S. National Institutes of Health.
• [132] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021046)
• [133] ClinicalTrials.gov (NCT00859729) Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [134] ClinicalTrials.gov (NCT05125016) Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [135] ClinicalTrials.gov (NCT03972657) Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT01931046) Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer. U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT03741712) A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC. U.S. National Institutes of Health.
• [138] ClinicalTrials.gov (NCT05489991) A Phase 1/2, Open-label, Multi-Center Study of Dually Armored Chimeric Antigen Receptor (CAR) T-cells (TmPSMA-02) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC). U.S.National Institutes of Health.
• [139] ClinicalTrials.gov (NCT02987829) Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients. U.S. National Institutes of Health.
• [140] ClinicalTrials.gov (NCT04843319) Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer. U.S.National Institutes of Health.
• [141] ClinicalTrials.gov (NCT03822871) A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [142] ClinicalTrials.gov (NCT03276572) Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [143] ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [144] ClinicalTrials.gov (NCT01261754) A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers. U.S. National Institutes of Health.
• [145] ClinicalTrials.gov (NCT05241613) A Phase I Study to Evaluate Safety, Tolerability, PK, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies. U.S.National Institutes of Health.
• [146] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007778)
• [147] Phase I trial of Ad5-TRAIL-mediated gene transfer in men with locally-confined prostate cancer prior to planned radical prostatectomy. The Journal of Urology. 04/2008; 179(4):396-396.
• [148] ClinicalTrials.gov (NCT00788307) Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy. U.S. NationalInstitutes of Health.
• [149] Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63.
• [150] ClinicalTrials.gov (NCT05077098) A Phase 1 Study of ADXS-504, a Cancer Type Specific Immunotherapy, With Biochemically Recurrent Prostate Cancer. U.S.National Institutes of Health.
• [151] ClinicalTrials.gov (NCT04740034) A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma. U.S.National Institutes of Health.
• [152] ClinicalTrials.gov (NCT04221542) Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [153] OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013 Dec 15;73(24):7189-98.
• [154] 2011 Pipeline of Seattle Genetics.
• [155] Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014 May 16;3(5):e16.
• [156] ClinicalTrials.gov (NCT01351688) An Open Label Prostate Cancer Study in Japanese Patients. U.S. National Institutes of Health.
• [157] Phase I Study: BAY 1075553 PET/CT in Staging and Re - Staging of Prostate Cancer Patients - Comparison with 18F-Choline PET/CT. World Molecular Imaging Society. September 20, 2013
• [158] ClinicalTrials.gov (NCT00872157) BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets. U.S. National Institutes of Health.
• [159] ClinicalTrials.gov (NCT00868595) MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
• [160] ClinicalTrials.gov (NCT01823978) Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer. U.S. National Institutes of Health.
• [161] ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [162] ClinicalTrials.gov (NCT04077021) First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [163] Clinical pipeline report, company report or official report of MannKind Corporation.
• [164] ClinicalTrials.gov (NCT00441571) Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
• [165] ClinicalTrials.gov (NCT04291664) PK and Dose Escalation and Expansion Study of DST-2970. U.S. National Institutes of Health.
• [166] ClinicalTrials.gov (NCT04421222) Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386). U.S. National Institutes of Health.
• [167] 2011 Pipeline of Santaris Pharma.
• [168] Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57.
• [169] ClinicalTrials.gov (NCT04575766) A Study of FT-7051 in Men With MCRPC. U.S. National Institutes of Health.
• [170] ClinicalTrials.gov (NCT03577028) Study of HPN424 in Patients With Advanced Prostate Cancer. U.S. National Institutes of Health.
• [171] DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunol Immunother. 2012 Nov; 61(11): 2161-2170.
• [172] J Clin Oncol 29: 2011 (suppl 7; abstr 148)
• [173] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026421)
• [174] ClinicalTrials.gov (NCT02438215) Study of IRX4204 for Treatment of Early Parkinson's Disease. U.S. National Institutes of Health.
• [175] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [176] ClinicalTrials.gov (NCT00676910) A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.. U.S. National Institutes of Health.
• [177] ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
• [178] ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
• [179] ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
• [180] ClinicalTrials.gov (NCT05441501) A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer. U.S.National Institutes of Health.
• [181] ClinicalTrials.gov (NCT03569280) Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients. U.S. National Institutes of Health.
• [182] ClinicalTrials.gov (NCT03873805) PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [183] ClinicalTrials.gov (NCT03030885) A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S.National Institutes of Health.
• [184] ClinicalTrials.gov (NCT00629057) A Safety Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer. U.S. National Institutes of Health.
• [185] ClinicalTrials.gov (NCT05413421) An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer. U.S.National Institutes of Health.
• [186] ClinicalTrials.gov (NCT04249947) P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.
• [187] ClinicalTrials.gov (NCT03460977) PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma. U.S. National Institutes of Health.
• [188] ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
• [189] ClinicalTrials.gov (NCT01262664) Prohibitin Targeting Peptide 1 (Fat Zapper). U.S. National Institutes of Health.
• [190] Clinical pipeline report, company report or official report of Tmunity.
• [191] Clinical pipeline report, company report or official report of Progenics Pharmaceuticals.
• [192] Clinical pipeline report, company report or official report of Alphavax.
• [193] Clinical pipeline report, company report or official report of AlphaVax.
• [194] Clinical pipeline report, company report or official report of Progenics Pharmaceuticals.
• [195] J Clin Oncol 33, 2015 (suppl; abstr e13527)
• [196] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012200)
• [197] Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 2584.
• [198] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033873)
• [199] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020388)
• [200] ClinicalTrials.gov (NCT02362464) Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139. U.S. National Institutes of Health.
• [201] A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer. National Cancer Institute.
• [202] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034068)
• [203] ClinicalTrials.gov (NCT00695851) Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.. U.S. National Institutes of Health.
• [204] ClinicalTrials.gov (NCT02502994) Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC.
• [205] ClinicalTrials.gov (NCT02705469) A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [206] ClinicalTrials.gov (NCT01611038) Methylselenocysteine Effects on Circadian Rhythm. U.S. National Institutes of Health.
• [207] Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
• [208] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [209] Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
• [210] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000844)
• [211] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3539).
• [212] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010708)
• [213] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012633)
• [214] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013130)
• [215] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007230)
• [216] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015769)
• [217] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623)
• [218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
• [219] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1178).
• [220] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4607).
• [221] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028256)
• [222] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025713)
• [223] 2011 Pipeline of Anavex.
• [224] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025724)
• [225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026363)
• [226] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023655)
• [227] A Special Report on Gene Therapy, K. K. Jain. Page(39).
• [228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
• [229] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007891)
• [230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011017)
• [231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015102)
• [232] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840)
• [233] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026172)
• [234] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
• [235] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
• [236] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1361).
• [237] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
• [238] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
• [239] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [240] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
• [241] Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011 Jun 6;8(3):901-12.
• [242] In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Regul Pept. 2006 Sep 11;136(1-3):122-9.
• [243] NSD2 is a conserved driver of metastatic prostate cancer progression.Nat Commun. 2018 Dec 5;9(1):5201.
• [244] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2800).
• [245] Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix.
• [246] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [247] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [248] PAC1-R null isoform expression in human prostate cancer tissue.Prostate. 2006 Apr 1;66(5):514-21. doi: 10.1002/pros.20356.
• [249] Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation.BMC Cancer. 2014 Dec 7;14:921. doi: 10.1186/1471-2407-14-921.
• [250] Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression.Cancer Sci. 2009 Sep;100(9):1631-8. doi: 10.1111/j.1349-7006.2009.01234.x. Epub 2009 May 31.
• [251] Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-B pathway.Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1622-1633. doi: 10.1016/j.bbadis.2018.01.021. Epub 2018 Feb 1.
• [252] Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12.Arch Biochem Biophys. 2018 Sep 15;654:47-54. doi: 10.1016/j.abb.2018.07.010. Epub 2018 Jul 18.
• [253] Consecutive Prostate Cancer Specimens Revealed Increased AldoKeto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.J Clin Med. 2019 May 1;8(5):601. doi: 10.3390/jcm8050601.
• [254] Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-B.Int J Cancer. 2013 Oct 15;133(8):1784-91. doi: 10.1002/ijc.28165. Epub 2013 Jul 13.
• [255] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [256] Mllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7.
• [257] Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.Mol Cancer Res. 2013 Oct;11(10):1203-14. doi: 10.1158/1541-7786.MCR-13-0072. Epub 2013 Jul 12.
• [258] Relationship between XPD, RAD51, and APEX1 DNA repair genotypes and prostate cancer risk in the male population of Rio de Janeiro, Brazil.Genet Mol Biol. 2017 Oct-Dec;40(4):751-758. doi: 10.1590/1678-4685-GMB-2017-0039. Epub 2017 Nov 6.
• [259] Validation of HB-EGF and amphiregulin as targets for human cancer therapy.Biochem Biophys Res Commun. 2008 Jan 18;365(3):555-61. doi: 10.1016/j.bbrc.2007.11.015. Epub 2007 Nov 20.
• [260] Characterization of CD133(+)/CD44(+) human prostate cancer stem cells with ATR-FTIR spectroscopy.Analyst. 2019 Mar 21;144(6):2138-2149. doi: 10.1039/c9an00093c. Epub 2019 Feb 11.
• [261] Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.Mol Cancer Ther. 2018 Dec;17(12):2796-2810. doi: 10.1158/1535-7163.MCT-18-0602. Epub 2018 Sep 21.
• [262] Germline BAP1 alterations in familial uveal melanoma.Genes Chromosomes Cancer. 2017 Feb;56(2):168-174. doi: 10.1002/gcc.22424. Epub 2016 Oct 26.
• [263] Investigation of the synergistic effects of paclitaxel and herbal substances and endemic plant extracts on cell cycle and apoptosis signal pathways in prostate cancer cell lines.Gene. 2019 Mar 1;687:261-271. doi: 10.1016/j.gene.2018.11.049. Epub 2018 Nov 17.
• [264] The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.Oncotarget. 2014 Aug 30;5(16):6896-908. doi: 10.18632/oncotarget.2229.
• [265] Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.Sci Rep. 2018 Jul 16;8(1):10748. doi: 10.1038/s41598-018-28566-9.
• [266] CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis.Oncogene. 2015 Oct 16;34(42):5383-94. doi: 10.1038/onc.2014.467. Epub 2015 Jan 26.
• [267] Calcitonin induces stem cell-like phenotype in prostate cancer cells.Endocr Relat Cancer. 2019 Nov;26(11):815-828. doi: 10.1530/ERC-19-0333.
• [268] A Single Nucleotide Polymorphism in HPGD Gene Is Associated with Prostate Cancer Risk.J Cancer. 2017 Oct 24;8(19):4083-4086. doi: 10.7150/jca.22025. eCollection 2017.
• [269] Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3K Inhibitor.Biol Pharm Bull. 2019;42(6):1013-1018. doi: 10.1248/bpb.b19-00080.
• [270] The gastrin/cholecystokinin-B receptor on prostate cells--a novel target for bifunctional prostate cancer imaging.Eur J Pharm Sci. 2014 Feb 14;52:69-76. doi: 10.1016/j.ejps.2013.10.013. Epub 2013 Nov 6.
• [271] Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.Prostate. 2019 Jun;79(9):1018-1031. doi: 10.1002/pros.23810. Epub 2019 Apr 24.
• [272] Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.Oncotarget. 2015 May 10;6(13):10712-27. doi: 10.18632/oncotarget.3544.
• [273] Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.J Clin Med. 2019 Mar 13;8(3):354. doi: 10.3390/jcm8030354.
• [274] Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size.Gene. 2017 Dec 15;636:96-102. doi: 10.1016/j.gene.2017.09.016. Epub 2017 Sep 10.
• [275] Tumor necrosis factor- induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation.Cancer Sci. 2018 May;109(5):1524-1531. doi: 10.1111/cas.13586. Epub 2018 Apr 29.
• [276] TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12.
• [277] iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis.J Cancer. 2019 Jul 10;10(18):4165-4177. doi: 10.7150/jca.33497. eCollection 2019.
• [278] miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion.Oncotarget. 2017 Dec 7;9(2):1980-1991. doi: 10.18632/oncotarget.23118. eCollection 2018 Jan 5.
• [279] Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of -catenin in cancer stem-like cells.EBioMedicine. 2019 Apr;42:397-407. doi: 10.1016/j.ebiom.2019.03.032. Epub 2019 Mar 21.
• [280] Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications.Int J Mol Sci. 2019 Aug 9;20(16):3881. doi: 10.3390/ijms20163881.
• [281] Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.
• [282] CCAAT enhancer binding protein promotes tumor growth and inhibits apoptosis in prostate cancer by methylating estrogen receptor .Neoplasma. 2018;65(1):34-41. doi: 10.4149/neo_2018_161205N620.
• [283] Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.Prostate. 2015 Aug 1;75(11):1197-205. doi: 10.1002/pros.23002. Epub 2015 Apr 15.
• [284] Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus.Radiother Oncol. 2019 Nov;140:131-142. doi: 10.1016/j.radonc.2019.06.023. Epub 2019 Jul 2.
• [285] CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors.Eur Urol. 2002 Mar;41(3):335-41. doi: 10.1016/s0302-2838(02)00020-9.
• [286] Targeting IB Kinase /NF-B Signaling in Human Prostate Cancer by a Novel IB Kinase Inhibitor CmpdA.Mol Cancer Ther. 2016 Jul;15(7):1504-14. doi: 10.1158/1535-7163.MCT-15-0999. Epub 2016 Apr 8.
• [287] Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.Dis Markers. 2015;2015:241301. doi: 10.1155/2015/241301. Epub 2015 Sep 28.
• [288] Chloride intracellular channel 1 regulates prostate cancer cell proliferation and migration through the MAPK/ERK pathway.Cancer Biother Radiopharm. 2014 Oct;29(8):339-44. doi: 10.1089/cbr.2014.1666.
• [289] Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.Cancer Res. 2016 Mar 15;76(6):1603-14. doi: 10.1158/0008-5472.CAN-15-1898. Epub 2016 Jan 21.
• [290] Investigating the Multi-Target Pharmacological Mechanism of Hedyotis diffusa Willd Acting on Prostate Cancer: A Network Pharmacology Approach.Biomolecules. 2019 Oct 9;9(10):591. doi: 10.3390/biom9100591.
• [291] The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.EMBO Mol Med. 2019 Nov 7;11(11):e10659. doi: 10.15252/emmm.201910659. Epub 2019 Sep 26.
• [292] Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.Cancer Res. 2009 Dec 15;69(24):9315-22. doi: 10.1158/0008-5472.CAN-09-0648.
• [293] Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer.Cell Death Dis. 2018 Oct 11;9(10):1041. doi: 10.1038/s41419-018-1096-6.
• [294] NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in Caucasians.Int J Mol Sci. 2012;13(9):10959-10969. doi: 10.3390/ijms130910959. Epub 2012 Jul 26.
• [295] Targeting CK2 for cancer therapy.Anticancer Drugs. 2005 Nov;16(10):1037-43. doi: 10.1097/00001813-200511000-00001.
• [296] Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.BJU Int. 2019 May;123(5):826-833. doi: 10.1111/bju.14540. Epub 2018 Oct 11.
• [297] CXXC5 expression in prostate cancer: implications for cancer progression.Int J Exp Pathol. 2017 Aug;98(4):234-243. doi: 10.1111/iep.12241.
• [298] Dietary lipids and environmental xenobiotics as risk factors for prostate cancer: The role of cytochrome P450.Pharmacol Rep. 2019 Oct;71(5):826-832. doi: 10.1016/j.pharep.2019.04.011. Epub 2019 Apr 15.
• [299] Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.Pharmacogenet Genomics. 2011 Oct;21(10):615-23. doi: 10.1097/FPC.0b013e3283493a57.
• [300] Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.Biochim Biophys Acta. 2014 Sep;1842(9):1350-63. doi: 10.1016/j.bbadis.2014.04.018. Epub 2014 Apr 27.
• [301] DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone Metastasis.Transl Oncol. 2018 Aug;11(4):873-882. doi: 10.1016/j.tranon.2018.04.013. Epub 2018 May 15.
• [302] The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.Cancer Med. 2014 Feb;3(1):14-24. doi: 10.1002/cam4.168. Epub 2013 Dec 18.
• [303] Antagonistic activities of miR-148a and DNMT1: Ectopic expression of miR-148a impairs DNMT1 mRNA and dwindle cell proliferation and survival.Gene. 2018 Jun 20;660:68-79. doi: 10.1016/j.gene.2018.03.075. Epub 2018 Mar 26.
• [304] The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.Mol Cancer Res. 2015 May;13(5):913-22. doi: 10.1158/1541-7786.MCR-14-0680. Epub 2015 Mar 16.
• [305] Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.Biochim Biophys Acta. 2014 Sep;1839(9):858-65. doi: 10.1016/j.bbagrm.2014.07.001. Epub 2014 Jul 10.
• [306] Methylated genes as potential biomarkers in prostate cancer.BJU Int. 2010 May;105(10):1364-70. doi: 10.1111/j.1464-410X.2009.09167.x. Epub 2010 Jan 8.
• [307] Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.Oncogene. 2019 Jun;38(23):4540-4559. doi: 10.1038/s41388-019-0736-3. Epub 2019 Feb 12.
• [308] PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.Oncotarget. 2017 Apr 11;8(15):24046-24062. doi: 10.18632/oncotarget.15733.
• [309] p-mTOR, p-4EBP-1 and eIF4E expression in canine prostatic carcinoma.Res Vet Sci. 2019 Feb;122:86-92. doi: 10.1016/j.rvsc.2018.11.006. Epub 2018 Nov 16.
• [310] Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.PLoS Biol. 2014 Feb 4;12(2):e1001784. doi: 10.1371/journal.pbio.1001784. eCollection 2014 Feb.
• [311] Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer.Cells. 2019 Sep 11;8(9):1067. doi: 10.3390/cells8091067.
• [312] Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.Int J Clin Exp Pathol. 2013 Aug 15;6(9):1854-60. eCollection 2013.
• [313] Downregulation of EphA5 by promoter methylation in human prostate cancer.BMC Cancer. 2015 Jan 22;15:18. doi: 10.1186/s12885-015-1025-3.
• [314] EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.Oncotarget. 2015 Sep 8;6(26):22587-97. doi: 10.18632/oncotarget.4088.
• [315] Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.Oncogene. 2018 Jun;37(25):3340-3355. doi: 10.1038/s41388-018-0198-z. Epub 2018 Mar 20.
• [316] Androgen receptor dampens tissue factor expression via nuclear factor-B and early growth response protein 1.J Thromb Haemost. 2018 Apr;16(4):749-758. doi: 10.1111/jth.13971. Epub 2018 Mar 13.
• [317] Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.
• [318] FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis.Oncogene. 2019 Jun;38(26):5265-5280. doi: 10.1038/s41388-019-0791-9. Epub 2019 Mar 26.
• [319] Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.Cancer Res. 2013 Apr 15;73(8):2551-62. doi: 10.1158/0008-5472.CAN-12-4108. Epub 2013 Feb 25.
• [320] Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.J Pathol. 2018 May;245(1):74-84. doi: 10.1002/path.5052. Epub 2018 Apr 2.
• [321] Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.Oncotarget. 2016 Oct 18;7(42):68072-68085. doi: 10.18632/oncotarget.10953.
• [322] Regulated expression of the TP isoform of the human T prostanoid receptor by the tumour suppressors FOXP1 and NKX3.1: Implications for the role of thromboxane in prostate cancer.Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3153-3169. doi: 10.1016/j.bbadis.2017.09.005. Epub 2017 Sep 8.
• [323] Screening, identification of prostate cancer urinary biomarkers and verification of important spots.Invest New Drugs. 2019 Oct;37(5):935-947. doi: 10.1007/s10637-018-0709-3. Epub 2019 Jan 4.
• [324] The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.Eur Urol. 2019 Apr;75(4):582-590. doi: 10.1016/j.eururo.2018.11.040. Epub 2018 Dec 3.
• [325] Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow.Mol Cancer Res. 2017 Dec;15(12):1644-1655. doi: 10.1158/1541-7786.MCR-17-0132. Epub 2017 Aug 16.
• [326] Glyceryl trinitrateinduced cytotoxicity of docetaxelresistant prostatic cancer cells is associated with differential regulation of clusterin.Int J Oncol. 2019 Apr;54(4):1446-1456. doi: 10.3892/ijo.2019.4708. Epub 2019 Feb 1.
• [327] Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.Prostate. 2019 Jan;79(1):21-30. doi: 10.1002/pros.23707. Epub 2018 Aug 14.
• [328] Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer.Clin Cancer Res. 2005 Dec 1;11(23):8295-303. doi: 10.1158/1078-0432.CCR-05-0443.
• [329] Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys(3)]-GHRP-6.Endocrine. 2019 May;64(2):393-405. doi: 10.1007/s12020-018-1796-9. Epub 2018 Nov 2.
• [330] An extensive study of the mechanism of prostate cancer metastasis.Neoplasma. 2018;65(2):253-261. doi: 10.4149/neo_2018_161217N648.
• [331] GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.Mol Cancer. 2016 Mar 18;15:25. doi: 10.1186/s12943-016-0508-4.
• [332] Preclinical evaluation of new GnRH-I receptor radionuclide therapy with (177) Lu-peptide tracer.J Labelled Comp Radiopharm. 2019 Jun 15;62(7):310-320. doi: 10.1002/jlcr.3742. Epub 2019 Jun 13.
• [333] G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer.Cancer Res. 2014 Jul 1;74(13):3489-500. doi: 10.1158/0008-5472.CAN-13-2708. Epub 2014 Apr 22.
• [334] Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/-Catenin Pathway and Epithelial-Mesenchymal Transition.Pharmacology. 2019;104(5-6):312-319. doi: 10.1159/000502400. Epub 2019 Sep 3.
• [335] Subditine, a new monoterpenoid indole alkaloid from bark of Nauclea subdita (Korth.) Steud. induces apoptosis in human prostate cancer cells.PLoS One. 2014 Feb 14;9(2):e87286. doi: 10.1371/journal.pone.0087286. eCollection 2014.
• [336] Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.J Cancer Res Clin Oncol. 2014 Nov;140(11):1849-61. doi: 10.1007/s00432-014-1738-8. Epub 2014 Jun 18.
• [337] Hepcidin and iron metabolism in the pathogenesis of prostate cancer.J BUON. 2017 Sep-Oct;22(5):1328-1332.
• [338] The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis.Eur J Cancer. 2014 Aug;50(12):2126-33. doi: 10.1016/j.ejca.2014.05.008. Epub 2014 Jun 5.
• [339] HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen.J Steroid Biochem Mol Biol. 2017 Apr;168:91-101. doi: 10.1016/j.jsbmb.2017.02.008. Epub 2017 Feb 14.
• [340] Molecular aspects on adriamycin interaction with hmga1 regulatory region and its inhibitory effect on HMGA1 expression in human cervical cancer.J Biomol Struct Dyn. 2016;34(4):877-91. doi: 10.1080/07391102.2015.1057617. Epub 2015 Jul 9.
• [341] Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer.Curr Med Chem. 2020;27(20):3271-3289. doi: 10.2174/0929867326666190123120338.
• [342] Heme Oxygenase 1 Impairs Glucocorticoid Receptor Activity in Prostate Cancer.Int J Mol Sci. 2019 Feb 26;20(5):1006. doi: 10.3390/ijms20051006.
• [343] The RNA-binding protein hnRNPA2 regulates -catenin protein expression and is overexpressed in prostate cancer.RNA Biol. 2014;11(6):755-65. doi: 10.4161/rna.28800. Epub 2014 Apr 24.
• [344] The long tail of oncogenic drivers in prostate cancer.Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.
• [345] The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence.Reprod Biol Endocrinol. 2015 Aug 7;13:88. doi: 10.1186/s12958-015-0087-z.
• [346] 17-Hydroxysteroid dehydrogenases (17-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.J Steroid Biochem Mol Biol. 2011 May;125(1-2):66-82. doi: 10.1016/j.jsbmb.2010.12.013. Epub 2010 Dec 28.
• [347] Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma.Dig Dis Sci. 2010 Aug;55(8):2219-26. doi: 10.1007/s10620-009-0992-0. Epub 2009 Oct 3.
• [348] miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.PLoS One. 2016 Jul 22;11(7):e0159601. doi: 10.1371/journal.pone.0159601. eCollection 2016.
• [349] Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.Clin Genitourin Cancer. 2014 Apr;12(2):87-93. doi: 10.1016/j.clgc.2013.08.007. Epub 2013 Oct 12.
• [350] PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.Prostate. 2019 Jun;79(9):969-979. doi: 10.1002/pros.23808. Epub 2019 Apr 18.
• [351] NAC1 promotes the migration of prostate cancer cells and participates in osteoclastogenesis by negatively regulating IFN.Oncol Lett. 2018 Mar;15(3):2921-2928. doi: 10.3892/ol.2017.7670. Epub 2017 Dec 20.
• [352] Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis.Cancer Causes Control. 2017 Jun;28(6):497-528. doi: 10.1007/s10552-017-0883-1. Epub 2017 Mar 30.
• [353] Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.Cancer Res. 2000 Jun 1;60(11):3058-64.
• [354] Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.PLoS One. 2007 Aug 22;2(8):e769. doi: 10.1371/journal.pone.0000769.
• [355] Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells.BJU Int. 2020 Jan;125(1):89-102. doi: 10.1111/bju.14893. Epub 2019 Aug 7.
• [356] Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer.Gene Ther. 2014 Apr;21(4):393-401. doi: 10.1038/gt.2014.10. Epub 2014 Feb 27.
• [357] Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk.Asian Pac J Cancer Prev. 2014;15(20):8741-7. doi: 10.7314/apjcp.2014.15.20.8741.
• [358] Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer.Transl Oncol. 2019 Mar;12(3):453-461. doi: 10.1016/j.tranon.2018.12.002. Epub 2018 Dec 20.
• [359] Immune analysis of expression of IL-17 relative ligands and their receptors in bladder cancer: comparison with polyp and cystitis.BMC Immunol. 2016 Oct 3;17(1):36. doi: 10.1186/s12865-016-0174-8.
• [360] Interleukin-7 Contributes to the Invasiveness of Prostate Cancer Cells by Promoting Epithelial-Mesenchymal Transition.Sci Rep. 2019 May 6;9(1):6917. doi: 10.1038/s41598-019-43294-4.
• [361] Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.
• [362] A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.Eur Urol. 2013 Dec;64(6):941-50. doi: 10.1016/j.eururo.2013.02.039. Epub 2013 Mar 7.
• [363] Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.
• [364] Upregulation of Circular RNA Itchy E3 Ubiquitin Protein Ligase Inhibits Cell Proliferation and Promotes Cell Apoptosis Through Targeting MiR-197 in Prostate Cancer.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819886867. doi: 10.1177/1533033819886867.
• [365] Methylation of Integrin 4 and E-Cadherin Genes in Human Prostate Cancer.Pathol Oncol Res. 2015 Sep;21(4):921-7. doi: 10.1007/s12253-015-9917-8. Epub 2015 Mar 6.
• [366] Tumor metastasis suppressor functions of Ets transcription factor through integrin 3-mediated signaling pathway.J Cell Physiol. 2019 Nov;234(11):20266-20274. doi: 10.1002/jcp.28627. Epub 2019 Apr 14.
• [367] Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.Cancer Lett. 2020 Jan 1;468:88-101. doi: 10.1016/j.canlet.2019.10.006. Epub 2019 Oct 5.
• [368] Endoplasmic reticulum Ca(2+) content decrease by PKA-dependent hyperphosphorylation of type 1 IP3 receptor contributes to prostate cancer cell resistance to androgen deprivation.Cell Calcium. 2015 Apr;57(4):312-20. doi: 10.1016/j.ceca.2015.02.004. Epub 2015 Feb 18.
• [369] KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.Int J Clin Exp Pathol. 2013 Nov 15;6(12):2864-71. eCollection 2013.
• [370] A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.J Med Chem. 2017 Mar 23;60(6):2597-2603. doi: 10.1021/acs.jmedchem.7b00133. Epub 2017 Mar 1.
• [371] MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.J Cell Biochem. 2019 Apr;120(4):4987-4997. doi: 10.1002/jcb.27774. Epub 2018 Oct 9.
• [372] Potential Prognostic Role for SPOP, DAXX, RARRES1, and LAMP2 as an Autophagy Related Genes in Prostate Cancer.Urol J. 2020 Mar 16;17(2):156-163. doi: 10.22037/uj.v0i0.4935.
• [373] miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression.Oncotarget. 2015 Mar 20;6(8):6092-104. doi: 10.18632/oncotarget.3341.
• [374] MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer.Int J Oncol. 2015 Aug;47(2):710-8. doi: 10.3892/ijo.2015.3043. Epub 2015 Jun 10.
• [375] Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.Clin Cancer Res. 2018 Sep 1;24(17):4319-4331. doi: 10.1158/1078-0432.CCR-18-0157. Epub 2018 Apr 17.
• [376] Effects of luteinizing hormone receptor signaling in prostate cancer cells.Prostate. 2015 Feb;75(2):141-50. doi: 10.1002/pros.22899. Epub 2014 Nov 12.
• [377] Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway.Oncotarget. 2015 Feb 28;6(6):3904-17. doi: 10.18632/oncotarget.2880.
• [378] Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.Mol Cancer Ther. 2014 Jul;13(7):1952-63. doi: 10.1158/1535-7163.MCT-14-0017. Epub 2014 May 9.
• [379] Mannose-6-phosphate receptor: a target for theranostics of prostate cancer.Angew Chem Int Ed Engl. 2015 May 11;54(20):5952-6. doi: 10.1002/anie.201500286. Epub 2015 Mar 20.
• [380] Total anatomical reconstruction during robot-assisted radical prostatectomy: focus on urinary continence recovery and related complications after 1000 procedures.BJU Int. 2019 Sep;124(3):477-486. doi: 10.1111/bju.14716. Epub 2019 Mar 15.
• [381] Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.J Cancer Res Clin Oncol. 2018 Sep;144(9):1685-1699. doi: 10.1007/s00432-018-2696-3. Epub 2018 Jun 29.
• [382] Mixed lineage kinase 3 modulates -catenin signaling in cancer cells.J Biol Chem. 2011 Oct 28;286(43):37470-82. doi: 10.1074/jbc.M111.298943. Epub 2011 Aug 31.
• [383] In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer.Med Oncol. 2019 Apr 1;36(5):43. doi: 10.1007/s12032-019-1268-y.
• [384] Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.Prostate. 2009 May 15;69(7):727-36. doi: 10.1002/pros.20920.
• [385] MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.J Exp Clin Cancer Res. 2019 Sep 5;38(1):391. doi: 10.1186/s13046-019-1374-x.
• [386] HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.Prostate. 2011 May 15;71(7):690-9. doi: 10.1002/pros.21285. Epub 2010 Oct 26.
• [387] Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers.Mutat Res. 2005 Apr 1;571(1-2):207-19. doi: 10.1016/j.mrfmmm.2004.09.015. Epub 2005 Jan 28.
• [388] Aberrant activation of hepatocyte growth factor/MET signaling promotes -catenin-mediated prostatic tumorigenesis.J Biol Chem. 2020 Jan 10;295(2):631-644. doi: 10.1074/jbc.RA119.011137. Epub 2019 Dec 9.
• [389] AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.J Pathol. 2015 Mar;235(4):581-92. doi: 10.1002/path.4485. Epub 2014 Dec 24.
• [390] MTA1-Dependent Anticancer Activity of Gnetin C in Prostate Cancer.Nutrients. 2019 Sep 4;11(9):2096. doi: 10.3390/nu11092096.
• [391] Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17.
• [392] The targeting of MTDH by miR?45?p or miR?45?p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells.Int J Oncol. 2019 Jun;54(6):1955-1968. doi: 10.3892/ijo.2019.4782. Epub 2019 Apr 12.
• [393] Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-B): potential implications on prostate cancer chemoprevention and therapy.J Pineal Res. 2013 Jan;54(1):69-79. doi: 10.1111/j.1600-079X.2012.01026.x. Epub 2012 Aug 1.
• [394] A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer.Aging (Albany NY). 2018 Oct 18;10(10):2741-2754. doi: 10.18632/aging.101584.
• [395] CD151 is associated with prostate cancer cell invasion and lymphangiogenesis in vivo.Oncol Rep. 2014 Jan;31(1):241-7. doi: 10.3892/or.2013.2823. Epub 2013 Oct 29.
• [396] Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.Mol Cell Proteomics. 2014 Jul;13(7):1753-68. doi: 10.1074/mcp.M114.038273. Epub 2014 Apr 16.
• [397] SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-B signaling pathway.Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):609-615. doi: 10.26355/eurrev_201802_14275.
• [398] Upregulation of GRIM-19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b.Clin Exp Pharmacol Physiol. 2020 Jan;47(1):76-84. doi: 10.1111/1440-1681.13179. Epub 2019 Oct 22.
• [399] p62 as a therapeutic target for inhibition of autophagy in prostate cancer.Prostate. 2018 Apr;78(5):390-400. doi: 10.1002/pros.23483. Epub 2018 Jan 25.
• [400] Nerve Growth Factor Induces Proliferation and Aggressiveness In Prostate Cancer Cells.Cancers (Basel). 2019 Jun 6;11(6):784. doi: 10.3390/cancers11060784.
• [401] C-type natriuretic peptide and its precursor: potential markers in human prostate cancer.Biomark Med. 2015;9(4):319-26. doi: 10.2217/bmm.14.74.
• [402] Meta-Analysis of steroid-converting enzymes and related receptors in prostate cancer suggesting novel combined therapies.J Steroid Biochem Mol Biol. 2020 Apr;198:105559. doi: 10.1016/j.jsbmb.2019.105559. Epub 2019 Nov 26.
• [403] Expression of neuregulin 4 splice variants in normal human tissues and prostate cancer and their effects on cell motility.Endocr Relat Cancer. 2010 Dec 13;18(1):39-49. doi: 10.1677/ERC-10-0112. Print 2011 Feb.
• [404] Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.Oncogene. 2019 Jun;38(24):4875-4884. doi: 10.1038/s41388-019-0750-5. Epub 2019 Feb 15.
• [405] Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.Int J Cancer. 2020 Mar 1;146(5):1346-1358. doi: 10.1002/ijc.32535. Epub 2019 Jul 9.
• [406] Oligophrenin-1 is associated with cell adhesion and migration in prostate cancer.Pathobiology. 2014;81(4):190-8. doi: 10.1159/000363345. Epub 2014 Aug 27.
• [407] P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells.Br J Cancer. 2013 Sep 17;109(6):1666-75. doi: 10.1038/bjc.2013.484. Epub 2013 Aug 22.
• [408] Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway.Oncotarget. 2017 Apr 4;8(14):22563-22580. doi: 10.18632/oncotarget.15124.
• [409] A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model.Cancer Res. 2009 Oct 1;69(19):7689-95. doi: 10.1158/0008-5472.CAN-08-2472. Epub 2009 Sep 22.
• [410] A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.Nucleic Acids Res. 2019 Jun 20;47(11):5634-5647. doi: 10.1093/nar/gkz286.
• [411] Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer.Neoplasia. 2017 Jun;19(6):451-459. doi: 10.1016/j.neo.2017.04.005. Epub 2017 May 7.
• [412] Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells.Onco Targets Ther. 2017 Apr 12;10:2139-2146. doi: 10.2147/OTT.S129413. eCollection 2017.
• [413] The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.Br J Cancer. 2014 Mar 4;110(5):1278-87. doi: 10.1038/bjc.2014.22. Epub 2014 Feb 11.
• [414] Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.Am J Pathol. 2014 Oct;184(10):2671-86. doi: 10.1016/j.ajpath.2014.06.030. Epub 2014 Aug 14.
• [415] Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.Prostate. 2019 Nov;79(15):1777-1788. doi: 10.1002/pros.23903. Epub 2019 Sep 10.
• [416] Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.ACS Nano. 2017 Mar 28;11(3):2618-2627. doi: 10.1021/acsnano.6b07195. Epub 2017 Mar 3.
• [417] Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.Prostate. 2019 Mar;79(4):370-378. doi: 10.1002/pros.23743. Epub 2018 Nov 28.
• [418] A novel cross-talk between CXCR4 and PI4KIII in prostate cancer cells.Oncogene. 2019 Jan;38(3):332-344. doi: 10.1038/s41388-018-0448-0. Epub 2018 Aug 15.
• [419] Prolyl isomerase Pin1 binds to and stabilizes acetyl CoA carboxylase 1 protein, thereby supporting cancer cell proliferation.Oncotarget. 2019 Feb 26;10(17):1637-1648. doi: 10.18632/oncotarget.26691. eCollection 2019 Feb 26.
• [420] KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.Oncogene. 2019 Jan;38(1):17-32. doi: 10.1038/s41388-018-0414-x. Epub 2018 Aug 2.
• [421] Phospholipase A2-Responsive Phosphate Micelle-Loaded UCNPs for Bioimaging of Prostate Cancer Cells.Sci Rep. 2017 Nov 22;7(1):16073. doi: 10.1038/s41598-017-16136-4.
• [422] Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.Mol Pharm. 2014 Oct 6;11(10):3443-51. doi: 10.1021/mp500174p. Epub 2014 Sep 22.
• [423] The malignancy index in plasma samples as a prostate cancer biomarker.Discov Med. 2018 May;25(139):235-242.
• [424] CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer.Neoplasia. 2012 Sep;14(9):799-806. doi: 10.1593/neo.12580.
• [425] Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition.BMC Med. 2017 Jul 5;15(1):122. doi: 10.1186/s12916-017-0885-6.
• [426] Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.Med Sci Monit. 2018 Jul 12;24:4807-4822. doi: 10.12659/MSM.908057.
• [427] PPP5C promotes cell proliferation and survival in human prostate cancer by regulating of the JNK and ERK1/2 phosphorylation.Onco Targets Ther. 2018 Sep 12;11:5797-5809. doi: 10.2147/OTT.S161280. eCollection 2018.
• [428] Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.J Proteome Res. 2012 Apr 6;11(4):2452-66. doi: 10.1021/pr201172n. Epub 2012 Mar 28.
• [429] The role of PKC and PKD in CXCL12 directed prostate cancer migration.Biochem Biophys Res Commun. 2019 Oct 29;519(1):86-92. doi: 10.1016/j.bbrc.2019.08.134. Epub 2019 Aug 30.
• [430] Activation of nuclear factor B (NF-B) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon).J Biol Chem. 2012 Oct 26;287(44):37570-82. doi: 10.1074/jbc.M112.398925. Epub 2012 Sep 6.
• [431] Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate. 2006 Jun 15;66(9):911-20. doi: 10.1002/pros.20325.
• [432] High Glucose Induces VEGF-C Expression via the LPA1/3-Akt-ROS-LEDGF Signaling Axis in Human Prostate Cancer PC-3 Cells.Cell Physiol Biochem. 2018;50(2):597-611. doi: 10.1159/000494177. Epub 2018 Oct 12.
• [433] COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.Prostate. 2014 Jul;74(10):999-1011. doi: 10.1002/pros.22815. Epub 2014 May 7.
• [434] Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.J Pharmacol Exp Ther. 2013 Feb;344(2):360-7. doi: 10.1124/jpet.112.200444. Epub 2012 Nov 28.
• [435] Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.Mol Cancer Res. 2013 Apr;11(4):427-39. doi: 10.1158/1541-7786.MCR-12-0464. Epub 2013 Jan 30.
• [436] Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.Cancer Lett. 2019 Jan;440-441:35-46. doi: 10.1016/j.canlet.2018.10.004. Epub 2018 Oct 9.
• [437] Protein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer.Int J Mol Sci. 2014 Jul 1;15(7):11665-77. doi: 10.3390/ijms150711665.
• [438] Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.Prostate. 2011 Feb 15;71(3):305-17. doi: 10.1002/pros.21244. Epub 2010 Sep 1.
• [439] Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.Urol Oncol. 2014 Aug;32(6):769-78. doi: 10.1016/j.urolonc.2014.03.007. Epub 2014 Jun 23.
• [440] Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells.Prostate. 2010 Oct 1;70(14):1491-500. doi: 10.1002/pros.21184.
• [441] Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.Food Chem Toxicol. 2019 Feb;124:273-279. doi: 10.1016/j.fct.2018.12.014. Epub 2018 Dec 12.
• [442] Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.Sci Rep. 2018 Mar 2;8(1):3947. doi: 10.1038/s41598-018-22289-7.
• [443] Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.Biol Pharm Bull. 2019;42(3):448-452. doi: 10.1248/bpb.b18-00782.
• [444] The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.BMC Cancer. 2014 Dec 23;14:994. doi: 10.1186/1471-2407-14-994.
• [445] Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.Oncotarget. 2017 Mar 21;8(12):20103-20112. doi: 10.18632/oncotarget.15384.
• [446] Rho-Associated Protein Kinase (ROCK) Promotes Proliferation and Migration of PC-3 and DU145 Prostate Cancer Cells by Targeting LIM Kinase 1 (LIMK1) and Matrix Metalloproteinase-2 (MMP-2).Med Sci Monit. 2019 Apr 26;25:3090-3099. doi: 10.12659/MSM.912098.
• [447] A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.J Nanobiotechnology. 2019 Aug 26;17(1):91. doi: 10.1186/s12951-019-0521-z.
• [448] Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813. Epub 2014 Apr 17.
• [449] A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.
• [450] Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and-Independent Mechanisms.Cancers (Basel). 2018 Jul 23;10(7):239. doi: 10.3390/cancers10070239.
• [451] Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.Neoplasia. 2019 Sep;21(9):872-881. doi: 10.1016/j.neo.2019.07.003. Epub 2019 Aug 2.
• [452] Extrinsic sphingosine 1-phosphate activates S1P5 and induces autophagy through generating endoplasmic reticulum stress in human prostate cancer PC-3 cells.Cell Signal. 2014 Mar;26(3):611-8. doi: 10.1016/j.cellsig.2013.11.024. Epub 2013 Dec 11.
• [453] Development and Preliminary Clinical Application of Circulating Tumor Cell Detection System for Prostate Cancer.J Biomed Nanotechnol. 2019 Mar 1;15(3):612-620. doi: 10.1166/jbn.2019.2706.
• [454] Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.Clin Prostate Cancer. 2002 Sep;1(2):118-24. doi: 10.3816/cgc.2002.n.014.
• [455] Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.Urol Oncol. 2018 Jun;36(6):312.e9-312.e15. doi: 10.1016/j.urolonc.2018.03.010. Epub 2018 Apr 5.
• [456] MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer.Sci Rep. 2014 Dec 18;4:7546. doi: 10.1038/srep07546.
• [457] Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.Transl Res. 2019 Oct;212:89-103. doi: 10.1016/j.trsl.2019.07.001. Epub 2019 Jul 9.
• [458] Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/-catenin signaling.J Mol Med (Berl). 2019 Aug;97(8):1169-1182. doi: 10.1007/s00109-019-01807-8. Epub 2019 Jun 11.
• [459] Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.Mol Cancer Res. 2015 Apr;13(4):620-635. doi: 10.1158/1541-7786.MCR-13-0182-T. Epub 2014 Dec 29.
• [460] SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.J Virol. 2019 Jul 17;93(15):e00626-19. doi: 10.1128/JVI.00626-19. Print 2019 Aug 1.
• [461] Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.
• [462] SOST Inhibits Prostate Cancer Invasion.PLoS One. 2015 Nov 6;10(11):e0142058. doi: 10.1371/journal.pone.0142058. eCollection 2015.
• [463] Sphingosine Kinase-1 Involves the Inhibitory Action of HIF-1 by Chlorogenic Acid in Hypoxic DU145 Cells.Int J Mol Sci. 2017 Feb 4;18(2):325. doi: 10.3390/ijms18020325.
• [464] The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.Mol Cancer Ther. 2015 Dec;14(12):2744-52. doi: 10.1158/1535-7163.MCT-15-0279. Epub 2015 Oct 22.
• [465] Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.Cancer Cell. 2018 Apr 9;33(4):770-784.e6. doi: 10.1016/j.ccell.2018.03.001.
• [466] Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.Biomed Pharmacother. 2018 Jun;102:531-538. doi: 10.1016/j.biopha.2018.03.079. Epub 2018 Mar 26.
• [467] Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.Mol Cell Endocrinol. 2014 Feb 15;382(2):860-70. doi: 10.1016/j.mce.2013.10.027. Epub 2013 Nov 5.
• [468] Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.Oncogene. 2019 Jul;38(28):5580-5598. doi: 10.1038/s41388-019-0833-3. Epub 2019 May 31.
• [469] IGF2 increases de novo steroidogenesis in prostate cancer cells.Endocr Relat Cancer. 2013 Mar 22;20(2):173-86. doi: 10.1530/ERC-12-0250. Print 2013 Apr.
• [470] Stanniocalcin-1 protein expression profile and mechanisms in proliferation and cell death pathways in prostate cancer.Mol Cell Endocrinol. 2020 Feb 15;502:110659. doi: 10.1016/j.mce.2019.110659. Epub 2019 Dec 7.
• [471] SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells.J Exp Clin Cancer Res. 2015 Mar 14;34(1):25. doi: 10.1186/s13046-015-0141-x.
• [472] Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.Oncotarget. 2015 Jun 10;6(16):14318-28. doi: 10.18632/oncotarget.3960.
• [473] Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.Cell Tissue Res. 2010 Feb;339(2):337-47. doi: 10.1007/s00441-009-0902-y. Epub 2009 Dec 11.
• [474] TBK1 regulates prostate cancer dormancy through mTOR inhibition.Neoplasia. 2013 Sep;15(9):1064-74. doi: 10.1593/neo.13402.
• [475] Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.Int J Med Sci. 2015 Feb 5;12(3):243-7. doi: 10.7150/ijms.10953. eCollection 2015.
• [476] CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.
• [477] Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway.Int J Mol Sci. 2019 Mar 7;20(5):1164. doi: 10.3390/ijms20051164.
• [478] Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.Crit Rev Oncol Hematol. 2018 Nov;131:1-6. doi: 10.1016/j.critrevonc.2018.07.008. Epub 2018 Aug 1.
• [479] Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas.Nanomedicine (Lond). 2014 Apr;9(4):421-34. doi: 10.2217/NNM.13.25.
• [480] Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFRIII-p38MAPK-pS249/T252RB Pathway.Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7.
• [481] Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.Int J Exp Pathol. 2019 Apr;100(2):123-132. doi: 10.1111/iep.12314. Epub 2019 May 14.
• [482] Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis.Mol Cancer Ther. 2018 Jun;17(6):1217-1228. doi: 10.1158/1535-7163.MCT-17-1157. Epub 2018 Mar 16.
• [483] UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction.Cancer Lett. 2011 Mar 28;302(2):128-35. doi: 10.1016/j.canlet.2011.01.006.
• [484] Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.PLoS One. 2016 Apr 13;11(4):e0153609. doi: 10.1371/journal.pone.0153609. eCollection 2016.
• [485] Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells.Int J Oncol. 2014 Oct;45(4):1489-96. doi: 10.3892/ijo.2014.2576.
• [486] VIP induces NF-B1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.Cell Signal. 2015 Feb;27(2):236-44. doi: 10.1016/j.cellsig.2014.11.005. Epub 2014 Nov 15.
• [487] Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer.Biochim Biophys Acta. 2013 Dec;1832(12):2127-35. doi: 10.1016/j.bbadis.2013.08.001. Epub 2013 Aug 9.
• [488] Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer.Radiother Oncol. 2015 May;115(2):235-9. doi: 10.1016/j.radonc.2015.04.008. Epub 2015 Apr 30.
• [489] MicroRNA-200c-3p/ZEB2 loop plays a crucial role in the tumor progression of prostate carcinoma.Ann Transl Med. 2019 Apr;7(7):141. doi: 10.21037/atm.2019.02.40.
• [490] Integrated Bioinformatics Analysis of Potential Biomarkers for Prostate Cancer.Pathol Oncol Res. 2019 Apr;25(2):455-460. doi: 10.1007/s12253-017-0346-8. Epub 2017 Dec 19.
• [491] Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.Prostate. 2013 Apr;73(5):455-66. doi: 10.1002/pros.22587. Epub 2012 Oct 4.
• [492] The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer.Clinics (Sao Paulo). 2013 May;68(5):652-7. doi: 10.6061/clinics/2013(05)12.
• [493] Characterization of hydrogen sulfide and its synthases, cystathionine -synthase and cystathionine -lyase, in human prostatic tissue and cells.Urology. 2012 Feb;79(2):483.e1-5. doi: 10.1016/j.urology.2011.10.013.
• [494] TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer.Cell Signal. 2019 Jul;59:152-162. doi: 10.1016/j.cellsig.2019.03.017. Epub 2019 Mar 26.
• [495] Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.Genes Chromosomes Cancer. 2016 Aug;55(8):661-73. doi: 10.1002/gcc.22368. Epub 2016 May 24.
• [496] The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.J Clin Lab Anal. 2019 Jun;33(5):e22871. doi: 10.1002/jcla.22871. Epub 2019 Apr 8.
• [497] Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.Prostate. 2020 Jan;80(1):88-98. doi: 10.1002/pros.23921. Epub 2019 Oct 29.
• [498] A genetic variant of FcRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer.Immunogenetics. 2013 Feb;65(2):91-6. doi: 10.1007/s00251-012-0660-y. Epub 2012 Nov 1.
• [499] Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.J Urol. 2013 Jun;189(6):2335-41. doi: 10.1016/j.juro.2012.11.074. Epub 2012 Nov 15.
• [500] Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.J Clin Invest. 2013 Apr;123(4):1615-29. doi: 10.1172/JCI59623. Epub 2013 Mar 15.
• [501] Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers.Int J Mol Sci. 2013 Jun 26;14(7):13329-45. doi: 10.3390/ijms140713329.
• [502] Activation of PSGR with -ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation.Cancer Lett. 2019 Jul 1;453:193-205. doi: 10.1016/j.canlet.2019.03.044. Epub 2019 Mar 27.
• [503] Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells.J Biol Chem. 2013 Oct 18;288(42):30054-30063. doi: 10.1074/jbc.M113.481283. Epub 2013 Aug 28.
• [504] Impact of Genetic and Epigenetic Variations Within the FADS Cluster on the Composition and Metabolism of Polyunsaturated Fatty Acids in Prostate Cancer.Prostate. 2016 Sep;76(13):1182-91. doi: 10.1002/pros.23205. Epub 2016 May 16.
• [505] ANP-NPRA signaling pathway--a potential therapeutic target for the treatment of malignancy.Crit Rev Eukaryot Gene Expr. 2013;23(2):93-101. doi: 10.1615/critreveukargeneexpr.2013006641.
• [506] Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7. Epub 2019 Feb 11.
• [507] In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.PLoS One. 2013;8(1):e53795. doi: 10.1371/journal.pone.0053795. Epub 2013 Jan 16.
• [508] Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.Oncogene. 2016 Dec 8;35(49):6350-6358. doi: 10.1038/onc.2016.171. Epub 2016 Jun 6.
• [509] Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.Mol Cancer Res. 2012 Jun;10(6):821-33. doi: 10.1158/1541-7786.MCR-11-0615. Epub 2012 Mar 27.
• [510] BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer.J Cell Physiol. 2019 Sep;234(9):15194-15205. doi: 10.1002/jcp.28161. Epub 2019 Jan 22.
• [511] The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.Asian J Androl. 2019 Sep-Oct;21(5):460-467. doi: 10.4103/aja.aja_1_19.
• [512] Frequent down-regulation of ABC transporter genes in prostate cancer. BMC Cancer. 2015 Oct 12;15:683.
• [513] Significantly altered expression of miR-511-3p and its target AKT3 has negative prognostic value in human prostate cancer.Biochimie. 2017 Sep;140:66-72. doi: 10.1016/j.biochi.2017.06.007. Epub 2017 Jun 15.
• [514] Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.Oncotarget. 2019 Oct 29;10(59):6362-6377. doi: 10.18632/oncotarget.27279. eCollection 2019 Oct 29.
• [515] Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients.PLoS One. 2017 Oct 5;12(10):e0183122. doi: 10.1371/journal.pone.0183122. eCollection 2017.
• [516] Synthesis and biological evaluation of novel Ani9 derivatives as potent and selective ANO1 inhibitors.Eur J Med Chem. 2018 Dec 5;160:245-255. doi: 10.1016/j.ejmech.2018.10.002. Epub 2018 Oct 11.
• [517] Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.Eur Urol. 2018 Dec;74(6):710-719. doi: 10.1016/j.eururo.2018.06.021. Epub 2018 Jul 7.
• [518] Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013;8(2):e55146.
• [519] AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5.
• [520] Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.Cancer Med. 2019 Sep;8(12):5716-5734. doi: 10.1002/cam4.2455. Epub 2019 Aug 7.
• [521] BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.Cancer Res. 2018 Sep 15;78(18):5203-5215. doi: 10.1158/0008-5472.CAN-17-3615. Epub 2018 Jul 16.
• [522] Comparative Proteome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteogenomics.Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):273-286. doi: 10.21873/cgp.20132.
• [523] Association of caspases with an increased prostate cancer risk in north Indian population.DNA Cell Biol. 2012 Jan;31(1):67-73. doi: 10.1089/dna.2011.1285. Epub 2011 Jun 13.
• [524] Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.Cancer Res. 2011 Nov 1;71(21):6738-6748. doi: 10.1158/0008-5472.CAN-11-1882. Epub 2011 Sep 7.
• [525] CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.Cytokine. 2013 Oct;64(1):251-7. doi: 10.1016/j.cyto.2013.06.313. Epub 2013 Jul 19.
• [526] Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression.Oncol Rep. 2014 May;31(5):2049-54. doi: 10.3892/or.2014.3060. Epub 2014 Mar 5.
• [527] Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.
• [528] Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5.
• [529] MZF1 and SCAND1 Reciprocally Regulate CDC37 Gene Expression in Prostate Cancer.Cancers (Basel). 2019 Jun 8;11(6):792. doi: 10.3390/cancers11060792.
• [530] Caffeic acid phenethyl ester suppresses androgen receptor signaling and stability via inhibition of phosphorylation on Ser81 and Ser213.Cell Commun Signal. 2019 Aug 20;17(1):100. doi: 10.1186/s12964-019-0404-9.
• [531] Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1.Cancer Discov. 2019 Nov;9(11):1490-1492. doi: 10.1158/2159-8290.CD-19-1028.
• [532] Novel identification of the ETS-1 splice variants p42 and p27 in prostate cancer cell lines.Oncol Rep. 2012 May;27(5):1321-4. doi: 10.3892/or.2012.1667. Epub 2012 Feb 1.
• [533] Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer.J Mol Med (Berl). 2012 Oct;90(10):1121-32. doi: 10.1007/s00109-012-0885-0. Epub 2012 Mar 16.
• [534] Circulating inflammation markers and prostate cancer.Prostate. 2019 Aug;79(11):1338-1346. doi: 10.1002/pros.23842. Epub 2019 Jun 18.
• [535] CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.Int J Oncol. 2018 Oct;53(4):1544-1556. doi: 10.3892/ijo.2018.4487. Epub 2018 Jul 18.
• [536] Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.
• [537] Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment.Sci Rep. 2019 Oct 18;9(1):14963. doi: 10.1038/s41598-019-46491-3.
• [538] Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility.Front Biosci. 2006 Sep 1;11:2052-60. doi: 10.2741/1947.
• [539] Anacardic acid induces cell apoptosis of prostatic cancer through autophagy by ER stress/DAPK3/Akt signaling pathway.Oncol Rep. 2017 Sep;38(3):1373-1382. doi: 10.3892/or.2017.5841. Epub 2017 Jul 20.
• [540] Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.Genome Res. 2012 Jun;22(6):1015-25. doi: 10.1101/gr.133280.111. Epub 2012 Apr 16.
• [541] Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study.Scand J Urol. 2019 Dec;53(6):378-384. doi: 10.1080/21681805.2019.1697358. Epub 2019 Dec 5.
• [542] Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21.
• [543] Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D.Cancer Res. 2006 Apr 15;66(8):4516-24. doi: 10.1158/0008-5472.CAN-05-3796.
• [544] Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.J Biol Chem. 2012 Oct 12;287(42):35251-35259. doi: 10.1074/jbc.M112.374686. Epub 2012 Aug 20.
• [545] Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.Anticancer Res. 2018 Mar;38(3):1391-1399. doi: 10.21873/anticanres.12362.
• [546] Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.Anticancer Res. 2019 Nov;39(11):6249-6257. doi: 10.21873/anticanres.13834.
• [547] Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.Am J Pathol. 2011 Feb;178(2):525-36. doi: 10.1016/j.ajpath.2010.10.002.
• [548] The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.Cell Death Dis. 2014 Apr 24;5(4):e1195. doi: 10.1038/cddis.2014.157.
• [549] Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.J Exp Clin Cancer Res. 2017 Oct 10;36(1):139. doi: 10.1186/s13046-017-0609-y.
• [550] Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer.Prostate Cancer Prostatic Dis. 2012 Dec;15(4):339-45. doi: 10.1038/pcan.2012.14. Epub 2012 May 1.
• [551] Novel biomarkers for prostate cancer including noncoding transcripts.Am J Pathol. 2009 Dec;175(6):2264-76. doi: 10.2353/ajpath.2009.080868. Epub 2009 Nov 5.
• [552] Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2.Front Endocrinol (Lausanne). 2019 Jul 17;10:481. doi: 10.3389/fendo.2019.00481. eCollection 2019.
• [553] Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer.Biomed Pharmacother. 2017 Nov;95:1112-1118. doi: 10.1016/j.biopha.2017.09.019. Epub 2017 Oct 6.
• [554] The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study.Genet Test Mol Biomarkers. 2018 Feb;22(2):79-84. doi: 10.1089/gtmb.2017.0146. Epub 2017 Dec 20.
• [555] Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.
• [556] Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells.Prostate. 2012 Sep 15;72(13):1431-42. doi: 10.1002/pros.22494. Epub 2012 Jan 30.
• [557] Distinct expression and activity of GSK-3 and GSK-3 in prostate cancer.Int J Cancer. 2012 Sep 15;131(6):E872-83. doi: 10.1002/ijc.27620. Epub 2012 May 22.
• [558] Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma.Mol Med Rep. 2018 Aug;18(2):1939-1946. doi: 10.3892/mmr.2018.9204. Epub 2018 Jun 22.
• [559] Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclinD1 and MMP-7.Oncol Rep. 2017 Feb;37(2):1045-1051. doi: 10.3892/or.2016.5288. Epub 2016 Dec 2.
• [560] A Prostate Cancer Risk Element Functions as a Repressive Loop that Regulates HOXA13.Cell Rep. 2017 Nov 7;21(6):1411-1417. doi: 10.1016/j.celrep.2017.10.048.
• [561] Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy.Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.
• [562] Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study.Genet Test Mol Biomarkers. 2012 Jun;16(6):598-604. doi: 10.1089/gtmb.2011.0279. Epub 2012 Mar 15.
• [563] Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.J Exp Clin Cancer Res. 2019 Jul 18;38(1):317. doi: 10.1186/s13046-019-1317-6.
• [564] Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells.J Cell Biochem. 2017 May;118(5):1038-1049. doi: 10.1002/jcb.25673. Epub 2017 Jan 5.
• [565] Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.Cancers (Basel). 2019 Nov 13;11(11):1785. doi: 10.3390/cancers11111785.
• [566] Long noncoding RNA LUCAT1 promotes migration and invasion of prostate cancer cells by inhibiting KISS1 expression.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3277-3283. doi: 10.26355/eurrev_201904_17689.
• [567] The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.Mol Oncol. 2020 Jan;14(1):105-128. doi: 10.1002/1878-0261.12587. Epub 2019 Nov 28.
• [568] Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.
• [569] Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population.Gene. 2017 Aug 30;626:354-357. doi: 10.1016/j.gene.2017.05.060. Epub 2017 Jun 1.
• [570] Detection of CK19 mRNA Using One-step Nucleic Acid Amplification (OSNA) in Prostate Cancer: Preliminary Results.J Cancer. 2018 Nov 24;9(24):4611-4617. doi: 10.7150/jca.26794. eCollection 2018.
• [571] LanCL1 protects prostate cancer cells from oxidative stress via suppression of JNK pathway.Cell Death Dis. 2018 Feb 7;9(2):197. doi: 10.1038/s41419-017-0207-0.
• [572] Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.Prostate. 2017 Feb;77(3):309-320. doi: 10.1002/pros.23269. Epub 2016 Oct 24.
• [573] Repression of MicroRNA-372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2.Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):256-263. doi: 10.1111/bcpt.12687. Epub 2016 Dec 28.
• [574] Imbalance of a KLF4-miR-7 auto-regulatory feedback loop promotes prostate cancer cell growth by impairing microRNA processing.Am J Cancer Res. 2018 Feb 1;8(2):226-244. eCollection 2018.
• [575] The impact of TRAIL on proliferation of secretory prostate cancer PC-3 cell and LMO2 gene expression.Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7172-7177. doi: 10.26355/eurrev_201811_16249.
• [576] Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.Andrologia. 2019 Sep;51(8):e13321. doi: 10.1111/and.13321. Epub 2019 May 30.
• [577] Genetic and epigenetic inactivation of LPL gene in human prostate cancer.Int J Cancer. 2009 Feb 1;124(3):734-8. doi: 10.1002/ijc.23972.
• [578] Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk.Prostate. 2011 Sep 15;71(13):1382-9. doi: 10.1002/pros.21354. Epub 2011 Feb 9.
• [579] Identification of potential therapeutic targets in prostate cancer through a cross-species approach.EMBO Mol Med. 2018 Mar;10(3):e8274. doi: 10.15252/emmm.201708274.
• [580] Suppression of cancer progression by MGAT1 shRNA knockdown.PLoS One. 2012;7(9):e43721. doi: 10.1371/journal.pone.0043721. Epub 2012 Sep 5.
• [581] Essential role of NADPH oxidase-dependent reactive oxygen species generation in regulating microRNA-21 expression and function in prostate cancer.Antioxid Redox Signal. 2013 Dec 1;19(16):1863-76. doi: 10.1089/ars.2012.4820. Epub 2013 Jul 5.
• [582] Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.Cell Cycle. 2011 Oct 15;10(20):3571-97. doi: 10.4161/cc.10.20.17842.
• [583] Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF- signaling.Clin Transl Oncol. 2018 Oct;20(10):1302-1313. doi: 10.1007/s12094-018-1862-z. Epub 2018 Mar 28.
• [584] pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1761-1767. doi: 10.1016/j.bbrc.2018.07.110. Epub 2018 Aug 18.
• [585] LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells.Cancer Lett. 2018 Feb 1;414:34-43. doi: 10.1016/j.canlet.2017.10.035. Epub 2017 Nov 14.
• [586] miR-181b/Oncostatin m axis inhibits prostate cancer bone metastasis via modulating osteoclast differentiation.J Cell Biochem. 2020 Feb;121(2):1664-1674. doi: 10.1002/jcb.29401. Epub 2019 Nov 3.
• [587] Membrane Androgen Receptors Unrelated to Nuclear Steroid Receptors.Endocrinology. 2019 Apr 1;160(4):772-781. doi: 10.1210/en.2018-00987.
• [588] Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14573-14582. doi: 10.1073/pnas.1908547116. Epub 2019 Jul 2.
• [589] Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.J Clin Endocrinol Metab. 2011 Jan;96(1):E135-40. doi: 10.1210/jc.2010-1655. Epub 2010 Sep 29.
• [590] PLAC1: biology and potential application in cancer immunotherapy.Cancer Immunol Immunother. 2019 Jul;68(7):1039-1058. doi: 10.1007/s00262-019-02350-8. Epub 2019 Jun 5.
• [591] Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer.PLoS One. 2012;7(11):e48709. doi: 10.1371/journal.pone.0048709. Epub 2012 Nov 1.
• [592] PRKAR2B promotes prostate cancer metastasis by activating Wnt/-catenin and inducing epithelial-mesenchymal transition.J Cell Biochem. 2018 Sep;119(9):7319-7327. doi: 10.1002/jcb.27030. Epub 2018 May 15.
• [593] PKC facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model.Oncogene. 2019 May;38(22):4215-4231. doi: 10.1038/s41388-019-0722-9. Epub 2019 Jan 31.
• [594] Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.Prostate. 2015 Oct;75(14):1586-600. doi: 10.1002/pros.23034. Epub 2015 Jun 12.
• [595] A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.Br J Cancer. 2012 Jun 26;107(1):53-62. doi: 10.1038/bjc.2012.243. Epub 2012 Jun 7.
• [596] PRL? increases the aggressive phenotype of prostate cancer cells invitro and its expression correlates with high-grade prostate tumors in patients.Int J Oncol. 2018 Feb;52(2):402-412. doi: 10.3892/ijo.2017.4208. Epub 2017 Nov 20.
• [597] Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the 1 integrin-RACK1 axis.J Cell Physiol. 2012 Nov;227(11):3670-7. doi: 10.1002/jcp.24074.
• [598] Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.PLoS One. 2013 Apr 30;8(4):e63150. doi: 10.1371/journal.pone.0063150. Print 2013.
• [599] Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study.Int J Cancer. 2019 Feb 1;144(3):440-447. doi: 10.1002/ijc.31802. Epub 2018 Nov 5.
• [600] In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review.Actas Urol Esp (Engl Ed). 2019 Sep;43(7):337-347. doi: 10.1016/j.acuro.2019.01.010. Epub 2019 May 17.
• [601] Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.Oncotarget. 2017 May 13;8(41):69508-69519. doi: 10.18632/oncotarget.17843. eCollection 2017 Sep 19.
• [602] Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-.Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11482-11487. doi: 10.1073/pnas.1705536114. Epub 2017 Oct 9.
• [603] Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1.Biomarkers. 2018 Jul;23(5):435-445. doi: 10.1080/1354750X.2018.1443509. Epub 2018 Mar 21.
• [604] Expression of LDL-A module of relaxin receptor in prostate cancer cells inhibits tumorigenesis.Int J Oncol. 2011 Dec;39(6):1559-65. doi: 10.3892/ijo.2011.1159. Epub 2011 Aug 12.
• [605] Lipid pathway deregulation in advanced prostate cancer.Pharmacol Res. 2018 May;131:177-184. doi: 10.1016/j.phrs.2018.02.022. Epub 2018 Feb 18.
• [606] Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Mol Oncol. 2016 Jun;10(6):825-37.
• [607] Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for (18)F-FDG Imaging of PSMA-Suppressed Tumors.J Nucl Med. 2020 Jun;61(6):904-910. doi: 10.2967/jnumed.119.231068. Epub 2019 Dec 5.
• [608] LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.PLoS One. 2011;6(11):e27720. doi: 10.1371/journal.pone.0027720. Epub 2011 Nov 16.
• [609] Correlation between (18)F-1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.EJNMMI Res. 2019 May 31;9(1):50. doi: 10.1186/s13550-019-0518-5.
• [610] Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.Prostate Cancer Prostatic Dis. 2019 Dec;22(4):560-568. doi: 10.1038/s41391-019-0141-6. Epub 2019 Mar 19.
• [611] MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1.Oncotarget. 2017 Apr 18;8(32):52465-52473. doi: 10.18632/oncotarget.17191. eCollection 2017 Aug 8.
• [612] High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.Urol Oncol. 2018 Apr;36(4):161.e7-161.e17. doi: 10.1016/j.urolonc.2017.10.028. Epub 2017 Nov 22.
• [613] Cholesterol uptake and regulation in high-grade and lethal prostate cancers.Carcinogenesis. 2017 Aug 1;38(8):806-811. doi: 10.1093/carcin/bgx058.
• [614] RNA splicing and splicing regulator changes in prostate cancer pathology.Hum Genet. 2017 Sep;136(9):1143-1154. doi: 10.1007/s00439-017-1792-9. Epub 2017 Apr 5.
• [615] IFN, a Double-Edged Sword in Cancer Immunity and Metastasis.Cancer Res. 2019 Mar 15;79(6):1032-1033. doi: 10.1158/0008-5472.CAN-19-0083.
• [616] Expression of Telomere Repeat Binding Factor 1 and TRF2 in Prostate Cancer and Correlation with Clinical Parameters.Biomed Res Int. 2017;2017:9764752. doi: 10.1155/2017/9764752. Epub 2017 Jul 20.
• [617] Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer.PLoS One. 2012;7(10):e45539. doi: 10.1371/journal.pone.0045539. Epub 2012 Oct 8.
• [618] Matriptase-2: monitoring and inhibiting its proteolytic activity.Future Med Chem. 2018 Dec;10(23):2745-2761. doi: 10.4155/fmc-2018-0346. Epub 2018 Dec 6.
• [619] Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer.Biochem Biophys Res Commun. 2017 May 6;486(3):607-612. doi: 10.1016/j.bbrc.2017.03.021. Epub 2017 Mar 21.
• [620] LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth.Oncogene. 2011 Apr 21;30(16):1892-900. doi: 10.1038/onc.2010.575. Epub 2011 Jan 10.
• [621] Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer.Onco Targets Ther. 2017 Jul 17;10:3531-3543. doi: 10.2147/OTT.S136491. eCollection 2017.
• [622] Knockdown of tripartite motif 59 (TRIM59) inhibits tumor growth in prostate cancer.Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4864-4873.
• [623] Isobavachalcone Induces ROS-Mediated Apoptosis via Targeting Thioredoxin Reductase 1 in Human Prostate Cancer PC-3 Cells.Oxid Med Cell Longev. 2018 Oct 16;2018:1915828. doi: 10.1155/2018/1915828. eCollection 2018.
• [624] Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.PLoS One. 2013 Jun 6;8(6):e60562. doi: 10.1371/journal.pone.0060562. Print 2013.
• [625] Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.Mol Cancer. 2011 Oct 14;10:129. doi: 10.1186/1476-4598-10-129.
• [626] Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.Bioorg Med Chem Lett. 2017 Sep 1;27(17):4015-4018. doi: 10.1016/j.bmcl.2017.07.059. Epub 2017 Jul 23.
• [627] VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen.World J Urol. 2018 May;36(5):719-726. doi: 10.1007/s00345-018-2263-1. Epub 2018 Mar 14.
• [628] Effect of high WDR5 expression on the hepatocellular carcinoma prognosis.Oncol Lett. 2018 May;15(5):7864-7870. doi: 10.3892/ol.2018.8298. Epub 2018 Mar 20.
• [629] Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer.Prostate. 2019 Jun;79(9):1032-1042. doi: 10.1002/pros.23813. Epub 2019 Apr 24.
• [630] Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.Oncotarget. 2016 Dec 20;7(51):84893-84906. doi: 10.18632/oncotarget.12753.
• [631] Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis.Aging (Albany NY). 2019 Jul 15;11(13):4736-4756. doi: 10.18632/aging.102087.
• [632] Upregulation of fractalkine contributes to theproliferative response of prostate cancer cells to hypoxia via promoting the G1/S phase transition.Mol Med Rep. 2015 Dec;12(6):7907-14. doi: 10.3892/mmr.2015.4438. Epub 2015 Oct 13.
• [633] LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.IUBMB Life. 2019 Oct;71(10):1537-1551. doi: 10.1002/iub.2075. Epub 2019 Jun 12.
• [634] Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.Carcinogenesis. 2018 Jul 3;39(7):879-888. doi: 10.1093/carcin/bgy062.
• [635] Contrasting roles of the ABCG2 Q141K variant in prostate cancer.Exp Cell Res. 2017 May 1;354(1):40-47. doi: 10.1016/j.yexcr.2017.03.020. Epub 2017 Mar 11.
• [636] Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics. 2015;10(4):319-28.
• [637] Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-B activation and recurrent dexamethasone administration fails to suppress it in vivo.Prostate. 2019 Feb;79(2):168-182. doi: 10.1002/pros.23722. Epub 2018 Sep 27.
• [638] Analysis of cholinesterases in human prostate and sperm: implications in cancer and fertility.Chem Biol Interact. 2010 Sep 6;187(1-3):432-5. doi: 10.1016/j.cbi.2010.03.038. Epub 2010 Mar 29.
• [639] Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.ACS Omega. 2019 Jan 31;4(1):1470-1478. doi: 10.1021/acsomega.8b03293. Epub 2019 Jan 16.
• [640] Identification of potential diagnostic and prognostic biomarkers for prostate cancer.Oncol Lett. 2019 Oct;18(4):4237-4245. doi: 10.3892/ol.2019.10765. Epub 2019 Aug 16.
• [641] Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation.Cancer Med. 2019 May;8(5):2462-2473. doi: 10.1002/cam4.2130. Epub 2019 Apr 10.
• [642] ACR Appropriateness Criteria() Post-treatmentFollow-up Prostate Cancer.J Am Coll Radiol. 2018 May;15(5S):S132-S149. doi: 10.1016/j.jacr.2018.03.019.
• [643] Early Response Monitoring Following Radiation Therapy by Using [(18)F]FDG and [(11)C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration.Molecules. 2017 Nov 10;22(11):1946. doi: 10.3390/molecules22111946.
• [644] ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models.Front Cell Dev Biol. 2017 Dec 5;5:104. doi: 10.3389/fcell.2017.00104. eCollection 2017.
• [645] Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.Cancer Genet Cytogenet. 2005 Dec;163(2):123-9. doi: 10.1016/j.cancergencyto.2005.05.007.
• [646] TMPRSS2:ERG gene fusion variants induce TGF- signaling and epithelial to mesenchymal transition in human prostate cancer cells.Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931.
• [647] Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer.Cancer Sci. 2007 Nov;98(11):1720-6. doi: 10.1111/j.1349-7006.2007.00601.x. Epub 2007 Aug 28.
• [648] CircHIPK3 overexpression accelerates the proliferation and invasion of prostate cancer cells through regulating miRNA-338-3p.Onco Targets Ther. 2019 May 2;12:3363-3372. doi: 10.2147/OTT.S196931. eCollection 2019.
• [649] ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.Virchows Arch. 2006 Dec;449(6):628-36. doi: 10.1007/s00428-006-0315-1. Epub 2006 Nov 8.
• [650] Overexpression of ADAM9 in oral squamous cell carcinoma.Oncol Lett. 2018 Jan;15(1):495-502. doi: 10.3892/ol.2017.7284. Epub 2017 Oct 30.
• [651] Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis.Prostate Cancer Prostatic Dis. 2020 Mar;23(1):11-23. doi: 10.1038/s41391-019-0154-1. Epub 2019 May 30.
• [652] MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3734-3741. doi: 10.26355/eurrev_201806_15253.
• [653] Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor.Oncotarget. 2018 Feb 14;9(17):13859-13869. doi: 10.18632/oncotarget.24492. eCollection 2018 Mar 2.
• [654] Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.Prostate. 2019 Dec;79(16):1823-1831. doi: 10.1002/pros.23907. Epub 2019 Sep 11.
• [655] Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.J Cell Physiol. 2019 Jul;234(7):11188-11199. doi: 10.1002/jcp.27768. Epub 2018 Nov 22.
• [656] Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.Prostate. 2014 May;74(6):637-46. doi: 10.1002/pros.22781. Epub 2014 Feb 5.
• [657] Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?.J Mol Med (Berl). 2005 Dec;83(12):1014-24. doi: 10.1007/s00109-005-0703-z. Epub 2005 Oct 7.
• [658] Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.Clin Cancer Res. 2017 Jan 1;23(1):311-319. doi: 10.1158/1078-0432.CCR-16-0549. Epub 2016 Jun 29.
• [659] 7-Farnesyloxycoumarin Exerts Anti-cancer Effects on a Prostate Cancer Cell Line by 15-LOX-1 Inhibition.Arch Iran Med. 2018 Jun 1;21(6):251-259.
• [660] Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.Br J Cancer. 2017 Jan 17;116(2):227-236. doi: 10.1038/bjc.2016.402. Epub 2016 Dec 22.
• [661] Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.Nature. 2018 Feb 22;554(7693):554. doi: 10.1038/nature25470. Epub 2018 Jan 17.
• [662] Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.Oncotarget. 2017 Feb 7;8(6):10145-10160. doi: 10.18632/oncotarget.14358.
• [663] Effects of testosterone and 17estradiol on angiotensininduced changes in tyrosine kinase activity in the androgenindependent human prostate cancer cell line, DU145.Int J Mol Med. 2017 Nov;40(5):1573-1581. doi: 10.3892/ijmm.2017.3149. Epub 2017 Sep 25.
• [664] Expression and function of ATIP/MTUS1 in human prostate cancer cell lines.Prostate. 2010 Oct 1;70(14):1563-74. doi: 10.1002/pros.21192.
• [665] Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.Oncol Rep. 2017 Jul;38(1):120-128. doi: 10.3892/or.2017.5669. Epub 2017 May 24.
• [666] Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients.Biomark Med. 2018 Oct;12(10):1125-1138. doi: 10.2217/bmm-2018-0069. Epub 2018 Sep 7.
• [667] Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.
• [668] Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness.Cell Adh Migr. 2017 May 4;11(3):247-260. doi: 10.1080/19336918.2016.1259056. Epub 2016 Nov 11.
• [669] Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.Prostate. 2017 Mar;77(4):337-349. doi: 10.1002/pros.23273. Epub 2016 Nov 8.
• [670] MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2.Oncol Lett. 2018 Jun;15(6):8295-8302. doi: 10.3892/ol.2018.8395. Epub 2018 Mar 30.
• [671] Design, synthesis and biological evaluation of new -carboline-bisindole compounds as DNA binding, photocleavage agents and topoisomerase I inhibitors.Eur J Med Chem. 2018 Jan 1;143:1563-1577. doi: 10.1016/j.ejmech.2017.10.054. Epub 2017 Oct 23.
• [672] Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma.Pathol Oncol Res. 2017 Jan;23(1):189-196. doi: 10.1007/s12253-016-0145-7. Epub 2016 Nov 5.
• [673] Subcellular localization of aquaporin 3 in prostate cancer is regulated by RalA.Oncol Rep. 2018 May;39(5):2171-2177. doi: 10.3892/or.2018.6308. Epub 2018 Mar 9.
• [674] Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue.BMC Urol. 2018 Sep 3;18(1):75. doi: 10.1186/s12894-018-0391-y.
• [675] Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.J Exp Clin Cancer Res. 2017 Aug 23;36(1):112. doi: 10.1186/s13046-017-0583-4.
• [676] Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.Mol Cancer Res. 2012 Feb;10(2):218-29. doi: 10.1158/1541-7786.MCR-11-0451. Epub 2011 Dec 5.
• [677] Dihydrotestosterone inhibits arylsulfatase B and Dickkopf Wnt signaling pathway inhibitor (DKK)-3 leading to enhanced Wnt signaling in prostate epithelium in response to stromal Wnt3A.Prostate. 2019 May;79(7):689-700. doi: 10.1002/pros.23776. Epub 2019 Feb 22.
• [678] Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520b.Acta Pharmacol Sin. 2019 Sep;40(9):1228-1236. doi: 10.1038/s41401-019-0234-8. Epub 2019 Apr 26.
• [679] Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer.Oncogene. 2019 Aug;38(35):6301-6318. doi: 10.1038/s41388-019-0879-2. Epub 2019 Jul 16.
• [680] Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.Clin Cancer Res. 2018 Sep 15;24(18):4612-4626. doi: 10.1158/1078-0432.CCR-18-0461. Epub 2018 Apr 24.
• [681] Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014 Oct 15;74(20):5819-31. doi: 10.1158/0008-5472.CAN-13-3527.
• [682] End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom.Radiother Oncol. 2019 Dec;141:200-207. doi: 10.1016/j.radonc.2019.09.014. Epub 2019 Oct 1.
• [683] AZGP1 is androgen responsive and involved in AR-induced prostate cancer cell proliferation and metastasis.J Cell Physiol. 2019 Aug;234(10):17444-17458. doi: 10.1002/jcp.28366. Epub 2019 Feb 28.
• [684] Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.Mol Cell Proteomics. 2015 Mar;14(3):471-83. doi: 10.1074/mcp.M114.039909. Epub 2014 Dec 19.
• [685] Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression.Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1495-1504. doi: 10.1080/21691401.2017.1374284. Epub 2017 Sep 11.
• [686] -Bourbonene attenuates proliferation and induces apoptosis of prostate cancer cells.Oncol Lett. 2018 Oct;16(4):4519-4525. doi: 10.3892/ol.2018.9183. Epub 2018 Jul 20.
• [687] Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains.ChemMedChem. 2018 Jul 18;13(14):1479-1487. doi: 10.1002/cmdc.201800234. Epub 2018 Jun 21.
• [688] PUMA decreases the growth of prostate cancer PC-3 cells independent of p53.Oncol Lett. 2017 Mar;13(3):1885-1890. doi: 10.3892/ol.2017.5657. Epub 2017 Jan 27.
• [689] MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.Mol Carcinog. 2017 Jun;56(6):1570-1577. doi: 10.1002/mc.22612. Epub 2017 Jan 18.
• [690] C/EBPbeta regulates metastatic gene expression and confers TNF-alpha resistance to prostate cancer cells.Prostate. 2009 Sep 15;69(13):1435-47. doi: 10.1002/pros.20993.
• [691] Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.
• [692] Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation.Mol Cancer. 2009 Jun 23;8:39. doi: 10.1186/1476-4598-8-39.
• [693] JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.Biochem Biophys Res Commun. 2019 Oct 15;518(2):374-380. doi: 10.1016/j.bbrc.2019.08.066. Epub 2019 Aug 18.
• [694] High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818809694. doi: 10.1177/1533033818809694.
• [695] BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer.Oncogene. 2020 Jan;39(1):17-29. doi: 10.1038/s41388-019-0966-4. Epub 2019 Aug 28.
• [696] Monoamine oxidase-A targeting probe for prostate cancer imaging and inhibition of metastasis.Chem Commun (Camb). 2019 Oct 31;55(88):13267-13270. doi: 10.1039/c9cc07009e.
• [697] Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer.Cancer Sci. 2010 Oct;101(10):2137-44. doi: 10.1111/j.1349-7006.2010.01648.x. Epub 2010 Jul 1.
• [698] Biological effects of BMP7 on small-cell lung cancer cells and its bone metastasis.Int J Oncol. 2018 Sep;53(3):1354-1362. doi: 10.3892/ijo.2018.4469. Epub 2018 Jul 4.
• [699] Opposing roles of TGF and BMP signaling in prostate cancer development.Genes Dev. 2017 Dec 1;31(23-24):2337-2342. doi: 10.1101/gad.307116.117.
• [700] Improving the genetic signature of prostate cancer, the somatic mutations.Urol Oncol. 2018 Jun;36(6):312.e17-312.e23. doi: 10.1016/j.urolonc.2018.03.012. Epub 2018 Apr 9.
• [701] Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.Sci Rep. 2019 Mar 7;9(1):3823. doi: 10.1038/s41598-019-40518-5.
• [702] Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer.Oncol Lett. 2019 Jan;17(1):849-856. doi: 10.3892/ol.2018.9665. Epub 2018 Nov 5.
• [703] Rare germline mutations in African American men diagnosed with early-onset prostate cancer.Prostate. 2018 Apr;78(5):321-326. doi: 10.1002/pros.23464. Epub 2018 Jan 21.
• [704] Identification of ADAM12 as a Novel Basigin Sheddase.Int J Mol Sci. 2019 Apr 22;20(8):1957. doi: 10.3390/ijms20081957.
• [705] Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.Asian J Androl. 2005 Dec;7(4):375-80. doi: 10.1111/j.1745-7262.2005.00031.x.
• [706] Exploration of the molecular mechanism of prostate cancer based on mRNA and miRNA expression profiles.Onco Targets Ther. 2017 Jun 29;10:3225-3232. doi: 10.2147/OTT.S135764. eCollection 2017.
• [707] Improvement of prostate cancer detection combining a computer-aided diagnostic system with TRUS-MRI targeted biopsy.Abdom Radiol (NY). 2019 Jan;44(1):264-271. doi: 10.1007/s00261-018-1712-z.
• [708] CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis.Cancer Res. 2018 Dec 15;78(24):6747-6761. doi: 10.1158/0008-5472.CAN-18-0585. Epub 2018 Sep 21.
• [709] Inhibition of androgen receptor and -catenin activity in prostate cancer.Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15710-5. doi: 10.1073/pnas.1218168110. Epub 2013 Sep 9.
• [710] Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.Oncotarget. 2018 Sep 25;9(75):34190. doi: 10.18632/oncotarget.26197. eCollection 2018 Sep 25.
• [711] TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.Cancer Biol Ther. 2006 Sep;5(9):1199-205. doi: 10.4161/cbt.5.9.3168. Epub 2006 Sep 9.
• [712] MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.Oncogene. 2013 Aug 29;32(35):4139-47. doi: 10.1038/onc.2012.424. Epub 2012 Sep 17.
• [713] Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer.J Cancer Res Clin Oncol. 2008 Nov;134(11):1181-9. doi: 10.1007/s00432-008-0403-5. Epub 2008 May 9.
• [714] Visual electrochemiluminescence ratiometry on bipolar electrode for bioanalysis.Biosens Bioelectron. 2018 Apr 15;102:624-630. doi: 10.1016/j.bios.2017.12.008. Epub 2017 Dec 6.
• [715] Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer.Mod Pathol. 2020 May;33(5):905-915. doi: 10.1038/s41379-019-0418-2. Epub 2019 Dec 4.
• [716] SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability.Cell Death Differ. 2019 Jun;26(6):1156-1168. doi: 10.1038/s41418-018-0198-0. Epub 2018 Sep 20.
• [717] miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer.Mol Med Rep. 2016 Sep;14(3):2077-84. doi: 10.3892/mmr.2016.5469. Epub 2016 Jul 6.
• [718] Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.Oncogene. 2019 Mar;38(12):2005-2019. doi: 10.1038/s41388-018-0575-7. Epub 2018 Nov 22.
• [719] Clinical Implications of Peripheral CD3+CD69+ T-Cell And CD8+CD28+ T-Cell Proportions in Patients Prior to Radical Prostatectomy.Urol J. 2020 May 16;17(3):257-261. doi: 10.22037/uj.v0i0.5103.
• [720] CDC25A functions as a novel Ar corepressor in prostate cancer cells.J Mol Biol. 2009 Jan 16;385(2):446-56. doi: 10.1016/j.jmb.2008.10.070. Epub 2008 Nov 3.
• [721] Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.Oncogene. 2003 Feb 6;22(5):734-9. doi: 10.1038/sj.onc.1206121.
• [722] Results, questions, perspectives of a study on human Polyomavirus BK and molecular actors in prostate cancer development.Cancer Genomics Proteomics. 2015 Mar-Apr;12(2):57-65.
• [723] The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer.J Cancer. 2019 Feb 23;10(6):1398-1408. doi: 10.7150/jca.29571. eCollection 2019.
• [724] Angiomotin is a novel component of cadherin-11/-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.FASEB J. 2015 Mar;29(3):1080-91. doi: 10.1096/fj.14-261594. Epub 2014 Dec 2.
• [725] Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.Cancer Med. 2019 Jun;8(6):2777-2783. doi: 10.1002/cam4.2163. Epub 2019 Apr 16.
• [726] Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Eur Urol. 2020 Mar;77(3):333-341. doi: 10.1016/j.eururo.2019.09.036. Epub 2019 Oct 20.
• [727] The co-chaperone p23 promotes prostate cancer motility and metastasis.Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.
• [728] Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.Sci Rep. 2019 Sep 23;9(1):13696. doi: 10.1038/s41598-019-50140-0.
• [729] Phase I trial of TAK-385 in hormone treatment-nave Japanese patients with nonmetastatic prostate cancer.Cancer Med. 2019 Oct;8(13):5891-5902. doi: 10.1002/cam4.2442. Epub 2019 Aug 19.
• [730] Engineered measles virus as a novel oncolytic therapy against prostate cancer.Prostate. 2009 Jan 1;69(1):82-91. doi: 10.1002/pros.20857.
• [731] Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.BMC Cancer. 2007 Jan 3;7:2. doi: 10.1186/1471-2407-7-2.
• [732] Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.
• [733] LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.
• [734] Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans.Biol Reprod. 1997 Jan;56(1):67-72. doi: 10.1095/biolreprod56.1.67.
• [735] Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment.Clin Cancer Res. 2017 Jul 15;23(14):3781-3793. doi: 10.1158/1078-0432.CCR-16-1716. Epub 2017 Feb 6.
• [736] Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling.Asian J Androl. 2018 Nov-Dec;20(6):608-614. doi: 10.4103/aja.aja_55_18.
• [737] MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.Int J Oncol. 2019 Feb;54(2):443-454. doi: 10.3892/ijo.2018.4647. Epub 2018 Nov 26.
• [738] Bcl-2-dependent modulation of swelling-activated Cl- current and ClC-3 expression in human prostate cancer epithelial cells.Cancer Res. 2004 Jul 15;64(14):4841-8. doi: 10.1158/0008-5472.CAN-03-3223.
• [739] Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.Int Urol Nephrol. 2013 Jun;45(3):727-33. doi: 10.1007/s11255-013-0406-2. Epub 2013 May 18.
• [740] Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.Biomolecules. 2019 Feb 22;9(2):77. doi: 10.3390/biom9020077.
• [741] Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study).Urol Int. 2019;103(1):8-18. doi: 10.1159/000496980. Epub 2019 Feb 7.
• [742] Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1.J Biol Chem. 2003 Apr 25;278(17):15381-9. doi: 10.1074/jbc.M212106200. Epub 2003 Feb 12.
• [743] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.Invest New Drugs. 2019 Jun;37(3):559-566. doi: 10.1007/s10637-019-00778-4. Epub 2019 Apr 30.
• [744] CRTC2 as a novel prognostic biomarker for worse pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with prostate cancer.Investig Clin Urol. 2019 Mar;60(2):84-90. doi: 10.4111/icu.2019.60.2.84. Epub 2019 Feb 19.
• [745] Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.PLoS One. 2018 Jan 11;13(1):e0191188. doi: 10.1371/journal.pone.0191188. eCollection 2018.
• [746] Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1581528. eCollection 2019.
• [747] FENDRR reduces tumor invasiveness in prostate cancer PC-3 cells by targeting CSNK1E.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7327-7337. doi: 10.26355/eurrev_201909_18838.
• [748] A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.J Biol Chem. 2001 Feb 23;276(8):5992-9. doi: 10.1074/jbc.M004862200. Epub 2000 Nov 7.
• [749] Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.Arch Pathol Lab Med. 2018 Sep;142(9):1106-1112. doi: 10.5858/arpa.2017-0185-OA. Epub 2018 Mar 16.
• [750] Dysregulation of cystathionine -lyase promotes prostate cancer progression and metastasis.EMBO Rep. 2019 Oct 4;20(10):e45986. doi: 10.15252/embr.201845986. Epub 2019 Aug 29.
• [751] Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18.
• [752] Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.Biol Chem. 2010 Aug;391(8):947-58. doi: 10.1515/BC.2010.087.
• [753] Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.J Cancer Res Clin Oncol. 2019 Aug;145(8):1999-2012. doi: 10.1007/s00432-019-02950-y. Epub 2019 Jun 6.
• [754] Snail transcription factor NLS and importin 1 regulate the subcellular localization of Cathepsin L and Cux1.Biochem Biophys Res Commun. 2017 Sep 9;491(1):59-64. doi: 10.1016/j.bbrc.2017.07.039. Epub 2017 Jul 8.
• [755] MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.Prostate. 2018 May;78(7):479-490. doi: 10.1002/pros.23468. Epub 2018 Mar 14.
• [756] CXCL9 promotes prostate cancer progression through inhibition of cytokines from Tcells.Mol Med Rep. 2018 Aug;18(2):1305-1310. doi: 10.3892/mmr.2018.9152. Epub 2018 Jun 11.
• [757] Expression of E-cadherin and specific CXCR3 isoforms impact each other in prostate cancer.Cell Commun Signal. 2019 Dec 12;17(1):164. doi: 10.1186/s12964-019-0489-1.
• [758] Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.Cancer Sci. 2018 Apr;109(4):1230-1238. doi: 10.1111/cas.13517. Epub 2018 Feb 19.
• [759] Integrative molecular profiling of routine clinical prostate cancer specimens.Ann Oncol. 2015 Jun;26(6):1110-1118. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.
• [760] Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.Bioorg Chem. 2019 May;86:401-409. doi: 10.1016/j.bioorg.2019.01.066. Epub 2019 Jan 30.
• [761] Correction to: Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan.Environ Health Prev Med. 2018 Jul 4;23(1):30. doi: 10.1186/s12199-018-0718-z.
• [762] Missense mutations in -1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum Mol Genet. 2013 May 1;22(9):1746-54. doi: 10.1093/hmg/ddt021. Epub 2013 Jan 28.
• [763] Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.Cancer Res. 2001 Oct 1;61(19):7217-24.
• [764] Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer.Onco Targets Ther. 2018 Feb 28;11:1077-1086. doi: 10.2147/OTT.S157295. eCollection 2018.
• [765] Dual regulation of decorin by androgen and Hedgehog signaling during prostate morphogenesis.Dev Dyn. 2018 May;247(5):679-685. doi: 10.1002/dvdy.24619. Epub 2018 Feb 19.
• [766] Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.Int J Biol Macromol. 2018 Oct 15;118(Pt A):599-609. doi: 10.1016/j.ijbiomac.2018.06.005. Epub 2018 Jun 3.
• [767] Molecular characteristic and physiological role of DOPA-decarboxylase.Postepy Hig Med Dosw (Online). 2016 Dec 31;70(0):1424-1440. doi: 10.5604/17322693.1227773.
• [768] REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.Oncogene. 2005 Feb 10;24(7):1138-49. doi: 10.1038/sj.onc.1208236.
• [769] LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P.Mol Cancer Ther. 2019 Dec;18(12):2469-2479. doi: 10.1158/1535-7163.MCT-19-0095. Epub 2019 Aug 6.
• [770] Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.Oncotarget. 2015 Jan 30;6(3):1806-20. doi: 10.18632/oncotarget.2809.
• [771] DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer.Biochem Biophys Res Commun. 2017 Aug 26;490(3):707-712. doi: 10.1016/j.bbrc.2017.06.105. Epub 2017 Jun 19.
• [772] DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.Oncogene. 2020 Feb;39(7):1557-1571. doi: 10.1038/s41388-019-1085-y. Epub 2019 Nov 4.
• [773] DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.Sci Rep. 2019 Feb 28;9(1):3035. doi: 10.1038/s41598-019-39537-z.
• [774] Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors.Oncotarget. 2019 Mar 12;10(21):2113. doi: 10.18632/oncotarget.26802. eCollection 2019 Mar 12.
• [775] Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential.J Mol Signal. 2007 Aug 24;2:7. doi: 10.1186/1750-2187-2-7.
• [776] Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.Sci Transl Med. 2019 Mar 20;11(484):eaav0891. doi: 10.1126/scitranslmed.aav0891.
• [777] Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.Cancer Res. 2007 Dec 1;67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969.
• [778] Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.Cancer Res. 2018 Jul 15;78(14):4022-4035. doi: 10.1158/0008-5472.CAN-17-3728. Epub 2018 May 15.
• [779] Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer.Curr Mol Med. 2019;19(8):605-619. doi: 10.2174/1566524019666190709180146.
• [780] The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.Cancer Res. 2008 Nov 15;68(22):9255-64. doi: 10.1158/0008-5472.CAN-08-1224.
• [781] DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.Sci Rep. 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9.
• [782] MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2.PLoS One. 2010 Apr 14;5(4):e10147. doi: 10.1371/journal.pone.0010147.
• [783] Herpesvirus saimiri-based endothelin-converting enzyme-1 shRNA expression decreases prostate cancer cell invasion and migration.Int J Cancer. 2011 Aug 1;129(3):586-98. doi: 10.1002/ijc.25719. Epub 2010 Dec 2.
• [784] Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.Cancer Lett. 2017 Apr 1;390:11-20. doi: 10.1016/j.canlet.2017.01.003. Epub 2017 Jan 13.
• [785] EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7808-7815. doi: 10.26355/eurrev_201909_18990.
• [786] The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.Mol Cancer Res. 2018 Apr;16(4):682-695. doi: 10.1158/1541-7786.MCR-17-0696. Epub 2018 Feb 16.
• [787] Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis.Exp Ther Med. 2019 May;17(5):3741-3747. doi: 10.3892/etm.2019.7331. Epub 2019 Mar 1.
• [788] Soluble CD105 is prognostic of disease recurrence in prostate cancer patients.Endocr Relat Cancer. 2020 Jan;27(1):1-9. doi: 10.1530/ERC-19-0370.
• [789] Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells.Prostate. 2008 Nov 1;68(15):1666-73. doi: 10.1002/pros.20835.
• [790] Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer.Cancer Sci. 2008 Jan;99(1):39-45. doi: 10.1111/j.1349-7006.2007.00655.x. Epub 2007 Oct 29.
• [791] Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.J Cell Physiol. 2007 Jan;210(1):111-21. doi: 10.1002/jcp.20828.
• [792] Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression.Cell Death Dis. 2017 Oct 12;8(10):e3122. doi: 10.1038/cddis.2017.507.
• [793] Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.Cancer Res. 2019 May 15;79(10):2580-2592. doi: 10.1158/0008-5472.CAN-18-2812. Epub 2019 Apr 5.
• [794] EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.Cell Death Dis. 2019 Oct 22;10(11):801. doi: 10.1038/s41419-019-2042-y.
• [795] Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.Cancer Lett. 2017 Nov 1;408:155-163. doi: 10.1016/j.canlet.2017.08.014. Epub 2017 Aug 18.
• [796] Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer.Asian J Androl. 2020 Jul-Aug;22(4):422-426. doi: 10.4103/aja.aja_80_19.
• [797] Antibody-based detection of ERG rearrangement-positive prostate cancer.Neoplasia. 2010 Jul;12(7):590-8. doi: 10.1593/neo.10726.
• [798] IRE1-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.Nat Commun. 2019 Jan 24;10(1):323. doi: 10.1038/s41467-018-08152-3.
• [799] Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.Prostate. 2018 Jan;78(1):2-10. doi: 10.1002/pros.23446. Epub 2017 Nov 2.
• [800] Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.Cancers (Basel). 2018 Jan 23;10(2):29. doi: 10.3390/cancers10020029.
• [801] ETS1 induces transforming growth factor signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.J Cell Biochem. 2019 Jan;120(1):848-860. doi: 10.1002/jcb.27446. Epub 2018 Aug 30.
• [802] Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.Biomed Res Int. 2019 Jun 16;2019:3808432. doi: 10.1155/2019/3808432. eCollection 2019.
• [803] Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10.
• [804] Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.
• [805] Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population.PLoS Genet. 2013 Mar;9(3):e1003419. doi: 10.1371/journal.pgen.1003419. Epub 2013 Mar 28.
• [806] Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.Biochem J. 1996 May 1;315 ( Pt 3)(Pt 3):901-8. doi: 10.1042/bj3150901.
• [807] Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1.Int J Cancer. 2010 Feb 1;126(3):599-610. doi: 10.1002/ijc.24904.
• [808] Expression of proteinase-activated receptor-2 (PAR2) is androgen-dependent in stromal cell line (hPCPs) from benign prostatic hyperplasia.Prostate. 2010 Sep 1;70(12):1350-8. doi: 10.1002/pros.21170.
• [809] FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma.Cancer Med. 2018 Jun;7(6):2629-2640. doi: 10.1002/cam4.1511. Epub 2018 May 7.
• [810] Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic 'activated' state that enhances prostate cancer cell migration.Int J Cancer. 2018 May 15;142(10):2056-2067. doi: 10.1002/ijc.31226. Epub 2018 Jan 4.
• [811] Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population.Prostate. 2011 Jul;71(10):1122-30. doi: 10.1002/pros.21328. Epub 2011 Jan 12.
• [812] Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.Prostate. 2019 Jun;79(8):864-871. doi: 10.1002/pros.23793. Epub 2019 Apr 7.
• [813] Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation.Mol Cancer Ther. 2008 Oct;7(10):3203-11. doi: 10.1158/1535-7163.MCT-08-0494.
• [814] Single Cell Gene Co-Expression Network Reveals FECH/CROT Signature as a Prognostic Marker.Cells. 2019 Jul 10;8(7):698. doi: 10.3390/cells8070698.
• [815] MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.Gastroenterology. 2017 Oct;153(4):1120-1132.e15. doi: 10.1053/j.gastro.2016.12.036. Epub 2017 Feb 27.
• [816] Oleic acid promotes prostate cancer malignant phenotype via the G protein-coupled receptor FFA1/GPR40.J Cell Physiol. 2018 Sep;233(9):7367-7378. doi: 10.1002/jcp.26572. Epub 2018 Apr 16.
• [817] Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer.J Natl Cancer Inst. 2019 Jan 1;111(1):52-59. doi: 10.1093/jnci/djy125.
• [818] Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer.Front Genet. 2019 Jan 30;10:12. doi: 10.3389/fgene.2019.00012. eCollection 2019.
• [819] Plant-based diets relatively low in bioavailable phosphate and calcium may aid prevention and control of prostate cancer by lessening production of fibroblast growth factor 23.Med Hypotheses. 2017 Feb;99:68-72. doi: 10.1016/j.mehy.2017.01.001. Epub 2017 Jan 3.
• [820] Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.Neoplasia. 2010 Nov;12(11):915-27. doi: 10.1593/neo.10776.
• [821] The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.Prostate. 2017 Feb;77(2):185-195. doi: 10.1002/pros.23259. Epub 2016 Oct 8.
• [822] Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.Clin Cancer Res. 2019 Jan 15;25(2):710-723. doi: 10.1158/1078-0432.CCR-18-0704. Epub 2018 Oct 15.
• [823] Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients.Cancer Med. 2019 Mar;8(3):1110-1123. doi: 10.1002/cam4.1885. Epub 2019 Jan 8.
• [824] A Bispecific Antibody Targeting the v and 51 Integrins Induces Integrin Degradation in Prostate Cancer Cells and Is Superior to Monospecific Antibodies.Mol Cancer Res. 2020 Jan;18(1):27-32. doi: 10.1158/1541-7786.MCR-19-0442. Epub 2019 Oct 21.
• [825] Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells.Life Sci. 2019 Sep 1;232:116626. doi: 10.1016/j.lfs.2019.116626. Epub 2019 Jul 2.
• [826] FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8609-8615. doi: 10.26355/eurrev_201812_16624.
• [827] Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31.
• [828] High FOXM1 expression is a prognostic marker for poor clinical outcomes in prostate cancer.J Cancer. 2019 Jan 1;10(3):749-756. doi: 10.7150/jca.28099. eCollection 2019.
• [829] Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.Cancer Res. 2019 Apr 1;79(7):1413-1425. doi: 10.1158/0008-5472.CAN-18-2049. Epub 2019 Feb 7.
• [830] TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.Cell Biol Int. 2018 Mar;42(3):273-280. doi: 10.1002/cbin.10832. Epub 2017 Aug 21.
• [831] Knockdown of fucosyltransferase III disrupts the adhesion of circulating cancer cells to E-selectin without affecting hematopoietic cell adhesion.Carbohydr Res. 2010 Nov 2;345(16):2334-42. doi: 10.1016/j.carres.2010.07.028. Epub 2010 Jul 21.
• [832] SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.
• [833] The roles and mechanisms of G3BP1 in tumour promotion. J Drug Target. 2019 Mar;27(3):300-305.
• [834] Prostate cancer-related anxiety in long-term survivors after radical prostatectomy.J Cancer Surviv. 2017 Dec;11(6):800-807. doi: 10.1007/s11764-017-0619-y. Epub 2017 May 21.
• [835] Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.Prostate. 2018 Apr;78(5):327-335. doi: 10.1002/pros.23469. Epub 2018 Jan 21.
• [836] An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation.PLoS One. 2017 Aug 3;12(8):e0182305. doi: 10.1371/journal.pone.0182305. eCollection 2017.
• [837] Association of XPD polymorphisms with prostate cancer in Taiwanese patients.Anticancer Res. 2007 Jul-Aug;27(4C):2893-6.
• [838] Fast automated multi-criteria planning for HDR brachytherapy explored for prostate cancer.Phys Med Biol. 2019 Oct 10;64(20):205002. doi: 10.1088/1361-6560/ab44ff.
• [839] High-Level -Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.Int J Mol Sci. 2017 Jan 29;18(2):286. doi: 10.3390/ijms18020286.
• [840] A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.Oncogene. 2005 Jul 7;24(29):4736-40. doi: 10.1038/sj.onc.1208572.
• [841] Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin.J Biol Chem. 2002 Dec 20;277(51):50087-97. doi: 10.1074/jbc.M202652200. Epub 2002 Aug 29.
• [842] GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism.J Cell Biochem. 2018 Apr;119(4):3641-3652. doi: 10.1002/jcb.26572. Epub 2018 Jan 5.
• [843] Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.J Cell Mol Med. 2018 May;22(5):2865-2883. doi: 10.1111/jcmm.13581. Epub 2018 Mar 5.
• [844] Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.Anticancer Agents Med Chem. 2019;19(4):509-514. doi: 10.2174/1871520618666180801101730.
• [845] Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer.Cancer Res. 2019 Sep 15;79(18):4638-4649. doi: 10.1158/0008-5472.CAN-19-0700. Epub 2019 Jun 10.
• [846] Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.Jpn J Clin Oncol. 2020 Jan 24;50(1):66-72. doi: 10.1093/jjco/hyz138.
• [847] Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.Macromol Biosci. 2017 Apr;17(4). doi: 10.1002/mabi.201600335. Epub 2016 Nov 15.
• [848] Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement.J Pharm Pharmacol. 2019 Jul;71(7):1065-1071. doi: 10.1111/jphp.13089. Epub 2019 Mar 28.
• [849] The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease.Int J Mol Sci. 2018 Feb 1;19(2):439. doi: 10.3390/ijms19020439.
• [850] DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.Br J Cancer. 2005 Oct 31;93(9):1029-37. doi: 10.1038/sj.bjc.6602837.
• [851] Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.
• [852] Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth.J Biol Chem. 2003 Sep 26;278(39):37569-73. doi: 10.1074/jbc.M306276200. Epub 2003 Jul 17.
• [853] GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.Oncotarget. 2016 Jul 19;7(29):45171-45185. doi: 10.18632/oncotarget.9359.
• [854] Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins.Anticancer Agents Med Chem. 2018;18(4):565-572. doi: 10.2174/1871520618666180228152713.
• [855] A genome-wide association study of prostate cancer in West African men.Hum Genet. 2014 May;133(5):509-21. doi: 10.1007/s00439-013-1387-z. Epub 2013 Nov 2.
• [856] Secreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer.Oncotarget. 2017 Aug 23;8(44):77152-77167. doi: 10.18632/oncotarget.20414. eCollection 2017 Sep 29.
• [857] Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics. 2004 Jan;14(1):35-44.
• [858] Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.Prostate. 2007 Jan 1;67(1):83-106. doi: 10.1002/pros.20505.
• [859] Enterolactone glucuronide and -glucuronidase in antibody directed enzyme prodrug therapy for targeted prostate cancer cell treatment.AAPS PharmSciTech. 2017 Aug;18(6):2336-2345. doi: 10.1208/s12249-017-0721-5. Epub 2017 Jan 23.
• [860] Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014.
• [861] YY1 negatively regulates the XAF1 gene expression in prostate cancer.Biochem Biophys Res Commun. 2019 Jan 15;508(3):973-979. doi: 10.1016/j.bbrc.2018.12.056. Epub 2018 Dec 11.
• [862] Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.Cancer Lett. 2020 Mar 31;473:118-129. doi: 10.1016/j.canlet.2019.12.018. Epub 2019 Dec 13.
• [863] Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.EMBO Mol Med. 2018 Apr;10(4):e8478. doi: 10.15252/emmm.201708478.
• [864] Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.Int J Cancer. 2015 May 15;136(10):2316-27. doi: 10.1002/ijc.29276. Epub 2014 Nov 8.
• [865] A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.Biomol Ther (Seoul). 2020 Mar 1;28(2):184-194. doi: 10.4062/biomolther.2019.074.
• [866] Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1.Exp Cell Res. 2019 Jan 1;374(1):249-258. doi: 10.1016/j.yexcr.2018.12.002. Epub 2018 Dec 4.
• [867] Long non-coding RNA-NEAT1, a sponge for miR-98-5p, promotes expression of oncogene HMGA2 in prostate cancer.Biosci Rep. 2019 Sep 24;39(9):BSR20190635. doi: 10.1042/BSR20190635. Print 2019 Sep 30.
• [868] Glycyrrhizin Attenuates the Process of Epithelial-to-Mesenchymal Transition by Modulating HMGB1 Initiated Novel Signaling Pathway in Prostate Cancer Cells.J Agric Food Chem. 2019 Mar 27;67(12):3323-3332. doi: 10.1021/acs.jafc.9b00251. Epub 2019 Mar 13.
• [869] Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.Oncol Lett. 2017 Dec;14(6):6533-6542. doi: 10.3892/ol.2017.7025. Epub 2017 Sep 22.
• [870] HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.Pathol Res Pract. 2019 Aug;215(8):152464. doi: 10.1016/j.prp.2019.152464. Epub 2019 May 22.
• [871] The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.Prostate. 2020 Feb;80(2):198-208. doi: 10.1002/pros.23932. Epub 2019 Dec 3.
• [872] Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.Med Sci Monit. 2019 Jan 7;25:193-239. doi: 10.12659/MSM.912294.
• [873] Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.Mol Cancer Ther. 2017 Dec;16(12):2770-2779. doi: 10.1158/1535-7163.MCT-17-0030. Epub 2017 Jul 20.
• [874] 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.Br J Cancer. 2008 Feb 26;98(4):792-802. doi: 10.1038/sj.bjc.6604227. Epub 2008 Feb 5.
• [875] VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription.Epigenetics. 2015;10(1):40-9. doi: 10.4161/15592294.2014.989088. Epub 2015 Jan 29.
• [876] Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.Clin Cancer Res. 2011 Sep 15;17(18):5844-9. doi: 10.1158/1078-0432.CCR-11-0644. Epub 2011 Jun 24.
• [877] Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.Clin Cancer Res. 2014 Jun 1;20(11):2971-83. doi: 10.1158/1078-0432.CCR-13-2567. Epub 2014 Mar 28.
• [878] Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.Proteomics. 2007 Jun;7(12):1973-83. doi: 10.1002/pmic.200600643.
• [879] GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.BMC Cancer. 2018 Dec 18;18(1):1263. doi: 10.1186/s12885-018-5178-8.
• [880] Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells.Br J Cancer. 2007 Oct 8;97(7):941-8. doi: 10.1038/sj.bjc.6603964. Epub 2007 Sep 11.
• [881] Hsp-27 and NF-B pathway is associated with AR/AR-V7 expression in prostate cancer cells.Gene. 2019 May 20;697:138-143. doi: 10.1016/j.gene.2019.02.055. Epub 2019 Feb 23.
• [882] The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers.Sci Rep. 2019 Jul 4;9(1):9715. doi: 10.1038/s41598-019-46064-4.
• [883] Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.Environ Toxicol Pharmacol. 2019 May;68:141-147. doi: 10.1016/j.etap.2019.03.014. Epub 2019 Mar 15.
• [884] Transcriptional activation by NFB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment.J Cell Biochem. 2014 Jul;115(7):1322-33. doi: 10.1002/jcb.24788.
• [885] NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis.J Exp Clin Cancer Res. 2019 Oct 16;38(1):416. doi: 10.1186/s13046-019-1429-z.
• [886] Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression.Clin Cancer Res. 2004 Mar 15;10(6):2044-51. doi: 10.1158/1078-0432.ccr-03-0933.
• [887] Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGF1/p-Smad2/3 signaling.Cancer Lett. 2020 Mar 1;472:151-164. doi: 10.1016/j.canlet.2019.12.014. Epub 2019 Dec 14.
• [888] IFNL4-G Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer.Clin Cancer Res. 2018 Nov 1;24(21):5471-5481. doi: 10.1158/1078-0432.CCR-18-1060. Epub 2018 Jul 16.
• [889] Efficient Photodynamic Therapy of Prostate Cancer Cells through an Improved Targeting of the Cation-Independent Mannose 6-Phosphate Receptor.Int J Mol Sci. 2019 Jun 8;20(11):2809. doi: 10.3390/ijms20112809.
• [890] Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer. 2005 Apr 25;92(8):1538-44. doi: 10.1038/sj.bjc.6602520.
• [891] IGFBP7 promoter methylation and gene expression analysis in prostate cancer.J Urol. 2012 Oct;188(4):1354-60. doi: 10.1016/j.juro.2012.06.002. Epub 2012 Aug 17.
• [892] Novel amplification unit at chromosome 3q25-q27 in human prostate cancer.Prostate. 2000 Nov 1;45(3):207-15. doi: 10.1002/1097-0045(20001101)45:3<207::aid-pros2>3.0.co;2-h.
• [893] Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells.Cancer Med. 2018 Sep;7(9):4639-4649. doi: 10.1002/cam4.1695. Epub 2018 Aug 9.
• [894] Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment.J Interferon Cytokine Res. 2019 Aug;39(8):483-494. doi: 10.1089/jir.2018.0166. Epub 2019 Apr 22.
• [895] Association between interleukin-18 variants and prostate cancer in Slovak population.Neoplasma. 2017;64(1):148-155. doi: 10.4149/neo_2017_119.
• [896] Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.Int J Oncol. 2007 Jan;30(1):193-200.
• [897] Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.Cancer Res. 2008 Nov 15;68(22):9311-7. doi: 10.1158/0008-5472.CAN-08-2810.
• [898] Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.Clin Transl Oncol. 2014 Oct;16(10):906-13. doi: 10.1007/s12094-014-1167-9. Epub 2014 Mar 22.
• [899] Polymorphism of the insulin gene is associated with increased prostate cancer risk.Br J Cancer. 2003 Jan 27;88(2):263-9. doi: 10.1038/sj.bjc.6600747.
• [900] USP15 attenuates IGF-I signaling by antagonizing Nedd4-induced IRS-2 ubiquitination.Biochem Biophys Res Commun. 2017 Mar 11;484(3):522-528. doi: 10.1016/j.bbrc.2017.01.101. Epub 2017 Jan 23.
• [901] High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.Clin Cancer Res. 2018 Sep 1;24(17):4309-4318. doi: 10.1158/1078-0432.CCR-18-0106. Epub 2018 May 18.
• [902] ITGB1-dependent upregulation of Caveolin-1 switches TGF signalling from tumour-suppressive to oncogenic in prostate cancer.Sci Rep. 2018 Feb 5;8(1):2338. doi: 10.1038/s41598-018-20161-2.
• [903] PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth.Nature. 2017 Jun 22;546(7659):554-558. doi: 10.1038/nature22965. Epub 2017 Jun 14.
• [904] STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. doi: 10.1158/1078-0432.CCR-17-2768. Epub 2018 Feb 26.
• [905] Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.Mol Cancer. 2019 Aug 6;18(1):122. doi: 10.1186/s12943-019-1051-x.
• [906] p300/CBP-associated factor promotes autophagic degradation of -catenin through acetylation and decreases prostate cancer tumorigenicity.Sci Rep. 2019 Mar 4;9(1):3351. doi: 10.1038/s41598-019-40238-w.
• [907] Prostate cancer tissues with positive TMPRSS2-ERG-gene-fusion status may display enhanced nerve density.Urol Oncol. 2020 Jan;38(1):3.e7-3.e15. doi: 10.1016/j.urolonc.2018.07.019. Epub 2018 Sep 18.
• [908] Role of KCNMA1 in breast cancer.PLoS One. 2012;7(8):e41664. doi: 10.1371/journal.pone.0041664. Epub 2012 Aug 10.
• [909] Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.
• [910] Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.Oncogene. 2009 Apr 16;28(15):1792-806. doi: 10.1038/onc.2009.25. Epub 2009 Mar 9.
• [911] ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.Cell Mol Life Sci. 2020 Mar;77(6):1135-1152. doi: 10.1007/s00018-019-03226-x. Epub 2019 Jul 18.
• [912] KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.Biomed Pharmacother. 2019 Jun;114:108793. doi: 10.1016/j.biopha.2019.108793. Epub 2019 Mar 25.
• [913] A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2.Oncotarget. 2018 May 4;9(34):23413-23425. doi: 10.18632/oncotarget.25182. eCollection 2018 May 4.
• [914] Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.Int J Cancer. 2018 Dec 1;143(11):2849-2861. doi: 10.1002/ijc.31843. Epub 2018 Oct 9.
• [915] Osteopontin And Angiogenic Factors As New Biomarkers Of Prostate Cancer.Urol J. 2019 May 5;16(2):134-140. doi: 10.22037/uj.v0i0.4282.
• [916] c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer.Nucleic Acids Res. 2019 Jul 9;47(12):6160-6171. doi: 10.1093/nar/gkz344.
• [917] Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.Clin Genitourin Cancer. 2017 Aug;15(4):450-454. doi: 10.1016/j.clgc.2016.10.005. Epub 2016 Oct 19.
• [918] Klotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.Oncol Rep. 2018 Jul;40(1):217-225. doi: 10.3892/or.2018.6399. Epub 2018 Apr 25.
• [919] Downregulated Krppellike factor4 expression is associated with the aggressiveness of prostate cancer.Oncol Rep. 2019 Mar;41(3):1789-1796. doi: 10.3892/or.2019.6975. Epub 2019 Jan 22.
• [920] Identification of potential key genes and high-frequency mutant genes in prostate cancer by using RNA-Seq data.Oncol Lett. 2018 Apr;15(4):4550-4556. doi: 10.3892/ol.2018.7846. Epub 2018 Jan 24.
• [921] Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.Prostate. 2020 Jan;80(1):51-56. doi: 10.1002/pros.23916. Epub 2019 Oct 11.
• [922] Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.Asian J Androl. 2015 Jan-Feb;17(1):106-10. doi: 10.4103/1008-682X.137613.
• [923] Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.Oncogene. 2019 Jun;38(24):4700-4714. doi: 10.1038/s41388-019-0745-2. Epub 2019 Feb 11.
• [924] Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.
• [925] Deacetylation of LAMP1 drives lipophagy-dependent generation of free fatty acids by Abrus agglutinin to promote senescence in prostate cancer.J Cell Physiol. 2020 Mar;235(3):2776-2791. doi: 10.1002/jcp.29182. Epub 2019 Sep 23.
• [926] MRI-based prostate cancer detection with high-level representation and hierarchical classification.Med Phys. 2017 Mar;44(3):1028-1039. doi: 10.1002/mp.12116.
• [927] Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth.Mol Cancer. 2019 Jun 28;18(1):113. doi: 10.1186/s12943-019-1039-6.
• [928] Targeting lactate dehydrogenaseA promotes docetaxelinduced cytotoxicity predominantly in castrationresistant prostate cancer cells.Oncol Rep. 2019 Jul;42(1):224-230. doi: 10.3892/or.2019.7171. Epub 2019 May 24.
• [929] Interlink between cholesterol & cell cycle in prostate carcinoma.Indian J Med Res. 2017 Nov;146(Suppl):S38-S44. doi: 10.4103/ijmr.IJMR_1639_15.
• [930] SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation.Int J Mol Sci. 2017 Apr 12;18(4):808. doi: 10.3390/ijms18040808.
• [931] Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition.J Biol Chem. 2017 Sep 15;292(37):15525-15537. doi: 10.1074/jbc.M116.771931. Epub 2017 Aug 2.
• [932] Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.Clin Cancer Res. 2019 Jul 1;25(13):4128-4140. doi: 10.1158/1078-0432.CCR-18-3239. Epub 2019 Apr 8.
• [933] Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.Cancer Lett. 2019 Jun 1;451:110-121. doi: 10.1016/j.canlet.2019.02.042. Epub 2019 Mar 6.
• [934] Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.Cancer Lett. 2019 Apr 28;448:182-196. doi: 10.1016/j.canlet.2019.01.035. Epub 2019 Feb 1.
• [935] Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.
• [936] Mice lacking lipid droplet-associated hydrolase, a gene linked to human prostate cancer, have normal cholesterol ester metabolism.J Lipid Res. 2017 Jan;58(1):226-235. doi: 10.1194/jlr.M072538. Epub 2016 Nov 11.
• [937] Urinary biomarkers in prostate cancer detection and monitoring progression.Crit Rev Oncol Hematol. 2017 Oct;118:15-26. doi: 10.1016/j.critrevonc.2017.08.002. Epub 2017 Aug 19.
• [938] Lysyl oxidase family members in urological tumorigenesis and fibrosis.Oncotarget. 2018 Apr 13;9(28):20156-20164. doi: 10.18632/oncotarget.24948. eCollection 2018 Apr 13.
• [939] Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process.Biomed Res Int. 2019 Jan 27;2019:4012590. doi: 10.1155/2019/4012590. eCollection 2019.
• [940] The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.J Oncol. 2019 Mar 26;2019:4536302. doi: 10.1155/2019/4536302. eCollection 2019.
• [941] TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer.EBioMedicine. 2019 Jul;45:192-207. doi: 10.1016/j.ebiom.2019.06.046. Epub 2019 Jun 28.
• [942] Down-regulation of Lsm1 is involved in human prostate cancer progression.Br J Cancer. 2002 Mar 18;86(6):940-6. doi: 10.1038/sj.bjc.6600163.
• [943] The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development.Oncogene. 2010 Sep 9;29(36):5006-18. doi: 10.1038/onc.2010.260. Epub 2010 Jul 5.
• [944] Silencing of Lactotransferrin expression by methylation in prostate cancer progression.Cancer Biol Ther. 2007 Jul;6(7):1088-95. doi: 10.4161/cbt.6.7.4327.
• [945] Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer.Cell Rep. 2018 Dec 18;25(12):3504-3518.e6. doi: 10.1016/j.celrep.2018.11.069.
• [946] Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial.BMC Cancer. 2018 Jan 10;18(1):64. doi: 10.1186/s12885-017-3979-9.
• [947] Biopsy undergrading in men with Gleason score6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.Int J Urol. 2017 Apr;24(4):281-286. doi: 10.1111/iju.13294. Epub 2017 Feb 7.
• [948] Functional interaction between co-expressed MAGE-A proteins.PLoS One. 2017 May 24;12(5):e0178370. doi: 10.1371/journal.pone.0178370. eCollection 2017.
• [949] NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.BMC Cancer. 2011 Aug 2;11:327. doi: 10.1186/1471-2407-11-327.
• [950] Expression of cancer/testis antigens in prostate cancer is associated with disease progression.Prostate. 2010 Dec 1;70(16):1778-87. doi: 10.1002/pros.21214.
• [951] Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.Prostate. 2019 May;79(6):667-677. doi: 10.1002/pros.23774. Epub 2019 Jan 28.
• [952] Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer.Oncogene. 2008 May 8;27(21):2978-88. doi: 10.1038/sj.onc.1210963. Epub 2007 Dec 10.
• [953] MicroRNA? suppresses human prostate cancer cell viability, invasion and migration via modulation of mitogenactivated protein kinase kinase kinase 3 expression.Mol Med Rep. 2019 May;19(5):4407-4418. doi: 10.3892/mmr.2019.10065. Epub 2019 Mar 21.
• [954] Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.Mod Pathol. 2009 Jul;22(7):866-71. doi: 10.1038/modpathol.2009.57. Epub 2009 Apr 24.
• [955] Parallel-Reaction-Monitoring-Based Proteome-Wide Profiling of Differential Kinase Protein Expression during Prostate Cancer Metastasis in Vitro.Anal Chem. 2019 Aug 6;91(15):9893-9900. doi: 10.1021/acs.analchem.9b01561. Epub 2019 Jul 10.
• [956] Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.Oncol Rep. 2013 Oct;30(4):1936-42. doi: 10.3892/or.2013.2637. Epub 2013 Jul 24.
• [957] MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.Oncogene. 2006 May 18;25(21):2987-98. doi: 10.1038/sj.onc.1209337.
• [958] MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer.Oncotarget. 2017 Jun 30;8(42):72021-72030. doi: 10.18632/oncotarget.18894. eCollection 2017 Sep 22.
• [959] S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis.Oncotarget. 2017 Aug 12;8(45):78851-78869. doi: 10.18632/oncotarget.20234. eCollection 2017 Oct 3.
• [960] Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer.J Clin Med. 2019 Nov 22;8(12):2056. doi: 10.3390/jcm8122056.
• [961] Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.Mol Cancer Res. 2019 May;17(5):1049-1062. doi: 10.1158/1541-7786.MCR-18-1220. Epub 2019 Feb 11.
• [962] Circular RNA circHIPK3 promotes cell proliferation and invasion of prostate cancer by sponging miR-193a-3p and regulating MCL1 expression.Cancer Manag Res. 2019 Feb 12;11:1415-1423. doi: 10.2147/CMAR.S190669. eCollection 2019.
• [963] Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation.Biomed Pharmacother. 2017 Sep;93:103-116. doi: 10.1016/j.biopha.2017.06.024. Epub 2017 Jun 17.
• [964] MeCP2 overexpression inhibits proliferation, migration and invasion of C6 glioma by modulating ERK signaling and gene expression.Neurosci Lett. 2018 May 1;674:42-48. doi: 10.1016/j.neulet.2018.03.020. Epub 2018 Mar 11.
• [965] Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.J Cell Biochem. 2017 Apr;118(4):891-902. doi: 10.1002/jcb.25768. Epub 2016 Nov 10.
• [966] Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II).Med Chem. 2020;16(6):735-749. doi: 10.2174/1573406415666190613162322.
• [967] FABP5 coordinates lipid signaling that promotes prostate cancer metastasis.Sci Rep. 2019 Dec 12;9(1):18944. doi: 10.1038/s41598-019-55418-x.
• [968] Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8179-84. doi: 10.1073/pnas.1321884111. Epub 2014 May 19.
• [969] Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study.PLoS One. 2019 Nov 7;14(11):e0224671. doi: 10.1371/journal.pone.0224671. eCollection 2019.
• [970] Metastatic Prostate Cancer: Effects of Genetic Testing on Care.Clin J Oncol Nurs. 2019 Feb 1;23(1):32-35. doi: 10.1188/19.CJON.32-35.
• [971] Prostate cancer cell phenotypes based on AGR2 and CD10 expression.Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25.
• [972] Upregulation of SPOCK2 inhibits the invasion and migration of prostate cancer cells by regulating the MT1-MMP/MMP2 pathway.PeerJ. 2019 Jul 12;7:e7163. doi: 10.7717/peerj.7163. eCollection 2019.
• [973] Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression.Carcinogenesis. 2019 Jul 4;40(5):633-642. doi: 10.1093/carcin/bgz058.
• [974] RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression.Cancer Sci. 2020 Feb;111(2):369-382. doi: 10.1111/cas.14280. Epub 2020 Jan 4.
• [975] Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.Neoplasia. 2018 Sep;20(9):917-929. doi: 10.1016/j.neo.2018.07.003. Epub 2018 Aug 15.
• [976] N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.Mol Cancer. 2019 Jan 18;18(1):11. doi: 10.1186/s12943-019-0941-2.
• [977] Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression.Med Sci Monit. 2018 May 25;24:3462-3471. doi: 10.12659/MSM.908009.
• [978] Altered expression of lncRNA NCK1-AS1 distinguished patients with prostate cancer from those with benign prostatic hyperplasia.Oncol Lett. 2019 Dec;18(6):6379-6384. doi: 10.3892/ol.2019.11039. Epub 2019 Nov 1.
• [979] Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway.Nat Commun. 2018 Oct 5;9(1):4113. doi: 10.1038/s41467-018-06606-2.
• [980] Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.Hum Mutat. 2013 Jan;34(1):149-56. doi: 10.1002/humu.22176. Epub 2012 Oct 4.
• [981] HIF-1 induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224.Biochem Biophys Res Commun. 2018 Sep 3;503(1):228-234. doi: 10.1016/j.bbrc.2018.06.007. Epub 2018 Jun 14.
• [982] Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.Oncotarget. 2015 Jun 20;6(17):15137-49. doi: 10.18632/oncotarget.3526.
• [983] Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression, and autophagy.Mol Carcinog. 2020 Feb;59(2):193-201. doi: 10.1002/mc.23140. Epub 2019 Nov 29.
• [984] Targeting epithelial to mesenchymal transition in prostate cancer by a novel compound, plectranthoic acid, isolated from Ficus microcarpa.Mol Carcinog. 2018 May;57(5):653-663. doi: 10.1002/mc.22790. Epub 2018 Feb 27.
• [985] Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.Int J Cancer. 2019 Aug 15;145(4):1055-1067. doi: 10.1002/ijc.32200. Epub 2019 Feb 25.
• [986] Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Cancer Res. 2017 Feb 1;77(3):753-765. doi: 10.1158/0008-5472.CAN-16-0455. Epub 2016 Nov 29.
• [987] Transcriptional Regulation in Prostate Cancer.Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a030437. doi: 10.1101/cshperspect.a030437.
• [988] Correlation of SOX9 and NM23 genes with the incidence and prognosis of prostate cancer.Oncol Lett. 2019 Feb;17(2):2296-2302. doi: 10.3892/ol.2018.9828. Epub 2018 Dec 12.
• [989] Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells.Oxid Med Cell Longev. 2019 May 9;2019:3685817. doi: 10.1155/2019/3685817. eCollection 2019.
• [990] Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-B pathway.Apoptosis. 2017 Jun;22(6):877-884. doi: 10.1007/s10495-017-1368-0.
• [991] Downregulated NOX4 underlies a novel inhibitory role of microRNA-137 in prostate cancer.J Cell Biochem. 2019 Jun;120(6):10215-10227. doi: 10.1002/jcb.28306. Epub 2019 Jan 13.
• [992] Identification of the key genes and pathways in prostate cancer.Oncol Lett. 2018 Nov;16(5):6663-6669. doi: 10.3892/ol.2018.9491. Epub 2018 Sep 24.
• [993] Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.Infect Agent Cancer. 2009 Feb 10;4 Suppl 1(Suppl 1):S3. doi: 10.1186/1750-9378-4-S1-S3.
• [994] Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer.Cancer Biomark. 2018;22(1):19-28. doi: 10.3233/CBM-170696.
• [995] Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.Oncotarget. 2017 Apr 11;8(15):24362-24371. doi: 10.18632/oncotarget.13848.
• [996] Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway.Pathol Res Pract. 2017 Mar;213(3):267-270. doi: 10.1016/j.prp.2016.04.013. Epub 2016 May 12.
• [997] Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.J Urol. 2020 Apr;203(4):706-712. doi: 10.1097/JU.0000000000000617. Epub 2019 Oct 23.
• [998] The Role of Nuclear Receptors in Prostate Cancer.Cells. 2019 Jun 17;8(6):602. doi: 10.3390/cells8060602.
• [999] Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.BMC Cancer. 2016 Mar 31;16:257. doi: 10.1186/s12885-016-2291-4.
• [1000] Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.Cancer Res. 2018 May 1;78(9):2205-2218. doi: 10.1158/0008-5472.CAN-17-2341. Epub 2018 Feb 8.
• [1001] Peptide-targeted, stimuli-responsive polymersomes for delivering a cancer stemness inhibitor to cancer stem cell microtumors.Colloids Surf B Biointerfaces. 2018 Mar 1;163:225-235. doi: 10.1016/j.colsurfb.2017.12.036. Epub 2017 Dec 24.
• [1002] Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.Int J Cancer. 2020 May 1;146(9):2619-2627. doi: 10.1002/ijc.32679. Epub 2019 Oct 16.
• [1003] Tumor-Suppressive Function of miR-30d-5p in Prostate Cancer Cell Proliferation and Migration by Targeting NT5E.Cancer Biother Radiopharm. 2018 Jun;33(5):203-211. doi: 10.1089/cbr.2018.2457.
• [1004] STIM1 accelerates cell senescence in a remodeled microenvironment but enhances the epithelial-to-mesenchymal transition in prostate cancer.Sci Rep. 2015 Aug 10;5:11754. doi: 10.1038/srep11754.
• [1005] Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926.
• [1006] Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.Psychoneuroendocrinology. 2013 Dec;38(12):2983-95. doi: 10.1016/j.psyneuen.2013.08.008. Epub 2013 Sep 6.
• [1007] D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate.Biochem Biophys Res Commun. 2004 Sep 10;322(1):239-49. doi: 10.1016/j.bbrc.2004.07.106.
• [1008] Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.Pathol Res Pract. 2017 Nov;213(11):1365-1369. doi: 10.1016/j.prp.2017.09.017. Epub 2017 Sep 18.
• [1009] PAX5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy.Cell Death Dis. 2019 Sep 30;10(10):734. doi: 10.1038/s41419-019-1932-3.
• [1010] A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.
• [1011] New Insights into the Role of Polybromo-1 in Prostate Cancer.Int J Mol Sci. 2019 Jun 12;20(12):2852. doi: 10.3390/ijms20122852.
• [1012] Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer.Cancers (Basel). 2019 Mar 14;11(3):364. doi: 10.3390/cancers11030364.
• [1013] Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter.Biochem Biophys Res Commun. 2007 May 25;357(1):8-13. doi: 10.1016/j.bbrc.2007.02.153. Epub 2007 Mar 7.
• [1014] Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.Sci Rep. 2019 Feb 14;9(1):2118. doi: 10.1038/s41598-018-37568-6.
• [1015] The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.
• [1016] Identification of zinc finger protein of the cerebellum 5 as a survival factor of prostate and colorectal cancer cells.Cancer Sci. 2017 Dec;108(12):2405-2412. doi: 10.1111/cas.13419. Epub 2017 Oct 25.
• [1017] Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.Neoplasia. 2010 Oct;12(10):826-36. doi: 10.1593/neo.10586.
• [1018] Tumor suppressor RKIP inhibits prostate cancer cell metastasis and sensitizes prostate cancer cells to docetaxel treatment.Neoplasma. 2018;65(2):228-233. doi: 10.4149/neo_2018_170203N72.
• [1019] Inactivation of the Wnt/-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial-mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2.Cancer Cell Int. 2019 Oct 21;19:271. doi: 10.1186/s12935-019-0977-9. eCollection 2019.
• [1020] Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins.Lab Chip. 2017 Jan 31;17(3):484-489. doi: 10.1039/c6lc01238h.
• [1021] MicroRNA-488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3.FEBS Open Bio. 2019 Oct;9(10):1798-1807. doi: 10.1002/2211-5463.12718. Epub 2019 Aug 22.
• [1022] Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts.Int J Mol Sci. 2013 Sep 3;14(9):17958-71. doi: 10.3390/ijms140917958.
• [1023] c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.Oncotarget. 2016 Nov 15;7(46):75585-75602. doi: 10.18632/oncotarget.12310.
• [1024] Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer.Pathol Oncol Res. 2019 Jan;25(1):341-348. doi: 10.1007/s12253-017-0353-9. Epub 2017 Nov 9.
• [1025] Mutational analysis of PINX1 in hereditary prostate cancer.Prostate. 2004 Sep 1;60(4):298-302. doi: 10.1002/pros.20075.
• [1026] The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1/pAKT in prostate cancer.Int J Cancer. 2020 Mar 15;146(6):1686-1699. doi: 10.1002/ijc.32607. Epub 2019 Aug 16.
• [1027] The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy.Endocrinology. 2006 Sep;147(9):4245-51. doi: 10.1210/en.2006-0614. Epub 2006 Jun 8.
• [1028] The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.Prostate. 2017 Nov;77(15):1452-1467. doi: 10.1002/pros.23400. Epub 2017 Sep 6.
• [1029] Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.Prostate. 2012 Jul 1;72(10):1140-9. doi: 10.1002/pros.22463. Epub 2011 Nov 29.
• [1030] AKT and cytosolic phospholipase A2 form a positive loop in prostate cancer cells.Curr Cancer Drug Targets. 2015;15(9):781-91. doi: 10.2174/1568009615666150706103234.
• [1031] Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.PLoS One. 2016 May 19;11(5):e0155901. doi: 10.1371/journal.pone.0155901. eCollection 2016.
• [1032] Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.J Med Chem. 2019 Feb 28;62(4):2172-2183. doi: 10.1021/acs.jmedchem.8b01908. Epub 2019 Feb 15.
• [1033] Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.J Control Release. 2011 Feb 10;149(3):314-22. doi: 10.1016/j.jconrel.2010.10.030. Epub 2010 Nov 1.
• [1034] Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells.Cancer Biol Ther. 2009 Dec;8(23):2286-96. doi: 10.4161/cbt.8.23.10138. Epub 2009 Dec 19.
• [1035] Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.Br J Cancer. 2018 Jan;118(2):189-199. doi: 10.1038/bjc.2017.391. Epub 2017 Nov 14.
• [1036] Phospholipase D2 in prostate cancer: protein expression changes with Gleason score.Br J Cancer. 2019 Dec;121(12):1016-1026. doi: 10.1038/s41416-019-0610-7. Epub 2019 Nov 1.
• [1037] Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.Ther Adv Med Oncol. 2019 May 8;11:1758835919846375. doi: 10.1177/1758835919846375. eCollection 2019.
• [1038] Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1234-1242. doi: 10.1016/j.ijrobp.2017.07.041. Epub 2017 Aug 2.
• [1039] An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.
• [1040] Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012 Jan 17;106(2):405-13.
• [1041] Understanding the loss-of-function in a triple missense mutant of DNA polymerase found in prostate cancer.Int J Oncol. 2013 Oct;43(4):1131-40. doi: 10.3892/ijo.2013.2022. Epub 2013 Jul 19.
• [1042] Impact of oxidative stress SNPs and dietary antioxidant quality score on prostate cancer.Int J Food Sci Nutr. 2020 Jun;71(4):500-508. doi: 10.1080/09637486.2019.1680958. Epub 2019 Oct 24.
• [1043] Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.Clin Genitourin Cancer. 2018 Dec;16(6):e1257-e1265. doi: 10.1016/j.clgc.2018.07.019. Epub 2018 Jul 29.
• [1044] Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.Prostate. 2020 Feb;80(2):162-172. doi: 10.1002/pros.23928. Epub 2019 Nov 26.
• [1045] Induction of apoptosis in prostate cancer by ginsenoside Rh2.Oncotarget. 2018 Jan 27;9(13):11109-11118. doi: 10.18632/oncotarget.24326. eCollection 2018 Feb 16.
• [1046] Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?.Int J Mol Med. 2006 Dec;18(6):1169-75.
• [1047] Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death.Cancer Res. 2007 Apr 15;67(8):3654-62. doi: 10.1158/0008-5472.CAN-06-1759.
• [1048] FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.Oncogene. 2010 Mar 18;29(11):1691-701. doi: 10.1038/onc.2009.458. Epub 2009 Dec 21.
• [1049] PPM1A is a RelA phosphatase with tumor suppressor-like activity.Oncogene. 2014 May 29;33(22):2918-27. doi: 10.1038/onc.2013.246. Epub 2013 Jul 1.
• [1050] Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.Br J Cancer. 2014 Apr 15;110(8):2000-10. doi: 10.1038/bjc.2014.141. Epub 2014 Mar 18.
• [1051] Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.Gene Ther. 2014 Aug;21(8):723-31. doi: 10.1038/gt.2014.46. Epub 2014 May 22.
• [1052] Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.Oncogene. 2009 Aug 13;28(32):2849-59. doi: 10.1038/onc.2009.144. Epub 2009 Jun 1.
• [1053] Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population.Mol Carcinog. 2015 Aug;54(8):632-41. doi: 10.1002/mc.22130. Epub 2014 Feb 10.
• [1054] Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.J Exp Clin Cancer Res. 2019 Mar 6;38(1):114. doi: 10.1186/s13046-019-1118-y.
• [1055] Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.Clin Cancer Res. 2019 Sep 15;25(18):5623-5637. doi: 10.1158/1078-0432.CCR-18-2207. Epub 2019 Jul 2.
• [1056] Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease.Urol Int. 2019;103(4):391-399. doi: 10.1159/000496833. Epub 2019 Feb 14.
• [1057] PRMT5 prognostic value in cancer.Oncotarget. 2019 May 7;10(34):3151-3153. doi: 10.18632/oncotarget.26883. eCollection 2019 May 7.
• [1058] Global analysis of differentially expressed genes in androgen-independent prostate cancer.Prostate Cancer Prostatic Dis. 2007;10(2):167-74. doi: 10.1038/sj.pcan.4500933. Epub 2007 Jan 2.
• [1059] Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.Clin Cancer Res. 2020 Mar 1;26(5):1054-1064. doi: 10.1158/1078-0432.CCR-19-1659. Epub 2019 Nov 15.
• [1060] Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.Cancer Res. 2017 Jun 15;77(12):3144-3150. doi: 10.1158/0008-5472.CAN-16-0708. Epub 2017 Apr 20.
• [1061] A PSCA/PGRN-NF-B-Integrin-4 Axis Promotes Prostate Cancer Cell Adhesion to Bone Marrow Endothelium and Enhances Metastatic Potential.Mol Cancer Res. 2020 Mar;18(3):501-513. doi: 10.1158/1541-7786.MCR-19-0278. Epub 2019 Nov 13.
• [1062] Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation.Hum Pathol. 1995 Aug;26(8):824-8. doi: 10.1016/0046-8177(95)90002-0.
• [1063] Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5.FEBS Lett. 2020 Feb;594(3):466-476. doi: 10.1002/1873-3468.13624. Epub 2019 Oct 7.
• [1064] Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.Neoplasma. 2017;64(5):732-737. doi: 10.4149/neo_2017_511.
• [1065] PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells.Oncotarget. 2017 Feb 21;8(8):13846-13854. doi: 10.18632/oncotarget.14647.
• [1066] The RNA-binding protein FXR1 modulates prostate cancer progression by regulating FBXO4.Funct Integr Genomics. 2019 May;19(3):487-496. doi: 10.1007/s10142-019-00661-8. Epub 2019 Feb 11.
• [1067] Synthesis and evaluation of (18)F-labeled CJ-042794 for imaging prostanoid EP4 receptor expression in cancer with positron emission tomography.Bioorg Med Chem Lett. 2017 May 15;27(10):2094-2098. doi: 10.1016/j.bmcl.2017.03.078. Epub 2017 Mar 27.
• [1068] Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b(+)Gr1(+)MDSCs from bone marrow.Biomed Pharmacother. 2020 Jan;121:109581. doi: 10.1016/j.biopha.2019.109581. Epub 2019 Nov 10.
• [1069] Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP? signaling pathway in DU145 cells.Mol Med Rep. 2018 May;17(5):6363-6370. doi: 10.3892/mmr.2018.8653. Epub 2018 Feb 28.
• [1070] Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells.Mol Cancer Ther. 2019 May;18(5):937-946. doi: 10.1158/1535-7163.MCT-18-0862. Epub 2019 Mar 29.
• [1071] Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene.Cancer Lett. 2002 Jan 10;175(1):63-9. doi: 10.1016/s0304-3835(01)00703-0.
• [1072] PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers.Cancer Res. 2016 Jun 1;76(11):3130-5. doi: 10.1158/0008-5472.CAN-15-1501. Epub 2016 Mar 28.
• [1073] PTPL1 and PKC contribute to proapoptotic signalling in prostate cancer cells.Cell Death Dis. 2013 Apr 4;4(4):e576. doi: 10.1038/cddis.2013.90.
• [1074] Mechanistic insights into Nav1.7-dependent regulation of rat prostate cancer cell invasiveness revealed by toxin probes and proteomic analysis.FEBS J. 2019 Jul;286(13):2549-2561. doi: 10.1111/febs.14823. Epub 2019 Apr 5.
• [1075] Prognostic relevance of increased Rac GTPase expression in prostate carcinomas.Endocr Relat Cancer. 2007 Jun;14(2):245-56. doi: 10.1677/ERC-06-0036.
• [1076] Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23.
• [1077] RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia. 2010 Dec;12(12):1003-12.
• [1078] Gene promoter methylation and cancer: An umbrella review.Gene. 2019 Aug 20;710:333-340. doi: 10.1016/j.gene.2019.06.023. Epub 2019 Jun 13.
• [1079] The miR-96 and RAR signaling axis governs androgen signaling and prostate cancer progression.Oncogene. 2019 Jan;38(3):421-444. doi: 10.1038/s41388-018-0450-6. Epub 2018 Aug 17.
• [1080] Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes.Sci Rep. 2016 Apr 22;6:24922. doi: 10.1038/srep24922.
• [1081] Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors.BMC Cancer. 2004 Aug 4;4:43. doi: 10.1186/1471-2407-4-43.
• [1082] RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res. 2017 Aug 15;77(16):4247-4257.
• [1083] Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression.Sci Rep. 2018 Nov 22;8(1):17259. doi: 10.1038/s41598-018-35332-4.
• [1084] RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.Oncotarget. 2017 Jan 24;8(4):5774-5788. doi: 10.18632/oncotarget.14391.
• [1085] Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.Urol Oncol. 2005 Nov-Dec;23(6):407-12. doi: 10.1016/j.urolonc.2005.04.002.
• [1086] RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway.Sci Rep. 2017 Mar 2;7:43683. doi: 10.1038/srep43683.
• [1087] Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature.Int J Med Sci. 2019 Jan 1;16(1):115-124. doi: 10.7150/ijms.28735. eCollection 2019.
• [1088] Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.Oncogene. 2010 Apr 8;29(14):2036-46. doi: 10.1038/onc.2009.496. Epub 2010 Jan 18.
• [1089] Association study of Retinoic Acid Related Orphan Receptor A (RORA) gene and risk of prostate disorders.Urol J. 2019 May 5;16(2):141-144. doi: 10.22037/uj.v0i0.4373.
• [1090] Peptide T7-modified polypeptide with disulfide bonds for targeted delivery of plasmid DNA for gene therapy of prostate cancer.Int J Nanomedicine. 2018 Oct 30;13:6913-6927. doi: 10.2147/IJN.S180957. eCollection 2018.
• [1091] Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation.Cancer Lett. 2018 Oct 1;433:232-241. doi: 10.1016/j.canlet.2018.07.009. Epub 2018 Jul 9.
• [1092] High RSF1 protein expression is an independent prognostic feature in prostate cancer.Acta Oncol. 2020 Mar;59(3):268-273. doi: 10.1080/0284186X.2019.1686537. Epub 2019 Nov 5.
• [1093] RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.J Transl Med. 2019 Apr 15;17(1):125. doi: 10.1186/s12967-019-1878-3.
• [1094] Cell fate regulation by reticulon-4 in human prostate cancers.J Cell Physiol. 2019 Jul;234(7):10372-10385. doi: 10.1002/jcp.27704. Epub 2018 Nov 27.
• [1095] Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.Prostate. 2005 Dec 1;65(4):322-30. doi: 10.1002/pros.20302.
• [1096] Loss of Sun2 promotes the progression of prostate cancer by regulating fatty acid oxidation.Oncotarget. 2017 Jul 12;8(52):89620-89630. doi: 10.18632/oncotarget.19210. eCollection 2017 Oct 27.
• [1097] Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines.Prostate. 2001 Aug 1;48(3):165-78. doi: 10.1002/pros.1095.
• [1098] Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate.Prostate Cancer Prostatic Dis. 2019 Dec;22(4):569-579. doi: 10.1038/s41391-019-0128-3. Epub 2019 Mar 20.
• [1099] Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer.Clin Cancer Res. 2014 Apr 1;20(7):1791-802. doi: 10.1158/1078-0432.CCR-13-2308. Epub 2014 Feb 13.
• [1100] Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.Int J Mol Med. 2015 May;35(5):1374-80. doi: 10.3892/ijmm.2015.2142. Epub 2015 Mar 17.
• [1101] SENP1 Interacts with HIF1 to Regulate Glycolysis of Prostatic Carcinoma Cells.Int J Biol Sci. 2019 Jan 1;15(2):395-403. doi: 10.7150/ijbs.27256. eCollection 2019.
• [1102] Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells.Electrophoresis. 2017 Oct;38(20):2638-2645. doi: 10.1002/elps.201700052. Epub 2017 Jul 10.
• [1103] Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies.Oncol Lett. 2018 Jan;15(1):1072-1078. doi: 10.3892/ol.2017.7374. Epub 2017 Nov 8.
• [1104] Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.Urol Oncol. 2018 Aug;36(8):366.e1-366.e9. doi: 10.1016/j.urolonc.2018.05.021. Epub 2018 Jun 19.
• [1105] Histone Methyltransferase Setd7 Regulates Nrf2 Signaling Pathway by Phenethyl Isothiocyanate and Ursolic Acid in Human Prostate Cancer Cells.Mol Nutr Food Res. 2018 Sep;62(18):e1700840. doi: 10.1002/mnfr.201700840. Epub 2018 Mar 6.
• [1106] SFRP4 gene expression is increased in aggressive prostate cancer.Sci Rep. 2017 Oct 27;7(1):14276. doi: 10.1038/s41598-017-14622-3.
• [1107] Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells.Front Oncol. 2019 Jul 11;9:565. doi: 10.3389/fonc.2019.00565. eCollection 2019.
• [1108] Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition.Onco Targets Ther. 2019 Feb 8;12:1111-1118. doi: 10.2147/OTT.S191157. eCollection 2019.
• [1109] Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.Sci Rep. 2015 Nov 19;5:16974. doi: 10.1038/srep16974.
• [1110] Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment.Carbohydr Polym. 2020 Feb 1;229:115498. doi: 10.1016/j.carbpol.2019.115498. Epub 2019 Oct 21.
• [1111] Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.BMC Cancer. 2017 Dec 20;17(1):874. doi: 10.1186/s12885-017-3853-9.
• [1112] SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt/-catenin pathway.Exp Cell Res. 2018 Mar 15;364(2):143-151. doi: 10.1016/j.yexcr.2018.01.036. Epub 2018 Feb 6.
• [1113] High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells.Sci Rep. 2019 Apr 5;9(1):5695. doi: 10.1038/s41598-019-42131-y.
• [1114] MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.EXCLI J. 2019 Mar 21;18:187-194. doi: 10.17179/excli2018-1879. eCollection 2019.
• [1115] Circular RNA Expression Profiling Identifies Prostate Cancer- Specific circRNAs in Prostate Cancer.Cell Physiol Biochem. 2018;50(5):1903-1915. doi: 10.1159/000494870. Epub 2018 Nov 5.
• [1116] Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.Pathol Oncol Res. 2020 Apr;26(2):1049-1056. doi: 10.1007/s12253-019-00659-4. Epub 2019 Apr 15.
• [1117] Protein expression information of prostate infection based on data mining.J Infect Public Health. 2020 Oct;13(10):1533-1536. doi: 10.1016/j.jiph.2019.07.019. Epub 2019 Aug 14.
• [1118] Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.Int J Urol. 2008 Jan;15(1):19-26. doi: 10.1111/j.1442-2042.2007.01937.x.
• [1119] Polymorphisms in XPC gene and risk for prostate cancer.Mol Biol Rep. 2019 Feb;46(1):1117-1125. doi: 10.1007/s11033-018-4572-2. Epub 2018 Dec 14.
• [1120] Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population.Prostate. 2005 Aug 1;64(3):246-52. doi: 10.1002/pros.20241.
• [1121] The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.Mol Cancer Ther. 2016 Nov;15(11):2679-2687. doi: 10.1158/1535-7163.MCT-16-0225. Epub 2016 Aug 22.
• [1122] Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.Int J Clin Oncol. 2017 Dec;22(6):1087-1093. doi: 10.1007/s10147-017-1160-8. Epub 2017 Jul 5.
• [1123] Extracellular redox state shift: A novel approach to target prostate cancer invasion.Free Radic Biol Med. 2018 Mar;117:99-109. doi: 10.1016/j.freeradbiomed.2018.01.023. Epub 2018 Feb 2.
• [1124] SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.Clin Epigenetics. 2019 Jul 9;11(1):99. doi: 10.1186/s13148-019-0693-2.
• [1125] The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.Oncogene. 2010 Sep 30;29(39):5370-80. doi: 10.1038/onc.2010.269. Epub 2010 Jul 12.
• [1126] Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-1/ Smad signaling pathway.Cancer Biomark. 2018 Feb 14;21(3):613-620. doi: 10.3233/CBM-170683.
• [1127] Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.BJU Int. 2018 Feb;121(2):194-202. doi: 10.1111/bju.14008. Epub 2017 Sep 22.
• [1128] miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer.BMC Urol. 2018 Mar 5;18(1):14. doi: 10.1186/s12894-018-0325-8.
• [1129] The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior.Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):324-329. doi: 10.1097/PAI.0000000000000438.
• [1130] Sorbitol dehydrogenase expression is regulated by androgens in the human prostate.Oncol Rep. 2010 May;23(5):1233-9. doi: 10.3892/or_00000755.
• [1131] Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer.Asian J Androl. 2019 Nov-Dec;21(6):557-564. doi: 10.4103/aja.aja_23_19.
• [1132] Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.J Cell Biochem. 2014 Sep;115(9):1505-15. doi: 10.1002/jcb.24805.
• [1133] Inverse Regulation of DHT Synthesis Enzymes 5-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.Endocrinology. 2017 Apr 1;158(4):1015-1021. doi: 10.1210/en.2016-1926.
• [1134] Interplay of PKD3 with SREBP1 Promotes Cell Growth via Upregulating Lipogenesis in Prostate Cancer Cells.J Cancer. 2019 Oct 19;10(25):6395-6404. doi: 10.7150/jca.31254. eCollection 2019.
• [1135] Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold.Small. 2019 Nov;15(45):e1903462. doi: 10.1002/smll.201903462. Epub 2019 Sep 16.
• [1136] Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis.Int J Oncol. 2009 Feb;34(2):425-31.
• [1137] Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells.Front Pharmacol. 2019 Feb 15;10:28. doi: 10.3389/fphar.2019.00028. eCollection 2019.
• [1138] Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.Prostate. 2017 Nov;77(15):1499-1511. doi: 10.1002/pros.23426. Epub 2017 Sep 14.
• [1139] Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.Endocr Relat Cancer. 2018 Nov 23;26(2):131-146. doi: 10.1530/ERC-18-0226.
• [1140] INSPstI polymorphism and prostate cancer in African-American men.Prostate. 2005 Sep 15;65(1):83-7. doi: 10.1002/pros.20271.
• [1141] Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.Cancer Sci. 2009 May;100(5):914-9. doi: 10.1111/j.1349-7006.2009.01117.x. Epub 2009 Feb 26.
• [1142] Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 (186-193).Biomed Pharmacother. 2019 Mar;111:1124-1131. doi: 10.1016/j.biopha.2019.01.012. Epub 2019 Jan 12.
• [1143] STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.Cancer Biol Ther. 2020;21(3):278-291. doi: 10.1080/15384047.2019.1685290. Epub 2019 Nov 7.
• [1144] Downregulation of NDR1 contributes to metastasis of prostate cancer cells via activating epithelial-mesenchymal transition.Cancer Med. 2018 Jul;7(7):3200-3212. doi: 10.1002/cam4.1532. Epub 2018 May 7.
• [1145] Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells.Mol Cell Endocrinol. 2001 Sep;182(2):181-92. doi: 10.1016/s0303-7207(01)00560-3.
• [1146] Mapping the STK4/Hippo signaling network in prostate cancer cell.PLoS One. 2017 Sep 7;12(9):e0184590. doi: 10.1371/journal.pone.0184590. eCollection 2017.
• [1147] miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.Mol Cancer Res. 2018 Jul;16(7):1125-1137. doi: 10.1158/1541-7786.MCR-17-0230. Epub 2017 Oct 12.
• [1148] Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.Cancer Sci. 2009 Nov;100(11):2109-14. doi: 10.1111/j.1349-7006.2009.01277.x. Epub 2009 Jul 7.
• [1149] Metformin inhibits SUV39H1-mediated migration of prostate cancer cells.Oncogenesis. 2017 May 1;6(5):e324. doi: 10.1038/oncsis.2017.28.
• [1150] Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer.Biochem Biophys Res Commun. 2017 May 13;486(4):872-878. doi: 10.1016/j.bbrc.2017.03.090. Epub 2017 Mar 20.
• [1151] The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.J Cancer Epidemiol. 2012;2012:358076. doi: 10.1155/2012/358076. Epub 2012 Aug 2.
• [1152] Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis.Biochem Biophys Res Commun. 2012 May 25;422(1):146-51. doi: 10.1016/j.bbrc.2012.04.126. Epub 2012 Apr 30.
• [1153] Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.Carcinogenesis. 2011 Dec;32(12):1773-81. doi: 10.1093/carcin/bgr212. Epub 2011 Sep 22.
• [1154] PPAR Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth.Cancer Res. 2018 Jan 15;78(2):399-409. doi: 10.1158/0008-5472.CAN-17-0908. Epub 2017 Nov 29.
• [1155] Validation of SE-EPI-based T2 mapping for characterization of prostate cancer: a new method compared with the traditional CPMG method.Abdom Radiol (NY). 2019 Oct;44(10):3432-3440. doi: 10.1007/s00261-019-02105-0.
• [1156] MicroRNA-124 regulates TGF--induced epithelial-mesenchymal transition in human prostate cancer cells.Int J Oncol. 2014 Sep;45(3):1225-31. doi: 10.3892/ijo.2014.2506. Epub 2014 Jun 19.
• [1157] Ethnic differences in TGF-signaling pathway may contribute to prostate cancer health disparity.Carcinogenesis. 2018 Apr 5;39(4):546-555. doi: 10.1093/carcin/bgy020.
• [1158] Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways.J Exp Clin Cancer Res. 2018 Apr 27;37(1):89. doi: 10.1186/s13046-018-0764-9.
• [1159] -Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins.Amino Acids. 2013 Jan;44(1):45-51. doi: 10.1007/s00726-012-1278-y. Epub 2012 Mar 30.
• [1160] Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.Appl Immunohistochem Mol Morphol. 2018 Nov/Dec;26(10):749-759. doi: 10.1097/PAI.0000000000000514.
• [1161] Identification of targets for prostate cancer immunotherapy.Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6.
• [1162] The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2563-8. doi: 10.1158/1055-9965.EPI-05-0356.
• [1163] The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.Prostate. 2019 Jun;79(8):856-863. doi: 10.1002/pros.23791. Epub 2019 Mar 19.
• [1164] Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. doi: 10.1016/j.urolonc.2018.06.010. Epub 2018 Aug 16.
• [1165] Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.Int J Cancer. 2008 Dec 1;123(11):2644-50. doi: 10.1002/ijc.23826.
• [1166] CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.Clin Cancer Res. 2007 Dec 1;13(23):6947-58. doi: 10.1158/1078-0432.CCR-07-0842.
• [1167] Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carc... Am J Pathol. 2003 Aug;163(2):543-52.
• [1168] Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.J Biol Chem. 2010 Sep 24;285(39):30233-46. doi: 10.1074/jbc.M110.122226. Epub 2010 Mar 30.
• [1169] Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells. J Androl. 2008 Mar-Apr;29(2):207-12. doi: 10.2164/jandrol.107.003608. Epub 2007 Oct 3.
• [1170] Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.Cancer Lett. 2017 Jul 1;397:103-110. doi: 10.1016/j.canlet.2017.03.034. Epub 2017 Mar 31.
• [1171] Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.J Transl Med. 2019 Sep 9;17(1):307. doi: 10.1186/s12967-019-2053-6.
• [1172] Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001 Nov 29;20(55):7965-75. doi: 10.1038/sj.onc.1204985.
• [1173] Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.Cancer Immunol Res. 2017 Aug;5(8):676-684. doi: 10.1158/2326-6066.CIR-17-0049. Epub 2017 Jul 3.
• [1174] Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding.PLoS One. 2015 May 7;10(5):e0126270. doi: 10.1371/journal.pone.0126270. eCollection 2015.
• [1175] Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.Cancer Lett. 2019 Feb 28;443:80-90. doi: 10.1016/j.canlet.2018.11.013. Epub 2018 Nov 22.
• [1176] Np63 Transcriptionally Regulates the Expression of CTEN That Is Associated with Prostate Cell Adhesion.PLoS One. 2016 Jan 19;11(1):e0147542. doi: 10.1371/journal.pone.0147542. eCollection 2016.
• [1177] Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.Cancer Res. 2001 Mar 1;61(5):1964-9.
• [1178] Pixelated spatial gene expression analysis from tissue.Nat Commun. 2018 Jan 15;9(1):202. doi: 10.1038/s41467-017-02623-9.
• [1179] Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2 expression to TMPRSS2-ERG fusion status in prostate cancer.Neoplasma. 2014;61(1):9-16.
• [1180] 53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.Nucleic Acids Res. 2020 Feb 20;48(3):1314-1326. doi: 10.1093/nar/gkz1139.
• [1181] Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.Theranostics. 2019 Feb 7;9(5):1247-1263. doi: 10.7150/thno.29884. eCollection 2019.
• [1182] TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.Nat Commun. 2018 Nov 27;9(1):5007. doi: 10.1038/s41467-018-07475-5.
• [1183] REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells.Oncogene. 2003 May 15;22(19):2920-5. doi: 10.1038/sj.onc.1206397.
• [1184] Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.PLoS One. 2009 Aug 5;4(8):e6523. doi: 10.1371/journal.pone.0006523.
• [1185] Transient Receptor Potential Channel Expression Signatures in Tumor-Derived Endothelial Cells: Functional Roles in Prostate Cancer Angiogenesis.Cancers (Basel). 2019 Jul 8;11(7):956. doi: 10.3390/cancers11070956.
• [1186] Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.J Physiol. 2003 May 1;548(Pt 3):823-36. doi: 10.1113/jphysiol.2002.036772.
• [1187] TRPM2 mediates distruption of autophagy machinery and correlates with the grade level in prostate cancer.J Cancer Res Clin Oncol. 2019 May;145(5):1297-1311. doi: 10.1007/s00432-019-02898-z. Epub 2019 Mar 19.
• [1188] Optimizing TRPM4 inhibitors in the MHFP6 chemical space.Eur J Med Chem. 2019 Mar 15;166:167-177. doi: 10.1016/j.ejmech.2019.01.048. Epub 2019 Jan 24.
• [1189] TGF-induced epithelial-to-mesenchymal transition in prostate cancer cells is mediated via TRPM7 expression.Mol Carcinog. 2018 Jun;57(6):752-761. doi: 10.1002/mc.22797. Epub 2018 Mar 15.
• [1190] ADP-Ribose and oxidative stress activate TRPM8 channel in prostate cancer and kidney cells.Sci Rep. 2019 Mar 11;9(1):4100. doi: 10.1038/s41598-018-37552-0.
• [1191] Natural product-drug conjugates for modulation of TRPV1-expressing tumors.Bioorg Med Chem. 2019 Jun 15;27(12):2531-2536. doi: 10.1016/j.bmc.2019.03.025. Epub 2019 Mar 13.
• [1192] Structure-Based Discovery of a Subtype-Selective Inhibitor Targeting a Transient Receptor Potential Vanilloid Channel.J Med Chem. 2019 Feb 14;62(3):1373-1384. doi: 10.1021/acs.jmedchem.8b01496. Epub 2019 Jan 16.
• [1193] Reduction of TSG101 protein has a negative impact on tumor cell growth.Int J Cancer. 2004 Apr 20;109(4):541-7. doi: 10.1002/ijc.20014.
• [1194] Silencing TTK expression inhibits the proliferation and progression of prostate cancer.Exp Cell Res. 2019 Dec 1;385(1):111669. doi: 10.1016/j.yexcr.2019.111669. Epub 2019 Oct 9.
• [1195] Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.Prostate. 2019 May;79(6):647-656. doi: 10.1002/pros.23772. Epub 2019 Feb 3.
• [1196] The Role of Genetic Variants in the Association between Dietary Acrylamide and Advanced Prostate Cancer in the Netherlands Cohort Study on Diet and Cancer.Nutr Cancer. 2018 May-Jun;70(4):620-631. doi: 10.1080/01635581.2018.1460682. Epub 2018 Apr 26.
• [1197] c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.Biochem Biophys Res Commun. 2018 Oct 2;504(2):415-421. doi: 10.1016/j.bbrc.2018.08.069. Epub 2018 Aug 10.
• [1198] Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.Prostate Cancer Prostatic Dis. 2005;8(3):260-5. doi: 10.1038/sj.pcan.4500817.
• [1199] Isolation, characterization, and bioactivities of compounds from Fuscoporia torulosa mushroom.J Food Biochem. 2019 Dec;43(12):e13074. doi: 10.1111/jfbc.13074. Epub 2019 Oct 10.
• [1200] GAS6 receptor status is associated with dormancy and bone metastatic tumor formation.PLoS One. 2013 Apr 24;8(4):e61873. doi: 10.1371/journal.pone.0061873. Print 2013.
• [1201] N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.Int J Biochem Cell Biol. 2010 Dec;42(12):2037-46. doi: 10.1016/j.biocel.2010.09.008. Epub 2010 Sep 18.
• [1202] Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics.Cell Biochem Funct. 2019 Jul;37(5):304-319. doi: 10.1002/cbf.3401. Epub 2019 May 6.
• [1203] Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.Oncol Res. 2016;24(5):361-369. doi: 10.3727/096504016X14685034103310.
• [1204] Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.Mol Cell Proteomics. 2018 Jun;17(6):1170-1183. doi: 10.1074/mcp.RA117.000504. Epub 2018 Feb 20.
• [1205] Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression.Autophagy. 2017 Mar 4;13(3):506-521. doi: 10.1080/15548627.2016.1268300. Epub 2016 Dec 15.
• [1206] Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.Oncol Rep. 2009 Jan;21(1):33-7.
• [1207] Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.Mol Cancer Res. 2018 May;16(5):846-856. doi: 10.1158/1541-7786.MCR-17-0471. Epub 2018 Jan 29.
• [1208] Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.J Exp Clin Cancer Res. 2019 May 24;38(1):220. doi: 10.1186/s13046-019-1227-7.
• [1209] USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.Mol Cells. 2019 Jan 31;42(1):17-27. doi: 10.14348/molcells.2018.0329. Epub 2019 Jan 2.
• [1210] Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.Cancer Lett. 2020 Feb 28;471:72-87. doi: 10.1016/j.canlet.2019.12.017. Epub 2019 Dec 12.
• [1211] Urotensin II receptor expression in prostate cancer patients: A new possible marker.Prostate. 2019 Feb;79(3):288-294. doi: 10.1002/pros.23734. Epub 2018 Nov 8.
• [1212] Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study.J Hematol Oncol. 2017 Mar 23;10(1):74. doi: 10.1186/s13045-017-0440-0.
• [1213] Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-B/DNMT1 signaling pathway.Prostate. 2018 Jun;78(9):682-690. doi: 10.1002/pros.23512. Epub 2018 Mar 30.
• [1214] Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.Histol Histopathol. 2012 Aug;27(8):1093-101. doi: 10.14670/HH-27.1093.
• [1215] Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.Oncol Rep. 2018 Aug;40(2):1174-1184. doi: 10.3892/or.2018.6503. Epub 2018 Jun 18.
• [1216] WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.Oncotarget. 2017 Nov 10;8(63):106352-106368. doi: 10.18632/oncotarget.22374. eCollection 2017 Dec 5.
• [1217] Validation of the prognostic value of NF-B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.
• [1218] Wnt5a induces and maintains prostate cancer cells dormancy in bone.J Exp Med. 2019 Feb 4;216(2):428-449. doi: 10.1084/jem.20180661. Epub 2018 Dec 28.
• [1219] 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.Oncol Lett. 2019 Dec;18(6):6917-6925. doi: 10.3892/ol.2019.11015. Epub 2019 Oct 29.
• [1220] Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer.Br J Cancer. 2016 May 10;114(10):1135-44. doi: 10.1038/bjc.2016.95. Epub 2016 Apr 12.
• [1221] Targeting the deubiquitinase STAMBPL1 triggers apoptosis in prostate cancer cells by promoting XIAP degradation.Cancer Lett. 2019 Aug 1;456:49-58. doi: 10.1016/j.canlet.2019.04.020. Epub 2019 Apr 17.
• [1222] XPNPEP2 is associated with lymph node metastasis in prostate cancer patients.Sci Rep. 2019 Jul 11;9(1):10078. doi: 10.1038/s41598-019-45245-5.
• [1223] YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells.Pathol Oncol Res. 2020 Apr;26(2):867-876. doi: 10.1007/s12253-019-00634-z. Epub 2019 Mar 11.
• [1224] MicroRNA-140 inhibit prostate cancer cell invasion and migration by targeting YES proto-oncogene 1.J Cell Biochem. 2020 Jan;121(1):482-488. doi: 10.1002/jcb.29231. Epub 2019 Jul 16.
• [1225] ADRB2-Targeting Therapies for Prostate Cancer.Cancers (Basel). 2019 Mar 13;11(3):358. doi: 10.3390/cancers11030358.
• [1226] Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase.Oncotarget. 2019 Jan 11;10(4):424-436. doi: 10.18632/oncotarget.13422. eCollection 2019 Jan 11.
• [1227] Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5(+)CK8(+) epithelial cells.Oncogene. 2016 Jul 7;35(27):3555-64. doi: 10.1038/onc.2015.417. Epub 2015 Nov 2.
• [1228] Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.Cancer Res. 2016 Apr 1;76(7):1869-81. doi: 10.1158/0008-5472.CAN-15-1911. Epub 2016 Feb 15.
• [1229] Inhibition of FOXQ1 induces apoptosis and suppresses proliferation in prostate cancer cells by controlling BCL11A/MDM2 expression.Oncol Rep. 2016 Oct;36(4):2349-56. doi: 10.3892/or.2016.5018. Epub 2016 Aug 11.
• [1230] Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729.
• [1231] Transcriptional regulatory networks in human lung adenocarcinoma.Mol Med Rep. 2012 Nov;6(5):961-6. doi: 10.3892/mmr.2012.1034. Epub 2012 Aug 14.
• [1232] Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Oncotarget. 2014 Feb 15;5(3):667-78. doi: 10.18632/oncotarget.1574.
• [1233] Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.BMC Cancer. 2014 Mar 5;14:154. doi: 10.1186/1471-2407-14-154.
• [1234] Circadian clock genes and risk of fatal prostate cancer.Cancer Causes Control. 2015 Jan;26(1):25-33. doi: 10.1007/s10552-014-0478-z. Epub 2014 Nov 12.
• [1235] Increased diacylglycerol kinase expression in human metastatic colon cancer cells augments Rho GTPase activity and contributes to enhanced invasion.BMC Cancer. 2014 Mar 19;14:208. doi: 10.1186/1471-2407-14-208.
• [1236] Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.Prostate. 2016 Feb 15;76(3):259-72. doi: 10.1002/pros.23120. Epub 2015 Nov 2.
• [1237] miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.Exp Cell Res. 2016 Nov 1;348(2):190-200. doi: 10.1016/j.yexcr.2016.09.021. Epub 2016 Sep 29.
• [1238] MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7.Biochem Biophys Res Commun. 2016 Jan 15;469(3):633-8. doi: 10.1016/j.bbrc.2015.12.054. Epub 2015 Dec 15.
• [1239] Knockdown of GPR137,G Protein-coupled receptor 137, Inhibits the Proliferation and Migration of Human Prostate Cancer Cells.Chem Biol Drug Des. 2016 May;87(5):704-13. doi: 10.1111/cbdd.12704. Epub 2016 Jan 17.
• [1240] 12-HETER1/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression.FASEB J. 2016 Jun;30(6):2360-9. doi: 10.1096/fj.201500076. Epub 2016 Mar 10.
• [1241] Lack of expression of preproorexin and orexin receptors genes in human normal and prostate cancer cell lines.Folia Histochem Cytobiol. 2015;53(4):333-41. doi: 10.5603/fhc.a2015.0035.
• [1242] Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.J BUON. 2014 Jan-Mar;19(1):215-20.
• [1243] Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012 Jan 12;366(2):141-9. doi: 10.1056/NEJMoa1110000.
• [1244] Ultrasound targeted microbubble destruction for novel dual targeting of HSP72 and HSC70 in prostate cancer.Asian Pac J Cancer Prev. 2014;15(3):1285-90. doi: 10.7314/apjcp.2014.15.3.1285.
• [1245] Differential expressions of integrin-linked kinase, -parvin and cofilin 1 in high-fat diet induced prostate cancer progression in a transgenic mouse model.Oncol Lett. 2018 Oct;16(4):4945-4952. doi: 10.3892/ol.2018.9276. Epub 2018 Aug 7.
• [1246] Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer.Prostate. 2015 May;75(7):723-34. doi: 10.1002/pros.22954. Epub 2015 Feb 7.
• [1247] DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.Mol Oncol. 2016 Jun;10(6):879-94. doi: 10.1016/j.molonc.2016.02.005. Epub 2016 Mar 3.
• [1248] SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.Oncotarget. 2015 Jan 20;6(2):771-88. doi: 10.18632/oncotarget.2718.
• [1249] KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.Biol Chem. 2010 Apr;391(4):467-74. doi: 10.1515/BC.2010.026.
• [1250] CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition.Cell Commun Signal. 2019 Sep 10;17(1):118. doi: 10.1186/s12964-019-0434-3.
• [1251] Galectin-3 Expression Correlates with Post-surgical Survival in Canine Oral Melanomas.J Comp Pathol. 2019 Nov;173:49-57. doi: 10.1016/j.jcpa.2019.10.003. Epub 2019 Nov 13.
• [1252] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
• [1253] Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-1).PLoS One. 2019 May 23;14(5):e0213127. doi: 10.1371/journal.pone.0213127. eCollection 2019.
• [1254] Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.Oncotarget. 2016 Aug 9;7(32):51284-51300. doi: 10.18632/oncotarget.9992.
• [1255] Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma.Mol Carcinog. 2017 Feb;56(2):781-788. doi: 10.1002/mc.22509. Epub 2016 Jun 10.
• [1256] Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma.Int J Oncol. 2014 Apr;44(4):1118-30. doi: 10.3892/ijo.2014.2278. Epub 2014 Jan 24.
• [1257] TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.J Clin Invest. 2018 Jul 2;128(7):3129-3143. doi: 10.1172/JCI96060. Epub 2018 Jun 18.
• [1258] Expression of netrin-1 by hypoxia contributes to the invasion and migration of prostate carcinoma cells by regulating YAP activity.Exp Cell Res. 2016 Dec 10;349(2):302-309. doi: 10.1016/j.yexcr.2016.10.023. Epub 2016 Nov 1.
• [1259] Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer.Nat Commun. 2016 Mar 15;7:10982. doi: 10.1038/ncomms10982.
• [1260] PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.Int Braz J Urol. 2013 Sep-Oct;39(5):649-56. doi: 10.1590/S1677-5538.IBJU.2013.05.06.
• [1261] Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.Med Sci Monit. 2016 Nov 9;22:4254-4260. doi: 10.12659/msm.898223.
• [1262] HES6 promotes prostate cancer aggressiveness independently of Notch signalling.J Cell Mol Med. 2015 Jul;19(7):1624-36. doi: 10.1111/jcmm.12537. Epub 2015 Apr 12.
• [1263] Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.Hum Pathol. 2016 Jan;47(1):109-14. doi: 10.1016/j.humpath.2015.08.021. Epub 2015 Sep 28.
• [1264] A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.J Bone Miner Res. 2020 Jan;35(1):155-166. doi: 10.1002/jbmr.3869. Epub 2019 Oct 31.
• [1265] Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development.Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):383-90.
• [1266] Uric acid: a modulator of prostate cells and activin sensitivity.Mol Cell Biochem. 2016 Mar;414(1-2):187-99. doi: 10.1007/s11010-016-2671-8. Epub 2016 Feb 24.
• [1267] SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.Lab Invest. 2020 Apr;100(4):570-582. doi: 10.1038/s41374-019-0343-5. Epub 2019 Nov 26.
• [1268] (68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer.Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):168-177. doi: 10.1007/s00259-019-04524-z. Epub 2019 Sep 16.
• [1269] Expression of the TP and TP isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.Oncotarget. 2016 Nov 8;7(45):73171-73187. doi: 10.18632/oncotarget.12256.
• [1270] Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.Medicine (Baltimore). 2016 Jul;95(29):e4326. doi: 10.1097/MD.0000000000004326.
• [1271] AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.Cancer Res. 2014 Aug 15;74(16):4306-17. doi: 10.1158/0008-5472.CAN-13-3233. Epub 2014 Jun 26.
• [1272] Effects of TRPC6 on invasibility of low-differentiated prostate cancer cells.Asian Pac J Trop Med. 2014 Jan;7(1):44-7. doi: 10.1016/S1995-7645(13)60190-X.
• [1273] Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.Prostate. 2016 Apr;76(5):479-90. doi: 10.1002/pros.23139. Epub 2015 Dec 28.
• [1274] Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.Oncotarget. 2015 Aug 28;6(25):21675-84. doi: 10.18632/oncotarget.4328.
• [1275] Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.Prostate. 2008 Sep 1;68(12):1354-61. doi: 10.1002/pros.20800.
• [1276] Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness.Urology. 2011 Oct;78(4):971.e1-9. doi: 10.1016/j.urology.2011.04.055. Epub 2011 Jul 29.
• [1277] The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: a pilot study.Mol Med Rep. 2013 Mar;7(3):986-90. doi: 10.3892/mmr.2012.1242. Epub 2012 Dec 18.
• [1278] Expression of the non-gastric H+/K+ ATPase ATP12A in normal and pathological human prostate tissue.Cell Physiol Biochem. 2011;28(6):1287-94. doi: 10.1159/000335860. Epub 2011 Dec 16.
• [1279] Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.J Cell Biochem. 2012 Feb;113(2):553-62. doi: 10.1002/jcb.23379.
• [1280] EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer.Cell Commun Signal. 2019 Jul 25;17(1):83. doi: 10.1186/s12964-019-0400-0.
• [1281] E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells.Acta Biochim Pol. 2017;64(2):371-374. doi: 10.18388/abp.2017_1521. Epub 2017 Jun 13.
• [1282] Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression.Onco Targets Ther. 2018 Jul 6;11:3853-3867. doi: 10.2147/OTT.S167463. eCollection 2018.
• [1283] Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.J Formos Med Assoc. 2000 Dec;99(12):885-94.
• [1284] Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1 Upregulation in PTEN Negative Prostate Cancer Cells.Int J Mol Sci. 2018 Jul 21;19(7):2129. doi: 10.3390/ijms19072129.
• [1285] Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.Prostate. 2005 Jun 15;64(1):29-39. doi: 10.1002/pros.20236.
• [1286] Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.Mol Cancer Res. 2017 Aug;15(8):1017-1028. doi: 10.1158/1541-7786.MCR-16-0480. Epub 2017 May 15.
• [1287] Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.BMC Urol. 2019 Jan 7;19(1):4. doi: 10.1186/s12894-018-0433-5.
• [1288] Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.Oncogene. 2017 Oct 26;36(43):6030-6040. doi: 10.1038/onc.2017.216. Epub 2017 Jul 3.
• [1289] Up-regulated miR-29c inhibits cell proliferation and glycolysis by inhibiting SLC2A3 expression in prostate cancer.Gene. 2018 Jul 30;665:26-34. doi: 10.1016/j.gene.2018.04.086. Epub 2018 Apr 30.
• [1290] Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues.Cancer Lett. 2003 Oct 28;200(2):187-95. doi: 10.1016/s0304-3835(03)00441-5.
• [1291] Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.Oncogene. 2003 Sep 4;22(38):6005-12. doi: 10.1038/sj.onc.1206797.
• [1292] A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer.J Cell Mol Med. 2018 Jul;22(7):3661-3670. doi: 10.1111/jcmm.13649. Epub 2018 Apr 23.
• [1293] Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11091-E11100. doi: 10.1073/pnas.1813956115. Epub 2018 Nov 5.
• [1294] Novel mechanism of endocrine disruption by fungicides through binding to the membrane androgen receptor, ZIP9 (SLC39A9), and antagonizing rapid testosterone induction of the intrinsic apoptotic pathway. Steroids. 2019 Sep;149:108415. doi: 10.1016/j.steroids.2019.05.007. Epub 2019 May 30.
• [1295] L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management.Cancer Biomark. 2015;15(4):365-74. doi: 10.3233/CBM-150486.
• [1296] Purification and Functional Characterization of the C-Terminal Domain of the -Actin-Binding Protein AIM1 In Vitro.Molecules. 2018 Dec 11;23(12):3281. doi: 10.3390/molecules23123281.
• [1297] Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United States.Appl Immunohistochem Mol Morphol. 2020 Aug;28(7):524-531. doi: 10.1097/PAI.0000000000000789.
• [1298] Cross-Kingdom Gene regulation via miRNAs of Hypericum perforatum (St. John's wort) flower dietetically absorbed: An in silico approach to define potential biomarkers for prostate cancer.Comput Biol Chem. 2019 Jun;80:16-22. doi: 10.1016/j.compbiolchem.2019.02.010. Epub 2019 Feb 28.
• [1299] Delivery of a TNF--derived peptide by nanoparticles enhances its antitumor activity by inducing cell-cycle arrest and caspase-dependent apoptosis.FASEB J. 2018 Aug 30:fj201800377R. doi: 10.1096/fj.201800377R. Online ahead of print.
• [1300] Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer.Oncotarget. 2015 Jul 30;6(21):18460-8. doi: 10.18632/oncotarget.3782.
• [1301] Analysis of Zinc-Exporters Expression in Prostate Cancer.Sci Rep. 2016 Nov 11;6:36772. doi: 10.1038/srep36772.
• [1302] The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.Endocr Relat Cancer. 2015 Feb;22(1):77-85. doi: 10.1530/ERC-14-0423. Epub 2014 Dec 1.
• [1303] Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.Int J Cancer. 2017 Jan 1;140(1):75-85. doi: 10.1002/ijc.30436. Epub 2016 Oct 8.
• [1304] Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.Cancer. 2015 Jun 15;121(12):1949-56. doi: 10.1002/cncr.29320. Epub 2015 Mar 2.
• [1305] The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer.PLoS One. 2013 Oct 23;8(10):e78711. doi: 10.1371/journal.pone.0078711. eCollection 2013.
• [1306] MicroRNA-135b regulates ER, AR and HIF1AN and affects breast and prostate cancer cell growth.Mol Oncol. 2015 Aug;9(7):1287-300. doi: 10.1016/j.molonc.2015.03.001. Epub 2015 Mar 21.
• [1307] Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.J Genet Couns. 2014 Jun;23(3):371-6. doi: 10.1007/s10897-013-9672-5. Epub 2013 Dec 7.
• [1308] HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.Endocrinology. 2019 Sep 1;160(9):2180-2188. doi: 10.1210/en.2019-00366.
• [1309] Differences in urinary proteins related to surgical margin status after radical prostatectomy.Oncol Rep. 2015 Dec;34(6):3247-55. doi: 10.3892/or.2015.4322.
• [1310] Circadian genes and risk of prostate cancer: Findings from the EPICAP study.Int J Cancer. 2019 Oct 1;145(7):1745-1753. doi: 10.1002/ijc.32149. Epub 2019 Feb 12.
• [1311] A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR.PLoS One. 2008;3(10):e3617. doi: 10.1371/journal.pone.0003617. Epub 2008 Oct 31.
• [1312] SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Mol Endocrinol. 2014 Jun;28(6):935-48. doi: 10.1210/me.2013-1339. Epub 2014 Apr 16.
• [1313] Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men.Genet Test Mol Biomarkers. 2012 Jul;16(7):661-6. doi: 10.1089/gtmb.2011.0212. Epub 2012 Feb 3.
• [1314] Knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis.Biosci Trends. 2016 May 23;10(2):133-9. doi: 10.5582/bst.2016.01045. Epub 2016 Apr 30.
• [1315] Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.Prostate. 2012 Oct 1;72(14):1542-9. doi: 10.1002/pros.22509. Epub 2012 Mar 13.
• [1316] The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients.Anticancer Res. 2017 Sep;37(9):4961-4965. doi: 10.21873/anticanres.11906.
• [1317] Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells.PLoS One. 2011 Jan 28;6(1):e14617. doi: 10.1371/journal.pone.0014617.
• [1318] Transcriptional regulation of type 11 17beta-hydroxysteroid dehydrogenase expression in prostate cancer cells. Mol Cell Endocrinol. 2011 Jun 6;339(1-2):45-53.
• [1319] The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.Eur Urol. 2012 Jul;62(1):88-96. doi: 10.1016/j.eururo.2011.12.021. Epub 2011 Dec 21.
• [1320] The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells.Int J Cancer. 2012 Feb 15;130(4):775-86. doi: 10.1002/ijc.26028. Epub 2011 Jun 18.
• [1321] Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer.Toxicol Appl Pharmacol. 2013 May 1;268(3):278-85. doi: 10.1016/j.taap.2013.02.013. Epub 2013 Mar 4.
• [1322] Association of common variations of 8q24 with the risk of prostate cancer in Koreans and a review of the Asian population.BJU Int. 2012 Sep;110(6 Pt B):E318-25. doi: 10.1111/j.1464-410X.2012.11211.x. Epub 2012 May 15.
• [1323] A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.Int J Cancer. 2012 Aug 1;131(3):662-72. doi: 10.1002/ijc.26414. Epub 2012 Jan 24.
• [1324] Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.Cancer Res. 2011 Feb 15;71(4):1486-96. doi: 10.1158/0008-5472.CAN-10-1343. Epub 2011 Feb 8.
• [1325] Activation of -catenin signaling in androgen receptor-negative prostate cancer cells.Clin Cancer Res. 2012 Feb 1;18(3):726-36. doi: 10.1158/1078-0432.CCR-11-2521.
• [1326] Loss of prostatic acid phosphatase and -synuclein cause motor circuit degeneration without altering cerebellar patterning.PLoS One. 2019 Sep 11;14(9):e0222234. doi: 10.1371/journal.pone.0222234. eCollection 2019.
• [1327] Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis.Genomics. 2001 Jun 15;74(3):385-95. doi: 10.1006/geno.2001.6556.
• [1328] Modified frailty index associated with Clavien-Dindo IV complications in robot-assisted radical prostatectomies: A retrospective study.Urol Oncol. 2017 Jun;35(6):425-431. doi: 10.1016/j.urolonc.2017.01.005. Epub 2017 Feb 9.
• [1329] Involvement of heparin affin regulatory peptide in human prostate cancer.Prostate. 1999 Feb 1;38(2):126-36. doi: 10.1002/(sici)1097-0045(19990201)38:2<126::aid-pros6>3.0.co;2-c.
• [1330] ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.Transl Res. 2019 Jan;203:49-56. doi: 10.1016/j.trsl.2018.08.007. Epub 2018 Sep 12.
• [1331] Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.
• [1332] Single Nucleotide Polymorphisms in -Carotene Oxygenase 1 are Associated with Plasma Lycopene Responses to a Tomato-Soy Juice Intervention in Men with Prostate Cancer.J Nutr. 2019 Mar 1;149(3):381-397. doi: 10.1093/jn/nxy304.
• [1333] Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.Prostate. 2019 Dec;79(16):1837-1851. doi: 10.1002/pros.23909. Epub 2019 Sep 16.
• [1334] Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer.BMC Cancer. 2009 Feb 26;9:69. doi: 10.1186/1471-2407-9-69.
• [1335] Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer.Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1052-1058. doi: 10.1158/1055-9965.EPI-18-1083. Epub 2019 Mar 13.
• [1336] The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.Cancer Treat Rev. 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9.
• [1337] Ligand-binding properties and catalytic activity of the purified human 24-hydroxycholesterol 7-hydroxylase, CYP39A1.J Steroid Biochem Mol Biol. 2019 Oct;193:105416. doi: 10.1016/j.jsbmb.2019.105416. Epub 2019 Jun 24.
• [1338] Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.Urol Oncol. 2016 Mar;34(3):120.e9-16. doi: 10.1016/j.urolonc.2015.10.009. Epub 2015 Nov 14.
• [1339] Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.Prostate. 2007 Sep 15;67(13):1439-46. doi: 10.1002/pros.20630.
• [1340] Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).Angiogenesis. 2018 Feb;21(1):79-94. doi: 10.1007/s10456-017-9587-0. Epub 2017 Nov 17.
• [1341] DHRS7 (SDR34C1) - A new player in the regulation of androgen receptor function by inactivation of 5-dihydrotestosterone?.J Steroid Biochem Mol Biol. 2017 Jul;171:288-295. doi: 10.1016/j.jsbmb.2017.04.013. Epub 2017 Apr 27.
• [1342] Gossypol inhibits 5-reductase 1 and 3-hydroxysteroid dehydrogenase: Its possible use for the treatment of prostate cancer.Fitoterapia. 2019 Mar;133:102-108. doi: 10.1016/j.fitote.2018.12.024. Epub 2018 Dec 31.
• [1343] miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.Clin Cancer Res. 2014 Dec 15;20(24):6559-69. doi: 10.1158/1078-0432.CCR-14-1784. Epub 2014 Oct 16.
• [1344] Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4.PLoS One. 2010 Aug 19;5(8):e12275. doi: 10.1371/journal.pone.0012275.
• [1345] Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer.Biosci Rep. 2019 Jun 25;39(6):BSR20181826. doi: 10.1042/BSR20181826. Print 2019 Jun 28.
• [1346] Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ER.Prostate. 2017 Feb;77(2):196-210. doi: 10.1002/pros.23261. Epub 2016 Oct 3.
• [1347] Characterization of prostate cancer cell progression in zebrafish xenograft model.Int J Oncol. 2018 Jan;52(1):252-260. doi: 10.3892/ijo.2017.4189. Epub 2017 Nov 6.
• [1348] A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships.J Med Chem. 2019 Aug 8;62(15):7070-7088. doi: 10.1021/acs.jmedchem.9b00624. Epub 2019 Jul 19.
• [1349] Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.BMC Endocr Disord. 2019 Oct 16;19(1):103. doi: 10.1186/s12902-019-0435-7.
• [1350] Nicotinamide N-methyltransferase enhances the progression of prostate cancer by stabilizing sirtuin 1.Oncol Lett. 2018 Jun;15(6):9195-9201. doi: 10.3892/ol.2018.8474. Epub 2018 Apr 12.
• [1351] Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.PLoS One. 2019 Aug 12;14(8):e0221051. doi: 10.1371/journal.pone.0221051. eCollection 2019.
• [1352] Inhibiting Glycine Decarboxylase Suppresses Pyruvate-to-Lactate Metabolism in Lung Cancer Cells.Front Oncol. 2018 Jun 1;8:196. doi: 10.3389/fonc.2018.00196. eCollection 2018.
• [1353] Genetic polymorphisms in MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G) genes associated with pathological characteristics of prostate cancer in the Ecuadorian population.Am J Med Sci. 2013 Dec;346(6):447-54. doi: 10.1097/MAJ.0b013e3182882578.
• [1354] Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.J Urol. 2016 Oct;196(4):1112-6. doi: 10.1016/j.juro.2016.04.079. Epub 2016 May 3.
• [1355] Oncogenic role of ABHD5 in endometrial cancer.Cancer Manag Res. 2019 Mar 14;11:2139-2150. doi: 10.2147/CMAR.S188648. eCollection 2019.
• [1356] A hnRNP KAR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.Int J Mol Sci. 2018 Jun 30;19(7):1920. doi: 10.3390/ijms19071920.
• [1357] Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.PLoS One. 2015 Aug 3;10(8):e0133449. doi: 10.1371/journal.pone.0133449. eCollection 2015.
• [1358] ARP2, a novel pro-apoptotic protein expressed in epithelial prostate cancer LNCaP cells and epithelial ovary CHO transformed cells.PLoS One. 2014 Jan 22;9(1):e86089. doi: 10.1371/journal.pone.0086089. eCollection 2014.
• [1359] The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine.Cell Death Dis. 2019 Mar 11;10(3):240. doi: 10.1038/s41419-019-1486-4.
• [1360] SP1 and RAR regulate AGAP2 expression in cancer.Sci Rep. 2019 Jan 23;9(1):390. doi: 10.1038/s41598-018-36888-x.
• [1361] Phenotype-specific CpG island methylation events in a murine model of prostate cancer.Cancer Res. 2008 Jun 1;68(11):4173-82. doi: 10.1158/0008-5472.CAN-07-6715.
• [1362] A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.Nat Genet. 2017 May;49(5):730-741. doi: 10.1038/ng.3817. Epub 2017 Mar 20.
• [1363] Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis.Br J Cancer. 2014 May 13;110(10):2593-603. doi: 10.1038/bjc.2014.201. Epub 2014 Apr 24.
• [1364] The associations of DNA methylation alterations in oxidative stress-related genes with cancer incidence and mortality outcomes: a population-based cohort study.Clin Epigenetics. 2019 Jan 24;11(1):14. doi: 10.1186/s13148-018-0604-y.
• [1365] D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.Carcinogenesis. 2007 Jan;28(1):151-62. doi: 10.1093/carcin/bgl144. Epub 2006 Aug 18.
• [1366] Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.J Nutr. 2014 May;144(5):729-33. doi: 10.3945/jn.113.189928. Epub 2014 Mar 12.
• [1367] Expression of DNA cytosine deaminase APOBEC3 proteins, a potential source for producing mutations, in gastric, colorectal and prostate cancers.Tumori. 2014 Jul-Aug;100(4):112e-7e. doi: 10.1700/1636.17922.
• [1368] BMCC1 is an AP-2 associated endosomal protein in prostate cancer cells.PLoS One. 2013 Sep 6;8(9):e73880. doi: 10.1371/journal.pone.0073880. eCollection 2013.
• [1369] RhoGDI downregulates androgen receptor signaling in prostate cancer cells.Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.
• [1370] Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.Cell Physiol Biochem. 2016;39(2):709-20. doi: 10.1159/000445662. Epub 2016 Jul 25.
• [1371] ASEQ: fast allele-specific studies from next-generation sequencing data.BMC Med Genomics. 2015 Mar 1;8:9. doi: 10.1186/s12920-015-0084-2.
• [1372] Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.J Biochem. 2015 Oct;158(4):309-19. doi: 10.1093/jb/mvv039. Epub 2015 Apr 17.
• [1373] ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer.Int J Mol Med. 2011 Jul;28(1):9-15. doi: 10.3892/ijmm.2011.670. Epub 2011 Apr 6.
• [1374] Genetic variants in ATP6 and ND3 mitochondrial genes are not associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity.Aging Male. 2016 Sep;19(3):187-191. doi: 10.1080/13685538.2016.1185409. Epub 2016 May 17.
• [1375] Silencing of vacuolar ATPase csubunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner.Oncol Rep. 2018 Jan;39(1):298-306. doi: 10.3892/or.2017.6092. Epub 2017 Nov 10.
• [1376] A novel approach to identify driver genes involved in androgen-independent prostate cancer.Mol Cancer. 2014 May 23;13:120. doi: 10.1186/1476-4598-13-120.
• [1377] HIF1 Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells.Mol Cancer Res. 2015 Mar;13(3):556-64. doi: 10.1158/1541-7786.MCR-14-0153-T. Epub 2014 Oct 27.
• [1378] Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer.Abdom Radiol (NY). 2019 Jun;44(6):2233-2243. doi: 10.1007/s00261-019-01936-1.
• [1379] Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.Cell Death Dis. 2017 Jun 1;8(6):e2844. doi: 10.1038/cddis.2017.226.
• [1380] BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells.Oncol Rep. 2008 Mar;19(3):689-96.
• [1381] Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.BMC Cancer. 2013 Mar 1;13:96. doi: 10.1186/1471-2407-13-96.
• [1382] Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.BMC Mol Biol. 2011 Jul 11;12:29. doi: 10.1186/1471-2199-12-29.
• [1383] High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.
• [1384] BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability.Br J Cancer. 2015 Jan 20;112(2):391-402. doi: 10.1038/bjc.2014.603. Epub 2014 Dec 2.
• [1385] Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.Cancer Res. 2008 Apr 15;68(8):2927-33. doi: 10.1158/0008-5472.CAN-07-5759.
• [1386] Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer.Oncogene. 2013 Mar 21;32(12):1601-8. doi: 10.1038/onc.2012.175. Epub 2012 May 14.
• [1387] Prediction nomogram for (68)Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer.Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):136-146. doi: 10.1007/s00259-019-04505-2. Epub 2019 Sep 6.
• [1388] CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.J Exp Clin Cancer Res. 2017 Jun 28;36(1):90. doi: 10.1186/s13046-017-0561-x.
• [1389] GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.Mol Biol Rep. 2013 Oct;40(10):5541-50. doi: 10.1007/s11033-013-2655-7. Epub 2013 Aug 24.
• [1390] Copy number alterations in prostate tumors and disease aggressiveness.Genes Chromosomes Cancer. 2012 Jan;51(1):66-76. doi: 10.1002/gcc.20932. Epub 2011 Oct 2.
• [1391] Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.Biomed Res Int. 2013;2013:624632. doi: 10.1155/2013/624632. Epub 2013 Jan 31.
• [1392] DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer.J Urol. 2002 Jan;167(1):335-8.
• [1393] Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis.Oncogene. 2012 Jul 5;31(27):3287-97. doi: 10.1038/onc.2011.491. Epub 2011 Oct 24.
• [1394] Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score.Med Oncol. 2013 Jun;30(2):526. doi: 10.1007/s12032-013-0526-7. Epub 2013 Mar 9.
• [1395] Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis.Cancer Sci. 2005 Sep;96(9):543-52. doi: 10.1111/j.1349-7006.2005.00089.x.
• [1396] Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon.Oncotarget. 2015 May 30;6(15):13591-606. doi: 10.18632/oncotarget.3792.
• [1397] The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.Cancer Res. 2005 Apr 15;65(8):3108-16. doi: 10.1158/0008-5472.CAN-04-3151.
• [1398] Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/-catenin signaling.Biomed Pharmacother. 2018 Dec;108:467-475. doi: 10.1016/j.biopha.2018.09.019. Epub 2018 Sep 18.
• [1399] Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis.Mol Cancer Res. 2020 Feb;18(2):240-252. doi: 10.1158/1541-7786.MCR-19-0722. Epub 2019 Nov 6.
• [1400] LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.Front Oncol. 2019 Aug 2;9:721. doi: 10.3389/fonc.2019.00721. eCollection 2019.
• [1401] Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer.J Mol Endocrinol. 2013 Apr 23;50(3):401-9. doi: 10.1530/JME-13-0024. Print 2013 Jun.
• [1402] Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells.Hum Pathol. 2016 Oct;56:64-73. doi: 10.1016/j.humpath.2016.06.001. Epub 2016 Jun 21.
• [1403] Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.Nat Genet. 2011 Jul 10;43(8):785-91. doi: 10.1038/ng.882.
• [1404] Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.Prostate. 2019 May;79(6):592-603. doi: 10.1002/pros.23764. Epub 2019 Jan 24.
• [1405] Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.Cancer Biol Ther. 2019;20(6):740-749. doi: 10.1080/15384047.2018.1564559. Epub 2019 Mar 8.
• [1406] CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer.J Korean Med Sci. 2018 Nov 2;33(47):e303. doi: 10.3346/jkms.2018.33.e303. eCollection 2018 Nov 19.
• [1407] Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.J Int Med Res. 2014 Oct;42(5):1085-92. doi: 10.1177/0300060514540631. Epub 2014 Jul 11.
• [1408] PCTAIRE1/CDK16/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle.J Dermatol Sci. 2017 May;86(2):149-157. doi: 10.1016/j.jdermsci.2017.02.281. Epub 2017 Feb 22.
• [1409] Downregulation of CENPF Remodels Prostate Cancer Cells and Alters Cellular Metabolism.Proteomics. 2019 Jun;19(11):e1900038. doi: 10.1002/pmic.201900038. Epub 2019 May 8.
• [1410] FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.Cancer Res. 2013 Feb 15;73(4):1400-10. doi: 10.1158/0008-5472.CAN-12-1857. Epub 2012 Dec 12.
• [1411] CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.Cancer Cell. 2019 Apr 15;35(4):603-617.e8. doi: 10.1016/j.ccell.2019.03.001. Epub 2019 Mar 28.
• [1412] Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells.PLoS One. 2014 Jan 31;9(1):e86238. doi: 10.1371/journal.pone.0086238. eCollection 2014.
• [1413] Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.
• [1414] PSMA SPECT/CT with (99m)Tc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.Ann Nucl Med. 2019 Dec;33(12):891-898. doi: 10.1007/s12149-019-01400-6. Epub 2019 Sep 9.
• [1415] CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.Clin Transl Oncol. 2015 Aug;17(8):632-9. doi: 10.1007/s12094-015-1288-9. Epub 2015 May 20.
• [1416] Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 9;8(34):56428-56442. doi: 10.18632/oncotarget.17701. eCollection 2017 Aug 22.
• [1417] Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.Oncotarget. 2015 Jun 10;6(16):14488-96. doi: 10.18632/oncotarget.3697.
• [1418] Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.Prostate. 2014 May;74(7):732-42. doi: 10.1002/pros.22793. Epub 2014 Feb 24.
• [1419] Multiple loci identified in a genome-wide association study of prostate cancer.Nat Genet. 2008 Mar;40(3):310-5. doi: 10.1038/ng.91. Epub 2008 Feb 10.
• [1420] The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.Oncogene. 2015 Jan 8;34(2):226-36. doi: 10.1038/onc.2013.538. Epub 2014 Jan 20.
• [1421] The role of CREB3L4 in the proliferation of prostate cancer cells.Sci Rep. 2017 Mar 24;7:45300. doi: 10.1038/srep45300.
• [1422] Analyzing the Association of Polymorphisms in the CRYBB2 Gene with Prostate Cancer Risk in African Americans.Anticancer Res. 2015 May;35(5):2565-70.
• [1423] Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.BMC Syst Biol. 2008 Dec 5;2:106. doi: 10.1186/1752-0509-2-106.
• [1424] Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.Ecotoxicol Environ Saf. 2018 Nov 30;164:61-68. doi: 10.1016/j.ecoenv.2018.07.070. Epub 2018 Aug 8.
• [1425] CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4.Oncogenesis. 2019 Mar 14;8(3):23. doi: 10.1038/s41389-019-0131-5.
• [1426] Delineation of TMPRSS2-ERG splice variants in prostate cancer.Clin Cancer Res. 2008 Aug 1;14(15):4719-25. doi: 10.1158/1078-0432.CCR-08-0531.
• [1427] CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9. doi: 10.1073/pnas.0813144106. Epub 2009 Feb 13.
• [1428] CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and v3 integrin clustering.Oncotarget. 2016 Feb 9;7(6):7343-53. doi: 10.18632/oncotarget.6944.
• [1429] Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.Prostate Cancer Prostatic Dis. 2013 Dec;16(4):292-300. doi: 10.1038/pcan.2013.21. Epub 2013 Jul 30.
• [1430] A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer.Pathol Res Pract. 2018 Dec;214(12):2018-2024. doi: 10.1016/j.prp.2018.09.019. Epub 2018 Sep 29.
• [1431] Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.J Biol Chem. 2015 Jun 19;290(25):15406-15420. doi: 10.1074/jbc.M115.658765. Epub 2015 Apr 22.
• [1432] Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7.
• [1433] Construction of a lncRNA-PCG bipartite network and identification of cancer-related lncRNAs: a case study in prostate cancer.Mol Biosyst. 2015 Feb;11(2):384-93. doi: 10.1039/c4mb00439f. Epub 2014 Nov 11.
• [1434] Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?.Int J Biol Sci. 2014 Jun 1;10(6):576-87. doi: 10.7150/ijbs.8479. eCollection 2014.
• [1435] Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression.Biomed Pharmacother. 2017 Oct;94:439-445. doi: 10.1016/j.biopha.2017.07.119. Epub 2017 Aug 2.
• [1436] Loss of Dlg5 expression promotes the migration and invasion of prostate cancer cells via Girdin phosphorylation.Oncogene. 2015 Feb 26;34(9):1141-9. doi: 10.1038/onc.2014.31. Epub 2014 Mar 24.
• [1437] Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features.Urology. 2011 Feb;77(2):509.e9-13. doi: 10.1016/j.urology.2010.09.023. Epub 2010 Dec 16.
• [1438] Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.Prostate. 2017 Sep;77(12):1251-1258. doi: 10.1002/pros.23384. Epub 2017 Jul 20.
• [1439] Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients.Asian J Androl. 2018 Jan-Feb;20(1):56-61. doi: 10.4103/aja.aja_3_17.
• [1440] Exposure to bisphenol A: current levels from food intake are toxic to human cells.Mol Biol Rep. 2019 Apr;46(2):2555-2559. doi: 10.1007/s11033-019-04666-1. Epub 2019 Feb 7.
• [1441] Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.Mol Med Rep. 2014 Dec;10(6):3052-8. doi: 10.3892/mmr.2014.2575. Epub 2014 Sep 18.
• [1442] Downregulation of several fibulin genes in prostate cancer.Prostate. 2007 Dec 1;67(16):1770-80. doi: 10.1002/pros.20667.
• [1443] Decreased expression of EFS is correlated with the advanced prostate cancer.Tumour Biol. 2015 Feb;36(2):799-805. doi: 10.1007/s13277-014-2703-5. Epub 2014 Oct 9.
• [1444] Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.Oncotarget. 2016 Sep 6;7(36):57978-57990. doi: 10.18632/oncotarget.11154.
• [1445] Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2 phosphorylation in prostate cancer.Cell Signal. 2015 Apr;27(4):789-97. doi: 10.1016/j.cellsig.2014.12.020. Epub 2015 Jan 7.
• [1446] The oncogenic role of EIF3D is associated with increased cell cycle progression and motility in prostate cancer.Med Oncol. 2015 Jul;32(7):518. doi: 10.1007/s12032-015-0518-x. Epub 2015 Jun 3.
• [1447] A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.Am J Pathol. 2012 Nov;181(5):1585-94. doi: 10.1016/j.ajpath.2012.08.005.
• [1448] Knockdown of MBP-1 in human prostate cancer cells delays cell cycle progression.J Biol Chem. 2006 Aug 18;281(33):23652-7. doi: 10.1074/jbc.M602930200. Epub 2006 Jun 8.
• [1449] An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.Cell Rep. 2016 Oct 25;17(5):1289-1301. doi: 10.1016/j.celrep.2016.10.001.
• [1450] Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.J Cell Biochem. 2019 Jul;120(7):11383-11389. doi: 10.1002/jcb.28415. Epub 2019 Feb 18.
• [1451] Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.Arch Toxicol. 2014 Apr;88(4):901-11. doi: 10.1007/s00204-014-1196-8. Epub 2014 Jan 22.
• [1452] Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer.Histol Histopathol. 2006 Apr;21(4):415-22. doi: 10.14670/HH-21.415.
• [1453] Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain.BMC Cancer. 2014 Nov 20;14:852. doi: 10.1186/1471-2407-14-852.
• [1454] Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Cell-Derived Factor That Induces Human Prostate Cancer Cell Death.Prostate. 2017 May;77(7):729-742. doi: 10.1002/pros.23303. Epub 2017 Feb 7.
• [1455] Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.Prostate. 2011 Jul;71(10):1115-21. doi: 10.1002/pros.21325. Epub 2011 Jan 12.
• [1456] Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.Sci Rep. 2017 Jul 11;7(1):5124. doi: 10.1038/s41598-017-05209-z.
• [1457] Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11miRNA-541androgen receptor (AR)MMP9 signaling.Mol Oncol. 2015 Jan;9(1):44-57. doi: 10.1016/j.molonc.2014.07.013. Epub 2014 Jul 29.
• [1458] Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.J Clin Invest. 2008 Aug;118(8):2697-710. doi: 10.1172/JCI33093.
• [1459] CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer.J Urol. 2013 Jan;189(1):329-35. doi: 10.1016/j.juro.2012.08.188. Epub 2012 Nov 20.
• [1460] Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.World J Urol. 2020 Mar;38(3):637-645. doi: 10.1007/s00345-019-02651-8. Epub 2019 Jan 30.
• [1461] Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.J Clin Pathol. 2013 Jul;66(7):563-8. doi: 10.1136/jclinpath-2012-201335. Epub 2013 Apr 4.
• [1462] LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.Cell Death Dis. 2019 Jun 17;10(7):472. doi: 10.1038/s41419-019-1699-6.
• [1463] Human fucosyltransferase 6 enables prostate cancer metastasis to bone.Br J Cancer. 2013 Dec 10;109(12):3014-22. doi: 10.1038/bjc.2013.690. Epub 2013 Oct 31.
• [1464] Chromium(VI) promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.Toxicol Lett. 2019 Jan;300:10-17. doi: 10.1016/j.toxlet.2018.10.012. Epub 2018 Oct 10.
• [1465] Mechanism of androgen receptor corepression by CKBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.Mol Cell Endocrinol. 2014 Jan 25;382(1):302-313. doi: 10.1016/j.mce.2013.09.036. Epub 2013 Oct 5.
• [1466] Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.Prostate. 2014 Jul;74(10):1059-67. doi: 10.1002/pros.22826. Epub 2014 May 22.
• [1467] microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells.J Cell Physiol. 2019 Aug;234(8):13182-13190. doi: 10.1002/jcp.27989. Epub 2018 Dec 10.
• [1468] GDF-9 promotes the growth of prostate cancer cells by protecting them from apoptosis.J Cell Physiol. 2010 Nov;225(2):529-36. doi: 10.1002/jcp.22235.
• [1469] RET Signaling in Prostate Cancer.Clin Cancer Res. 2017 Aug 15;23(16):4885-4896. doi: 10.1158/1078-0432.CCR-17-0528. Epub 2017 May 10.
• [1470] Evaluation of PSF1 as a prognostic biomarker for prostate cancer.Prostate Cancer Prostatic Dis. 2015 Mar;18(1):56-62. doi: 10.1038/pcan.2014.46. Epub 2014 Nov 18.
• [1471] Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells.J Clin Endocrinol Metab. 2009 May;94(5):1761-7. doi: 10.1210/jc.2008-1741. Epub 2009 Feb 3.
• [1472] GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Mar;17(3):4187-4194. doi: 10.3892/mmr.2018.8430. Epub 2018 Jan 15.
• [1473] Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.PLoS One. 2015 Feb 18;10(2):e0117758. doi: 10.1371/journal.pone.0117758. eCollection 2015.
• [1474] Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.BMC Cancer. 2016 Aug 2;16:567. doi: 10.1186/s12885-016-2632-3.
• [1475] Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells.J Control Release. 2019 Feb 10;295:102-117. doi: 10.1016/j.jconrel.2018.12.034. Epub 2018 Dec 21.
• [1476] A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.PLoS Genet. 2014 Nov 20;10(11):e1004809. doi: 10.1371/journal.pgen.1004809. eCollection 2014 Nov.
• [1477] HES5 silencing is an early and recurrent change in prostate tumourigenesis.Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5.
• [1478] Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1744-56. doi: 10.1158/1078-0432.CCR-15-1606. Epub 2015 Nov 9.
• [1479] High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.PLoS One. 2015 Jul 31;10(7):e0134614. doi: 10.1371/journal.pone.0134614. eCollection 2015.
• [1480] HOXA1 enhances the cell proliferation, invasion and metastasis of prostate cancer cells.Oncol Rep. 2015 Sep;34(3):1203-10. doi: 10.3892/or.2015.4085. Epub 2015 Jun 26.
• [1481] HOXA10 expression profiling in prostate cancer.Prostate. 2019 Apr;79(5):554-563. doi: 10.1002/pros.23761. Epub 2019 Jan 6.
• [1482] Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.J Urol. 2019 Aug;202(2):256-263. doi: 10.1097/JU.0000000000000293. Epub 2019 Jul 8.
• [1483] Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis.Mol Carcinog. 1999 Mar;24(3):160-8. doi: 10.1002/(sici)1098-2744(199903)24:3<160::aid-mc2>3.0.co;2-m.
• [1484] HRK inactivation associated with promoter methylation and LOH in prostate cancer.Prostate. 2008 Jan 1;68(1):105-13. doi: 10.1002/pros.20600.
• [1485] Heat-shock factor 2 is a suppressor of prostate cancer invasion.Oncogene. 2016 Apr 7;35(14):1770-84. doi: 10.1038/onc.2015.241. Epub 2015 Jun 29.
• [1486] Synergistic effect and VEGF/HSP70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome.Hum Immunol. 2010 Apr;71(4):377-82. doi: 10.1016/j.humimm.2010.01.017. Epub 2010 Feb 4.
• [1487] Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.
• [1488] Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B.Cancer Med. 2012 Oct;1(2):187-97. doi: 10.1002/cam4.19. Epub 2012 Aug 28.
• [1489] Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.Mol Oncol. 2017 Apr;11(4):337-357. doi: 10.1002/1878-0261.12028. Epub 2017 Mar 2.
• [1490] IFI16 in human prostate cancer.Mol Cancer Res. 2007 Mar;5(3):251-9. doi: 10.1158/1541-7786.MCR-06-0269. Epub 2007 Mar 5.
• [1491] EZH2-mediated inactivation of IFN--JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.Cell Rep. 2014 Jul 10;8(1):204-16. doi: 10.1016/j.celrep.2014.05.045. Epub 2014 Jun 19.
• [1492] Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.Oncotarget. 2015 May 30;6(15):13088-104. doi: 10.18632/oncotarget.3743.
• [1493] Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers.Neoplasia. 2007 Jun;9(6):464-70. doi: 10.1593/neo.07109.
• [1494] Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease.Br J Cancer. 2009 Dec 1;101(11):1891-9. doi: 10.1038/sj.bjc.6605379. Epub 2009 Nov 3.
• [1495] Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.Mol Cell Biochem. 2020 Jan;464(1-2):153-167. doi: 10.1007/s11010-019-03657-x. Epub 2019 Nov 27.
• [1496] Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.Br J Cancer. 2009 Jun 2;100(11):1784-93. doi: 10.1038/sj.bjc.6605089. Epub 2009 May 12.
• [1497] Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.Oncogene. 2019 Feb;38(7):1121-1135. doi: 10.1038/s41388-018-0498-3. Epub 2018 Sep 18.
• [1498] Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.Cancer Res. 2014 May 1;74(9):2591-603. doi: 10.1158/0008-5472.CAN-13-1606. Epub 2014 Mar 7.
• [1499] IL6 sensitizes prostate cancer to the antiproliferative effect of IFN2 through IRF9.Endocr Relat Cancer. 2013 Aug 23;20(5):677-89. doi: 10.1530/ERC-13-0222. Print 2013 Oct.
• [1500] Long noncoding RNA DANCR contributes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway.Onco Targets Ther. 2019 Jul 9;12:5485-5497. doi: 10.2147/OTT.S197009. eCollection 2019.
• [1501] Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).Osteoporos Int. 2019 Jan;30(1):115-125. doi: 10.1007/s00198-018-4722-3. Epub 2018 Oct 15.
• [1502] The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.Int J Cancer. 2019 Aug 1;145(3):614-620. doi: 10.1002/ijc.32116. Epub 2019 Jan 28.
• [1503] Effects of KIF2A on the prognosis of nasopharyngeal carcinoma and nasopharyngeal carcinoma cells.Oncol Lett. 2019 Sep;18(3):2718-2723. doi: 10.3892/ol.2019.10597. Epub 2019 Jul 9.
• [1504] Mutational landscape of candidate genes in familial prostate cancer.Prostate. 2014 Oct;74(14):1371-8. doi: 10.1002/pros.22849. Epub 2014 Aug 11.
• [1505] KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer.Mol Cancer Res. 2014 Apr;12(4):491-503. doi: 10.1158/1541-7786.MCR-13-0418. Epub 2014 Jan 10.
• [1506] Krppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.Acta Pharmacol Sin. 2013 Feb;34(2):282-8. doi: 10.1038/aps.2012.130. Epub 2012 Oct 1.
• [1507] NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells.Sci Rep. 2015 Nov 30;5:17426. doi: 10.1038/srep17426.
• [1508] Knockdown of KLK12 inhibits viability and inducesapoptosis in human colorectal cancer HT-29 cell line.Int J Mol Med. 2019 Nov;44(5):1667-1676. doi: 10.3892/ijmm.2019.4327. Epub 2019 Aug 30.
• [1509] Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.Urol Oncol. 2013 Jul;31(5):635-43. doi: 10.1016/j.urolonc.2011.05.011. Epub 2011 Jul 8.
• [1510] Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer.Clin Biochem. 2018 Aug;58:108-115. doi: 10.1016/j.clinbiochem.2018.06.007. Epub 2018 Jun 18.
• [1511] Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.J Clin Endocrinol Metab. 2013 Mar;98(3):E586-94. doi: 10.1210/jc.2012-3490. Epub 2013 Feb 5.
• [1512] EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence?.Front Oncol. 2019 Mar 11;9:131. doi: 10.3389/fonc.2019.00131. eCollection 2019.
• [1513] Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.Cancer Res. 2015 Jul 15;75(14):2949-60. doi: 10.1158/0008-5472.CAN-14-3297. Epub 2015 May 27.
• [1514] miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Mol Endocrinol. 2015 Jul;29(7):1037-54. doi: 10.1210/me.2014-1358. Epub 2015 Jun 8.
• [1515] Loss of LDAH associated with prostate cancer and hearing loss.Hum Mol Genet. 2018 Dec 15;27(24):4194-4203. doi: 10.1093/hmg/ddy310.
• [1516] Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer.Cancer Res. 2018 Aug 15;78(16):4459-4470. doi: 10.1158/0008-5472.CAN-17-3226. Epub 2018 Jun 11.
• [1517] A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.PLoS One. 2015 Jul 13;10(7):e0131307. doi: 10.1371/journal.pone.0131307. eCollection 2015.
• [1518] An exome-wide rare variant analysis of Korean men identifies three novel genes predisposing to prostate cancer.Sci Rep. 2019 Nov 20;9(1):17173. doi: 10.1038/s41598-019-53445-2.
• [1519] Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.Oncotarget. 2016 Apr 19;7(16):22271-84. doi: 10.18632/oncotarget.7926.
• [1520] High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.Mol Oncol. 2013 Dec;7(6):1001-11. doi: 10.1016/j.molonc.2013.07.009. Epub 2013 Jul 19.
• [1521] Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment.Oncotarget. 2015 May 10;6(13):11264-80. doi: 10.18632/oncotarget.3595.
• [1522] Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3.
• [1523] Prostate cancer in Germany among migrants from the Former Soviet Union.Glob Health Action. 2012;5:9135. doi: 10.3402/gha.v5i0.9135. Epub 2012 Jan 2.
• [1524] -Mannosidase 2C1 attenuates PTEN function in prostate cancer cells.Nat Commun. 2011;2:307. doi: 10.1038/ncomms1309.
• [1525] Genistein treatment duration effects biomarkers of cell motility in human prostate.PLoS One. 2019 Mar 27;14(3):e0214078. doi: 10.1371/journal.pone.0214078. eCollection 2019.
• [1526] Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.Int J Oncol. 2000 Dec;17(6):1077-86. doi: 10.3892/ijo.17.6.1077.
• [1527] Heme oxygenase-1 in macrophages controls prostate cancer progression.Oncotarget. 2015 Oct 20;6(32):33675-88. doi: 10.18632/oncotarget.5284.
• [1528] The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer.PLoS One. 2015 Nov 11;10(11):e0142662. doi: 10.1371/journal.pone.0142662. eCollection 2015.
• [1529] AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.Mol Cancer Ther. 2019 Feb;18(2):356-363. doi: 10.1158/1535-7163.MCT-18-0141. Epub 2018 Nov 16.
• [1530] Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.Cancer Res. 2010 Apr 1;70(7):2809-18. doi: 10.1158/0008-5472.CAN-09-4176. Epub 2010 Mar 23.
• [1531] MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer.Nucleic Acids Res. 2015 May 26;43(10):4893-908. doi: 10.1093/nar/gkv394. Epub 2015 Apr 30.
• [1532] Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.Oncotarget. 2017 Apr 25;8(17):27966-27975. doi: 10.18632/oncotarget.15854.
• [1533] MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.
• [1534] HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.Prostate. 2019 Mar;79(4):414-424. doi: 10.1002/pros.23747. Epub 2018 Dec 17.
• [1535] A genetic screen in Drosophila for regulators of human prostate cancer progression.Biochem Biophys Res Commun. 2014 Sep 5;451(4):548-55. doi: 10.1016/j.bbrc.2014.08.015. Epub 2014 Aug 10.
• [1536] Mitofusin 1 degradation is induced by a disruptor of mitochondrial calcium homeostasis, CGP37157: a role in apoptosis in prostate cancer cells.Int J Oncol. 2014 May;44(5):1767-73. doi: 10.3892/ijo.2014.2343. Epub 2014 Mar 13.
• [1537] Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor.Cell Res. 2006 Sep;16(9):750-8. doi: 10.1038/sj.cr.7310089.
• [1538] Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.Genet Mol Res. 2014 Jan 24;13(2):4419-24. doi: 10.4238/2014.January.24.20.
• [1539] MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.BMC Cancer. 2016 Nov 16;16(1):894. doi: 10.1186/s12885-016-2941-6.
• [1540] MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.Clin Exp Metastasis. 2005;22(7):565-73. doi: 10.1007/s10585-005-5376-z. Epub 2006 Feb 11.
• [1541] Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas.Oncotarget. 2017 Feb 21;8(8):14147-14157. doi: 10.18632/oncotarget.13122.
• [1542] NDP52 activates nuclear myosin VI to enhance RNA polymerase II transcription.Nat Commun. 2017 Nov 30;8(1):1871. doi: 10.1038/s41467-017-02050-w.
• [1543] Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.Med Oncol. 2014 Jan;31(1):820. doi: 10.1007/s12032-013-0820-4. Epub 2013 Dec 14.
• [1544] The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression.Pathobiology. 2013;80(2):60-9. doi: 10.1159/000341396. Epub 2012 Aug 29.
• [1545] The activity and expression of microRNAs in prostate cancers.Mol Biosyst. 2010 Dec;6(12):2561-72. doi: 10.1039/c0mb00100g. Epub 2010 Oct 19.
• [1546] Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.Biochem Biophys Res Commun. 2012 Jul 6;423(3):564-70. doi: 10.1016/j.bbrc.2012.06.005. Epub 2012 Jun 10.
• [1547] The mitotic regulator Hec1 is a critical modulator of prostate cancer through the long non-coding RNA BX647187 invitro.Biosci Rep. 2015 Nov 26;35(6):e00273. doi: 10.1042/BSR20150003. Print 2015.
• [1548] A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.Hum Gene Ther. 2012 Jan;23(1):70-82. doi: 10.1089/hum.2011.016. Epub 2011 Oct 12.
• [1549] Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling.Cell Death Differ. 2012 Jan;19(1):170-9. doi: 10.1038/cdd.2011.83. Epub 2011 Jun 17.
• [1550] Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.Int J Cancer. 2019 Jul 1;145(1):40-48. doi: 10.1002/ijc.32068. Epub 2019 Jan 17.
• [1551] NOL8, the binding protein for beta-catenin, promoted the growth and migration of prostate cancer cells.Chem Biol Interact. 2018 Oct 1;294:40-47. doi: 10.1016/j.cbi.2018.08.019. Epub 2018 Aug 18.
• [1552] NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1 and p27(Kip1) expression in malignant melanoma and other human tumors.Mol Carcinog. 2017 Dec;56(12):2643-2662. doi: 10.1002/mc.22708. Epub 2017 Aug 30.
• [1553] Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci.Br J Cancer. 2004 Jan 26;90(2):510-4. doi: 10.1038/sj.bjc.6601417.
• [1554] Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.Anat Rec (Hoboken). 2012 Dec;295(12):2114-21. doi: 10.1002/ar.22571. Epub 2012 Sep 7.
• [1555] The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.Oncotarget. 2014 Mar 30;5(6):1666-82. doi: 10.18632/oncotarget.1850.
• [1556] Association of the innate immunity and inflammation pathway with advanced prostate cancer risk.PLoS One. 2012;7(12):e51680. doi: 10.1371/journal.pone.0051680. Epub 2012 Dec 14.
• [1557] Overexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cells.Oncol Rep. 2014 Nov;32(5):1939-46. doi: 10.3892/or.2014.3407. Epub 2014 Aug 14.
• [1558] Combining Optical Reporter Proteins with Different Half-lives to Detect Temporal Evolution of Hypoxia and Reoxygenation in Tumors.Neoplasia. 2015 Dec;17(12):871-881. doi: 10.1016/j.neo.2015.11.007.
• [1559] Surface functionalized folate targeted oleuropein nano-liposomes for prostate tumor targeting: Invitro and invivo activity.Life Sci. 2019 Mar 1;220:136-146. doi: 10.1016/j.lfs.2019.01.053. Epub 2019 Jan 31.
• [1560] Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.Cancer Res. 2000 Oct 1;60(19):5522-8.
• [1561] Bringing Prostate Cancer Germline Genetics into Clinical Practice.J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
• [1562] Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis.J Biol Chem. 2019 Mar 22;294(12):4572-4582. doi: 10.1074/jbc.RA118.006057. Epub 2019 Feb 4.
• [1563] Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.Mol Cancer. 2011 May 6;10:50. doi: 10.1186/1476-4598-10-50.
• [1564] Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.Med Sci Monit. 2014 Aug 5;20:1376-82. doi: 10.12659/MSM.891247.
• [1565] Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.Med Sci Monit. 2017 Oct 13;23:4895-4900. doi: 10.12659/msm.904366.
• [1566] MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):278-289. doi: 10.1080/21691401.2018.1553783.
• [1567] Cisplatin in combination with programmed cell death protein5 increases antitumor activity in prostate cancer cells by promoting apoptosis.Mol Med Rep. 2015 Jun;11(6):4561-6. doi: 10.3892/mmr.2015.3252. Epub 2015 Jan 26.
• [1568] LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer.PLoS One. 2016 Jan 15;11(1):e0146549. doi: 10.1371/journal.pone.0146549. eCollection 2016.
• [1569] A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis.Prostate. 2014 Sep;74(12):1171-82. doi: 10.1002/pros.22833. Epub 2014 Jun 24.
• [1570] Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells.J Pineal Res. 2010 Aug;49(1):60-8. doi: 10.1111/j.1600-079X.2010.00767.x. Epub 2010 May 27.
• [1571] PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/-catenin signaling pathway.J Exp Clin Cancer Res. 2017 Jun 23;36(1):85. doi: 10.1186/s13046-017-0560-y.
• [1572] A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies.Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1599-610. doi: 10.1158/1055-9965.EPI-11-0312. Epub 2011 Jun 29.
• [1573] CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.Oncogene. 2014 Jan 23;33(4):504-13. doi: 10.1038/onc.2012.602. Epub 2013 Jan 14.
• [1574] Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.Prostate. 2015 Sep;75(12):1264-76. doi: 10.1002/pros.23008. Epub 2015 May 25.
• [1575] Germline mutations in PPFIBP2 are associated with lethal prostate cancer.Prostate. 2018 Dec;78(16):1222-1228. doi: 10.1002/pros.23697. Epub 2018 Jul 24.
• [1576] Bioinformatics Analysis of Stromal Molecular Signatures Associated with Breast and Prostate Cancer.J Comput Biol. 2019 Oct;26(10):1130-1139. doi: 10.1089/cmb.2019.0045. Epub 2019 Jun 11.
• [1577] TGF- cascade regulation by PPP1 and its interactors -impact on prostate cancer development and therapy.J Cell Mol Med. 2014 Apr;18(4):555-67. doi: 10.1111/jcmm.12266. Epub 2014 Mar 15.
• [1578] PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55/PP2A reconstitution that triggers centrosome destabilization.Oncogenesis. 2019 Dec 10;8(12):72. doi: 10.1038/s41389-019-0180-9.
• [1579] Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in prostate cancer cells.Prostate. 2012 May 1;72(6):597-611. doi: 10.1002/pros.21463. Epub 2011 Jul 27.
• [1580] The human oncogene SCL/TAL1 interrupting locus (STIL) promotes tumor growth through MAPK/ERK, PI3K/Akt and AMPK pathways in prostate cancer.Gene. 2019 Feb 20;686:220-227. doi: 10.1016/j.gene.2018.11.048. Epub 2018 Nov 16.
• [1581] Protein kinase A type II- regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Cell Cycle. 2014;13(20):3292-301. doi: 10.4161/15384101.2014.949501.
• [1582] Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.J Cell Biochem. 2008 Aug 15;104(6):2272-85. doi: 10.1002/jcb.21786.
• [1583] Inhibition on Proteasome 1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.PLoS One. 2015 Oct 29;10(10):e0141681. doi: 10.1371/journal.pone.0141681. eCollection 2015.
• [1584] Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of -catenin activation of the DKK1 promoter in prostate cancer.Oncogene. 2014 May 8;33(19):2464-77. doi: 10.1038/onc.2013.203. Epub 2013 Jun 10.
• [1585] The role of prostate tumor overexpressed 1 in cancer progression.Oncotarget. 2017 Feb 14;8(7):12451-12471. doi: 10.18632/oncotarget.14104.
• [1586] Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins.Prostate. 2011 Dec;71(16):1810-7. doi: 10.1002/pros.21398. Epub 2011 Apr 7.
• [1587] Receptor-like protein tyrosine phosphatase negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.Int J Oncol. 2013 Nov;43(5):1560-8. doi: 10.3892/ijo.2013.2082. Epub 2013 Aug 29.
• [1588] The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein.Cancer Biol Ther. 2014 Jan;15(1):108-18. doi: 10.4161/cbt.26722. Epub 2013 Oct 23.
• [1589] RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.Int J Oncol. 2017 Mar;50(3):920-932. doi: 10.3892/ijo.2017.3872. Epub 2017 Feb 10.
• [1590] Intracellular oxygen determined by respiration regulates localization of Ras and prenylated proteins.Cell Death Dis. 2015 Jul 16;6(7):e1825. doi: 10.1038/cddis.2015.64.
• [1591] TCEB1 promotes invasion of prostate cancer cells.Int J Cancer. 2009 Jan 1;124(1):95-102. doi: 10.1002/ijc.23916.
• [1592] Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition.PLoS One. 2017 Jul 5;12(7):e0180344. doi: 10.1371/journal.pone.0180344. eCollection 2017.
• [1593] Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.
• [1594] Com-1/p8 acts as a putative tumour suppressor in prostate cancer.Int J Mol Med. 2006 Nov;18(5):981-6.
• [1595] Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays.Genet Test Mol Biomarkers. 2013 Nov;17(11):807-13. doi: 10.1089/gtmb.2013.0226. Epub 2013 Aug 28.
• [1596] EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.Int J Cancer. 2005 Feb 10;113(4):561-7. doi: 10.1002/ijc.20612.
• [1597] Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men.J BUON. 2015 Sep-Oct;20(5):1223-8.
• [1598] Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.Mol Endocrinol. 2007 Feb;21(2):343-58. doi: 10.1210/me.2006-0104. Epub 2006 Nov 2.
• [1599] Expression of ribosomal proteins in normal and cancerous human prostate tissue.PLoS One. 2017 Oct 10;12(10):e0186047. doi: 10.1371/journal.pone.0186047. eCollection 2017.
• [1600] Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.Mol Cancer Res. 2011 Jan;9(1):36-50. doi: 10.1158/1541-7786.MCR-10-0158. Epub 2010 Dec 8.
• [1601] miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.Clin Cancer Res. 2015 Nov 1;21(21):4922-34. doi: 10.1158/1078-0432.CCR-15-0217. Epub 2015 Jun 16.
• [1602] How to make clinical decisions to avoid unnecessary prostate screening in biopsy-nave men with PI-RADs v2 score??.Int J Clin Oncol. 2020 Jan;25(1):175-186. doi: 10.1007/s10147-019-01524-9. Epub 2019 Aug 31.
• [1603] Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.Oncogene. 2014 Jun 19;33(25):3235-45. doi: 10.1038/onc.2013.294. Epub 2013 Jul 29.
• [1604] Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers.Prostate. 2014 May;74(5):547-60. doi: 10.1002/pros.22777. Epub 2014 Jan 16.
• [1605] Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model.Eur J Pharmacol. 2018 Mar 5;822:138-146. doi: 10.1016/j.ejphar.2018.01.012.
• [1606] Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells.Int J Cancer. 2011 May 15;128(10):2284-95. doi: 10.1002/ijc.25580.
• [1607] Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.Endocrinology. 2014 Feb;155(2):358-69. doi: 10.1210/en.2013-1583. Epub 2013 Nov 21.
• [1608] Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.Int J Mol Sci. 2019 Feb 12;20(3):774. doi: 10.3390/ijms20030774.
• [1609] Substitution at carbon 2 of 19-nor-1,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):269-75. doi: 10.1016/j.jsbmb.2011.08.010. Epub 2011 Sep 3.
• [1610] Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2.Cancer Biol Ther. 2007 Mar;6(3):419-25. doi: 10.4161/cbt.6.3.3757. Epub 2007 Mar 28.
• [1611] Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels.Biofactors. 2015 Jan-Feb;41(1):52-7. doi: 10.1002/biof.1200.
• [1612] Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer.J Investig Med. 2019 Aug;67(6):1009-1017. doi: 10.1136/jim-2018-000849. Epub 2019 Feb 20.
• [1613] CIN85 modulates TGF signaling by promoting the presentation of TGF receptors on the cell surface.J Cell Biol. 2015 Jul 20;210(2):319-32. doi: 10.1083/jcb.201411025. Epub 2015 Jul 13.
• [1614] Consumption of caffeinated beverages and serum concentrations of sex steroid hormones in US men.Cancer Causes Control. 2018 Jan;29(1):157-166. doi: 10.1007/s10552-017-0985-9. Epub 2017 Nov 24.
• [1615] The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers.Cytokine Growth Factor Rev. 2015 Aug;26(4):405-13. doi: 10.1016/j.cytogfr.2015.04.002. Epub 2015 May 12.
• [1616] DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.Oncogene. 2018 Feb 1;37(5):638-650. doi: 10.1038/onc.2017.371. Epub 2017 Oct 9.
• [1617] GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes.Clin Exp Metastasis. 2015 Dec;32(8):769-82. doi: 10.1007/s10585-015-9745-y. Epub 2015 Oct 1.
• [1618] Differential role of Sloan-Kettering Institute (Ski) protein in Nodal and transforming growth factor-beta (TGF-)-induced Smad signaling in prostate cancer cells.Carcinogenesis. 2012 Nov;33(11):2054-64. doi: 10.1093/carcin/bgs252. Epub 2012 Jul 27.
• [1619] Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359.
• [1620] A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.Oncogene. 2012 Feb 9;31(6):716-27. doi: 10.1038/onc.2011.273. Epub 2011 Jul 18.
• [1621] Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.Clin Nucl Med. 2020 Jan;45(1):e63-e64. doi: 10.1097/RLU.0000000000002781.
• [1622] Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.Int J Oncol. 2014 Oct;45(4):1469-78. doi: 10.3892/ijo.2014.2545. Epub 2014 Jul 17.
• [1623] Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.Am J Pathol. 2019 Jun;189(6):1180-1189. doi: 10.1016/j.ajpath.2019.02.009. Epub 2019 May 9.
• [1624] ErbB-2 signaling in advanced prostate cancer progression and potential therapy.Endocr Relat Cancer. 2019 Apr 1;26(4):R195-R209. doi: 10.1530/ERC-19-0009.
• [1625] Hepcidin regulation in prostate and its disruption in prostate cancer.Cancer Res. 2015 Jun 1;75(11):2254-63. doi: 10.1158/0008-5472.CAN-14-2465. Epub 2015 Apr 9.
• [1626] miR-539 inhibits prostate cancer progression by directly targeting SPAG5.J Exp Clin Cancer Res. 2016 Apr 1;35:60. doi: 10.1186/s13046-016-0337-8.
• [1627] SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment.J BUON. 2019 Sep-Oct;24(5):2099-2106.
• [1628] Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):61-67.
• [1629] Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer.Br J Cancer. 2013 Feb 19;108(3):597-601. doi: 10.1038/bjc.2012.507. Epub 2012 Nov 20.
• [1630] Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel.Arch Biochem Biophys. 2019 Apr 15;665:69-78. doi: 10.1016/j.abb.2018.01.013. Epub 2018 Jan 31.
• [1631] ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.Clin Cancer Res. 2008 Jun 15;14(12):3754-60. doi: 10.1158/1078-0432.CCR-07-4763.
• [1632] The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90 and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.J Cell Biochem. 2020 Jan;121(1):407-417. doi: 10.1002/jcb.29195. Epub 2019 Jun 21.
• [1633] STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization.J Biol Chem. 2017 Nov 24;292(47):19392-19399. doi: 10.1074/jbc.M117.802884. Epub 2017 Oct 6.
• [1634] Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.Prostate. 2009 Feb 15;69(3):234-48. doi: 10.1002/pros.20867.
• [1635] Important role of SUMOylation of Spliceosome factors in prostate cancer cells.J Proteome Res. 2014 Aug 1;13(8):3571-82. doi: 10.1021/pr4012848. Epub 2014 Jul 24.
• [1636] Synaptopodin-2 induces assembly of peripheral actin bundles and immature focal adhesions to promote lamellipodia formation and prostate cancer cell migration.Oncotarget. 2015 May 10;6(13):11162-74. doi: 10.18632/oncotarget.3578.
• [1637] Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.World J Urol. 2015 Oct;33(10):1481-6. doi: 10.1007/s00345-014-1469-0. Epub 2014 Dec 28.
• [1638] Reliable housekeeping gene combination for quantitative PCR of lymph nodes in patients with prostate cancer.Anticancer Res. 2013 Dec;33(12):5243-8.
• [1639] Tectonic? contributes to the growth and migration of prostate cancer cells invitro.Int J Mol Med. 2015 Oct;36(4):931-8. doi: 10.3892/ijmm.2015.2313. Epub 2015 Aug 14.
• [1640] TFDP3 was expressed in coordination with E2F1 to inhibit E2F1-mediated apoptosis in prostate cancer.Gene. 2014 Mar 10;537(2):253-9. doi: 10.1016/j.gene.2013.12.051. Epub 2014 Jan 7.
• [1641] Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.Mol Cell Proteomics. 2019 Sep;18(9):1807-1823. doi: 10.1074/mcp.RA119.001612. Epub 2019 Jun 27.
• [1642] PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo.Cancer Biol Ther. 2009 Jan;8(1):54-63. doi: 10.4161/cbt.8.1.7119. Epub 2009 Jan 4.
• [1643] The mouse thymosin beta15 gene family displays unique complexity and encodes a functional thymosin repeat.J Mol Biol. 2009 Apr 10;387(4):809-25. doi: 10.1016/j.jmb.2009.02.026. Epub 2009 Feb 20.
• [1644] Vasitis nodosa and related lesions: a modern immunohistochemical staining profile with special emphasis on novel diagnostic dilemmas.Hum Pathol. 2018 Mar;73:164-170. doi: 10.1016/j.humpath.2017.12.001. Epub 2017 Dec 11.
• [1645] Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer.Cell Death Dis. 2018 Feb 21;9(3):301. doi: 10.1038/s41419-018-0293-7.
• [1646] MicroRNA-1180 is associated with growth and apoptosis in prostate cancer via TNF receptor associated factor 1 expression regulation and nuclear factor-B signaling pathway activation.Oncol Lett. 2018 Apr;15(4):4775-4780. doi: 10.3892/ol.2018.7914. Epub 2018 Jan 31.
• [1647] Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.BMC Cancer. 2014 Dec 18;14:977. doi: 10.1186/1471-2407-14-977.
• [1648] The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.Oncogene. 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13.
• [1649] The Arf-like GTPase Arl8b is essential for three-dimensional invasive growth of prostate cancer in vitro and xenograft formation and growth in vivo.Oncotarget. 2016 May 24;7(21):31037-52. doi: 10.18632/oncotarget.8832.
• [1650] In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer.Cancer Control. 2019 Jan-Dec;26(1):1073274819846590. doi: 10.1177/1073274819846590.
• [1651] BAP18 coactivates androgen receptor action and promotes prostate cancer progression.Nucleic Acids Res. 2016 Sep 30;44(17):8112-28. doi: 10.1093/nar/gkw472. Epub 2016 May 25.
• [1652] Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer.Int J Oncol. 2018 Sep;53(3):1279-1288. doi: 10.3892/ijo.2018.4464. Epub 2018 Jun 29.
• [1653] Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.Oncotarget. 2016 Jul 26;7(30):48011-48026. doi: 10.18632/oncotarget.10333.
• [1654] NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy.Anticancer Agents Med Chem. 2013 Mar;13(3):502-14.
• [1655] Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancer.Cancer Lett. 2016 Sep 28;380(1):39-46. doi: 10.1016/j.canlet.2016.06.013. Epub 2016 Jun 17.
• [1656] Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer.Oncotarget. 2016 Aug 23;7(34):54616-54626. doi: 10.18632/oncotarget.10520.
• [1657] Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.Oncotarget. 2016 Jun 21;7(25):37846-37856. doi: 10.18632/oncotarget.9344.
• [1658] Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.
• [1659] A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling.J Mol Med (Berl). 2016 Oct;94(10):1167-1179. doi: 10.1007/s00109-016-1440-1. Epub 2016 Jun 16.
• [1660] Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression.J Cell Physiol. 2019 Aug;234(8):12727-12744. doi: 10.1002/jcp.27893. Epub 2019 Jan 5.
• [1661] MicroRNA-1291 mediates cell proliferation and tumorigenesis by downregulating MED1 in prostate cancer.Oncol Lett. 2019 Mar;17(3):3253-3260. doi: 10.3892/ol.2019.9980. Epub 2019 Jan 28.
• [1662] Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer.Curr Gene Ther. 2013 Jun 1;13(3):163-74. doi: 10.2174/1566523211313030001.
• [1663] The role of katanin p60 in breast cancer bone metastasis.Oncol Lett. 2018 Apr;15(4):4963-4969. doi: 10.3892/ol.2018.7942. Epub 2018 Feb 2.
• [1664] PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.J Exp Clin Cancer Res. 2019 Jan 18;38(1):24. doi: 10.1186/s13046-019-1032-3.
• [1665] PEBP4 silencing inhibits hypoxia-induced epithelial-to-mesenchymal transition in prostate cancer cells.Biomed Pharmacother. 2016 Jul;81:1-6. doi: 10.1016/j.biopha.2016.03.030. Epub 2016 Apr 6.
• [1666] miR?9a?p targets PMEPA1 and induces prostate cancer cell proliferation, migration and invasion.Mol Med Rep. 2016 May;13(5):4030-8. doi: 10.3892/mmr.2016.5033. Epub 2016 Mar 21.
• [1667] TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.Oncogene. 2020 Jan;39(2):356-367. doi: 10.1038/s41388-019-0991-3. Epub 2019 Sep 2.
• [1668] Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.Oncotarget. 2016 Aug 16;7(33):53018-53028. doi: 10.18632/oncotarget.10061.
• [1669] RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.Am J Pathol. 2013 Sep;183(3):951-63. doi: 10.1016/j.ajpath.2013.05.021. Epub 2013 Jul 16.
• [1670] CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
• [1671] Common gene pathways and families altered by DNA methylation in breast and prostate cancers.Endocr Relat Cancer. 2013 Aug 19;20(5):R215-32. doi: 10.1530/ERC-13-0204. Print 2013 Oct.
• [1672] S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.Tumour Biol. 2016 Sep;37(9):12241-12250. doi: 10.1007/s13277-016-5096-9. Epub 2016 May 30.
• [1673] Effects of siRNA-mediated silencing of Sal-like 4 expression on proliferation and apoptosis of prostate cancer C4-2 cells.Genet Mol Res. 2016 May 13;15(2). doi: 10.4238/gmr.15027885.
• [1674] Variation in selenoenzyme genes and prostate cancer risk and survival.Prostate. 2013 May;73(7):734-42. doi: 10.1002/pros.22617. Epub 2012 Nov 9.
• [1675] Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1.Tumour Biol. 2016 Sep;37(9):12843-12854. doi: 10.1007/s13277-016-5158-z. Epub 2016 Jul 23.
• [1676] SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.Oncotarget. 2016 Jul 26;7(30):48250-48264. doi: 10.18632/oncotarget.10198.
• [1677] Folate and B12 in prostate cancer.Adv Clin Chem. 2013;60:1-63. doi: 10.1016/b978-0-12-407681-5.00001-5.
• [1678] Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1.Oncol Lett. 2019 Feb;17(2):2257-2265. doi: 10.3892/ol.2018.9822. Epub 2018 Dec 11.
• [1679] Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.BJU Int. 2019 May;123 Suppl 5:27-35. doi: 10.1111/bju.14695.
• [1680] Reciprocal regulation of long noncoding RNAs THBS4?03 and THBS4 control migration and invasion in prostate cancer cell lines.Mol Med Rep. 2016 Aug;14(2):1451-8. doi: 10.3892/mmr.2016.5443. Epub 2016 Jun 23.
• [1681] High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.
• [1682] Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.Neoplasia. 2017 Apr;19(4):279-287. doi: 10.1016/j.neo.2017.01.005. Epub 2017 Mar 8.
• [1683] LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.Cancer Res. 2011 Dec 1;71(23):7301-11. doi: 10.1158/0008-5472.CAN-11-2381. Epub 2011 Oct 6.
• [1684] Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2618-27. doi: 10.1158/1055-9965.EPI-11-0434. Epub 2011 Sep 29.
• [1685] AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer.Mol Cancer Res. 2013 Oct;11(10):1193-202. doi: 10.1158/1541-7786.MCR-13-0145. Epub 2013 Jul 17.
• [1686] ALDH1A3 correlates with luminal phenotype in prostate cancer.Tumour Biol. 2017 Apr;39(4):1010428317703652. doi: 10.1177/1010428317703652.
• [1687] Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.
• [1688] gp78 is specifically expressed in human prostate cancer rather than normal prostate tissue.J Mol Histol. 2013 Dec;44(6):653-9. doi: 10.1007/s10735-013-9512-9. Epub 2013 May 12.
• [1689] Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36. doi: 10.1158/1055-9965.EPI-11-0236. Epub 2011 Aug 16.
• [1690] Deprivation of arginine by recombinant human arginase in prostate cancer cells.J Hematol Oncol. 2012 Apr 30;5:17. doi: 10.1186/1756-8722-5-17.
• [1691] Functional and cancer genomics of ASXL family members.Br J Cancer. 2013 Jul 23;109(2):299-306. doi: 10.1038/bjc.2013.281. Epub 2013 Jun 4.
• [1692] SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.J Exp Clin Cancer Res. 2018 Jul 11;37(1):145. doi: 10.1186/s13046-018-0809-0.
• [1693] O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.Cancer Res. 2013 Aug 15;73(16):5277-87. doi: 10.1158/0008-5472.CAN-13-0549. Epub 2013 May 29.
• [1694] The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem. 2013 Mar 8;288(10):6980-90. doi: 10.1074/jbc.M112.414177. Epub 2013 Jan 22.
• [1695] Correlation between DEC1/DEC2 and epithelialmesenchymal transition in human prostate cancer PC? cells.Mol Med Rep. 2018 Oct;18(4):3859-3865. doi: 10.3892/mmr.2018.9367. Epub 2018 Aug 9.
• [1696] Expression of EMT-Related Genes CAMK2N1 and WNT5A is increased in Locally Invasive and Metastatic Prostate Cancer.J Cancer. 2019 Oct 15;10(24):5915-5925. doi: 10.7150/jca.34564. eCollection 2019.
• [1697] High Dimensional Variable Selection with Error Control.Biomed Res Int. 2016;2016:8209453. doi: 10.1155/2016/8209453. Epub 2016 Aug 15.
• [1698] A regulatory circuit HP1/miR-451a/c-Myc promotes prostate cancer progression.Oncogene. 2018 Jan 25;37(4):415-426. doi: 10.1038/onc.2017.332. Epub 2017 Oct 2.
• [1699] Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.Mol Oncol. 2018 Apr;12(4):545-560. doi: 10.1002/1878-0261.12183. Epub 2018 Mar 13.
• [1700] CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.Am J Pathol. 2019 Jul;189(7):1451-1461. doi: 10.1016/j.ajpath.2019.04.006. Epub 2019 Jun 12.
• [1701] Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion.Pathobiology. 2011;78(5):277-84. doi: 10.1159/000329588. Epub 2011 Aug 17.
• [1702] Copy number polymorphisms in new HapMap III and Singapore populations.J Hum Genet. 2011 Aug;56(8):552-60. doi: 10.1038/jhg.2011.54. Epub 2011 Jun 16.
• [1703] Mesenchymal stem cells modified to express lentivirus TNF- Tumstatin(45-132) inhibit the growth of prostate cancer.J Cell Mol Med. 2011 Feb;15(2):433-44. doi: 10.1111/j.1582-4934.2009.00920.x.
• [1704] Identification of new genes downregulated in prostate cancer and investigation of their effects on prognosis.Genet Test Mol Biomarkers. 2013 Jul;17(7):562-6. doi: 10.1089/gtmb.2012.0524. Epub 2013 Apr 27.
• [1705] COX-2 mediates pro-tumorigenic effects of PKC in prostate cancer.Oncogene. 2018 Aug;37(34):4735-4749. doi: 10.1038/s41388-018-0318-9. Epub 2018 May 16.
• [1706] Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade.Oncotarget. 2017 Apr 21;8(34):56051-56065. doi: 10.18632/oncotarget.17359. eCollection 2017 Aug 22.
• [1707] Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer.Exp Mol Pathol. 2011 Apr;90(2):226-30. doi: 10.1016/j.yexmp.2011.01.003. Epub 2011 Jan 18.
• [1708] CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice.Cell Death Dis. 2019 Apr 1;10(4):299. doi: 10.1038/s41419-019-1535-z.
• [1709] Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.Mol Oncol. 2020 Jan;14(1):129-138. doi: 10.1002/1878-0261.12597. Epub 2019 Nov 29.
• [1710] Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells.Int J Urol. 2012 Jan;19(1):71-9. doi: 10.1111/j.1442-2042.2011.02888.x. Epub 2011 Nov 3.
• [1711] NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer.Oncotarget. 2017 Mar 28;8(13):21501-21515. doi: 10.18632/oncotarget.15308.
• [1712] Inhibition of cytohesin-1 by siRNA leads to reduced IGFR signaling in prostate cancer.Braz J Med Biol Res. 2011 Jul;44(7):642-6. doi: 10.1590/s0100-879x2011007500072. Epub 2011 Jun 10.
• [1713] Insulin resistance in prostate cancer patients and predisposing them to acute ischemic heart disease.Biosci Rep. 2019 Jul 29;39(7):BSR20182313. doi: 10.1042/BSR20182313. Print 2019 Jul 31.
• [1714] DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.PLoS One. 2016 Nov 11;11(11):e0166664. doi: 10.1371/journal.pone.0166664. eCollection 2016.
• [1715] Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.PLoS One. 2014 Mar 24;9(3):e92815. doi: 10.1371/journal.pone.0092815. eCollection 2014.
• [1716] Dishevelled-2 silencing reduces androgen-dependent prostate tumor cell proliferation and migration and expression of Wnt-3a and matrix metalloproteinases.Mol Biol Rep. 2013 Jul;40(7):4241-50. doi: 10.1007/s11033-013-2506-6. Epub 2013 May 8.
• [1717] Geraniol suppresses prostate cancer growth through down-regulation of E2F8. Cancer Med. 2016 Oct;5(10):2899-2908.
• [1718] Electrochemical detection of methylated DNA on a microfluidic chip with nanoelectrokinetic pre-concentration.Biosens Bioelectron. 2018 Jun 1;107:103-110. doi: 10.1016/j.bios.2018.01.067. Epub 2018 Feb 1.
• [1719] Inhibition of eukaryotic initiation factor 3B suppresses proliferation and promotes apoptosis of chronic myeloid leukemia cells.Adv Clin Exp Med. 2019 Dec;28(12):1639-1645. doi: 10.17219/acem/110323.
• [1720] ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-B and drives prostate cancer progression.Cancer Res. 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16.
• [1721] Linkage between prostate cancer occurrence and Y-chromosomal DYS loci in Malaysian subjects.Asian Pac J Cancer Prev. 2011;12(5):1265-8.
• [1722] High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.PLoS One. 2012;7(6):e39801. doi: 10.1371/journal.pone.0039801. Epub 2012 Jun 28.
• [1723] Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.Prostate. 2012 May 15;72(7):789-802. doi: 10.1002/pros.21487. Epub 2011 Sep 14.
• [1724] Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation.Pathol Res Pract. 2011 Jul 15;207(7):417-22. doi: 10.1016/j.prp.2011.04.007. Epub 2011 Jun 12.
• [1725] Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.Oncogene. 2012 Apr 26;31(17):2153-63. doi: 10.1038/onc.2011.401. Epub 2011 Sep 12.
• [1726] Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis.Epigenetics. 2017 Aug;12(8):591-606. doi: 10.1080/15592294.2017.1334023. Epub 2017 May 30.
• [1727] Role and expression of FRS2 and FRS3 in prostate cancer.BMC Cancer. 2011 Nov 11;11:484. doi: 10.1186/1471-2407-11-484.
• [1728] Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.Oncotarget. 2018 Jun 5;9(43):27293-27304. doi: 10.18632/oncotarget.25551. eCollection 2018 Jun 5.
• [1729] Frizzled-8 integrates Wnt-11 and transforming growth factor- signaling in prostate cancer.Nat Commun. 2018 May 1;9(1):1747. doi: 10.1038/s41467-018-04042-w.
• [1730] TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.Oncogene. 2018 Apr;37(16):2165-2180. doi: 10.1038/s41388-017-0095-x. Epub 2018 Jan 30.
• [1731] Genetic variants in the microRNA machinery gene GEMIN4 are associated with risk of prostate cancer: a case-control study of the Chinese Han population.DNA Cell Biol. 2012 Jul;31(7):1296-302. doi: 10.1089/dna.2011.1600. Epub 2012 Apr 16.
• [1732] G-13 induces CXC motif chemokine ligand 5 expression in prostate cancer cells by transactivating NF-B.J Biol Chem. 2019 Nov 29;294(48):18192-18206. doi: 10.1074/jbc.RA119.010018. Epub 2019 Oct 21.
• [1733] G Protein 3 subunit gene C825T polymorphism and its association with the presence and clinicopathological characteristics of prostate cancer.J Urol. 2012 Jul;188(1):287-93. doi: 10.1016/j.juro.2012.02.2557. Epub 2012 May 16.
• [1734] Genetic polymorphisms of the glycine N-methyltransferase and prostate cancer risk in the health professionals follow-up study.PLoS One. 2014 May 6;9(5):e94683. doi: 10.1371/journal.pone.0094683. eCollection 2014.
• [1735] GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.Int J Cancer. 2020 Mar 1;146(5):1369-1382. doi: 10.1002/ijc.32554. Epub 2019 Jul 22.
• [1736] Prostate Cancer Patients with Late Radiation Toxicity Exhibit Reduced Expression of Genes Involved in DNA Double-Strand Break Repair and Homologous Recombination.Cancer Res. 2017 Mar 15;77(6):1485-1491. doi: 10.1158/0008-5472.CAN-16-1966. Epub 2017 Jan 20.
• [1737] Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors.J Biol Chem. 2011 May 20;286(20):17796-808. doi: 10.1074/jbc.M110.198655. Epub 2011 Mar 17.
• [1738] HtrA4 Protease Promotes Chemotherapeutic-Dependent Cancer Cell Death.Cells. 2019 Sep 20;8(10):1112. doi: 10.3390/cells8101112.
• [1739] Downregulation of IQGAP2 Correlates with Prostate Cancer Recurrence and Metastasis.Transl Oncol. 2019 Feb;12(2):236-244. doi: 10.1016/j.tranon.2018.10.009. Epub 2018 Nov 11.
• [1740] SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.Oncotarget. 2017 Jun 21;8(32):53518-53530. doi: 10.18632/oncotarget.18591. eCollection 2017 Aug 8.
• [1741] Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.Front Genet. 2018 Dec 18;9:675. doi: 10.3389/fgene.2018.00675. eCollection 2018.
• [1742] HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population.Gene. 2017 May 20;613:20-24. doi: 10.1016/j.gene.2017.02.031. Epub 2017 Mar 1.
• [1743] Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells.Cancer Biomark. 2018;22(3):533-541. doi: 10.3233/CBM-181196.
• [1744] Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35.Prostate. 2011 May 15;71(7):682-9. doi: 10.1002/pros.21284. Epub 2010 Oct 13.
• [1745] The mutational landscape of lethal castration-resistant prostate cancer.Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.
• [1746] Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.Oncotarget. 2016 Dec 20;7(51):84645-84657. doi: 10.18632/oncotarget.13175.
• [1747] Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.J Biol Chem. 2011 Oct 28;286(43):37108-17. doi: 10.1074/jbc.M111.292771. Epub 2011 Aug 19.
• [1748] Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.BMC Cancer. 2018 Oct 10;18(1):960. doi: 10.1186/s12885-018-4848-x.
• [1749] LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese Population.Int J Mol Sci. 2013 Apr 24;14(5):8832-40. doi: 10.3390/ijms14058832.
• [1750] Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes.Cancer Biol Ther. 2013 Sep;14(9):840-52. doi: 10.4161/cbt.25329. Epub 2013 Jul 26.
• [1751] CAPC negatively regulates NF-B activation and suppresses tumor growth and metastasis.Oncogene. 2012 Mar 29;31(13):1673-82. doi: 10.1038/onc.2011.355. Epub 2011 Aug 8.
• [1752] LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication.Biochimie. 2012 May;94(5):1151-7. doi: 10.1016/j.biochi.2012.01.019. Epub 2012 Feb 2.
• [1753] ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.
• [1754] LZTS2 and PTEN collaboratively regulate -catenin in prostatic tumorigenesis.PLoS One. 2017 Mar 21;12(3):e0174357. doi: 10.1371/journal.pone.0174357. eCollection 2017.
• [1755] Transforming Growth Factor TGF Increases Levels of Microtubule-Associated Protein MAP1S and Autophagy Flux in Pancreatic Ductal Adenocarcinomas.PLoS One. 2015 Nov 16;10(11):e0143150. doi: 10.1371/journal.pone.0143150. eCollection 2015.
• [1756] Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.
• [1757] Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6686-91. doi: 10.1073/pnas.1117405109. Epub 2012 Apr 10.
• [1758] Abituzumab Targeting of V-Class Integrins Inhibits Prostate Cancer Progression.Mol Cancer Res. 2017 Jul;15(7):875-883. doi: 10.1158/1541-7786.MCR-16-0447. Epub 2017 Mar 17.
• [1759] Elevated MRE11 expression associated with progression and poor outcome in prostate cancer.J Cancer. 2019 Jul 10;10(18):4333-4340. doi: 10.7150/jca.31454. eCollection 2019.
• [1760] p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3.J Biol Chem. 2012 May 11;287(20):16890-902. doi: 10.1074/jbc.M111.322636. Epub 2012 Mar 29.
• [1761] Association between mismatch repair gene MSH3 codons 1036 and 222 polymorphisms and sporadic prostate cancer in the Iranian population.Asian Pac J Cancer Prev. 2012;13(12):6055-7. doi: 10.7314/apjcp.2012.13.12.6055.
• [1762] CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells.Oncotarget. 2018 Apr 3;9(25):17645-17655. doi: 10.18632/oncotarget.24824. eCollection 2018 Apr 3.
• [1763] N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.Oncogene. 2014 Nov 6;33(45):5274-87. doi: 10.1038/onc.2013.464. Epub 2013 Nov 18.
• [1764] Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer.Int J Biochem Cell Biol. 2019 Mar;108:21-28. doi: 10.1016/j.biocel.2019.01.002. Epub 2019 Jan 8.
• [1765] Human cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival.Biochem Biophys Res Commun. 2012 Nov 9;428(1):142-9. doi: 10.1016/j.bbrc.2012.10.028. Epub 2012 Oct 12.
• [1766] High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer.Tumour Biol. 2017 Jul;39(7):1010428317703817. doi: 10.1177/1010428317703817.
• [1767] Inducible expression of antizyme 1 in prostate cancer cell lines after lentivirus mediated gene transfer.Amino Acids. 2012 Feb;42(2-3):559-64. doi: 10.1007/s00726-011-1033-9. Epub 2011 Jul 29.
• [1768] Epigenetic markers of prostate cancer in plasma circulating DNA.Hum Mol Genet. 2012 Aug 15;21(16):3619-31. doi: 10.1093/hmg/dds192. Epub 2012 May 22.
• [1769] Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.Cancer Res. 2016 Jul 15;76(14):4192-204. doi: 10.1158/0008-5472.CAN-15-3339. Epub 2016 May 23.
• [1770] The RNA-Binding Protein PCBP1 Functions as a Tumor Suppressor in Prostate Cancer by Inhibiting Mitogen Activated Protein Kinase 1.Cell Physiol Biochem. 2018;48(4):1747-1754. doi: 10.1159/000492315. Epub 2018 Aug 3.
• [1771] PEG10 is associated with treatment-induced neuroendocrine prostate cancer.J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226.
• [1772] Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.Mol Cancer. 2016 Dec 12;15(1):81. doi: 10.1186/s12943-016-0567-6.
• [1773] The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.J Cell Biol. 2019 Jun 3;218(6):1943-1957. doi: 10.1083/jcb.201902048. Epub 2019 May 15.
• [1774] FAM84B promotes prostate tumorigenesis through a network alteration.Ther Adv Med Oncol. 2019 May 13;11:1758835919846372. doi: 10.1177/1758835919846372. eCollection 2019.
• [1775] Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.Int J Oncol. 2013 Aug;43(2):365-74. doi: 10.3892/ijo.2013.1954. Epub 2013 May 24.
• [1776] SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689.
• [1777] PGC1 Suppresses Prostate Cancer Cell Invasion through ERR Transcriptional Control.Cancer Res. 2019 Dec 15;79(24):6153-6165. doi: 10.1158/0008-5472.CAN-19-1231. Epub 2019 Oct 8.
• [1778] Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-B and CHOP expression.Cell Signal. 2011 May;23(5):857-65. doi: 10.1016/j.cellsig.2011.01.010. Epub 2011 Jan 27.
• [1779] Coordinated regulation of polycomb group complexes through microRNAs in cancer.Cancer Cell. 2011 Aug 16;20(2):187-99. doi: 10.1016/j.ccr.2011.06.016.
• [1780] Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.Free Radic Biol Med. 2011 Jul 1;51(1):78-87. doi: 10.1016/j.freeradbiomed.2011.04.001. Epub 2011 Apr 14.
• [1781] PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-B- and HDAC1-mediated expression and activation of uPA.J Cell Sci. 2012 Oct 15;125(Pt 20):4800-11. doi: 10.1242/jcs.106542. Epub 2012 Jul 13.
• [1782] PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314.
• [1783] Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.PLoS One. 2012;7(6):e38950. doi: 10.1371/journal.pone.0038950. Epub 2012 Jun 27.
• [1784] Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.Mol Cell Biol. 2012 Jan;32(2):399-414. doi: 10.1128/MCB.05958-11. Epub 2011 Nov 14.
• [1785] RAD9A promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 (AGR2).Carcinogenesis. 2019 Mar 12;40(1):164-172. doi: 10.1093/carcin/bgy131.
• [1786] A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.J Transl Med. 2011 Oct 28;9:185. doi: 10.1186/1479-5876-9-185.
• [1787] HNF1b is involved in prostate cancer risk via modulating androgenic hormone effects and coordination with other genes.Genet Mol Res. 2013 Apr 25;12(2):1327-35. doi: 10.4238/2013.April.25.4.
• [1788] Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3284-3290. doi: 10.26355/eurrev_201904_17690.
• [1789] AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.Prostate. 2012 Jul 1;72(10):1133-9. doi: 10.1002/pros.22461. Epub 2011 Nov 29.
• [1790] Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth.Mol Cell Endocrinol. 2012 Mar 5;350(1):87-98. doi: 10.1016/j.mce.2011.11.025. Epub 2011 Dec 2.
• [1791] Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.Int J Cancer. 2019 Jul 1;145(1):49-57. doi: 10.1002/ijc.32073. Epub 2019 Jan 5.
• [1792] Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.PLoS One. 2014 Oct 6;9(10):e108743. doi: 10.1371/journal.pone.0108743. eCollection 2014.
• [1793] The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.Cancer Res. 2003 Oct 15;63(20):6583-94.
• [1794] SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.J Clin Invest. 2011 Nov;121(11):4257-67. doi: 10.1172/JCI58509. Epub 2011 Oct 3.
• [1795] SEL1L expression in non-small cell lung cancer.Hum Pathol. 2006 May;37(5):505-12. doi: 10.1016/j.humpath.2005.12.012. Epub 2006 Mar 20.
• [1796] A role for class 3 semaphorins in prostate cancer.Prostate. 2011 May;71(6):649-58. doi: 10.1002/pros.21281. Epub 2010 Oct 14.
• [1797] Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.Radiother Oncol. 2019 Oct;139:83-86. doi: 10.1016/j.radonc.2019.07.018. Epub 2019 Aug 17.
• [1798] SOXs in human prostate cancer: implication as progression and prognosis factors.BMC Cancer. 2012 Jun 15;12:248. doi: 10.1186/1471-2407-12-248.
• [1799] SPAG9 promotes prostate cancer proliferation and metastasis via MAPK signaling pathway.Am J Transl Res. 2019 Aug 15;11(8):5249-5260. eCollection 2019.
• [1800] Mutational analysis of SPANX genes in families with X-linked prostate cancer.Prostate. 2007 Jun 1;67(8):820-8. doi: 10.1002/pros.20561.
• [1801] Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.APMIS. 2017 Dec;125(12):1092-1101. doi: 10.1111/apm.12775. Epub 2017 Oct 3.
• [1802] Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.J Transl Med. 2017 Aug 15;15(1):175. doi: 10.1186/s12967-017-1276-7.
• [1803] Inducible expression of cancer-testis antigens in human prostate cancer.Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711.
• [1804] Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.PLoS One. 2019 Aug 8;14(8):e0220456. doi: 10.1371/journal.pone.0220456. eCollection 2019.
• [1805] Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.Oncol Rep. 2017 Nov;38(5):2629-2636. doi: 10.3892/or.2017.5961. Epub 2017 Sep 18.
• [1806] SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer.Prostate. 2011 Oct 1;71(14):1559-67. doi: 10.1002/pros.21372. Epub 2011 Feb 25.
• [1807] TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.Mol Endocrinol. 2012 May;26(5):748-61. doi: 10.1210/me.2011-1242. Epub 2012 Mar 28.
• [1808] Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis.Prostate. 2012 May 1;72(6):626-37. doi: 10.1002/pros.21466. Epub 2011 Aug 1.
• [1809] Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression.J Hematol Oncol. 2017 Jan 25;10(1):33. doi: 10.1186/s13045-017-0390-6.
• [1810] The expression of Tousled kinases in CaP cell lines and its relation to radiation response and DSB repair.Prostate. 2011 Sep 15;71(13):1367-73. doi: 10.1002/pros.21358. Epub 2011 Feb 14.
• [1811] TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration.Prostate. 2011 Aug 1;71(11):1239-50. doi: 10.1002/pros.21340. Epub 2011 Jan 12.
• [1812] Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.Cancer Lett. 2012 Feb 1;315(1):38-47. doi: 10.1016/j.canlet.2011.10.003. Epub 2011 Oct 12.
• [1813] TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.Med Sci Monit. 2017 Aug 31;23:4192-4204. doi: 10.12659/msm.903500.
• [1814] Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development.J Biol Chem. 2016 Nov 25;291(48):25247-25254. doi: 10.1074/jbc.M116.745950. Epub 2016 Oct 17.
• [1815] TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.Cell Death Dis. 2018 Feb 5;9(2):155. doi: 10.1038/s41419-017-0197-y.
• [1816] PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.Prostate. 2018 Aug;78(11):819-829. doi: 10.1002/pros.23539. Epub 2018 Apr 16.
• [1817] Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.Mol Carcinog. 2019 Jul;58(7):1118-1133. doi: 10.1002/mc.22996. Epub 2019 Mar 4.
• [1818] Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.Cell Commun Signal. 2019 Sep 18;17(1):120. doi: 10.1186/s12964-019-0410-y.
• [1819] Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.Prostate. 2005 Jun 1;63(4):316-23. doi: 10.1002/pros.20177.
• [1820] Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses.Biochim Biophys Acta. 1990 Jan 30;1048(1):72-7. doi: 10.1016/0167-4781(90)90024-v.
• [1821] ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.Cancer Sci. 2017 Oct;108(10):2011-2021. doi: 10.1111/cas.13339. Epub 2017 Sep 10.
• [1822] Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.Biochem Pharmacol. 2019 Jan;159:52-63. doi: 10.1016/j.bcp.2018.11.005. Epub 2018 Nov 9.
• [1823] Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer.J Steroid Biochem Mol Biol. 2017 Nov;174:56-64. doi: 10.1016/j.jsbmb.2017.07.029. Epub 2017 Jul 27.
• [1824] BAF53A regulates androgen receptor-mediated gene expression and proliferation in LNCaP cells.Biochem Biophys Res Commun. 2018 Oct 28;505(2):618-623. doi: 10.1016/j.bbrc.2018.09.149. Epub 2018 Sep 29.
• [1825] GPR56 plays varying roles in endogenous cancer progression.Clin Exp Metastasis. 2010 Apr;27(4):241-9. doi: 10.1007/s10585-010-9322-3. Epub 2010 Mar 24.
• [1826] C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.Med Sci Monit. 2017 Oct 30;23:5176-5183. doi: 10.12659/msm.906680.
• [1827] The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial.J Cancer. 2019 Oct 16;10(25):6217-6224. doi: 10.7150/jca.35510. eCollection 2019.
• [1828] AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.J Clin Invest. 2007 Oct;117(10):2962-73. doi: 10.1172/JCI30710.
• [1829] Stroma-induced Jagged1 expression drives PC3 prostate cancer cell migration; disparate effects of RIP-generated proteolytic fragments on cell behaviour and Notch signaling.Biochem Biophys Res Commun. 2016 Mar 25;472(1):255-61. doi: 10.1016/j.bbrc.2016.02.101. Epub 2016 Feb 26.
• [1830] Targeting Nucleoporin POM121-Importin Axis in Prostate Cancer.Cell Chem Biol. 2018 Sep 20;25(9):1056-1058. doi: 10.1016/j.chembiol.2018.09.003.
• [1831] Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.Int J Oncol. 2014 Jul;45(1):362-72. doi: 10.3892/ijo.2014.2413. Epub 2014 Apr 30.
• [1832] AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment.Oncogenesis. 2018 May 25;7(5):43. doi: 10.1038/s41389-018-0053-7.
• [1833] Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.Prostate. 2017 Jun;77(9):1000-1011. doi: 10.1002/pros.23356. Epub 2017 Apr 19.
• [1834] PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.Int J Oncol. 2006 Jan;28(1):245-51.
• [1835] Overexpression of AKIP1 promotes angiogenesis and lymphangiogenesis in human esophageal squamous cell carcinoma.Oncogene. 2015 Jan 15;34(3):384-93. doi: 10.1038/onc.2013.559. Epub 2014 Jan 13.
• [1836] ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding.PLoS Comput Biol. 2017 Feb 23;13(2):e1005345. doi: 10.1371/journal.pcbi.1005345. eCollection 2017 Feb.
• [1837] Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker.J Am Chem Soc. 2016 Mar 23;138(11):3647-50. doi: 10.1021/jacs.6b00986. Epub 2016 Mar 15.
• [1838] Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer.Cell Cycle. 2014;13(11):1798-810. doi: 10.4161/cc.28757. Epub 2014 Apr 14.
• [1839] Ambra1 induces autophagy and desensitizes human prostate cancer cells to cisplatin.Biosci Rep. 2019 Aug 23;39(8):BSR20170770. doi: 10.1042/BSR20170770. Print 2019 Aug 30.
• [1840] A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.
• [1841] Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway.Oncogene. 2019 Apr;38(14):2516-2532. doi: 10.1038/s41388-018-0602-8. Epub 2018 Dec 7.
• [1842] Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand.J Immunother. 2005 May-Jun;28(3):268-75. doi: 10.1097/01.cji.0000158853.15664.0c.
• [1843] ANKRD22 is involved in the progression of prostate cancer.Oncol Lett. 2019 Oct;18(4):4106-4113. doi: 10.3892/ol.2019.10738. Epub 2019 Aug 9.
• [1844] Evaluating genetic risk for prostate cancer among Japanese and Latinos.Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2048-58. doi: 10.1158/1055-9965.EPI-12-0598. Epub 2012 Aug 24.
• [1845] Tumor suppression and potentiation by manipulation of pp32 expression.Oncogene. 2001 Apr 19;20(17):2153-60. doi: 10.1038/sj.onc.1204294.
• [1846] Modulation of oncogenic potential by alternative gene use in human prostate cancer.Nat Med. 1999 Mar;5(3):275-9. doi: 10.1038/6488.
• [1847] Self-Normalized Detection of ANXA3 from Untreated Urine of Prostate Cancer Patients without Digital Rectal Examination.Adv Healthc Mater. 2017 Sep;6(17). doi: 10.1002/adhm.201700449. Epub 2017 Jul 13.
• [1848] The role of annexin A4 in cancer.Front Biosci (Landmark Ed). 2016 Jun 1;21(5):949-57. doi: 10.2741/4432.
• [1849] Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells.J Biol Chem. 2011 May 27;286(21):18492-504. doi: 10.1074/jbc.M110.189811. Epub 2011 Mar 26.
• [1850] Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP.Cancer Res. 2019 Jun 15;79(12):3063-3075. doi: 10.1158/0008-5472.CAN-18-3295. Epub 2019 Apr 15.
• [1851] APOBEC3A/B deletion polymorphism and cancer risk.Carcinogenesis. 2018 Feb 9;39(2):118-124. doi: 10.1093/carcin/bgx131.
• [1852] Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro.J Biochem Mol Toxicol. 2018 May 2;32(7):e22158. doi: 10.1002/jbt.22158. Online ahead of print.
• [1853] Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.Prostate. 2004 Feb 1;58(2):103-8. doi: 10.1002/pros.10343.
• [1854] The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.Oncotarget. 2017 May 9;8(19):31215-31226. doi: 10.18632/oncotarget.16107.
• [1855] Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.Hum Pathol. 2016 Feb;48:102-10. doi: 10.1016/j.humpath.2015.09.026. Epub 2015 Oct 22.
• [1856] Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.Mol Carcinog. 2016 Nov;55(11):1761-1771. doi: 10.1002/mc.22425. Epub 2015 Oct 29.
• [1857] ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Biochim Biophys Acta. 2013 Feb;1832(2):365-74. doi: 10.1016/j.bbadis.2012.11.010. Epub 2012 Nov 28.
• [1858] Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.Oncotarget. 2017 May 9;8(19):30992-31002. doi: 10.18632/oncotarget.16047.
• [1859] Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.Nat Commun. 2019 Sep 24;10(1):4332. doi: 10.1038/s41467-019-12184-8.
• [1860] AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells.Prostate. 2018 Dec;78(16):1238-1247. doi: 10.1002/pros.23699. Epub 2018 Jul 19.
• [1861] ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITG4 Pathway.Curr Mol Med. 2017;17(3):221-229. doi: 10.2174/1566524017666170807144711.
• [1862] ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.Cancer Res. 2008 Jun 1;68(11):4352-9. doi: 10.1158/0008-5472.CAN-07-5237.
• [1863] Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.
• [1864] Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.Cancer Res. 2003 May 1;63(9):2206-15.
• [1865] hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.Sci Rep. 2019 Dec 13;9(1):19076. doi: 10.1038/s41598-019-55665-y.
• [1866] Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.Int J Oncol. 2018 Nov;53(5):2056-2066. doi: 10.3892/ijo.2018.4526. Epub 2018 Aug 16.
• [1867] Correction: ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3--catenin signaling.Oncogene. 2019 Feb;38(8):1354. doi: 10.1038/s41388-018-0561-0.
• [1868] Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis.Oncogene. 2019 Feb;38(6):838-851. doi: 10.1038/s41388-018-0462-2. Epub 2018 Sep 3.
• [1869] Targeting ATF5 in Cancer.Trends Cancer. 2017 Jul;3(7):471-474. doi: 10.1016/j.trecan.2017.05.004. Epub 2017 Jun 13.
• [1870] Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.Prostate. 2017 Feb;77(3):274-281. doi: 10.1002/pros.23264. Epub 2016 Oct 8.
• [1871] Dynamics of Atg5-Atg12-Atg16L1 Aggregation and Deaggregation.Methods Enzymol. 2017;587:247-255. doi: 10.1016/bs.mie.2016.09.059. Epub 2016 Dec 3.
• [1872] Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK/mTOR pathway in prostate cancer.Oncol Rep. 2016 Jan;35(1):64-72. doi: 10.3892/or.2015.4331. Epub 2015 Oct 16.
• [1873] Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.BMC Cancer. 2019 Apr 25;19(1):381. doi: 10.1186/s12885-019-5590-8.
• [1874] Reduced Levels of ATP Synthase Subunit ATP5F1A Correlate with Earlier-Onset Prostate Cancer.Oxid Med Cell Longev. 2018 Nov 14;2018:1347174. doi: 10.1155/2018/1347174. eCollection 2018.
• [1875] Ectopic expression of the ATP synthase subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.Int J Oncol. 2017 Apr;50(4):1312-1320. doi: 10.3892/ijo.2017.3878. Epub 2017 Feb 16.
• [1876] V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss.Oncotarget. 2019 Aug 13;10(48):4923-4936. doi: 10.18632/oncotarget.27075. eCollection 2019 Aug 13.
• [1877] Mutations in the AXIN1 gene in advanced prostate cancer.Eur Urol. 2009 Sep;56(3):486-94. doi: 10.1016/j.eururo.2008.05.029. Epub 2008 May 23.
• [1878] The association between three AXIN2 variants and cancer risk.J Cell Biochem. 2019 Sep;120(9):15561-15571. doi: 10.1002/jcb.28823. Epub 2019 Apr 30.
• [1879] Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.J Exp Clin Cancer Res. 2017 Dec 8;36(1):178. doi: 10.1186/s13046-017-0649-3.
• [1880] Analysis of candidate genes for prostate cancer.Hum Hered. 2004;57(4):172-8. doi: 10.1159/000081443.
• [1881] Bcl-B expression in human epithelial and nonepithelial malignancies.Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.
• [1882] Expression mapping at 12p12-13 in advanced prostate carcinoma.Int J Cancer. 2004 May 1;109(5):668-72. doi: 10.1002/ijc.20060.
• [1883] -Carotene 9',10' Oxygenase Modulates the Anticancer Activity of Dietary Tomato or Lycopene on Prostate Carcinogenesis in the TRAMP Model.Cancer Prev Res (Phila). 2017 Feb;10(2):161-169. doi: 10.1158/1940-6207.CAPR-15-0402. Epub 2016 Nov 2.
• [1884] Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.Bone. 2019 Oct;127:367-375. doi: 10.1016/j.bone.2019.06.005. Epub 2019 Jun 9.
• [1885] High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer.Oncol Lett. 2018 Nov;16(5):6749-6755. doi: 10.3892/ol.2018.9490. Epub 2018 Sep 24.
• [1886] Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.Oncogene. 2001 Sep 20;20(42):6073-83. doi: 10.1038/sj.onc.1204736.
• [1887] KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer.Cell Commun Signal. 2018 Sep 3;16(1):53. doi: 10.1186/s12964-018-0270-x.
• [1888] Germline BLM mutations and metastatic prostate cancer.Prostate. 2020 Feb;80(2):235-237. doi: 10.1002/pros.23924. Epub 2019 Nov 5.
• [1889] Sequence and expression of bone morphogenetic protein 3 mRNA in prolonged cultures of fetal rat calvarial osteoblasts and in rat prostate adenocarcinoma PA III cells.DNA Cell Biol. 1995 Mar;14(3):235-9. doi: 10.1089/dna.1995.14.235.
• [1890] PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.Genes Chromosomes Cancer. 2012 Feb;51(2):149-60. doi: 10.1002/gcc.20939. Epub 2011 Nov 1.
• [1891] A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China.Mol Biol Rep. 2012 Jan;39(1):369-73. doi: 10.1007/s11033-011-0747-9. Epub 2011 May 10.
• [1892] BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.Oncogene. 2020 Feb;39(8):1797-1806. doi: 10.1038/s41388-019-1106-x. Epub 2019 Nov 18.
• [1893] Breast cancer metastasis suppressor 1 (BRMS1) suppresses prostate cancer progression by inducing apoptosis and regulating invasion.Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):68-75.
• [1894] Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.Sci Rep. 2018 Apr 25;8(1):6509. doi: 10.1038/s41598-018-24270-w.
• [1895] BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1.J Exp Clin Cancer Res. 2019 May 28;38(1):227. doi: 10.1186/s13046-019-1222-z.
• [1896] Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.Cancer Res. 2014 Jun 15;74(12):3228-37. doi: 10.1158/0008-5472.CAN-13-2699. Epub 2014 Apr 8.
• [1897] New Insights into the Binding Mechanism of Co-regulator BUD31 to AR AF2 Site: Structural Determination and Analysis of the Mutation Effect.Curr Comput Aided Drug Des. 2020;16(1):45-53. doi: 10.2174/1573409915666190502153307.
• [1898] O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer.FASEB J. 2018 Jun 15:fj201800687. doi: 10.1096/fj.201800687. Online ahead of print.
• [1899] Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.BMC Cancer. 2017 Jun 26;17(1):447. doi: 10.1186/s12885-017-3413-3.
• [1900] Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.J Pathol. 2007 Aug;212(4):395-401. doi: 10.1002/path.2186.
• [1901] RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.EBioMedicine. 2018 Jun;32:234-244. doi: 10.1016/j.ebiom.2018.05.010. Epub 2018 Jun 1.
• [1902] Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4283-4291.
• [1903] Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.Clin Cancer Res. 2010 Nov 15;16(22):5390-401. doi: 10.1158/1078-0432.CCR-10-1461. Epub 2010 Nov 9.
• [1904] Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer.Prostate. 1999 Sep 15;41(1):31-8. doi: 10.1002/(sici)1097-0045(19990915)41:1<31::aid-pros5>3.0.co;2-p.
• [1905] Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.Semin Oncol. 1999 Apr;26(2):227-33.
• [1906] Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer.Magn Reson Med. 2020 Jun;83(6):2293-2309. doi: 10.1002/mrm.28058. Epub 2019 Nov 8.
• [1907] NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy.J Clin Med. 2019 Mar 31;8(4):442. doi: 10.3390/jcm8040442.
• [1908] Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.Mol Cancer. 2019 Nov 26;18(1):170. doi: 10.1186/s12943-019-1096-x.
• [1909] Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.Mol Cancer. 2006 Mar 1;5:9. doi: 10.1186/1476-4598-5-9.
• [1910] Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.PLoS One. 2015 May 5;10(5):e0126056. doi: 10.1371/journal.pone.0126056. eCollection 2015.
• [1911] The migration and invasion of human prostate cancer cell lines involves CD151 expression.Oncol Rep. 2010 Dec;24(6):1593-7. doi: 10.3892/or_00001022.
• [1912] Heterochromatin Protein 1 Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.
• [1913] Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity.J Biol Chem. 2009 Mar 13;284(11):6832-40. doi: 10.1074/jbc.M808988200. Epub 2009 Jan 5.
• [1914] Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.BMC Genomics. 2018 Jun 11;19(1):450. doi: 10.1186/s12864-018-4827-2.
• [1915] The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.Oncotarget. 2017 May 9;8(19):31815-31829. doi: 10.18632/oncotarget.16463.
• [1916] Expression and functional role of CCR9 in prostate cancer cell migration and invasion.Clin Cancer Res. 2004 Dec 15;10(24):8743-50. doi: 10.1158/1078-0432.CCR-04-0266.
• [1917] Circ_KATNAL1 regulates prostate cancer cell growth and invasiveness through the miR-145-3p/WISP1 pathway.Biochem Cell Biol. 2020 Jun;98(3):396-404. doi: 10.1139/bcb-2019-0211. Epub 2019 Dec 4.
• [1918] Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.Cancer Res. 2016 Apr 15;76(8):2453-64. doi: 10.1158/0008-5472.CAN-15-2340. Epub 2016 Feb 26.
• [1919] MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.Tumour Biol. 2018 Nov;40(11):1010428318803011. doi: 10.1177/1010428318803011.
• [1920] Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
• [1921] Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.Int J Cancer. 2017 Oct 15;141(8):1643-1653. doi: 10.1002/ijc.30864. Epub 2017 Jul 12.
• [1922] Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).Clin Oncol (R Coll Radiol). 2018 Sep;30(9):527-533. doi: 10.1016/j.clon.2018.05.007. Epub 2018 Jun 11.
• [1923] Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity.Eur J Med Chem. 2017 Aug 18;136:212-222. doi: 10.1016/j.ejmech.2017.05.017. Epub 2017 May 5.
• [1924] Comparative transcriptional study of the effects of high intracellular zinc on prostate carcinoma cells.Oncol Rep. 2010 Jun;23(6):1501-16. doi: 10.3892/or_00000789.
• [1925] Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.Prostate. 2006 Feb 1;66(2):135-45. doi: 10.1002/pros.20310.
• [1926] Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression.Cell Rep. 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058.
• [1927] A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease.Nucleic Acids Res. 2003 May 1;31(9):2272-8. doi: 10.1093/nar/gkg337.
• [1928] Androgen regulation of the human pseudoautosomal gene MIC2, a potential marker for prostate cancer.Mol Carcinog. 1998 Sep;23(1):13-9.
• [1929] Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit.Cancer Res. 2018 Aug 1;78(15):4138-4149. doi: 10.1158/0008-5472.CAN-18-0688. Epub 2018 Jun 5.
• [1930] R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.Mol Cancer Res. 2018 Dec;16(12):1940-1951. doi: 10.1158/1541-7786.MCR-16-0346. Epub 2018 Jul 24.
• [1931] Regulation of inside-out 1-integrin activation by CDCP1.Oncogene. 2018 May;37(21):2817-2836. doi: 10.1038/s41388-018-0142-2. Epub 2018 Mar 7.
• [1932] Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy.J Clin Oncol. 2008 Aug 20;26(24):3930-6. doi: 10.1200/JCO.2007.15.6752.
• [1933] The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.J Exp Clin Cancer Res. 2018 Sep 5;37(1):219. doi: 10.1186/s13046-018-0895-z.
• [1934] Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.Prostate. 2009 Oct 1;69(14):1586-97. doi: 10.1002/pros.21007.
• [1935] Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study.Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):558-65. doi: 10.1158/1055-9965.EPI-09-0902.
• [1936] Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.Biomed Pharmacother. 2017 Dec;96:1109-1118. doi: 10.1016/j.biopha.2017.11.112. Epub 2017 Nov 28.
• [1937] Long noncoding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR?656 to modulate CEMIP expression.Oncol Rep. 2020 Jan;43(1):328-336. doi: 10.3892/or.2019.7404. Epub 2019 Nov 8.
• [1938] Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.Cell Syst. 2017 Jan 25;4(1):31-45.e6. doi: 10.1016/j.cels.2016.10.018. Epub 2016 Dec 1.
• [1939] MicroRNA-144-3p inhibits cell proliferation and induces cell apoptosis in prostate cancer by targeting CEP55.Am J Transl Res. 2018 Aug 15;10(8):2457-2468. eCollection 2018.
• [1940] Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.Mol Cancer Ther. 2018 Sep;17(9):1927-1940. doi: 10.1158/1535-7163.MCT-17-1138. Epub 2018 Jun 11.
• [1941] DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.Prostate. 2007 Mar 1;67(4):341-7. doi: 10.1002/pros.20401.
• [1942] Genome-wide association study identifies new prostate cancer susceptibility loci.Hum Mol Genet. 2011 Oct 1;20(19):3867-75. doi: 10.1093/hmg/ddr295. Epub 2011 Jul 8.
• [1943] Design and synthesis of substituted dihydropyrimidinone derivatives as cytotoxic and tubulin polymerization inhibitors.Bioorg Chem. 2019 Dec;93:103317. doi: 10.1016/j.bioorg.2019.103317. Epub 2019 Sep 26.
• [1944] Ursolic acid activates the apoptosis of prostate cancer via ROCK/PTEN mediated mitochondrial translocation of cofilin-1.Oncol Lett. 2018 Mar;15(3):3202-3206. doi: 10.3892/ol.2017.7689. Epub 2017 Dec 27.
• [1945] Long noncoding RNA SOX2-OT facilitates prostate cancer cell proliferation and migration via miR-369-3p/CFL2 axis.Biochem Biophys Res Commun. 2019 Dec 10;520(3):586-593. doi: 10.1016/j.bbrc.2019.09.108. Epub 2019 Oct 14.
• [1946] Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.Oncotarget. 2017 Jan 3;8(1):1495-1507. doi: 10.18632/oncotarget.13646.
• [1947] Role of CHD5 in human cancers: 10 years later.Cancer Res. 2014 Feb 1;74(3):652-8. doi: 10.1158/0008-5472.CAN-13-3056. Epub 2014 Jan 13.
• [1948] Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia. 2014 Dec;16(12):1018-27. doi: 10.1016/j.neo.2014.10.003.
• [1949] Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.Sci Rep. 2017 Feb 17;7:42961. doi: 10.1038/srep42961.
• [1950] DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.Epigenetics. 2016 Sep;11(9):674-689. doi: 10.1080/15592294.2016.1208891. Epub 2016 Jul 14.
• [1951] Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.J Cell Biochem. 2009 May 1;107(1):179-88. doi: 10.1002/jcb.22114.
• [1952] p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.Oncogene. 2017 Jan 5;36(1):60-70. doi: 10.1038/onc.2016.175. Epub 2016 May 16.
• [1953] Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.Int J Cancer. 2008 Aug 1;123(3):543-51. doi: 10.1002/ijc.23548.
• [1954] CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.Int J Cancer. 2018 Aug 15;143(4):897-906. doi: 10.1002/ijc.31379. Epub 2018 Mar 30.
• [1955] Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.World J Urol. 2020 Sep;38(9):2185-2196. doi: 10.1007/s00345-019-03017-w. Epub 2019 Nov 19.
• [1956] CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration.Cancer Sci. 2017 Jul;108(7):1386-1393. doi: 10.1111/cas.13269. Epub 2017 Jun 2.
• [1957] Disruption by SaCas9 Endonuclease of HERV-Kenv, a Retroviral Gene with Oncogenic and Neuropathogenic Potential, Inhibits Molecules Involved in Cancer and Amyotrophic Lateral Sclerosis.Viruses. 2018 Aug 7;10(8):412. doi: 10.3390/v10080412.
• [1958] Heritable methylation marks associated with breast and prostate cancer risk.Prostate. 2018 Sep;78(13):962-969. doi: 10.1002/pros.23654. Epub 2018 May 29.
• [1959] Age-related DNA methylation changes in normal human prostate tissues.Clin Cancer Res. 2007 Jul 1;13(13):3796-802. doi: 10.1158/1078-0432.CCR-07-0085.
• [1960] Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1.J Nanosci Nanotechnol. 2019 Apr 1;19(4):1942-1950. doi: 10.1166/jnn.2019.16404.
• [1961] COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer.Proc Natl Acad Sci U S A. 2018 May 8;115(19):4975-4980. doi: 10.1073/pnas.1721957115. Epub 2018 Apr 23.
• [1962] Screening and identification of key biomarkers in prostate cancer using bioinformatics.Mol Med Rep. 2020 Jan;21(1):311-319. doi: 10.3892/mmr.2019.10799. Epub 2019 Nov 6.
• [1963] Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.Mol Cancer Res. 2010 Jan;8(1):119-30. doi: 10.1158/1541-7786.MCR-09-0277. Epub 2010 Jan 12.
• [1964] COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer.Mol Cancer Ther. 2019 Nov;18(11):2111-2123. doi: 10.1158/1535-7163.MCT-19-0150. Epub 2019 Aug 29.
• [1965] Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer.Oncotarget. 2019 Jul 30;10(46):4776-4785. doi: 10.18632/oncotarget.27113. eCollection 2019 Jul 30.
• [1966] Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells.Biochem Biophys Res Commun. 2018 Jan 1;495(1):473-480. doi: 10.1016/j.bbrc.2017.11.040. Epub 2017 Nov 10.
• [1967] Silencing of MALAT1 inhibits migration and invasion by sponging miR??p in prostate cancer cells.Mol Med Rep. 2019 Oct;20(4):3499-3508. doi: 10.3892/mmr.2019.10602. Epub 2019 Aug 22.
• [1968] Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans.Mol Vis. 2016 May 16;22:454-71. eCollection 2016.
• [1969] Identification of PCAG1 as a novel prostate cancer-associated gene.Mol Med Rep. 2013 Mar;7(3):755-60. doi: 10.3892/mmr.2012.1249. Epub 2012 Dec 24.
• [1970] CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.Med Sci Monit. 2017 Nov 19;23:5504-5514. doi: 10.12659/msm.904720.
• [1971] Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer.Int J Oncol. 2005 Nov;27(5):1273-82.
• [1972] Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44. doi: 10.1093/jnci/djm250. Epub 2007 Dec 11.
• [1973] CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.Cell Rep. 2019 Nov 19;29(8):2355-2370.e6. doi: 10.1016/j.celrep.2019.10.068.
• [1974] The expression of inducible cAMP early repressor (ICER) is altered in prostate cancer cells and reverses the transformed phenotype of the LNCaP prostate tumor cell line.Cancer Res. 2001 Aug 15;61(16):6055-9.
• [1975] Androgen receptor mediated epigenetic regulation of CRISP3 promoter in prostate cancer cells.J Steroid Biochem Mol Biol. 2018 Jul;181:20-27. doi: 10.1016/j.jsbmb.2018.02.012. Epub 2018 Feb 22.
• [1976] Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.Cell Signal. 2010 Dec;22(12):1874-81. doi: 10.1016/j.cellsig.2010.07.015. Epub 2010 Aug 2.
• [1977] Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene. 2009 Aug 6;28(31):2829-38. doi: 10.1038/onc.2009.134. Epub 2009 Jun 8.
• [1978] CTHRC1 and PD?/PDL1 expression predicts tumor recurrence in prostate cancer.Mol Med Rep. 2019 Nov;20(5):4244-4252. doi: 10.3892/mmr.2019.10690. Epub 2019 Sep 19.
• [1979] Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.Oncol Lett. 2018 Apr;15(4):5149-5154. doi: 10.3892/ol.2018.7936. Epub 2018 Feb 2.
• [1980] Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia.Proteomics. 2019 Nov;19(21-22):e1900174. doi: 10.1002/pmic.201900174. Epub 2019 Oct 20.
• [1981] Demethoxycurcumin: A naturally occurring curcumin analogue with antitumor properties.J Cell Physiol. 2018 Dec;233(12):9247-9260. doi: 10.1002/jcp.27029. Epub 2018 Aug 4.
• [1982] Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.Int Urol Nephrol. 2018 May;50(5):861-868. doi: 10.1007/s11255-018-1818-9. Epub 2018 Mar 9.
• [1983] Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.J Clin Invest. 2018 Jan 2;128(1):248-266. doi: 10.1172/JCI92466. Epub 2017 Nov 27.
• [1984] Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.Eur Urol. 2020 Jan;77(1):78-94. doi: 10.1016/j.eururo.2019.06.023. Epub 2019 Jul 18.
• [1985] MiR-93 functions as a tumor promoter in prostate cancer by targeting disabled homolog 2 (DAB2) and an antitumor polysaccharide from green tea (Camellia sinensis) on their expression.Int J Biol Macromol. 2019 Mar 15;125:557-565. doi: 10.1016/j.ijbiomac.2018.12.088. Epub 2018 Dec 10.
• [1986] The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.Cancer Res. 2009 Apr 15;69(8):3347-55. doi: 10.1158/0008-5472.CAN-08-3821. Epub 2009 Apr 7.
• [1987] Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer.J Cancer. 2019 Apr 20;10(7):1755-1763. doi: 10.7150/jca.28577. eCollection 2019.
• [1988] UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating death-associated protein kinase 1 in prostate cancer.Cancer Sci. 2019 Apr;110(4):1244-1255. doi: 10.1111/cas.13935. Epub 2019 Feb 20.
• [1989] The drebrin/EB3 pathway drives invasive activity in prostate cancer.Oncogene. 2017 Jul 20;36(29):4111-4123. doi: 10.1038/onc.2017.45. Epub 2017 Mar 20.
• [1990] Novel centrosome protein, TCC52, is a cancer-testis antigen.Cancer Sci. 2008 Nov;99(11):2274-9. doi: 10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14.
• [1991] Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.Anticancer Agents Med Chem. 2019;19(10):1262-1275. doi: 10.2174/1871520619666190318152726.
• [1992] Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.Cancer Res. 2003 May 15;63(10):2470-6.
• [1993] Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.Hum Mutat. 2014 Sep;35(9):1142-51. doi: 10.1002/humu.22614. Epub 2014 Jul 23.
• [1994] High expression of DDX20 enhances the proliferation and metastatic potential of prostate cancer cells through the NF-B pathway.Int J Mol Med. 2016 Jun;37(6):1551-7. doi: 10.3892/ijmm.2016.2575. Epub 2016 Apr 25.
• [1995] The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.Biochem Biophys Res Commun. 2017 Jan 29;483(1):271-276. doi: 10.1016/j.bbrc.2016.12.153. Epub 2016 Dec 23.
• [1996] Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis.Am J Pathol. 2019 Jun;189(6):1256-1267. doi: 10.1016/j.ajpath.2019.02.011. Epub 2019 Mar 27.
• [1997] Hyaluronan stimulates transformation of androgen-independent prostate cancer.Carcinogenesis. 2007 Feb;28(2):310-20. doi: 10.1093/carcin/bgl134. Epub 2006 Jul 24.
• [1998] p68/DdX5 supports -catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.PLoS One. 2013;8(1):e54150. doi: 10.1371/journal.pone.0054150. Epub 2013 Jan 17.
• [1999] Genetic variants of the copy number polymorphic beta-defensin locus are associated with sporadic prostate cancer.Tumour Biol. 2008;29(2):83-92. doi: 10.1159/000135688. Epub 2008 Jun 2.
• [2000] High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.Oncol Lett. 2017 Dec;14(6):6801-6808. doi: 10.3892/ol.2017.7027. Epub 2017 Sep 22.
• [2001] Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies.Lab Invest. 2019 Oct;99(10):1561-1571. doi: 10.1038/s41374-019-0265-2. Epub 2019 Jun 3.
• [2002] Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene.Nat Biotechnol. 2017 Jun;35(6):543-550. doi: 10.1038/nbt.3843. Epub 2017 May 1.
• [2003] Long noncoding RNA TUG1 promotes progression via upregulating DGCR8 in prostate cancer.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2391-2398. doi: 10.26355/eurrev_201903_17385.
• [2004] Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes.Urol Oncol. 2018 Jan;36(1):13.e11-13.e18. doi: 10.1016/j.urolonc.2017.08.023. Epub 2017 Sep 14.
• [2005] DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.Prostate. 2019 May;79(6):657-666. doi: 10.1002/pros.23773. Epub 2019 Feb 3.
• [2006] Identification of TWIST-interacting genes in prostate cancer.Sci China Life Sci. 2017 Apr;60(4):386-396. doi: 10.1007/s11427-016-0262-6. Epub 2017 Jan 22.
• [2007] The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.Oncogene. 2019 May;38(22):4412-4424. doi: 10.1038/s41388-019-0712-y. Epub 2019 Feb 11.
• [2008] Oncogenic DIRAS3 promotes malignant phenotypes of glioma by activating EGFR-AKT signaling.Biochem Biophys Res Commun. 2018 Oct 28;505(2):413-418. doi: 10.1016/j.bbrc.2018.09.119. Epub 2018 Sep 25.
• [2009] Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.Invest New Drugs. 2019 Dec;37(6):1177-1186. doi: 10.1007/s10637-019-00748-w. Epub 2019 Mar 7.
• [2010] DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.Oncogene. 2014 Feb 6;33(6):724-33. doi: 10.1038/onc.2013.7. Epub 2013 Feb 4.
• [2011] Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.Cancer Sci. 2019 Nov;110(11):3476-3485. doi: 10.1111/cas.14183. Epub 2019 Sep 16.
• [2012] Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.Mol Endocrinol. 2005 Sep;19(9):2273-82. doi: 10.1210/me.2005-0134. Epub 2005 May 26.
• [2013] Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression.Cancer Genet Cytogenet. 1999 Nov;115(1):65-9. doi: 10.1016/s0165-4608(99)00081-3.
• [2014] High Norwegian prostate cancer mortality: evidence of over-reporting.Scand J Urol. 2018 Apr;52(2):122-128. doi: 10.1080/21681805.2017.1421260. Epub 2018 Jan 11.
• [2015] Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk.Hum Genet. 2002 Feb;110(2):122-9. doi: 10.1007/s00439-001-0662-6. Epub 2002 Jan 23.
• [2016] The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.Cancer Res. 2005 Nov 1;65(21):9906-13. doi: 10.1158/0008-5472.CAN-05-1481.
• [2017] Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.PLoS One. 2008 Apr 30;3(4):e2079. doi: 10.1371/journal.pone.0002079.
• [2018] miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5.Cancer Biomark. 2019;26(2):193-202. doi: 10.3233/CBM-190128.
• [2019] Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.Cancer Res. 2009 Aug 1;69(15):6115-21. doi: 10.1158/0008-5472.CAN-08-3024. Epub 2009 Jul 21.
• [2020] Generation and characterization of a specific single-chain antibody against DSPP as a prostate cancer biomarker: Involvement of bioinformatics-based design of novel epitopes.Int Immunopharmacol. 2019 Apr;69:217-224. doi: 10.1016/j.intimp.2019.01.016. Epub 2019 Feb 6.
• [2021] DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.FASEB J. 2019 Dec;33(12):14653-14667. doi: 10.1096/fj.201802558RR. Epub 2019 Nov 5.
• [2022] Upregulation and overexpression of DVL1, the human counterpart of the Drosophila dishevelled gene, in prostate cancer.Tumori. 2005 Nov-Dec;91(6):546-51. doi: 10.1177/030089160509100616.
• [2023] Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.Clin Cancer Res. 2018 Nov 15;24(22):5622-5634. doi: 10.1158/1078-0432.CCR-18-0420. Epub 2018 Jul 16.
• [2024] Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer.Cancer Res. 2001 May 15;61(10):4283-6.
• [2025] Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer.Int J Mol Med. 2018 Apr;41(4):2429-2433. doi: 10.3892/ijmm.2018.3421. Epub 2018 Jan 23.
• [2026] Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.Neoplasia. 2019 Aug;21(8):752-764. doi: 10.1016/j.neo.2019.05.005. Epub 2019 Jun 21.
• [2027] Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression.Oncogenesis. 2018 Jan 24;7(1):7. doi: 10.1038/s41389-017-0022-6.
• [2028] HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.Oncol Lett. 2019 Jan;17(1):1094-1100. doi: 10.3892/ol.2018.9677. Epub 2018 Nov 8.
• [2029] Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.Oncogene. 2018 Sep;37(39):5305-5324. doi: 10.1038/s41388-018-0294-0. Epub 2018 Jun 1.
• [2030] Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.Med Oncol. 2017 Jan;34(1):13. doi: 10.1007/s12032-016-0872-3. Epub 2016 Dec 23.
• [2031] Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression.Br J Cancer. 2012 Jan 3;106(1):166-73. doi: 10.1038/bjc.2011.500. Epub 2011 Nov 17.
• [2032] The EEF1A2 gene expression as risk predictor in localized prostate cancer.BMC Urol. 2017 Sep 18;17(1):86. doi: 10.1186/s12894-017-0278-3.
• [2033] Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer.Pathol Oncol Res. 2018 Oct;24(4):885-890. doi: 10.1007/s12253-017-0302-7. Epub 2017 Sep 14.
• [2034] Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.Nat Genet. 2009 Oct;41(10):1122-6. doi: 10.1038/ng.448. Epub 2009 Sep 20.
• [2035] Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1.Cancer Sci. 2018 Oct;109(10):3159-3170. doi: 10.1111/cas.13754. Epub 2018 Aug 29.
• [2036] Overexpressing miR?35 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer.Int J Oncol. 2019 Jun;54(6):1981-1994. doi: 10.3892/ijo.2019.4778. Epub 2019 Apr 9.
• [2037] Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells.Onco Targets Ther. 2019 Jun 5;12:4451-4459. doi: 10.2147/OTT.S193480. eCollection 2019.
• [2038] Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.J Biol Chem. 2018 Nov 30;293(48):18624-18635. doi: 10.1074/jbc.RA118.003352. Epub 2018 Oct 12.
• [2039] ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.Sci Rep. 2017 Mar 13;7:42759. doi: 10.1038/srep42759.
• [2040] Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.PLoS One. 2013 Nov 18;8(11):e79542. doi: 10.1371/journal.pone.0079542. eCollection 2013.
• [2041] ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.Cancer Lett. 2018 Feb 28;415:198-207. doi: 10.1016/j.canlet.2017.11.028. Epub 2017 Nov 26.
• [2042] The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis.Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):834-845. doi: 10.1016/j.bbagrm.2019.05.005. Epub 2019 May 30.
• [2043] Maximizing RNA Loading for Gene Silencing Using Porous Silicon Nanoparticles.ACS Appl Mater Interfaces. 2019 Jul 3;11(26):22993-23005. doi: 10.1021/acsami.9b05577. Epub 2019 Jun 24.
• [2044] Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.Cancer Res. 2009 Oct 15;69(20):8133-40. doi: 10.1158/0008-5472.CAN-09-0775. Epub 2009 Oct 13.
• [2045] Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.Cancer Res. 2018 Nov 1;78(21):6086-6097. doi: 10.1158/0008-5472.CAN-18-0608. Epub 2018 Aug 28.
• [2046] Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1.Oncogene. 2018 Oct;37(40):5416-5434. doi: 10.1038/s41388-018-0286-0. Epub 2018 Jun 4.
• [2047] Is Engrailed-2 (EN2) a truly promising biomarker in prostate cancer detection?.Biomarkers. 2020 Feb;25(1):34-39. doi: 10.1080/1354750X.2019.1690047. Epub 2019 Nov 14.
• [2048] Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation.Cancer Lett. 2008 Oct 18;270(1):132-43. doi: 10.1016/j.canlet.2008.04.053. Epub 2008 Jun 18.
• [2049] The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.Int J Biol Markers. 2018 Jan;33(1):10-21. doi: 10.5301/ijbm.5000286.
• [2050] PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.Cancer Res. 2009 Jan 1;69(1):102-10. doi: 10.1158/0008-5472.CAN-08-2922.
• [2051] Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.Mol Cancer. 2007 Feb 5;6:14. doi: 10.1186/1476-4598-6-14.
• [2052] Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression.Mol Cancer Res. 2010 Nov;8(11):1501-12. doi: 10.1158/1541-7786.MCR-10-0186. Epub 2010 Oct 5.
• [2053] Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.J Urol. 2007 May;177(5):1753-8. doi: 10.1016/j.juro.2007.01.010.
• [2054] Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res. 2009 Mar 1;69(5):1877-84. doi: 10.1158/0008-5472.CAN-08-2447. Epub 2009 Feb 17.
• [2055] Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.BMC Cancer. 2017 Jul 26;17(1):504. doi: 10.1186/s12885-017-3489-9.
• [2056] From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator.J Biol Chem. 2000 Mar 31;275(13):9308-13. doi: 10.1074/jbc.275.13.9308.
• [2057] PTX1(ERGIC2)-VP22 fusion protein upregulates interferon-beta in prostate cancer cell line PC-3.DNA Cell Biol. 2006 Sep;25(9):523-9. doi: 10.1089/dna.2006.25.523.
• [2058] Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5. doi: 10.1158/1055-9965.EPI-09-0772. Epub 2009 Oct 27.
• [2059] Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression.Oncotarget. 2017 Feb 21;8(8):13886-13897. doi: 10.18632/oncotarget.14684.
• [2060] Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.Nat Med. 2010 Jul;16(7):793-8. doi: 10.1038/nm.2166. Epub 2010 Jun 6.
• [2061] Optimization of diarylpentadienones as chemotherapeutics for prostate cancer.Bioorg Med Chem. 2018 Sep 1;26(16):4751-4760. doi: 10.1016/j.bmc.2018.08.018. Epub 2018 Aug 13.
• [2062] Cooperation between ETS variant 2 and Jumonji domaincontaining 2 histone demethylases.Mol Med Rep. 2018 Apr;17(4):5518-5527. doi: 10.3892/mmr.2018.8507. Epub 2018 Jan 26.
• [2063] Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.Virchows Arch. 2019 Oct;475(4):457-466. doi: 10.1007/s00428-019-02573-1. Epub 2019 Apr 23.
• [2064] Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis.Oncogene. 2020 Feb;39(6):1246-1259. doi: 10.1038/s41388-019-1061-6. Epub 2019 Oct 15.
• [2065] Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357.
• [2066] FAM3B promotes progression of oesophageal carcinoma via regulating the AKT-MDM2-p53 signalling axis and the epithelial-mesenchymal transition.J Cell Mol Med. 2019 Feb;23(2):1375-1385. doi: 10.1111/jcmm.14040. Epub 2018 Dec 18.
• [2067] The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI).IUBMB Life. 2017 Jan;69(1):16-21. doi: 10.1002/iub.1585. Epub 2016 Nov 10.
• [2068] A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.
• [2069] The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.Cell Cycle. 2019 Oct;18(19):2432-2446. doi: 10.1080/15384101.2019.1648956. Epub 2019 Aug 25.
• [2070] F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage.Nature. 2009 Jun 4;459(7247):722-5. doi: 10.1038/nature08011. Epub 2009 May 3.
• [2071] Downregulation of IgG Fc binding protein (Fc gammaBP) in prostate cancer.Cancer Biol Ther. 2008 Jan;7(1):70-5. doi: 10.4161/cbt.7.1.5131. Epub 2007 Oct 8.
• [2072] Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.BMC Cancer. 2018 Dec 17;18(1):1257. doi: 10.1186/s12885-018-5096-9.
• [2073] FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.
• [2074] Fibroblast growth factor 17 is over-expressed in human prostate cancer.J Pathol. 2004 Dec;204(5):578-86. doi: 10.1002/path.1668.
• [2075] Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.Differentiation. 2007 Nov;75(9):831-42. doi: 10.1111/j.1432-0436.2007.00210.x. Epub 2007 Aug 14.
• [2076] Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.Prostate. 2019 May;79(6):628-639. doi: 10.1002/pros.23767. Epub 2019 Jan 20.
• [2077] The FHL2 regulation in the transcriptional circuitry of human cancers.Gene. 2015 Nov 1;572(1):1-7. doi: 10.1016/j.gene.2015.07.043. Epub 2015 Jul 26.
• [2078] Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer.Pathol Res Pract. 2020 Jan;216(1):152732. doi: 10.1016/j.prp.2019.152732. Epub 2019 Nov 11.
• [2079] Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
• [2080] Locus-specific gene repositioning in prostate cancer.Mol Biol Cell. 2016 Jan 15;27(2):236-46. doi: 10.1091/mbc.E15-05-0280. Epub 2015 Nov 12.
• [2081] Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.Clin Cancer Res. 2016 Mar 15;22(6):1531-44. doi: 10.1158/1078-0432.CCR-15-1632. Epub 2015 Nov 2.
• [2082] Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration.Oncotarget. 2017 Jul 19;8(47):82430-82436. doi: 10.18632/oncotarget.19397. eCollection 2017 Oct 10.
• [2083] microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer.Biosci Rep. 2017 Mar 15;37(2):BSR20160521. doi: 10.1042/BSR20160521. Print 2017 Apr 30.
• [2084] The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue.Cancer Biomark. 2016;16(1):191-202. doi: 10.3233/CBM-150555.
• [2085] Wnt activator FOXB2 drives the neuroendocrine differentiation of prostate cancer.Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22189-22195. doi: 10.1073/pnas.1906484116. Epub 2019 Oct 14.
• [2086] Gene expression of forkhead transcription factors in the normal and diseased human prostate.BJU Int. 2009 Jun;103(11):1574-80. doi: 10.1111/j.1464-410X.2009.08351.x. Epub 2009 Feb 11.
• [2087] Significance of the detection of TIM-3 and FOXJ1 in prostate cancer.J BUON. 2017 Jul-Aug;22(4):1017-1021.
• [2088] Knockdown of FOXK1 Suppresses Proliferation, Migration, and Invasion in Prostate Cancer Cells.Oncol Res. 2017 Sep 21;25(8):1261-1267. doi: 10.3727/096504017X14871164924588. Epub 2017 Mar 2.
• [2089] Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p.J Cell Mol Med. 2020 Jan;24(1):799-813. doi: 10.1111/jcmm.14791. Epub 2019 Nov 16.
• [2090] Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.Cancer Res. 2017 Dec 1;77(23):6524-6537. doi: 10.1158/0008-5472.CAN-17-0686. Epub 2017 Oct 6.
• [2091] Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.BMC Cancer. 2019 Apr 11;19(1):346. doi: 10.1186/s12885-019-5509-4.
• [2092] MicroRNA?98 suppresses prostate tumorigenesis by targeting MIB1.Oncol Rep. 2019 Sep;42(3):1047-1056. doi: 10.3892/or.2019.7234. Epub 2019 Jul 15.
• [2093] A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.Oncotarget. 2017 Dec 16;9(3):3631-3640. doi: 10.18632/oncotarget.23341. eCollection 2018 Jan 9.
• [2094] Overexpression of (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.Prostate Cancer Prostatic Dis. 2018 Apr;21(1):137-146. doi: 10.1038/s41391-017-0016-7. Epub 2018 Jan 16.
• [2095] Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.Int J Oncol. 2004 Jan;24(1):97-105.
• [2096] Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.Prostate. 2018 Dec;78(16):1311-1320. doi: 10.1002/pros.23704. Epub 2018 Jul 26.
• [2097] A novel non-canonical Wnt signature for prostate cancer aggressiveness.Oncotarget. 2017 Feb 7;8(6):9572-9586. doi: 10.18632/oncotarget.14161.
• [2098] Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.Sci Rep. 2018 Jun 4;8(1):8537. doi: 10.1038/s41598-018-26761-2.
• [2099] E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer.Urol Int. 2005;75(4):350-3. doi: 10.1159/000089173.
• [2100] beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.Cancer Res. 2005 Aug 1;65(15):6692-700. doi: 10.1158/0008-5472.CAN-04-4315.
• [2101] GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation.Front Oncol. 2019 Nov 15;9:1254. doi: 10.3389/fonc.2019.01254. eCollection 2019.
• [2102] GABA promotes gastrin-releasing peptide secretion in NE/NE-like cells: Contribution to prostate cancer progression.Sci Rep. 2018 Jul 6;8(1):10272. doi: 10.1038/s41598-018-28538-z.
• [2103] Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.Br J Cancer. 2015 Jul 28;113(3):460-8. doi: 10.1038/bjc.2015.240. Epub 2015 Jul 14.
• [2104] Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens.J Biol Chem. 1998 Jul 10;273(28):17618-25. doi: 10.1074/jbc.273.28.17618.
• [2105] MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4.Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5133-5138. doi: 10.26355/eurrev_201906_18177.
• [2106] Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer.BMC Genomics. 2008 Jul 16;9:337. doi: 10.1186/1471-2164-9-337.
• [2107] The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer.Mol Cancer Res. 2019 Jun;17(6):1264-1278. doi: 10.1158/1541-7786.MCR-18-1231. Epub 2019 Mar 4.
• [2108] Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer.Carcinogenesis. 2009 May;30(5):851-60. doi: 10.1093/carcin/bgp052. Epub 2009 Feb 23.
• [2109] Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.Cancer Res. 1998 Apr 1;58(7):1391-4.
• [2110] Downregulated GBX2 gene suppresses proliferation, invasion and angiogenesis of breast cancer cells through inhibiting the Wnt/-catenin signaling pathway.Cancer Biomark. 2018;23(3):405-418. doi: 10.3233/CBM-181466.
• [2111] GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.Front Biosci. 1999 Jul 15;4:D596-600. doi: 10.2741/reichardt.
• [2112] Growth Factor-Independent 1 Is a Tumor Suppressor Gene in Colorectal Cancer.Mol Cancer Res. 2019 Mar;17(3):697-708. doi: 10.1158/1541-7786.MCR-18-0666. Epub 2019 Jan 3.
• [2113] Effects of gametogenetin-binding protein 2 on proliferation, invasion and migration of prostate cancer PC-3 cells.Andrologia. 2020 Mar;52(2):e13488. doi: 10.1111/and.13488. Epub 2019 Dec 3.
• [2114] Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis.Cancer Biol Ther. 2017 Nov 2;18(11):872-882. doi: 10.1080/15384047.2016.1219817. Epub 2016 Sep 13.
• [2115] Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.Invest New Drugs. 2020 Jun;38(3):746-754. doi: 10.1007/s10637-019-00831-2. Epub 2019 Jul 17.
• [2116] Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.Cancer Sci. 2019 Jan;110(1):245-255. doi: 10.1111/cas.13869. Epub 2018 Dec 12.
• [2117] Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells.Mol Nutr Food Res. 2009 Jul;53(7):878-86. doi: 10.1002/mnfr.200800253.
• [2118] Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.Prostate. 2019 Oct;79(14):1629-1639. doi: 10.1002/pros.23887. Epub 2019 Aug 2.
• [2119] c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells.Molecules. 2017 Apr 10;22(4):612. doi: 10.3390/molecules22040612.
• [2120] The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2.J Biol Chem. 2002 Apr 12;277(15):12622-31. doi: 10.1074/jbc.M110568200. Epub 2002 Jan 25.
• [2121] Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth.Sci Rep. 2019 Aug 7;9(1):11478. doi: 10.1038/s41598-019-47874-2.
• [2122] Overexpression of Glypican 5 (GPC5) Inhibits Prostate Cancer Cell Proliferation and Invasion via Suppressing Sp1-Mediated EMT and Activation of Wnt/-Catenin Signaling.Oncol Res. 2018 May 7;26(4):565-572. doi: 10.3727/096504017X15044461944385. Epub 2017 Sep 6.
• [2123] Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.Cancer Lett. 2018 Jun 1;423:28-35. doi: 10.1016/j.canlet.2018.03.006. Epub 2018 Mar 8.
• [2124] Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor.Mol Cancer Ther. 2003 Nov;2(11):1139-47.
• [2125] Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.J Natl Cancer Inst. 2007 Sep 5;99(17):1313-27. doi: 10.1093/jnci/djm107. Epub 2007 Aug 28.
• [2126] Activator of G protein signaling 3 modulates prostate tumor development and progression.Carcinogenesis. 2019 Dec 31;40(12):1504-1513. doi: 10.1093/carcin/bgz076.
• [2127] Troglitazone inhibits the migration and invasion of PC-3 human prostate cancer cells by upregulating E-cadherin and glutathione peroxidase 3.Oncol Lett. 2018 Oct;16(4):5482-5488. doi: 10.3892/ol.2018.9278. Epub 2018 Aug 8.
• [2128] Proproliferative function of adaptor protein GRB10 in prostate carcinoma.FASEB J. 2019 Mar;33(3):3198-3211. doi: 10.1096/fj.201800265RR. Epub 2018 Oct 31.
• [2129] Physiological (68)Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements.Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):115-122. doi: 10.1007/s00259-019-04503-4. Epub 2019 Sep 2.
• [2130] A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.Urol Int. 2016;97(1):16-25. doi: 10.1159/000446446. Epub 2016 May 25.
• [2131] Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.Ann Oncol. 2017 Mar 1;28(3):569-575. doi: 10.1093/annonc/mdw646.
• [2132] KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.Oncogene. 2005 Jan 20;24(4):637-49. doi: 10.1038/sj.onc.1208216.
• [2133] Germline genetic variants in men with prostate cancer and one or more additional cancers.Cancer. 2017 Oct 15;123(20):3925-3932. doi: 10.1002/cncr.30817. Epub 2017 Jun 28.
• [2134] Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression.Oncotarget. 2018 Dec 11;9(97):37054-37068. doi: 10.18632/oncotarget.26457. eCollection 2018 Dec 11.
• [2135] Regulation of protein kinase C-related kinase (PRK) signalling by the TP and TP isoforms of the human thromboxane A(2) receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer.Biochim Biophys Acta Mol Basis Dis. 2017 Apr;1863(4):838-856. doi: 10.1016/j.bbadis.2017.01.011. Epub 2017 Jan 18.
• [2136] Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells.Cancer Res. 2001 Jul 1;61(13):5207-14.
• [2137] Transcription Factor HBP1 Enhances Radiosensitivity by Inducing Apoptosis in Prostate Cancer Cell Lines.Anal Cell Pathol (Amst). 2016;2016:7015659. doi: 10.1155/2016/7015659. Epub 2016 Jan 28.
• [2138] Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.Cancer Med. 2018 Apr;7(4):1546-1559. doi: 10.1002/cam4.1419. Epub 2018 Mar 13.
• [2139] HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain.Mol Med Rep. 2019 Mar;19(3):2115-2124. doi: 10.3892/mmr.2019.9841. Epub 2019 Jan 10.
• [2140] CK2 abrogates the inhibitory effects of PRH/HHEX on prostate cancer cell migration and invasion and acts through PRH to control cell proliferation.Oncogenesis. 2017 Jan 30;6(1):e293. doi: 10.1038/oncsis.2016.82.
• [2141] HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition.J Pathol. 2017 Aug;242(4):409-420. doi: 10.1002/path.4913. Epub 2017 Jun 13.
• [2142] Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.Neoplasia. 2008 Aug;10(8):847-56. doi: 10.1593/neo.08450.
• [2143] Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer.Oncol Lett. 2019 Dec;18(6):6697-6703. doi: 10.3892/ol.2019.11061. Epub 2019 Nov 5.
• [2144] Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.J Hum Genet. 2018 Feb;63(2):195-205. doi: 10.1038/s10038-017-0371-1. Epub 2017 Dec 1.
• [2145] microRNA-183-3p Inhibits Progression of Human Prostate Cancer by Downregulating High-Mobility Group Nucleosome Binding Domain 5.DNA Cell Biol. 2019 Aug;38(8):840-848. doi: 10.1089/dna.2019.4642. Epub 2019 Jul 17.
• [2146] RB Loss Promotes Prostate Cancer Metastasis.Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.
• [2147] Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.Cell. 2018 Jul 26;174(3):564-575.e18. doi: 10.1016/j.cell.2018.06.014. Epub 2018 Jul 19.
• [2148] A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.Mol Cancer. 2019 Jun 20;18(1):109. doi: 10.1186/s12943-019-1037-8.
• [2149] HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.Oncotarget. 2017 Mar 21;8(12):19342-19353. doi: 10.18632/oncotarget.14258.
• [2150] hnRNPM, a potential mediator of YY1 in promotingthe epithelial-mesenchymal transition of prostate cancer cells.Prostate. 2019 Aug;79(11):1199-1210. doi: 10.1002/pros.23790.
• [2151] TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis.Cancer Res. 2017 Jun 15;77(12):3181-3193. doi: 10.1158/0008-5472.CAN-16-2797. Epub 2017 May 8.
• [2152] The relationship between homeobox B7 expression and the clinical characteristics of patient with prostate cancer.J Cell Biochem. 2019 Apr;120(4):6395-6401. doi: 10.1002/jcb.27926. Epub 2018 Oct 14.
• [2153] Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
• [2154] HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.Mol Cancer Res. 2010 Dec;8(12):1643-55. doi: 10.1158/1541-7786.MCR-10-0111. Epub 2010 Nov 2.
• [2155] Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.Curr Mol Med. 2017;17(1):70-78. doi: 10.2174/1566524017666170220104920.
• [2156] A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.Clin Epigenetics. 2018 Nov 23;10(1):147. doi: 10.1186/s13148-018-0575-z.
• [2157] A novel human hydroxysteroid dehydrogenase like 1 gene (HSDL1) is highly expressed in reproductive tissues.Mol Biol Rep. 2001;28(4):185-91. doi: 10.1023/a:1015726217890.
• [2158] The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer.Cancers (Basel). 2019 Aug 16;11(8):1194. doi: 10.3390/cancers11081194.
• [2159] Mutation detection in the human HSP7OB' gene by denaturing high-performance liquid chromatography.Cell Stress Chaperones. 2000 Nov;5(5):415-24. doi: 10.1379/1466-1268(2000)005<0415:mdithh>2.0.co;2.
• [2160] Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.APMIS. 2006 Dec;114(12):893-8. doi: 10.1111/j.1600-0463.2006.apm_271.x.
• [2161] Meta-analysis of gene expression alterations and clinical significance of the HECT domain-containing ubiquitin ligase HUWE1 in cancer.Oncol Lett. 2019 Sep;18(3):2292-2303. doi: 10.3892/ol.2019.10579. Epub 2019 Jul 5.
• [2162] Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling.Matrix Biol. 2019 May;78-79:165-179. doi: 10.1016/j.matbio.2018.05.002. Epub 2018 May 10.
• [2163] Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells.Int J Urol. 2002 Oct;9(10):577-85. doi: 10.1046/j.1442-2042.2002.00519.x.
• [2164] ICAM gene cluster SNPs and prostate cancer risk in African Americans.Hum Genet. 2006 Aug;120(1):69-76. doi: 10.1007/s00439-006-0184-3. Epub 2006 May 30.
• [2165] Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.Prostate. 2009 Sep 1;69(12):1281-91. doi: 10.1002/pros.20972.
• [2166] Biology of insulin-like growth factor binding protein-4 and its role in cancer (review).Int J Oncol. 2006 Jun;28(6):1317-25.
• [2167] TET2 binds the androgen receptor and loss is associated with prostate cancer.Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.
• [2168] Repurposing antitubercular agent isoniazid for treatment of prostate cancer.Biomater Sci. 2018 Dec 18;7(1):296-306. doi: 10.1039/c8bm01189c.
• [2169] Identification of prognostic biomarkers of prostate cancer with long non-coding RNA-mediated competitive endogenous RNA network.Exp Ther Med. 2019 Apr;17(4):3035-3040. doi: 10.3892/etm.2019.7277. Epub 2019 Feb 14.
• [2170] Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.J Cell Physiol. 2016 Jun;231(6):1364-74. doi: 10.1002/jcp.25240. Epub 2015 Nov 24.
• [2171] Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.PLoS Genet. 2017 Apr 27;13(4):e1006748. doi: 10.1371/journal.pgen.1006748. eCollection 2017 Apr.
• [2172] The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.J Mol Cell Biol. 2016 Jun;8(3):207-20. doi: 10.1093/jmcb/mjw007. Epub 2016 Mar 18.
• [2173] Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.Br J Cancer. 2018 Mar 6;118(5):713-726. doi: 10.1038/bjc.2017.447. Epub 2018 Jan 30.
• [2174] ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer.Cell Biol Int. 2020 Jan;44(1):242-252. doi: 10.1002/cbin.11227. Epub 2019 Sep 10.
• [2175] PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.Mol Endocrinol. 2009 Feb;23(2):169-75. doi: 10.1210/me.2008-0168. Epub 2008 Dec 18.
• [2176] Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study.Cancer Causes Control. 2017 Jul;28(7):767-777. doi: 10.1007/s10552-017-0896-9. Epub 2017 Apr 27.
• [2177] Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth.Oncotarget. 2017 Jul 17;8(47):82231-82243. doi: 10.18632/oncotarget.19288. eCollection 2017 Oct 10.
• [2178] Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice.Oncol Res. 2017 Apr 14;25(4):511-522. doi: 10.3727/096504016X14756226781802. Epub 2016 Oct 11.
• [2179] The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.Clin Cancer Res. 2008 Jun 1;14(11):3562-70. doi: 10.1158/1078-0432.CCR-07-4649.
• [2180] Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.J Gene Med. 2010 Sep;12(9):755-65. doi: 10.1002/jgm.1495.
• [2181] Tenascin-C and Integrin 9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.Cancer Res. 2017 Nov 1;77(21):5977-5988. doi: 10.1158/0008-5472.CAN-17-0064. Epub 2017 Sep 15.
• [2182] ITGBL1 promotes EMT, invasion and migration by activating NF-B signaling pathway in prostate cancer.Onco Targets Ther. 2019 May 16;12:3753-3763. doi: 10.2147/OTT.S200082. eCollection 2019.
• [2183] Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.Oncogenesis. 2019 Feb 19;8(3):14. doi: 10.1038/s41389-019-0122-6.
• [2184] Stable lower PAR expression decreased DU145 prostate cancer cell growth in SCID mice.Prostate. 2001 Nov 1;49(3):200-7. doi: 10.1002/pros.1135.
• [2185] GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1.Biosci Rep. 2018 Nov 30;38(6):BSR20180816. doi: 10.1042/BSR20180816. Print 2018 Dec 21.
• [2186] GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells.Regul Pept. 2002 Nov 15;109(1-3):141-8. doi: 10.1016/s0167-0115(02)00197-0.
• [2187] KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.Biomed Res Int. 2014;2014:380398. doi: 10.1155/2014/380398. Epub 2014 Jun 19.
• [2188] Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.J Cell Physiol. 2020 Mar;235(3):2129-2138. doi: 10.1002/jcp.29117. Epub 2019 Aug 29.
• [2189] ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.
• [2190] SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis.Int J Biochem Cell Biol. 2018 Sep;102:138-150. doi: 10.1016/j.biocel.2018.07.009. Epub 2018 Jul 24.
• [2191] Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.Oncotarget. 2017 Jul 11;8(28):45459-45469. doi: 10.18632/oncotarget.17564.
• [2192] Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.Med Sci Monit. 2019 Aug 27;25:6418-6428. doi: 10.12659/MSM.917352.
• [2193] High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.Med Sci Monit. 2018 Nov 14;24:8190-8197. doi: 10.12659/MSM.912643.
• [2194] Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.Clin Cancer Res. 2020 Mar 15;26(6):1516-1528. doi: 10.1158/1078-0432.CCR-19-0396. Epub 2019 Dec 3.
• [2195] KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition.Oncotarget. 2017 Apr 26;8(33):54558-54571. doi: 10.18632/oncotarget.17421. eCollection 2017 Aug 15.
• [2196] KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer.J Clin Med. 2019 Feb 9;8(2):225. doi: 10.3390/jcm8020225.
• [2197] Defining a common region of deletion at 13q21 in human cancers.Genes Chromosomes Cancer. 2001 Aug;31(4):333-44. doi: 10.1002/gcc.1152.
• [2198] Upregulation of MicroRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5.Cancer Biol Ther. 2019;20(8):1149-1161. doi: 10.1080/15384047.2019.1599659. Epub 2019 Apr 19.
• [2199] MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression.Biochem Biophys Res Commun. 2017 Jan 22;482(4):1381-1386. doi: 10.1016/j.bbrc.2016.12.045. Epub 2016 Dec 9.
• [2200] Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer.Med Oncol. 2010 Mar;27(1):145-51. doi: 10.1007/s12032-009-9185-0. Epub 2009 Feb 26.
• [2201] Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.Epigenetics. 2019 Dec;14(12):1194-1208. doi: 10.1080/15592294.2019.1634985. Epub 2019 Jun 28.
• [2202] Septin 9 isoform 1 (SEPT9_i1) specifically interacts with importin-7 to drive hypoxia-inducible factor (HIF)-1 nuclear translocation.Cytoskeleton (Hoboken). 2019 Jan;76(1):123-130. doi: 10.1002/cm.21450. Epub 2018 Aug 24.
• [2203] KPNA2/ERG Coexpression is Associated With Early Recurrence in Advanced Prostate Cancers.Appl Immunohistochem Mol Morphol. 2020 Jan;28(1):62-66. doi: 10.1097/PAI.0000000000000706.
• [2204] Inhibition of KPNA4 attenuates prostate cancer metastasis.Oncogene. 2017 May 18;36(20):2868-2878. doi: 10.1038/onc.2016.440. Epub 2016 Dec 12.
• [2205] Prostate-Derived Ets Factor (PDEF) Inhibits Metastasis by Inducing Epithelial/Luminal Phenotype in Prostate Cancer Cells. Mol Cancer Res. 2018 Sep;16(9):1430-1440.
• [2206] Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.Clin Cancer Res. 2003 Dec 15;9(17):6395-400.
• [2207] The glycosyltransferase LARGE2 is repressed by Snail and ZEB1 in prostate cancer.Cancer Biol Ther. 2015;16(1):125-36. doi: 10.4161/15384047.2014.987078.
• [2208] MicroRNA?06b functions as an oncogene and regulates tumor viability and metastasis by targeting LARP4B in prostate cancer.Mol Med Rep. 2019 Aug;20(2):951-958. doi: 10.3892/mmr.2019.10343. Epub 2019 Jun 5.
• [2209] The study of PSA gene expression on urogenital cell lines.Int J Urol. 1999 Oct;6(10):526-31. doi: 10.1046/j.1442-2042.1999.00104.x.
• [2210] Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.J Urol. 2016 May;195(5):1588-1597. doi: 10.1016/j.juro.2015.11.071. Epub 2015 Dec 9.
• [2211] Limb-bud and Heart Overexpression Inhibits the Proliferation and Migration of PC3M Cells.J Cancer. 2018 Jan 1;9(2):424-432. doi: 10.7150/jca.21375. eCollection 2018.
• [2212] Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer.Arch Med Res. 2010 Apr;41(3):195-200. doi: 10.1016/j.arcmed.2010.04.003.
• [2213] Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.Oncotarget. 2017 Jul 4;8(27):44654-44668. doi: 10.18632/oncotarget.17963.
• [2214] Mechanistic insights of epithelial protein lost in neoplasm in prostate cancer metastasis.Int J Cancer. 2018 Nov 15;143(10):2537-2550. doi: 10.1002/ijc.31786. Epub 2018 Sep 19.
• [2215] Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.Med Princ Pract. 2016;25 Suppl 2(Suppl 2):11-7. doi: 10.1159/000439307. Epub 2015 Oct 27.
• [2216] LITAF Enhances Radiosensitivity of Human Glioma Cells via the FoxO1 Pathway.Cell Mol Neurobiol. 2019 Aug;39(6):871-882. doi: 10.1007/s10571-019-00686-4. Epub 2019 May 16.
• [2217] LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.Nat Commun. 2019 Dec 2;10(1):5494. doi: 10.1038/s41467-019-13532-4.
• [2218] Overexpressed LRIG3 gene ameliorates prostate cancer through suppression of cell invasion and migration.Int J Biol Macromol. 2019 Mar 1;124:1-9. doi: 10.1016/j.ijbiomac.2018.11.028. Epub 2018 Nov 7.
• [2219] A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec.
• [2220] Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.Mol Cancer Res. 2017 Apr;15(4):457-466. doi: 10.1158/1541-7786.MCR-16-0392. Epub 2017 Jan 13.
• [2221] Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter.Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):401-6. doi: 10.1073/pnas.012574899. Epub 2001 Dec 18.
• [2222] Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype.Cancer Cell Int. 2019 Apr 29;19:112. doi: 10.1186/s12935-019-0835-9. eCollection 2019.
• [2223] Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.Int Urol Nephrol. 2017 May;49(5):811-816. doi: 10.1007/s11255-017-1546-6. Epub 2017 Feb 17.
• [2224] Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):621-627. doi: 10.1016/j.ijrobp.2019.06.2510. Epub 2019 Jul 2.
• [2225] Multiple newly identified loci associated with prostate cancer susceptibility.Nat Genet. 2008 Mar;40(3):316-21. doi: 10.1038/ng.90. Epub 2008 Feb 10.
• [2226] MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.Prostate. 2018 Jun;78(8):616-622. doi: 10.1002/pros.23506. Epub 2018 Mar 14.
• [2227] USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination.Autophagy. 2018;14(11):1976-1990. doi: 10.1080/15548627.2018.1496877. Epub 2018 Aug 10.
• [2228] Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection.World J Urol. 2020 Feb;38(2):361-369. doi: 10.1007/s00345-019-02695-w. Epub 2019 Apr 24.
• [2229] The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study.Urology. 2018 Jan;111:122-128. doi: 10.1016/j.urology.2017.08.039. Epub 2017 Sep 6.
• [2230] Consulting prostate cancer cohort data uncovers transcriptional control: Regulation of the MARCH6 gene.Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Nov;1864(11):1656-1668. doi: 10.1016/j.bbalip.2019.08.006. Epub 2019 Aug 15.
• [2231] Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer.Methods Mol Biol. 2018;1856:255-267. doi: 10.1007/978-1-4939-8751-1_15.
• [2232] A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells.Oncogene. 2009 Jul 16;28(28):2556-68. doi: 10.1038/onc.2009.118. Epub 2009 May 18.
• [2233] Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance.Tumori. 2018 Jun;104(3):172-178. doi: 10.5301/tj.5000646. Epub 2018 May 9.
• [2234] Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer.Oncol Lett. 2019 May;17(5):4640-4646. doi: 10.3892/ol.2019.10109. Epub 2019 Mar 5.
• [2235] Evaluating the Association between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study).Environ Health Perspect. 2018 Apr 23;126(4):047011. doi: 10.1289/EHP1837.
• [2236] Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.Prostate. 2018 Dec;78(16):1299-1310. doi: 10.1002/pros.23703. Epub 2018 Aug 10.
• [2237] Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer.Oncotarget. 2017 Jun 13;8(24):39209-39217. doi: 10.18632/oncotarget.16835.
• [2238] Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments.J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9. doi: 10.1093/jnci/94.14.1071.
• [2239] Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies.Oncogene. 2017 Jun 22;36(25):3629-3639. doi: 10.1038/onc.2017.123. Epub 2017 May 8.
• [2240] Knockdown of Mediator Complex Subunit 19 Suppresses the Growth and Invasion of Prostate Cancer Cells.PLoS One. 2017 Jan 26;12(1):e0171134. doi: 10.1371/journal.pone.0171134. eCollection 2017.
• [2241] The novel gene EG-1 stimulates cellular proliferation.Cancer Res. 2005 Jul 15;65(14):6159-66. doi: 10.1158/0008-5472.CAN-04-4016.
• [2242] ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain.J Mol Biol. 2017 Oct 13;429(20):2975-2995. doi: 10.1016/j.jmb.2017.06.024. Epub 2017 Jul 17.
• [2243] Epigenetic silencing of MEIS2 in prostate cancer recurrence.Clin Epigenetics. 2019 Oct 22;11(1):147. doi: 10.1186/s13148-019-0742-x.
• [2244] Silencing of MEOX1 Gene Inhibits Proliferation and Promotes Apoptosis of LNCaP Cells in Prostate Cancer.Cancer Biother Radiopharm. 2019 Mar;34(2):91-102. doi: 10.1089/cbr.2018.2545. Epub 2018 Dec 12.
• [2245] RNA m(6)A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.Onco Targets Ther. 2019 Nov 5;12:9143-9152. doi: 10.2147/OTT.S226796. eCollection 2019.
• [2246] Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.Anticancer Res. 2008 Jul-Aug;28(4A):1993-9.
• [2247] Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer.Exp Mol Pathol. 2019 Jun;108:173-182. doi: 10.1016/j.yexmp.2019.04.010. Epub 2019 Apr 17.
• [2248] Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression.Clin Cancer Res. 2006 May 1;12(9):2767-73. doi: 10.1158/1078-0432.CCR-05-1995.
• [2249] A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.Mol Cancer. 2014 Jun 9;13:146. doi: 10.1186/1476-4598-13-146.
• [2250] Correction to: MIIP inhibits the growth of prostate cancer via interaction with PP1 and negative modulation of AKT signaling.Cell Commun Signal. 2019 Oct 21;17(1):130. doi: 10.1186/s12964-019-0441-4.
• [2251] Volumetric modulated arc therapy with dynamic collimator rotation for improved multileaf collimator tracking of the prostate.Radiother Oncol. 2017 Jan;122(1):109-115. doi: 10.1016/j.radonc.2016.11.004. Epub 2016 Nov 28.
• [2252] TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.Prostate. 2017 Sep;77(12):1271-1278. doi: 10.1002/pros.23387. Epub 2017 Jul 21.
• [2253] Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer.Prostate. 2001 Sep 15;48(4):292-6. doi: 10.1002/pros.1109.
• [2254] Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.Oncol Rep. 2018 Mar;39(3):1276-1282. doi: 10.3892/or.2017.6172. Epub 2017 Dec 20.
• [2255] Texture analysis of T1-w and T2-w MR images allows a quantitative evaluation of radiation-induced changes of internal obturator muscles after radiotherapy for prostate cancer.Med Phys. 2018 Apr;45(4):1518-1528. doi: 10.1002/mp.12798. Epub 2018 Feb 26.
• [2256] Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.Eur Urol. 2000 Oct;38(4):475-82. doi: 10.1159/000020327.
• [2257] Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72.
• [2258] Elevated Expression Levels of PC3-Secreted Microprotein (PSMP) in Prostate Cancer Associated With Increased Xenograft Growth and Modification of Immune-Related Microenvironment.Front Oncol. 2019 Aug 28;9:724. doi: 10.3389/fonc.2019.00724. eCollection 2019.
• [2259] The role of the intravascular microenvironment in spontaneous metastasis development.Int J Cancer. 2010 Jun 1;126(11):2534-41. doi: 10.1002/ijc.24979.
• [2260] Circ-MTO1 correlates with favorable prognosis and inhibits cell proliferation, invasion as well as miR-17-5p expression in prostate cancer.J Clin Lab Anal. 2020 Mar;34(3):e23086. doi: 10.1002/jcla.23086. Epub 2019 Nov 11.
• [2261] Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft.Br J Cancer. 2004 Feb 9;90(3):720-7. doi: 10.1038/sj.bjc.6601570.
• [2262] Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.Prostate Cancer Prostatic Dis. 2016 Mar;19(1):28-34. doi: 10.1038/pcan.2015.63. Epub 2016 Jan 12.
• [2263] Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells.Prostate. 2001 May 15;47(3):194-204. doi: 10.1002/pros.1063.
• [2264] Spatial genomic heterogeneity within localized, multifocal prostate cancer.Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.
• [2265] Somatic mutation analysis of MYH11 in breast and prostate cancer.BMC Cancer. 2008 Sep 17;8:263. doi: 10.1186/1471-2407-8-263.
• [2266] Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.Gynecol Oncol. 2018 Apr;149(1):188-197. doi: 10.1016/j.ygyno.2018.01.024. Epub 2018 Feb 1.
• [2267] Selective expression of myosin IC Isoform A in mouse and human cell lines and mouse prostate cancer tissues.PLoS One. 2014 Sep 26;9(9):e108609. doi: 10.1371/journal.pone.0108609. eCollection 2014.
• [2268] Myosin Va plays essential roles in maintaining normal mitosis, enhancing tumor cell motility and viability.Oncotarget. 2017 May 17;8(33):54654-54671. doi: 10.18632/oncotarget.17920. eCollection 2017 Aug 15.
• [2269] The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy.BJU Int. 2019 Mar;123(3):439-446. doi: 10.1111/bju.14615. Epub 2018 Nov 30.
• [2270] MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 signaling impedes castration-resistant prostate cancer growth.Aging (Albany NY). 2019 Nov 24;11(22):10644-10663. doi: 10.18632/aging.102482. Epub 2019 Nov 24.
• [2271] ARD1/NAA10 acetylation in prostate cancer.Exp Mol Med. 2018 Jul 27;50(7):1-8. doi: 10.1038/s12276-018-0107-0.
• [2272] Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.Cancer Lett. 2010 Jun 28;292(2):176-85. doi: 10.1016/j.canlet.2009.11.023. Epub 2009 Dec 30.
• [2273] Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.Mol Cancer Ther. 2004 Jan;3(1):11-20.
• [2274] Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.Urology. 2017 Sep;107:67-75. doi: 10.1016/j.urology.2017.02.052. Epub 2017 Apr 25.
• [2275] hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.Am J Surg Pathol. 2008 Feb;32(2):205-9. doi: 10.1097/PAS.0b013e318124a865.
• [2276] Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer.Oncol Lett. 2019 Jun;17(6):5768-5776. doi: 10.3892/ol.2019.10260. Epub 2019 Apr 17.
• [2277] Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.Am J Hum Genet. 2010 Dec 10;87(6):802-12. doi: 10.1016/j.ajhg.2010.11.001.
• [2278] Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/-catenin signaling.Biomed Pharmacother. 2018 Jan;97:120-127. doi: 10.1016/j.biopha.2017.10.115. Epub 2017 Nov 6.
• [2279] NDRG3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors.Exp Mol Med. 2018 May 14;50(5):1-13. doi: 10.1038/s12276-018-0089-y.
• [2280] Is there any association between nek3 and cancers with frequent 13q14 deletion?.Cancer Invest. 2006 Nov;24(7):682-8. doi: 10.1080/07357900600981364.
• [2281] BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions.Int J Mol Sci. 2018 Jul 20;19(7):2104. doi: 10.3390/ijms19072104.
• [2282] Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.Prostate. 2003 Oct 1;57(2):134-9. doi: 10.1002/pros.10284.
• [2283] NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?.Eur Urol. 2007 Nov;52(5):1365-73. doi: 10.1016/j.eururo.2006.11.030. Epub 2006 Nov 20.
• [2284] Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells.Med Sci Monit. 2019 Feb 28;25:1572-1581. doi: 10.12659/MSM.910998.
• [2285] Integrative molecular concept modeling of prostate cancer progression.Nat Genet. 2007 Jan;39(1):41-51. doi: 10.1038/ng1935. Epub 2006 Dec 17.
• [2286] Incidental Finding of Intrathyroid Metastases of Prostatic Cancer on 18F-Choline PET/CT.Clin Nucl Med. 2019 Feb;44(2):e101-e103. doi: 10.1097/RLU.0000000000002374.
• [2287] Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men.Clin Cancer Res. 2010 Jul 15;16(14):3539-47. doi: 10.1158/1078-0432.CCR-09-3342. Epub 2010 Jul 6.
• [2288] Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer.Sci Rep. 2017 Jun 29;7(1):4378. doi: 10.1038/s41598-017-04286-4.
• [2289] The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778. Epub 2014 Feb 26.
• [2290] MiR-192 suppresses the tumorigenicity of prostate cancer cells by targeting and inhibiting nin one binding protein.Int J Mol Med. 2016 Feb;37(2):485-92. doi: 10.3892/ijmm.2016.2449. Epub 2016 Jan 5.
• [2291] An ALP-activatable and mitochondria-targeted probe for prostate cancer-specific bimodal imaging and aggregation-enhanced photothermal therapy.Nanoscale. 2019 Mar 28;11(13):6307-6314. doi: 10.1039/c9nr00913b.
• [2292] The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.Biotechnol Appl Biochem. 2018 May;65(3):407-418. doi: 10.1002/bab.1619. Epub 2017 Nov 2.
• [2293] Reproducibility of FCM-DNA ploidy analysis in prostatic cancer: comparison between needle biopsy and surgical specimens.Anal Cell Pathol. 1993 Jan;5(1):17-21.
• [2294] Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression.Cancer Cell Int. 2019 Apr 5;19:87. doi: 10.1186/s12935-019-0811-4. eCollection 2019.
• [2295] Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 2007 Nov-Dec;27(6B):3813-8.
• [2296] NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3.
• [2297] TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.Prostate. 2003 Oct 1;57(2):129-33. doi: 10.1002/pros.10282.
• [2298] Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.Int J Cancer. 2018 Jul 1;143(1):100-112. doi: 10.1002/ijc.31289. Epub 2018 Apr 2.
• [2299] MPC1, a key gene in cancer metabolism, is regulated by COUPTFII in human prostate cancer.Oncotarget. 2016 Mar 22;7(12):14673-83. doi: 10.18632/oncotarget.7405.
• [2300] Positive expression of NR6A1/CT150 as a predictor of biochemical recurrence-free survival in prostate cancer patients.Oncotarget. 2016 Aug 31;8(38):64427-64439. doi: 10.18632/oncotarget.11749. eCollection 2017 Sep 8.
• [2301] CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7. doi: 10.1073/pnas.131590998.
• [2302] Numb(-/low) Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling.Clin Cancer Res. 2017 Nov 1;23(21):6744-6756. doi: 10.1158/1078-0432.CCR-17-0913. Epub 2017 Jul 27.
• [2303] Nucleoporin 153 regulates estrogen-dependent nuclear translocation of endothelial nitric oxide synthase and estrogen receptor beta in prostate cancer.Oncotarget. 2018 Jun 15;9(46):27985-27997. doi: 10.18632/oncotarget.25462. eCollection 2018 Jun 15.
• [2304] SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone.J Proteomics. 2019 Feb 20;193:217-229. doi: 10.1016/j.jprot.2018.10.012. Epub 2018 Oct 25.
• [2305] Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient.Genet Mol Res. 2012 Oct 4;11(4):3642-8. doi: 10.4238/2012.October.4.11.
• [2306] Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.J Cell Biochem. 2019 Oct;120(10):16946-16955. doi: 10.1002/jcb.28954. Epub 2019 May 17.
• [2307] ONECUT2 is a driver of neuroendocrine prostate cancer.Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.
• [2308] The activation of OR51E1 causes growth suppression of human prostate cancer cells.Oncotarget. 2016 Jul 26;7(30):48231-48249. doi: 10.18632/oncotarget.10197.
• [2309] Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.Prostate. 2019 Dec;79(16):1793-1804. doi: 10.1002/pros.23904. Epub 2019 Sep 2.
• [2310] Ovol2 induces mesenchymal-epithelial transition via targeting ZEB1 in osteosarcoma.Onco Targets Ther. 2018 May 22;11:2963-2973. doi: 10.2147/OTT.S157119. eCollection 2018.
• [2311] Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer.Br J Cancer. 2000 Sep;83(6):743-9. doi: 10.1054/bjoc.2000.1365.
• [2312] The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.Mol Cell Biochem. 2014 Nov;396(1-2):175-85. doi: 10.1007/s11010-014-2153-9. Epub 2014 Aug 1.
• [2313] HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer.Oncotarget. 2017 Dec 8;9(1):512-523. doi: 10.18632/oncotarget.23070. eCollection 2018 Jan 2.
• [2314] PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.Cancer Res. 2017 Nov 1;77(21):5755-5768. doi: 10.1158/0008-5472.CAN-17-0150. Epub 2017 Aug 17.
• [2315] Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).BMC Cancer. 2019 Sep 10;19(1):903. doi: 10.1186/s12885-019-6117-z.
• [2316] Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer.Pathol Res Pract. 2018 Jan;214(1):126-129. doi: 10.1016/j.prp.2017.10.010. Epub 2017 Oct 10.
• [2317] Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer.Cancer Res. 1993 Sep 1;53(17):3869-73.
• [2318] Human PARM-1 is a novel mucin-like, androgen-regulated gene exhibiting proliferative effects in prostate cancer cells.Int J Cancer. 2008 Mar 15;122(6):1229-35. doi: 10.1002/ijc.23185.
• [2319] PARP9 is overexpressed in human breast cancer and promotes cancer cell migration.Oncol Lett. 2018 Sep;16(3):4073-4077. doi: 10.3892/ol.2018.9124. Epub 2018 Jul 11.
• [2320] PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3058-63. doi: 10.1073/pnas.052713699.
• [2321] Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.FEBS J. 2014 Oct;281(19):4506-18. doi: 10.1111/febs.12959. Epub 2014 Aug 26.
• [2322] PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.Prostate. 2018 May;78(7):547-559. doi: 10.1002/pros.23499. Epub 2018 Mar 9.
• [2323] Protocadherin-PC promotes androgen-independent prostate cancer cell growth.Prostate. 2006 Jul 1;66(10):1100-13. doi: 10.1002/pros.20446.
• [2324] Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling.Prostate. 2019 Nov;79(15):1739-1751. doi: 10.1002/pros.23898. Epub 2019 Aug 26.
• [2325] Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.Eur Urol. 2018 Mar;73(3):322-339. doi: 10.1016/j.eururo.2017.08.027. Epub 2017 Sep 18.
• [2326] Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.Prostate. 2019 Feb;79(2):234-242. doi: 10.1002/pros.23728. Epub 2018 Oct 16.
• [2327] Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features.Urol Oncol. 2011 May-Jun;29(3):244-51. doi: 10.1016/j.urolonc.2009.02.004. Epub 2009 Apr 22.
• [2328] Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells.Oncotarget. 2017 Jun 28;8(48):83602-83618. doi: 10.18632/oncotarget.18787. eCollection 2017 Oct 13.
• [2329] PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.Mol Cancer Res. 2019 Feb;17(2):618-627. doi: 10.1158/1541-7786.MCR-18-0837. Epub 2018 Dec 5.
• [2330] PRLTS gene alterations in human prostate cancer.Jpn J Cancer Res. 1997 Apr;88(4):389-93. doi: 10.1111/j.1349-7006.1997.tb00394.x.
• [2331] Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15.
• [2332] CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.World J Urol. 2017 Aug;35(8):1213-1221. doi: 10.1007/s00345-016-1996-y. Epub 2017 Jan 19.
• [2333] AMPK/GSK3/-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming.FASEB J. 2018 Jul;32(7):3924-3935. doi: 10.1096/fj.201701078R. Epub 2018 Mar 5.
• [2334] PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.Cancer Invest. 2009 Mar;27(3):264-72. doi: 10.1080/07357900802406319.
• [2335] High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer.Oncotarget. 2017 Sep 18;8(58):98117-98134. doi: 10.18632/oncotarget.20981. eCollection 2017 Nov 17.
• [2336] Correlation of genomic and expression alterations of AS3 with esophageal squamous cell carcinoma.J Genet Genomics. 2008 May;35(5):267-71. doi: 10.1016/S1673-8527(08)60038-7.
• [2337] Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.BJU Int. 2007 May;99(5):1047-55. doi: 10.1111/j.1464-410X.2007.06763.x.
• [2338] Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6997-7002. doi: 10.1073/pnas.1304502110. Epub 2013 Apr 4.
• [2339] Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2572-2579. doi: 10.26355/eurrev_201805_14950.
• [2340] Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.Asian J Androl. 2019 Jul-Aug;21(4):387-392. doi: 10.4103/aja.aja_117_18.
• [2341] Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion.Asian J Androl. 2018 Mar-Apr;20(2):178-183. doi: 10.4103/aja.aja_57_17.
• [2342] Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis.Cancer Chemother Pharmacol. 2017 May;79(5):985-994. doi: 10.1007/s00280-017-3301-1. Epub 2017 Apr 8.
• [2343] Prohibitin-2 negatively regulates AKT2 expression to promote prostate cancer cell migration.Int J Mol Med. 2018 Feb;41(2):1147-1155. doi: 10.3892/ijmm.2017.3307. Epub 2017 Dec 4.
• [2344] RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.Eur Urol. 2019 Aug;76(2):157-166. doi: 10.1016/j.eururo.2019.03.011. Epub 2019 Mar 23.
• [2345] Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids.Biochem J. 2005 Jan 1;385(Pt 1):105-14. doi: 10.1042/BJ20040290.
• [2346] PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.PLoS One. 2019 Oct 22;14(10):e0224085. doi: 10.1371/journal.pone.0224085. eCollection 2019.
• [2347] The TGF- signalling negative regulator PICK1 represses prostate cancer metastasis to bone.Br J Cancer. 2017 Aug 22;117(5):685-694. doi: 10.1038/bjc.2017.212. Epub 2017 Jul 11.
• [2348] Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle.Int J Oncol. 2019 Sep;55(3):629-644. doi: 10.3892/ijo.2019.4839. Epub 2019 Jul 15.
• [2349] Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia.Prostate. 2007 Sep 1;67(12):1308-17. doi: 10.1002/pros.20618.
• [2350] Novel roles for class II Phosphoinositide 3-Kinase C2 in signalling pathways involved in prostate cancer cell invasion.Sci Rep. 2016 Mar 17;6:23277. doi: 10.1038/srep23277.
• [2351] Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.Cancer Res. 2010 Mar 15;70(6):2389-96. doi: 10.1158/0008-5472.CAN-09-3575. Epub 2010 Mar 2.
• [2352] PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.Medicine (Baltimore). 2019 Jan;98(1):e13820. doi: 10.1097/MD.0000000000013820.
• [2353] Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1.Br J Cancer. 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20.
• [2354] Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.APMIS. 2009 Mar;117(3):151-61. doi: 10.1111/j.1600-0463.2008.00002.x.
• [2355] Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.PLoS One. 2019 Jun 24;14(6):e0218950. doi: 10.1371/journal.pone.0218950. eCollection 2019.
• [2356] Combination of phospholipase C knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.Oncol Rep. 2019 May;41(5):2689-2702. doi: 10.3892/or.2019.7054. Epub 2019 Mar 7.
• [2357] Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.J Natl Cancer Inst. 2001 Sep 5;93(17):1314-24. doi: 10.1093/jnci/93.17.1314.
• [2358] Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer.Cancer Manag Res. 2019 Feb 14;11:1517-1524. doi: 10.2147/CMAR.S176762. eCollection 2019.
• [2359] Loss of ABHD5 promotes the aggressiveness of prostate cancer cells.Sci Rep. 2017 Oct 12;7(1):13021. doi: 10.1038/s41598-017-13398-w.
• [2360] Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.Anticancer Res. 2018 Nov;38(11):6361-6366. doi: 10.21873/anticanres.12994.
• [2361] Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis.Hum Mutat. 2015 Sep;36(9):873-80. doi: 10.1002/humu.22820. Epub 2015 Jun 25.
• [2362] Hypothesis driven single nucleotide polymorphism search (HyDn-SNP-S).DNA Repair (Amst). 2013 Sep;12(9):733-40. doi: 10.1016/j.dnarep.2013.06.001. Epub 2013 Jul 5.
• [2363] The POLR2E rs3787016 polymorphism is strongly associated with the risk of female breast and cervical cancer.Pathol Res Pract. 2019 May;215(5):1061-1065. doi: 10.1016/j.prp.2019.02.015. Epub 2019 Feb 27.
• [2364] Effects on prostate cancer cells of targeting RNA polymerase III.Nucleic Acids Res. 2019 May 7;47(8):3937-3956. doi: 10.1093/nar/gkz128.
• [2365] POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer.Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16975-80. doi: 10.1073/pnas.262655399. Epub 2002 Dec 10.
• [2366] Clinical and molecular features of treatment-related neuroendocrine prostate cancer.Int J Urol. 2018 Apr;25(4):345-351. doi: 10.1111/iju.13526. Epub 2018 Feb 3.
• [2367] Brn-3a neuronal transcription factor functional expression in human prostate cancer.Prostate Cancer Prostatic Dis. 2006;9(1):83-91. doi: 10.1038/sj.pcan.4500837.
• [2368] Elimination of SOX2/OCT4-Associated Prostate Cancer Stem Cells Blocks Tumor Development and Enhances Therapeutic Response.Cancers (Basel). 2019 Sep 8;11(9):1331. doi: 10.3390/cancers11091331.
• [2369] Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.Br J Cancer. 2017 May 23;116(11):1470-1479. doi: 10.1038/bjc.2017.104. Epub 2017 May 2.
• [2370] Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.Int J Mol Med. 2002 Aug;10(2):173-6.
• [2371] CYP 1A1 polymorphism and organochlorine pesticides levels in the etiology of prostate cancer.Chemosphere. 2010 Sep;81(4):464-8. doi: 10.1016/j.chemosphere.2010.07.067.
• [2372] Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.Nat Commun. 2019 Jul 15;10(1):3107. doi: 10.1038/s41467-019-10808-7.
• [2373] Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.Cancer Res. 2005 Sep 15;65(18):8397-405. doi: 10.1158/0008-5472.CAN-05-1203.
• [2374] miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C.Biomed Pharmacother. 2016 Jul;81:25-30. doi: 10.1016/j.biopha.2016.03.043. Epub 2016 Apr 8.
• [2375] Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.World J Urol. 2020 Oct;38(10):2501-2511. doi: 10.1007/s00345-019-03038-5. Epub 2019 Dec 4.
• [2376] Anticancer activity of the PR domain of tumor suppressor RIZ1.Int J Med Sci. 2011 Feb 21;8(2):161-7. doi: 10.7150/ijms.8.161.
• [2377] Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.Oncogene. 2009 Apr 23;28(16):1853-63. doi: 10.1038/onc.2009.30. Epub 2009 Mar 23.
• [2378] Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal. 2007 Feb;19(2):401-9. doi: 10.1016/j.cellsig.2006.07.011. Epub 2006 Jul 25.
• [2379] The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies.Oncotarget. 2017 Jul 11;8(28):45994-46005. doi: 10.18632/oncotarget.17522.
• [2380] Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer.Oncotarget. 2015 Sep 22;6(28):26437-56. doi: 10.18632/oncotarget.4664.
• [2381] Identification and characterization of a novel testosterone-regulated prominin-like gene in the rat ventral prostate.Endocrinology. 2002 Dec;143(12):4788-96. doi: 10.1210/en.2002-220522.
• [2382] Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer.Biosci Rep. 2018 Oct 31;38(5):BSR20171571. doi: 10.1042/BSR20171571. Print 2018 Oct 31.
• [2383] PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.
• [2384] Predictive value of the UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classification for patients treated with radical prostatectomy.Cancer Epidemiol. 2018 Oct;56:126-132. doi: 10.1016/j.canep.2018.08.007. Epub 2018 Aug 31.
• [2385] PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.Anticancer Drugs. 2019 Aug;30(7):e0773. doi: 10.1097/CAD.0000000000000773.
• [2386] Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.Prostate. 2019 Aug;79(11):1304-1315. doi: 10.1002/pros.23838. Epub 2019 Jun 18.
• [2387] Knockdown of REG inhibits proliferation by inducing apoptosis and cell cycle arrest in prostate cancer.Am J Transl Res. 2017 Aug 15;9(8):3787-3795. eCollection 2017.
• [2388] Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.Mol Med Rep. 2018 Oct;18(4):3914-3922. doi: 10.3892/mmr.2018.9402. Epub 2018 Aug 20.
• [2389] Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer.Clin Proteomics. 2019 Apr 13;16:15. doi: 10.1186/s12014-019-9236-2. eCollection 2019.
• [2390] High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.BMC Cancer. 2019 Oct 12;19(1):944. doi: 10.1186/s12885-019-6182-3.
• [2391] Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.Sci Rep. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.
• [2392] Loss of receptor protein tyrosine phosphatase / (RPTP/) promotes prostate cancer metastasis.J Biol Chem. 2012 Nov 23;287(48):40339-49. doi: 10.1074/jbc.M112.405852. Epub 2012 Oct 11.
• [2393] The bispecific anti-CD3anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.Invest New Drugs. 2019 Oct;37(5):810-817. doi: 10.1007/s10637-018-0683-9. Epub 2018 Oct 29.
• [2394] Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer.Int J Mol Sci. 2019 Jun 21;20(12):3046. doi: 10.3390/ijms20123046.
• [2395] PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model.Oncogene. 2004 Jan 8;23(1):250-9. doi: 10.1038/sj.onc.1207076.
• [2396] Paxillin regulated genomic networks in prostate cancer.Steroids. 2019 Nov;151:108463. doi: 10.1016/j.steroids.2019.108463. Epub 2019 Jul 22.
• [2397] Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.Oncol Lett. 2018 Jan;15(1):731-740. doi: 10.3892/ol.2017.7400. Epub 2017 Nov 14.
• [2398] PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.J Clin Pathol. 2018 May;71(5):402-411. doi: 10.1136/jclinpath-2017-204718. Epub 2017 Sep 18.
• [2399] Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.Oncol Rep. 2019 Feb;41(2):1140-1150. doi: 10.3892/or.2018.6893. Epub 2018 Nov 27.
• [2400] A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes.Oncogene. 2009 Oct 29;28(43):3847-56. doi: 10.1038/onc.2009.243. Epub 2009 Aug 17.
• [2401] Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer.Mol Cancer Res. 2018 Aug;16(8):1319-1331. doi: 10.1158/1541-7786.MCR-17-0589. Epub 2018 May 14.
• [2402] miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells.Am J Cancer Res. 2018 Dec 1;8(12):2564-2574. eCollection 2018.
• [2403] High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy.Cancer Cell Int. 2017 Apr 11;17:45. doi: 10.1186/s12935-017-0411-0. eCollection 2017.
• [2404] Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells.Eur J Cancer Prev. 2017 Jan;26(1):71-77. doi: 10.1097/CEJ.0000000000000230.
• [2405] PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer.Cancer Res. 2002 Oct 1;62(19):5420-4.
• [2406] Tissue ACE phenotyping in prostate cancer.Oncotarget. 2019 Oct 29;10(59):6349-6361. doi: 10.18632/oncotarget.27276. eCollection 2019 Oct 29.
• [2407] DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.Acta Biomater. 2019 Sep 15;96:480-490. doi: 10.1016/j.actbio.2019.07.003. Epub 2019 Jul 9.
• [2408] Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population.Anticancer Res. 2003 May-Jun;23(3C):2897-902.
• [2409] SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells.J Pathol. 2009 Feb;217(3):389-97. doi: 10.1002/path.2456.
• [2410] Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia.Endokrynol Pol. 2018;69(2):120-127. doi: 10.5603/EP.a2018.0006. Epub 2018 Feb 21.
• [2411] Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.J Clin Invest. 2018 Oct 1;128(10):4472-4484. doi: 10.1172/JCI99397. Epub 2018 Jul 26.
• [2412] Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.Urology. 2019 Jun;128:62-65. doi: 10.1016/j.urology.2018.04.001. Epub 2018 Apr 13.
• [2413] Impact of RNAbinding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study.Oncol Rep. 2018 Oct;40(4):2307-2315. doi: 10.3892/or.2018.6618. Epub 2018 Aug 1.
• [2414] CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer.Int J Cancer. 2002 Jun 10;99(5):689-96. doi: 10.1002/ijc.10393.
• [2415] Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.Mol Cell Biol. 2006 Sep;26(17):6502-10. doi: 10.1128/MCB.00147-06.
• [2416] Downregulation of reticulocalbin-1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells.Cancer Sci. 2018 Apr;109(4):1147-1157. doi: 10.1111/cas.13541. Epub 2018 Mar 31.
• [2417] Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.PLoS Genet. 2018 Apr 16;14(4):e1007355. doi: 10.1371/journal.pgen.1007355. eCollection 2018 Apr.
• [2418] Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating TGF- signaling.Cell Death Dis. 2018 Jul 13;9(7):779. doi: 10.1038/s41419-018-0807-3.
• [2419] Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. Int J Oncol. 2011 Apr;38(4):893-902. doi: 10.3892/ijo.2011.938. Epub 2011 Feb 9.
• [2420] Suppressed glycolytic metabolism in the prostate of transgenic rats overexpressing calcium-binding protein regucalcin underpins reduced cell proliferation.Transgenic Res. 2016 Apr;25(2):139-48. doi: 10.1007/s11248-015-9918-0. Epub 2015 Nov 9.
• [2421] MiR-203 inhibits the malignant behavior of prostate cancer cells by targeting RGS17.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5667-5674. doi: 10.26355/eurrev_201907_18303.
• [2422] Predictive factors for prolonged hospital stay after retropubic radical prostatectomy in a high-volume teaching center.Int Braz J Urol. 2018 Nov-Dec;44(6):1089-1105. doi: 10.1590/S1677-5538.IBJU.2017.0339.
• [2423] Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.Prostate. 2010 Jun 1;70(8):866-74. doi: 10.1002/pros.21120.
• [2424] RhoBTB1 interacts with ROCKs and inhibits invasion.Biochem J. 2019 Sep 13;476(17):2499-2514. doi: 10.1042/BCJ20190203.
• [2425] Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the progression of prostate cancer through suppression of RHPN2.J Exp Clin Cancer Res. 2019 Dec 17;38(1):495. doi: 10.1186/s13046-019-1488-1.
• [2426] Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma.Tumour Biol. 2015 Dec;36(12):9579-88. doi: 10.1007/s13277-015-3721-7. Epub 2015 Jul 4.
• [2427] Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.Int J Urol. 2002 Oct;9(10):567-76. doi: 10.1046/j.1442-2042.2002.00513.x.
• [2428] Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation.Sci Rep. 2017 Dec 4;7(1):16824. doi: 10.1038/s41598-017-17207-2.
• [2429] Identification of novel alternative transcripts of the human Ribonuclease (RNASEK) gene using 3' RACE and high-throughput sequencing approaches.Genomics. 2020 Jan;112(1):943-951. doi: 10.1016/j.ygeno.2019.06.010. Epub 2019 Jun 11.
• [2430] Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP.Oncotarget. 2017 Jan 17;8(3):5323-5338. doi: 10.18632/oncotarget.14142.
• [2431] Role of RNF20 in cancer development and progression - a comprehensive review.Biosci Rep. 2018 Jul 12;38(4):BSR20171287. doi: 10.1042/BSR20171287. Print 2018 Aug 31.
• [2432] Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness.Oncotarget. 2017 Jul 18;8(29):47110-47120. doi: 10.18632/oncotarget.16943.
• [2433] Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.Am J Pathol. 1999 May;154(5):1335-43. doi: 10.1016/S0002-9440(10)65387-4.
• [2434] siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer.PLoS One. 2011;6(7):e22672. doi: 10.1371/journal.pone.0022672. Epub 2011 Jul 22.
• [2435] Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.Med Oncol. 2019 May 14;36(6):56. doi: 10.1007/s12032-019-1283-z.
• [2436] RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.Urol Oncol. 2019 May;37(5):297.e1-297.e7. doi: 10.1016/j.urolonc.2019.01.011. Epub 2019 Feb 6.
• [2437] hZIP1 zinc transporter down-regulation in prostate cancer involves the overexpression of ras responsive element binding protein-1 (RREB-1).Prostate. 2011 Oct 1;71(14):1518-24. doi: 10.1002/pros.21368. Epub 2011 Feb 25.
• [2438] RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.Oncogene. 2004 Apr 15;23(17):3080-8. doi: 10.1038/sj.onc.1207435.
• [2439] P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage.Cell Cycle. 2018;17(17):2175-2186. doi: 10.1080/15384101.2018.1520565. Epub 2018 Sep 22.
• [2440] Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.Hum Pathol. 2004 Nov;35(11):1385-91. doi: 10.1016/j.humpath.2004.07.015.
• [2441] Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells.Urol Oncol. 2013 Nov;31(8):1576-83. doi: 10.1016/j.urolonc.2012.05.006. Epub 2012 Jun 12.
• [2442] Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.Int J Cancer. 2017 Jan 15;140(2):358-369. doi: 10.1002/ijc.30450. Epub 2016 Oct 20.
• [2443] miR-4286 promotes prostate cancer progression by targeting the expression of SALL1.J Gene Med. 2023 Jul;25(7):e3127. doi: 10.1002/jgm.3127. Epub 2023 May 30.
• [2444] SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.Int Urol Nephrol. 2019 Mar;51(3):443-451. doi: 10.1007/s11255-019-02096-3. Epub 2019 Feb 9.
• [2445] Long non-coding RNA SAP30L-AS1 promotes prostate cancer growth through repressing SAP30L.Gene. 2019 Mar 30;690:120-128. doi: 10.1016/j.gene.2018.12.047. Epub 2018 Dec 29.
• [2446] HOX genes: Major actors in resistance to selective endocrine response modifiers.Biochim Biophys Acta. 2016 Apr;1865(2):105-10. doi: 10.1016/j.bbcan.2016.01.003. Epub 2016 Jan 22.
• [2447] Silver nanoparticles deposited on graphene oxide for ultrasensitive surface-enhanced Raman scattering immunoassay of cancer biomarker.Nanoscale. 2018 Jul 5;10(25):11942-11947. doi: 10.1039/c8nr02820f.
• [2448] Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.Int J Oncol. 2009 Feb;34(2):529-36.
• [2449] Sumoylation Negatively Regulates CSR1-Dependent Prostate Cancer Cell Death.Cell Physiol Biochem. 2018;46(5):1861-1867. doi: 10.1159/000489370. Epub 2018 Apr 25.
• [2450] Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.Clin Cancer Res. 2019 Jan 15;25(2):595-608. doi: 10.1158/1078-0432.CCR-18-0729. Epub 2018 Oct 1.
• [2451] Loss of scinderin decreased expression of epidermal growth factor receptor and promoted apoptosis of castration-resistant prostate cancer cells.FEBS Open Bio. 2018 Apr 10;8(5):743-750. doi: 10.1002/2211-5463.12412. eCollection 2018 May.
• [2452] Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers.Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):148-59. doi: 10.1158/1055-9965.EPI-10-0719. Epub 2010 Nov 23.
• [2453] Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor.Mol Cancer Ther. 2019 Nov;18(11):1997-2007. doi: 10.1158/1535-7163.MCT-18-1019. Epub 2019 Jul 25.
• [2454] Molecular cloning and characterization of human homeobox gene Nkx3.1 promoter.Acta Biochim Biophys Sin (Shanghai). 2004 Jan;36(1):64-7. doi: 10.1093/abbs/36.1.64.
• [2455] Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.Hum Pathol. 2015 Apr;46(4):514-23. doi: 10.1016/j.humpath.2014.06.006. Epub 2014 Jun 26.
• [2456] Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.Prostate. 2019 Apr;79(5):462-467. doi: 10.1002/pros.23752. Epub 2018 Dec 23.
• [2457] Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.J Urol. 2009 Oct;182(4):1614-20. doi: 10.1016/j.juro.2009.06.016. Epub 2009 Aug 15.
• [2458] SSeCKS/AKAP12 induces repulsion between human prostate cancer and microvessel endothelial cells through the activation of Semaphorin 3F.Biochem Biophys Res Commun. 2017 Sep 2;490(4):1394-1398. doi: 10.1016/j.bbrc.2017.07.043. Epub 2017 Jul 8.
• [2459] Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer.Clin Cancer Res. 2013 Nov 15;19(22):6101-11. doi: 10.1158/1078-0432.CCR-12-3669. Epub 2013 Oct 4.
• [2460] Targeting the androgen receptor and overcoming resistance in prostate cancer.Curr Opin Oncol. 2019 May;31(3):175-182. doi: 10.1097/CCO.0000000000000520.
• [2461] The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.Br J Cancer. 2018 Feb 6;118(3):416-420. doi: 10.1038/bjc.2017.404. Epub 2017 Nov 14.
• [2462] Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.Prostate. 2009 Nov 1;69(15):1694-703. doi: 10.1002/pros.21020.
• [2463] Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells.Anticancer Res. 2017 Dec;37(12):6609-6618. doi: 10.21873/anticanres.12118.
• [2464] Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression.Mol Cancer Res. 2019 Apr;17(4):845-859. doi: 10.1158/1541-7786.MCR-18-0638. Epub 2019 Jan 4.
• [2465] Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.J Hum Genet. 2005;50(10):507-515. doi: 10.1007/s10038-005-0285-1. Epub 2005 Sep 20.
• [2466] Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.Int J Cancer. 2005 Jul 20;115(6):911-6. doi: 10.1002/ijc.20967.
• [2467] Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.Int J Cancer. 2019 Feb 1;144(3):558-568. doi: 10.1002/ijc.31877. Epub 2018 Oct 31.
• [2468] Transcriptional regulation of FoxM1 by HIF? mediates hypoxiainduced EMT in prostate cancer.Oncol Rep. 2019 Oct;42(4):1307-1318. doi: 10.3892/or.2019.7248. Epub 2019 Jul 25.
• [2469] PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.Tumour Biol. 2015 Aug;36(8):5753-5. doi: 10.1007/s13277-015-3849-5. Epub 2015 Aug 4.
• [2470] SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.Cancer Res. 2019 Oct 15;79(20):5204-5217. doi: 10.1158/0008-5472.CAN-18-3965. Epub 2019 Aug 20.
• [2471] miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3.Biomed Pharmacother. 2018 Mar;99:369-374. doi: 10.1016/j.biopha.2018.01.086.
• [2472] Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.Oncogene. 2003 Feb 27;22(8):1247-52. doi: 10.1038/sj.onc.1206247.
• [2473] Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.J Clin Endocrinol Metab. 2007 Dec;92(12):4820-6. doi: 10.1210/jc.2007-0887. Epub 2007 Oct 2.
• [2474] Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk.Prostate. 2005 Sep 15;65(1):58-65. doi: 10.1002/pros.20230.
• [2475] Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.
• [2476] Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.EBioMedicine. 2018 May;31:267-275. doi: 10.1016/j.ebiom.2018.05.002. Epub 2018 May 16.
• [2477] SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26.
• [2478] Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
• [2479] Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells.Oncogene. 2005 Nov 3;24(48):7203-12. doi: 10.1038/sj.onc.1208852.
• [2480] FAM35A associates with REV7 and modulates DNAdamage responses of normal and BRCA1-defective cells.EMBO J. 2018 Jun 15;37(12):e99543. doi: 10.15252/embj.201899543. Epub 2018 May 22.
• [2481] Reduced number of CD169(+) macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.Prostate. 2017 Nov;77(15):1468-1477. doi: 10.1002/pros.23407. Epub 2017 Sep 7.
• [2482] Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.PLoS One. 2017 Sep 14;12(9):e0184094. doi: 10.1371/journal.pone.0184094. eCollection 2017.
• [2483] Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing Senescence.Cancer Res. 2017 Oct 1;77(19):5339-5348. doi: 10.1158/0008-5472.CAN-16-3410. Epub 2017 Aug 14.
• [2484] SIPA1 promotes invasion and migration in human oral squamous cell carcinoma by ITGB1 and MMP7.Exp Cell Res. 2017 Mar 15;352(2):357-363. doi: 10.1016/j.yexcr.2017.02.026. Epub 2017 Feb 22.
• [2485] Sirtuin 7: a new marker of aggressiveness in prostate cancer.Oncotarget. 2017 Aug 24;8(44):77309-77316. doi: 10.18632/oncotarget.20468. eCollection 2017 Sep 29.
• [2486] New sparse implantation technique of I-125 low-dose-rate brachytherapy using concomitant short-term hormonal treatment for low and intermediate-risk prostate cancer: An initial study of therapeutic feasibility.Sci Rep. 2019 Dec 10;9(1):18674. doi: 10.1038/s41598-019-55317-1.
• [2487] MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1.Hum Cell. 2017 Oct;30(4):290-299. doi: 10.1007/s13577-017-0170-1. Epub 2017 Jun 1.
• [2488] Overexpression of spindle and kinetochore-associated protein 1 contributes to the progression of prostate cancer.Tumour Biol. 2017 Jun;39(6):1010428317701918. doi: 10.1177/1010428317701918.
• [2489] miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF- Signaling.Mol Ther Nucleic Acids. 2019 Jun 7;16:91-104. doi: 10.1016/j.omtn.2019.01.004. Epub 2019 Jan 15.
• [2490] Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.Prostate. 2007 Feb 1;67(2):203-13. doi: 10.1002/pros.20521.
• [2491] Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer.Biochem Biophys Res Commun. 2017 Nov 25;493(3):1217-1223. doi: 10.1016/j.bbrc.2017.07.162. Epub 2017 Jul 29.
• [2492] Aberrant BAF57 signaling facilitates prometastatic phenotypes.Clin Cancer Res. 2013 May 15;19(10):2657-67. doi: 10.1158/1078-0432.CCR-12-3049. Epub 2013 Mar 14.
• [2493] SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties.Mol Carcinog. 2019 Jan;58(1):113-125. doi: 10.1002/mc.22913. Epub 2018 Oct 5.
• [2494] Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep. 2008 Jul;20(1):151-4.
• [2495] Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.Clin Cancer Res. 2006 Nov 1;12(21):6452-8. doi: 10.1158/1078-0432.CCR-06-1485.
• [2496] SNW1 is a prognostic biomarker in prostate cancer.Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.
• [2497] MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):992-1001. doi: 10.26355/eurrev_201902_16986.
• [2498] SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.Curr Cancer Drug Targets. 2018;18(9):894-904. doi: 10.2174/1568009618666180102101442.
• [2499] SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation.Anticancer Res. 2014 Jun;34(6):2821-31.
• [2500] Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.Mol Cancer. 2010 Oct 7;9:267. doi: 10.1186/1476-4598-9-267.
• [2501] Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.Int J Exp Pathol. 2017 Dec;98(6):341-346. doi: 10.1111/iep.12257. Epub 2018 Jan 8.
• [2502] PseudoFuN: Deriving functional potentials of pseudogenes from integrative relationships with genes and microRNAs across 32 cancers.Gigascience. 2019 May 1;8(5):giz046. doi: 10.1093/gigascience/giz046.
• [2503] MicroRNA-140 inhibits proliferation and promotes apoptosis and cell cycle arrest of prostate cancer via degrading SOX4.J BUON. 2019 Jan-Feb;24(1):249-255.
• [2504] miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6.Eur J Pharmacol. 2018 Mar 15;823:65-71. doi: 10.1016/j.ejphar.2018.01.016. Epub 2018 Jan 31.
• [2505] Interplay Between SOX9, Wnt/-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.Int J Mol Sci. 2019 Apr 26;20(9):2066. doi: 10.3390/ijms20092066.
• [2506] Entering an era of radiogenomics in prostate cancer risk stratification.Transl Androl Urol. 2018 Sep;7(Suppl 4):S443-S452. doi: 10.21037/tau.2018.07.04.
• [2507] Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer.Int J Cancer. 2002 Feb 1;97(4):416-24. doi: 10.1002/ijc.1638.
• [2508] Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.Cancer Res. 2015 Oct 15;75(20):4322-34. doi: 10.1158/0008-5472.CAN-15-0024. Epub 2015 Aug 20.
• [2509] The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy.J Cancer. 2019 Jun 2;10(14):3102-3111. doi: 10.7150/jca.30384. eCollection 2019.
• [2510] Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer.Oncol Lett. 2018 Apr;15(4):5712-5720. doi: 10.3892/ol.2018.8003. Epub 2018 Feb 8.
• [2511] Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk.Cancer Res. 2019 Sep 15;79(18):4592-4598. doi: 10.1158/0008-5472.CAN-18-3997. Epub 2019 Jul 23.
• [2512] The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.J Cell Physiol. 2010 Aug;224(2):369-75. doi: 10.1002/jcp.22132.
• [2513] Knockdown of SRPX2 inhibits the proliferation, migration, and invasion of prostate cancer cells through the PI3K/Akt/mTOR signaling pathway.J Biochem Mol Toxicol. 2018 Dec 9:e22237. doi: 10.1002/jbt.22237. Online ahead of print.
• [2514] SRRM4 gene expression correlates with neuroendocrine prostate cancer.Prostate. 2019 Jan;79(1):96-104. doi: 10.1002/pros.23715. Epub 2018 Aug 28.
• [2515] A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.Cancer Res. 2005 Feb 15;65(4):1213-22. doi: 10.1158/0008-5472.CAN-04-4249.
• [2516] Gene structure and transcriptional regulation of human Gal beta1,4(3) GlcNAc alpha2,3-sialyltransferase VI (hST3Gal VI) gene in prostate cancer cell line.Biochem Biophys Res Commun. 2001 Oct 12;287(5):1148-56. doi: 10.1006/bbrc.2001.5709.
• [2517] Sialyltransferase-Based Chemoenzymatic Histology for the Detection of N- and O-Glycans.Bioconjug Chem. 2018 Apr 18;29(4):1231-1239. doi: 10.1021/acs.bioconjchem.8b00021. Epub 2018 Mar 23.
• [2518] Prostate--specific G protein couple receptor genes and STAG1/PMEPA1 in peripheral blood from patients with prostatic cancer.Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):871-8. doi: 10.1177/039463200601900416.
• [2519] Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13.Cell Mol Biol Lett. 2019 Mar 8;24:20. doi: 10.1186/s11658-019-0145-1. eCollection 2019.
• [2520] Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.Oncogene. 2007 Jul 5;26(31):4580-9. doi: 10.1038/sj.onc.1210244. Epub 2007 Feb 5.
• [2521] Direct Targeting Options for STAT3 and STAT5 in Cancer.Cancers (Basel). 2019 Dec 3;11(12):1930. doi: 10.3390/cancers11121930.
• [2522] The Ste20 kinase MST4 plays a role in prostate cancer progression.Cancer Res. 2003 Jun 15;63(12):3356-63.
• [2523] Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.
• [2524] Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers.Cancer Genet Cytogenet. 2000 Oct 1;122(1):43-8. doi: 10.1016/s0165-4608(00)00276-4.
• [2525] Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.Mol Carcinog. 2020 Jan;59(1):62-72. doi: 10.1002/mc.23129. Epub 2019 Nov 1.
• [2526] 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population.Nat Commun. 2019 Sep 27;10(1):4422. doi: 10.1038/s41467-019-12267-6.
• [2527] High sulfite oxidase expression could predict postoperative biochemical recurrence in patients with prostate cancer.Med Mol Morphol. 2019 Sep;52(3):164-172. doi: 10.1007/s00795-018-00214-1. Epub 2019 Jan 10.
• [2528] Molecular characterization of prostatic small-cell neuroendocrine carcinoma.Prostate. 2003 Apr 1;55(1):55-64. doi: 10.1002/pros.10217.
• [2529] Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.BJU Int. 2019 Nov;124(5):758-767. doi: 10.1111/bju.14800. Epub 2019 Jun 2.
• [2530] Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers.Am J Pathol. 2001 Nov;159(5):1603-12. doi: 10.1016/S0002-9440(10)63006-4.
• [2531] A bioinformatics-to-clinic sequential approach to analysis of prostate cancer biomarkers using TCGA datasets and clinical samples: a new method for precision oncology?.Oncotarget. 2017 Aug 24;8(59):99601-99611. doi: 10.18632/oncotarget.20448. eCollection 2017 Nov 21.
• [2532] Downregulation of SYT7 inhibits glioblastoma growth by promoting cellular apoptosis.Mol Med Rep. 2017 Dec;16(6):9017-9022. doi: 10.3892/mmr.2017.7723. Epub 2017 Oct 4.
• [2533] TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains.Mol Endocrinol. 2010 Apr;24(4):696-708. doi: 10.1210/me.2009-0229. Epub 2010 Feb 24.
• [2534] Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.Mol Endocrinol. 1997 Apr;11(4):450-9. doi: 10.1210/mend.11.4.9906.
• [2535] Assessment of the Utility of Gene Positioning Biomarkers in the Stratification of Prostate Cancers.Front Genet. 2019 Oct 17;10:1029. doi: 10.3389/fgene.2019.01029. eCollection 2019.
• [2536] NF-B Mediates the Expression of TBX15 in Cancer Cells.PLoS One. 2016 Jun 21;11(6):e0157761. doi: 10.1371/journal.pone.0157761. eCollection 2016.
• [2537] Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.
• [2538] Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.Tumour Biol. 2017 Jun;39(6):1010428317703924. doi: 10.1177/1010428317703924.
• [2539] TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.Epigenetics. 2011 Sep 1;6(9):1120-30. doi: 10.4161/epi.6.9.16376. Epub 2011 Sep 1.
• [2540] TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.Prostate Cancer Prostatic Dis. 2017 Jun;20(2):172-178. doi: 10.1038/pcan.2017.2. Epub 2017 Feb 21.
• [2541] Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2833-8. doi: 10.1158/1055-9965.EPI-10-0582. Epub 2010 Sep 17.
• [2542] FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of -catenin.Exp Mol Med. 2018 Dec 10;50(12):1-12. doi: 10.1038/s12276-018-0184-0.
• [2543] Association of testis derived transcript gene variants and prostate cancer risk.J Urol. 2007 Mar;177(3):894-8. doi: 10.1016/j.juro.2006.10.057.
• [2544] Association of a TFAM haplotype with aggressive prostate cancer in overweight or obese Mexican Mestizo men.Urol Oncol. 2017 Mar;35(3):111.e9-111.e14. doi: 10.1016/j.urolonc.2016.10.011. Epub 2016 Nov 11.
• [2545] Development of Bispecific NT-PSMA Heterodimer for Prostate Cancer Imaging: A Potential Approach to Address Tumor Heterogeneity.Bioconjug Chem. 2019 May 15;30(5):1314-1322. doi: 10.1021/acs.bioconjchem.9b00252. Epub 2019 May 7.
• [2546] TGFBR3 loss and consequences in prostate cancer.Prostate. 2007 Feb 15;67(3):301-11. doi: 10.1002/pros.20526.
• [2547] Association of TGIFLX/Y mRNA expression with prostate cancer.Med Oncol. 2009;26(1):73-7. doi: 10.1007/s12032-008-9086-7. Epub 2008 Jul 29.
• [2548] THADA gene polymorphism and prostate cancer risk: a meta-analysis.Oncol Res Treat. 2014;37(3):106-10. doi: 10.1159/000360206. Epub 2014 Feb 21.
• [2549] Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?.Prostate. 2019 Feb;79(3):320-330. doi: 10.1002/pros.23738. Epub 2018 Nov 28.
• [2550] Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors.Biochem Biophys Res Commun. 2007 Dec 28;364(4):918-23. doi: 10.1016/j.bbrc.2007.10.097. Epub 2007 Oct 26.
• [2551] Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.Cancer Sci. 2017 Apr;108(4):744-752. doi: 10.1111/cas.13187. Epub 2017 Apr 12.
• [2552] Transmembrane Channel-Like 5 (TMC5) promotes prostate cancer cell proliferation through cell cycle regulation.Biochimie. 2019 Oct;165:115-122. doi: 10.1016/j.biochi.2019.07.017. Epub 2019 Jul 26.
• [2553] Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA.Curr Probl Cancer. 2019 Dec;43(6):100503. doi: 10.1016/j.currproblcancer.2019.100503. Epub 2019 Sep 20.
• [2554] Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.J Biol Chem. 2004 Jul 9;279(28):29302-7. doi: 10.1074/jbc.M403664200. Epub 2004 Apr 30.
• [2555] Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.Oncotarget. 2019 Oct 22;10(58):6234-6244. doi: 10.18632/oncotarget.27263. eCollection 2019 Oct 22.
• [2556] TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis.Neoplasma. 2018 Sep 19;65(5):815-821. doi: 10.4149/neo_2018_170822N551. Epub 2018 Sep 4.
• [2557] TMPRSS4 Upregulates TWIST1 Expression through STAT3 Activation to Induce Prostate Cancer Cell Migration.Pathol Oncol Res. 2018 Apr;24(2):251-257. doi: 10.1007/s12253-017-0237-z. Epub 2017 May 2.
• [2558] Oncogenic Role of Tumor Necrosis Factor -Induced Protein 8 (TNFAIP8).Cells. 2018 Dec 24;8(1):9. doi: 10.3390/cells8010009.
• [2559] Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.Prostate. 2009 Feb 15;69(3):327-35. doi: 10.1002/pros.20882.
• [2560] Differential gene methylation patterns in cancerous and noncancerous cells.Oncol Rep. 2019 Jul;42(1):43-54. doi: 10.3892/or.2019.7159. Epub 2019 May 15.
• [2561] 4-1BBL has a Possible Role in Mediating Castration-Resistant Conversion of Prostate Cancer via Up-Regulation of Androgen Receptor.J Cancer. 2019 Jun 2;10(11):2464-2471. doi: 10.7150/jca.29648. eCollection 2019.
• [2562] Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-B signaling pathway.Mol Cancer. 2017 Jul 10;16(1):117. doi: 10.1186/s12943-017-0688-6.
• [2563] Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach.Sci Rep. 2017 Aug 10;7(1):7755. doi: 10.1038/s41598-017-08209-1.
• [2564] Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.J Biol Chem. 2008 Feb 22;283(8):4834-40. doi: 10.1074/jbc.M708630200. Epub 2007 Dec 12.
• [2565] Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration.Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1298-1309. doi: 10.1016/j.bbamcr.2019.04.007. Epub 2019 Apr 11.
• [2566] Increased expression of tumor protein D54 is associated with clinical progression and poor prognosis in patients with prostate cancer.Oncol Lett. 2017 Dec;14(6):7739-7744. doi: 10.3892/ol.2017.7214. Epub 2017 Oct 18.
• [2567] A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer.Mol Carcinog. 2010 Jun;49(6):525-31. doi: 10.1002/mc.20626.
• [2568] Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.J Urol. 2004 Sep;172(3):1145-50. doi: 10.1097/01.ju.0000135117.40086.fa.
• [2569] Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193.Med Sci Monit. 2019 Jan 4;25:98-106. doi: 10.12659/MSM.911818.
• [2570] TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway.Int J Mol Med. 2016 Dec;38(6):1734-1742. doi: 10.3892/ijmm.2016.2774. Epub 2016 Oct 17.
• [2571] Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells.Oncol Res. 2017 Sep 21;25(8):1253-1259. doi: 10.3727/096504017X14854310794561. Epub 2017 Feb 3.
• [2572] Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.Epigenetics. 2012 Aug;7(8):940-9. doi: 10.4161/epi.21236. Epub 2012 Jul 18.
• [2573] TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.Int J Biol Macromol. 2019 Jan;121:200-206. doi: 10.1016/j.ijbiomac.2018.09.168. Epub 2018 Sep 26.
• [2574] TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.Oncol Rep. 2019 Feb;41(2):1169-1179. doi: 10.3892/or.2018.6854. Epub 2018 Nov 9.
• [2575] Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.Horm Cancer. 2010 Feb;1(1):21-33. doi: 10.1007/s12672-010-0008-8. Epub 2010 Feb 13.
• [2576] Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
• [2577] Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers.PLoS One. 2011 Mar 14;6(3):e17149. doi: 10.1371/journal.pone.0017149.
• [2578] The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration.Sci Rep. 2017 Jul 12;7(1):5249. doi: 10.1038/s41598-017-05489-5.
• [2579] Localization of candidate genes in a region of high frequency of microvariant alleles for prostate cancer susceptibility: the chromosome region Yp11.2 genetic variation.DNA Cell Biol. 2010 Jan;29(1):3-7. doi: 10.1089/dna.2009.0905.
• [2580] Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.BMC Cancer. 2017 Feb 24;17(1):158. doi: 10.1186/s12885-017-3134-7.
• [2581] Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy.Int J Cancer. 2010 Dec 1;127(11):2542-53. doi: 10.1002/ijc.25261.
• [2582] Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.Eur J Cancer. 2016 Apr;57:39-49. doi: 10.1016/j.ejca.2016.01.002. Epub 2016 Feb 6.
• [2583] Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.BMC Cancer. 2016 Feb 24;16:151. doi: 10.1186/s12885-016-2178-4.
• [2584] XB130 is overexpressed in prostate cancer and involved in cell growth and invasion.Oncotarget. 2016 Sep 13;7(37):59377-59387. doi: 10.18632/oncotarget.11074.
• [2585] SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.Cancer Lett. 2018 Mar 1;416:11-23. doi: 10.1016/j.canlet.2017.12.008. Epub 2017 Dec 13.
• [2586] Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Urology. 2015 Jan;85(1):165-70. doi: 10.1016/j.urology.2014.07.081.
• [2587] miR?0c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.Mol Med Rep. 2017 Sep;16(3):2431-2438. doi: 10.3892/mmr.2017.6910. Epub 2017 Jul 4.
• [2588] Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.Metallomics. 2019 Aug 1;11(8):1430-1440. doi: 10.1039/c9mt00042a. Epub 2019 Jul 18.
• [2589] III-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.
• [2590] MiR-185 attenuates androgen receptor function in prostate cancer indirectly by targeting bromodomain containing 8 isoform 2, an androgen receptor co-activator.Mol Cell Endocrinol. 2016 May 15;427:13-20. doi: 10.1016/j.mce.2016.02.023. Epub 2016 Mar 3.
• [2591] Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma.JAMA Ophthalmol. 2016 Oct 1;134(10):1125-1133. doi: 10.1001/jamaophthalmol.2016.2691.
• [2592] A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.Eur Urol. 2014 Jan;65(1):169-76. doi: 10.1016/j.eururo.2012.07.027. Epub 2012 Jul 20.
• [2593] Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.Clin Epigenetics. 2016 Feb 12;8:16. doi: 10.1186/s13148-016-0182-9. eCollection 2016.
• [2594] Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer.Cytokine. 2016 Oct;86:110-118. doi: 10.1016/j.cyto.2016.07.006. Epub 2016 Aug 5.
• [2595] The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer.Tumour Biol. 2015 Jan;36(1):329-35. doi: 10.1007/s13277-014-2642-1. Epub 2014 Sep 26.
• [2596] CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.Epigenetics. 2016 Dec;11(12):871-880. doi: 10.1080/15592294.2016.1241931. Epub 2016 Sep 30.
• [2597] The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.Cell Death Dis. 2014 May 8;5(5):e1220. doi: 10.1038/cddis.2014.106.
• [2598] Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.Oncotarget. 2016 Oct 18;7(42):68650-68661. doi: 10.18632/oncotarget.11896.
• [2599] Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells.Biochem Biophys Res Commun. 2017 Mar 18;484(4):794-800. doi: 10.1016/j.bbrc.2017.01.169. Epub 2017 Jan 31.
• [2600] Identifying cancer origin using circulating tumor cells.Cancer Biol Ther. 2016 Apr 2;17(4):430-8. doi: 10.1080/15384047.2016.1141839.
• [2601] DLEC1, a 3p tumor suppressor, represses NF-B signaling and is methylated in prostate cancer.J Mol Med (Berl). 2015 Jun;93(6):691-701. doi: 10.1007/s00109-015-1255-5. Epub 2015 Feb 5.
• [2602] Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclinD2 pathway.Oncol Rep. 2016 Nov;36(5):3058-3064. doi: 10.3892/or.2016.5073. Epub 2016 Sep 7.
• [2603] PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.Cancer Med. 2015 Aug;4(8):1258-71. doi: 10.1002/cam4.463. Epub 2015 May 29.
• [2604] Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer.Mol Carcinog. 2016 Sep;55(9):1378-86. doi: 10.1002/mc.22381. Epub 2015 Aug 10.
• [2605] Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.Tumour Biol. 2016 Apr;37(4):5365-74. doi: 10.1007/s13277-015-4398-7. Epub 2015 Nov 11.
• [2606] The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.Oncotarget. 2016 Dec 13;7(50):82783-82797. doi: 10.18632/oncotarget.12635.
• [2607] Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.Epigenetics. 2016 Apr 2;11(4):247-58. doi: 10.1080/15592294.2016.1148867. Epub 2016 Feb 18.
• [2608] D-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells.Tumour Biol. 2014 Apr;35(4):3237-45. doi: 10.1007/s13277-013-1423-6. Epub 2013 Nov 22.
• [2609] PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence.Oncotarget. 2016 Aug 16;7(33):53837-53852. doi: 10.18632/oncotarget.10782.
• [2610] Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.Exp Cell Res. 2016 Nov 15;349(1):77-84. doi: 10.1016/j.yexcr.2016.09.023. Epub 2016 Oct 12.
• [2611] GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.Carcinogenesis. 2014 Sep;35(9):1962-7. doi: 10.1093/carcin/bgu048. Epub 2014 Feb 22.
• [2612] Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1037-46. doi: 10.1158/1055-9965.EPI-13-0670. Epub 2014 Apr 7.
• [2613] Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers.Int J Mol Sci. 2018 Aug 28;19(9):2543. doi: 10.3390/ijms19092543.
• [2614] Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.
• [2615] The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.Oncogene. 2016 Sep 8;35(36):4752-61. doi: 10.1038/onc.2016.6. Epub 2016 Feb 22.
• [2616] The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.Mol Cancer Ther. 2014 Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29.
• [2617] Genetic Variants of DICE1/INTS6 in German Prostate Cancer Families with Linkage to 13q14.Urol Int. 2015;95(4):386-9. doi: 10.1159/000366229. Epub 2015 Jan 31.
• [2618] Variants at IRX4 as prostate cancer expression quantitative trait loci.Eur J Hum Genet. 2014 Apr;22(4):558-63. doi: 10.1038/ejhg.2013.195. Epub 2013 Sep 11.
• [2619] An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.Int J Cancer. 2016 Jan 1;138(1):74-86. doi: 10.1002/ijc.29677. Epub 2015 Jul 17.
• [2620] A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.Oncotarget. 2016 Nov 1;7(44):71833-71840. doi: 10.18632/oncotarget.12377.
• [2621] Single-nucleotide polymorphism rs13426236 contributes to an increased prostate cancer risk via regulating MLPH splicing variant 4.Mol Carcinog. 2020 Jan;59(1):45-55. doi: 10.1002/mc.23127. Epub 2019 Oct 29.
• [2622] mLST8 Promotes mTOR-Mediated Tumor Progression.PLoS One. 2015 Apr 23;10(4):e0119015. doi: 10.1371/journal.pone.0119015. eCollection 2015.
• [2623] BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts.Int J Oncol. 2015 Aug;47(2):719-27. doi: 10.3892/ijo.2015.3060. Epub 2015 Jun 22.
• [2624] Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.Br J Cancer. 2016 Apr 12;114(8):945-52. doi: 10.1038/bjc.2016.50.
• [2625] Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.Prostate. 2015 Feb 15;75(3):266-79. doi: 10.1002/pros.22912. Epub 2014 Oct 18.
• [2626] Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.Eur Urol. 2007 Mar;51(3):665-74; discussion 674. doi: 10.1016/j.eururo.2006.08.008. Epub 2006 Aug 23.
• [2627] NKAIN2 functions as a novel tumor suppressor in prostate cancer.Oncotarget. 2016 Sep 27;7(39):63793-63803. doi: 10.18632/oncotarget.11690.
• [2628] Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.Oncotarget. 2016 Oct 18;7(42):68688-68707. doi: 10.18632/oncotarget.11925.
• [2629] Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.Med Sci Monit. 2014 Aug 3;20:1363-8. doi: 10.12659/MSM.891241.
• [2630] MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.Prostate. 2016 May;76(6):543-51. doi: 10.1002/pros.23143. Epub 2016 Jan 15.
• [2631] PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.Prostate. 2016 Feb 15;76(3):273-85. doi: 10.1002/pros.23118. Epub 2015 Oct 26.
• [2632] Strong cis-acting expression quantitative trait loci for the genes encoding SNHG5 and PEX6.Medicine (Baltimore). 2016 Dec;95(52):e5793. doi: 10.1097/MD.0000000000005793.
• [2633] PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.Cell Physiol Biochem. 2018;50(6):2108-2123. doi: 10.1159/000495055. Epub 2018 Nov 9.
• [2634] Cathepsin X Cleaves Profilin 1 C-Terminal Tyr139 and Influences Clathrin-Mediated Endocytosis.PLoS One. 2015 Sep 1;10(9):e0137217. doi: 10.1371/journal.pone.0137217. eCollection 2015.
• [2635] Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression.Tumour Biol. 2015 Dec;36(12):9567-77. doi: 10.1007/s13277-015-3628-3. Epub 2015 Jul 4.
• [2636] MicroRNA124 regulate cell growth of prostate cancer cells by targeting iASPP.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2283-90. eCollection 2014.
• [2637] Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.Biomed Pharmacother. 2016 Mar;78:116-120. doi: 10.1016/j.biopha.2016.01.004. Epub 2016 Jan 24.
• [2638] Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.Clin Cancer Res. 2016 May 15;22(10):2545-54. doi: 10.1158/1078-0432.CCR-15-1927. Epub 2015 Dec 28.
• [2639] DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1 protein.Cell Signal. 2016 Nov;28(11):1623-30. doi: 10.1016/j.cellsig.2016.07.011. Epub 2016 Jul 27.
• [2640] Expression of RABEX-5 and its clinical significance in prostate cancer.J Exp Clin Cancer Res. 2014 Apr 9;33(1):31. doi: 10.1186/1756-9966-33-31.
• [2641] CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer.Exp Cell Res. 2018 Sep 1;370(1):58-67. doi: 10.1016/j.yexcr.2018.06.006. Epub 2018 Jun 15.
• [2642] Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis. 2014 Jun;17(2):119-25. doi: 10.1038/pcan.2013.51. Epub 2014 Jan 14.
• [2643] Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial-mesenchymal transition in prostate cancer cell.Oncotarget. 2016 Oct 4;7(40):65553-65567. doi: 10.18632/oncotarget.11549.
• [2644] miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.Cell Cycle. 2014;13(2):227-39. doi: 10.4161/cc.26984. Epub 2013 Nov 7.
• [2645] Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer.Mol Cell Endocrinol. 2016 Jan 15;420:159-68. doi: 10.1016/j.mce.2015.10.011. Epub 2015 Oct 21.
• [2646] Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.Int J Oncol. 2016 Jun;48(6):2619-28. doi: 10.3892/ijo.2016.3458. Epub 2016 Mar 24.
• [2647] Clinical significance of RKIP mRNA expression in non-small cell lung cancer.Tumour Biol. 2014 May;35(5):4377-80. doi: 10.1007/s13277-013-1575-4. Epub 2014 Jan 14.
• [2648] Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.Endocr Relat Cancer. 2015 Jun;22(3):369-86. doi: 10.1530/ERC-15-0021. Epub 2015 Mar 10.
• [2649] miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.Mol Cancer. 2016 Nov 10;15(1):70. doi: 10.1186/s12943-016-0556-9.
• [2650] Molecular cloning of canine co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein (SGTA) and investigation of its ability to suppress androgen receptor signalling in androgen-independent prostate cancer.Vet J. 2015 Nov;206(2):143-8. doi: 10.1016/j.tvjl.2015.08.002. Epub 2015 Aug 7.
• [2651] SHISA2 enhances the aggressive phenotype in prostate cancer through the regulation of WNT5A expression.Oncol Lett. 2017 Dec;14(6):6650-6658. doi: 10.3892/ol.2017.7099. Epub 2017 Sep 28.
• [2652] Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.Prostate. 2015 May;75(6):561-72. doi: 10.1002/pros.22935. Epub 2015 Jan 28.
• [2653] The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells.Oncogene. 2014 Jul 17;33(29):3794-802. doi: 10.1038/onc.2013.360. Epub 2013 Sep 2.
• [2654] First-of-its-kind STARD(3) Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent.ACS Med Chem Lett. 2019 Feb 20;10(4):475-480. doi: 10.1021/acsmedchemlett.8b00509. eCollection 2019 Apr 11.
• [2655] Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.Oncotarget. 2016 Apr 26;7(17):24326-38. doi: 10.18632/oncotarget.8220.
• [2656] TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells.APMIS. 2017 Feb;125(2):101-105. doi: 10.1111/apm.12638. Epub 2016 Dec 28.
• [2657] Gelsolin-like actin-capping proteinis associated with patient prognosis, cellular apoptosis and proliferation in prostate cancer.Biomark Med. 2016 Dec;10(12):1251-1260. doi: 10.2217/bmm-2016-0186. Epub 2016 Dec 7.
• [2658] TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway.Oncol Res. 2016;24(5):305-313. doi: 10.3727/096504016X14666990347437.
• [2659] Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.
• [2660] MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1.Eur Rev Med Pharmacol Sci. 2016;20(1):92-100.
• [2661] Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease.Curr Mol Pharmacol. 2015;9(1):66-95. doi: 10.2174/1874467208666150519113639.
• [2662] TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer.Acta Histochem. 2014 Jun;116(5):708-12. doi: 10.1016/j.acthis.2013.12.009. Epub 2014 Jan 30.
• [2663] Germline Variants of Prostate Cancer in Japanese Families.PLoS One. 2016 Oct 4;11(10):e0164233. doi: 10.1371/journal.pone.0164233. eCollection 2016.
• [2664] Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.J Korean Med Sci. 2015 Dec;30(12):1784-92. doi: 10.3346/jkms.2015.30.12.1784. Epub 2015 Nov 30.
• [2665] TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins.Mol Endocrinol. 2016 Jan;30(1):13-25. doi: 10.1210/me.2015-1075. Epub 2015 Dec 9.